# Patent

## Title
Protein showing enhanced expression in cancer cells

## Abstract

A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. Ser. No. 11/751,621, filed May 21, 2007 and now U.S. Pat. No. 7,795,391, which is a divisional application of U.S. Ser. No. 10/147,368 filed May 15, 2002, now U.S. Pat. No. 7,361,338, which is a continuation-in-part of U.S. application Ser. No. 10/001,469, filed Oct. 31, 2001, now U.S. Pat. No. 7,208,280, which is a continuation-in-part of U.S. application Ser. No. 09/680,728, filed Oct. 5, 2000, now U.S. Pat. No. 6,790,631, which claims benefit of priority from U.S. Provisional Application Ser. No. 60/157,902, filed Oct. 5, 1999. Application Ser. No. 10/001,469 also claims priority under 35 U.S.C. §119(e) to Provisional Application 60/291,118, filed May 15, 2001. Each of the applications referenced in this paragraph are hereby incorporated in their entireties as if fully set forth herein.


REFERENCE TO SEQUENCE LISTING SUBMITTED VIA EFS-WEB
This application was filed electronically via the USPTO EFS-WEB server, as authorized and set forth in MPEP §1730 II.B.2.(a)(A), and this electronic filing includes an electronically submitted sequence (SEQ ID) listing; the entire content of this sequence listing is herein incorporated by reference for all purposes. The sequence listing is identified on the electronically filed .txt file as follows:















File Name
Date of Creation
Size (bytes)









511582002402Seqlist.txt
Jul. 21, 2010
77854










FIELD OF THE INVENTION
The invention described herein relates to a gene and its encoded protein, termed 101P3A11 or PHOR-1, expressed in certain cancers, and to diagnostic and therapeutic methods and compositions useful in the management of cancers that express 101P3A11. The PHOR-1 cDNA was deposited under the terms of the Budapest Treaty on Jul. 2, 1999, with the American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as plasmid p101P3A11, and has been assigned Accession No. PTA-312.
BACKGROUND OF THE INVENTION
Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the next century, cancer is predicted to become the leading cause of death.
Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death. These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal. Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment. Furthermore, many cancer patients experience a recurrence.
Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common cancer in males and is the second leading cause of cancer death in men. In the United States alone, well over 30,000 men die annually of this disease—second only to lung cancer. Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer. Surgical prostatectomy, radiation therapy, hormone ablation therapy, surgical castration and chemotherapy continue to be the main treatment modalities. Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.
On the diagnostic front, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the diagnosis and management of this disease. Although the serum prostate specific antigen (PSA) assay has been a very useful tool, however its specificity and general utility is widely regarded as lacking in several important respects.
Progress in identifying additional specific markers for prostate cancer has been improved by the generation of prostate cancer xenografts that can recapitulate different stages of the disease in mice. The LAPC (Los Angeles Prostate Cancer) xenografts are prostate cancer xenografts that have survived passage in severe combined immune deficient (SCID) mice and have exhibited the capacity to mimic the transition from androgen dependence to androgen independence (Klein et al., 1997, Nat. Med. 3:402). More recently identified prostate cancer markers include PCTA-1 (Su et al., 1996, Proc. Natl. Acad. Sci. USA 93: 7252), prostate-specific membrane (PSM) antigen (Pinto et al., Clin Cancer Res 1996 Sep. 2 (9): 1445-51), STEAP (Hubert, et al., Proc Natl Acad Sci USA. 1999 Dec. 7; 96(25): 14523-8) and prostate stem cell antigen (PSCA) (Reiter et al., 1998, Proc. Natl. Acad. Sci. USA 95: 1735).
While previously identified markers such as PSA, PSM, PCTA and PSCA have facilitated efforts to diagnose and treat prostate cancer, there is need for the identification of additional markers and therapeutic targets for prostate and related cancers in order to further improve diagnosis and therapy.
Renal cell carcinoma (RCC) accounts for approximately 3 percent of adult malignancies. Once adenomas reach a diameter of 2 to 3 cm, malignant potential exists. In the adult, the two principal malignant renal tumors are renal cell adenocarcinoma and transitional cell carcinoma of the renal pelvis or ureter. The incidence of renal cell adenocarcinoma is estimated at more than 29,000 cases in the United States, and more than 11,600 patients died of this disease in 1998. Transitional cell carcinoma is less frequent, with an incidence of approximately 500 cases per year in the United States.
Surgery has been the primary therapy for renal cell adenocarcinoma for many decades. Until recently, metastatic disease has been refractory to any systemic therapy. With recent developments in systemic therapies, particularly immunotherapies, metastatic renal cell carcinoma may be approached aggressively in appropriate patients with a possibility of durable responses. Nevertheless, there is a remaining need for effective therapies for these patients.
Of all new cases of cancer in the United States, bladder cancer represents approximately 5 percent in men (fifth most common neoplasm) and 3 percent in women (eighth most common neoplasm). The incidence is increasing slowly, concurrent with an increasing older population. In 1998, there was an estimated 54,500 cases, including 39,500 in men and 15,000 in women. The age-adjusted incidence in the United States is 32 per 100,000 for men and 8 per 100,000 in women. The historic male/female ratio of 3:1 may be decreasing related to smoking patterns in women. There were an estimated 11,000 deaths from bladder cancer in 1998 (7,800 in men and 3,900 in women). Bladder cancer incidence and mortality strongly increase with age and will be an increasing problem as the population becomes more elderly.
Most bladder cancers recur in the bladder. Bladder cancer is managed with a combination of transurethral resection of the bladder (TUR) and intravesical chemotherapy or immunotherapy. The multifocal and recurrent nature of bladder cancer points out the limitations of TUR. Most muscle-invasive cancers are not cured by TUR alone. Radical cystectomy and urinary diversion is the most effective means to eliminate the cancer but carry an undeniable impact on urinary and sexual function. There continues to be a significant need for treatment modalities that are beneficial for bladder cancer patients.
An estimated 130,200 cases of colorectal cancer occurred in 2000 in the United States, including 93,800 cases of colon cancer and 36,400 of rectal cancer. Colorectal cancers are the third most common cancers in men and women. Incidence rates declined significantly during 1992-1996 (−2.1% per year). Research suggests that these declines have been due to increased screening and polyp removal, preventing progression of polyps to invasive cancers. There were an estimated 56,300 deaths (47,700 from colon cancer, 8,600 from rectal cancer) in 2000, accounting for about 1% of all U.S. cancer deaths.
At present, surgery is the most common form of therapy for colorectal cancer, and for cancers that have not spread, it is frequently curative. Chemotherapy, or chemotherapy plus radiation, is given before or after surgery to most patients whose cancer has deeply perforated the bowel wall or has spread to the lymph nodes. A permanent colostomy (creation of an abdominal opening for elimination of body wastes) is occasionally needed for colon cancer and is infrequently required for rectal cancer. There continues to be a need for effective diagnostic and treatment modalities for colorectal cancer.
There were an estimated 164,100 new cases of lung and bronchial cancer in 2000, accounting for 14% of all U.S. cancer diagnoses. The incidence rate of lung and bronchial cancer is declining significantly in men, from a high of 86.5 per 100,000 in 1984 to 70.0 in 1996. In the 1990s, the rate of increase among women began to slow. In 1996, the incidence rate in women was 42.3 per 100,000.
Lung and bronchial cancer caused an estimated 156,900 deaths in 2000, accounting for 28% of all cancer deaths. During 1992-1996, mortality from lung cancer declined significantly among men (−1.7% per year) while rates for women were still significantly increasing (0.9% per year). Since 1987, more women have died each year of lung cancer than breast cancer, which, for over 40 years, was the major cause of cancer death in women. Decreasing lung cancer incidence and mortality rates most likely resulted from decreased smoking rates over the previous 30 years; however, decreasing smoking patterns among women lag behind those of men. Of concern, although the declines in adult tobacco use have slowed, tobacco use in youth is increasing again.
Treatment options for lung and bronchial cancer are determined by the type and stage of the cancer and include surgery, radiation therapy, and chemotherapy. For many localized cancers, surgery is usually the treatment of choice. Because the disease has usually spread by the time it is discovered, radiation therapy and chemotherapy are often needed in combination with surgery. Chemotherapy alone or combined with radiation is the treatment of choice for small cell lung cancer; on this regimen, a large percentage of patients experience remission, which in some cases is long lasting. There is however, an ongoing need for effective treatment and diagnostic approaches for lung and bronchial cancers.
An estimated 182,800 new invasive cases of breast cancer were expected to occur among women in the United States during 2000. Additionally, about 1,400 new cases of breast cancer were expected to be diagnosed in men in 2000. After increasing about 4% per year in the 1980s, breast cancer incidence rates in women have leveled off in the 1990s to about 110.6 cases per 100,000.
In the U.S. alone, there were an estimated 41,200 deaths (40,800 women, 400 men) in 2000 due to breast cancer. Breast cancer ranks second among cancer deaths in women. According to the most recent data, mortality rates declined significantly during 1992-1996 with the largest decreases in younger women, both white and black. These decreases were probably the result of earlier detection and improved treatment.
Taking into account the medical circumstances and the patient's preferences, treatment of breast cancer may involve lumpectomy (local removal of the tumor) and removal of the lymph nodes under the arm; mastectomy (surgical removal of the breast) and removal of the lymph nodes under the arm; radiation therapy; chemotherapy; or hormone therapy. Often, two or more methods are used in combination. Numerous studies have shown that, for early stage disease, long-term survival rates after lumpectomy plus radiotherapy are similar to survival rates after modified radical mastectomy. Significant advances in reconstruction techniques provide several options for breast reconstruction after mastectomy. Recently, such reconstruction has been done at the same time as the mastectomy.
Local excision of ductal carcinoma in situ (DCIS) with adequate amounts of surrounding normal breast tissue may prevent the local recurrence of the DCIS. Radiation to the breast and/or tamoxifen may reduce the chance of DCIS occurring in the remaining breast tissue. This is important because DCIS, if left untreated, may develop into invasive breast cancer. Nevertheless, there are serious side effects or sequalae to these treatments. There is, therefore, a need for efficacious breast cancer treatments.
There were an estimated 23,100 new cases of ovarian cancer in the United States in 2000. It accounts for 4% of all cancers among women and ranks second among gynecologic cancers. During 1992-1996, ovarian cancer incidence rates were significantly declining. Consequent to ovarian cancer, there were an estimated 14,000 deaths in 2000. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.
Surgery, radiation therapy, and chemotherapy are treatment options for ovarian cancer. Surgery usually includes the removal of one or both ovaries, the fallopian tubes (salpingo-oophorectomy), and the uterus (hysterectomy). In some very early tumors, only the involved ovary will be removed, especially in young women who wish to have children. In advanced disease, an attempt is made to remove all intra-abdominal disease to enhance the effect of chemotherapy. There continues to be an important need for effective treatment options for ovarian cancer.
There were an estimated 28,300 new cases of pancreatic cancer in the United States in 2000. Over the past 20 years, rates of pancreatic cancer have declined in men. Rates among women have remained approximately constant but may be beginning to decline. Pancreatic cancer caused an estimated 28,200 deaths in 2000 in the United States. Over the past 20 years, there has been a slight but significant decrease in mortality rates among men (about −0.9% per year) while rates have increased slightly among women.
Surgery, radiation therapy, and chemotherapy are treatment options for pancreatic cancer. These treatment options can extend survival and/or relieve symptoms in many patients but are not likely to produce a cure for most. There is a significant need for additional therapeutic and diagnostic options for pancreatic cancer.
G protein-coupled receptors (GPCR) share a common structural motif. All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane. The transmembrane helices are joined by strands of amino acids having a larger loop between the fourth and fifth transmembrane helix on the extracellular side of the membrane. Another larger loop, composed primarily of hydrophilic amino acids, joins transmembrane helices five and six on the intracellular side of the membrane. The carboxy terminus of the receptor lies intracellularly with the amino terminus in the extracellular space. It is thought that the loop joining helices five and six, as well as the carboxy terminus, interact with the G protein. There is evidence that in certain GPCRs the first intracellular loop is also important for G-protein interactions. Currently, Gq, Gs, Gi, and Go are G proteins that have been identified.
Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between two different states or conformations: an “inactive” state and an “active” state. A receptor in an inactive state is unable to link to the intracellular transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway and produces a biological response.
A receptor may be stabilized in an active state by an endogenous ligand or an exogenous agonist ligand. Recent discoveries, including but not exclusively limited to, modifications to the amino acid sequence of the receptor, provide alternative mechanisms other than ligands to stabilize the active state conformation. These approaches effectively stabilize the receptor in an active state by simulating the effect of a ligand binding to the receptor. Stabilization by such ligand-independent approaches is termed “constitutive receptor activation.” A receptor for which the endogenous ligand is unknown or not identified is referred to as an “orphan receptor.”
Concerning traditional compound screening, in general, the use of an orphan receptor for screening purposes to identify compounds that modulate a biological response associated with such receptor has not been possible. This is because the traditional “dogma” regarding screening of compounds mandates that the ligand for the receptor be known, whereby compounds that competitively bind with the receptor, i.e., by interfering or blocking the binding of the natural ligand with the receptor, are selected. By definition, then, this approach has no applicability with respect to orphan receptors. Thus, by adhering to this dogmatic approach to the discovery of therapeutics, the art, in essence, has taught and has been taught to forsake the use of orphan receptors unless and until the natural ligand for the receptor is discovered. The pursuit of an endogenous ligand for an orphan receptor can take several years and cost millions of dollars.
Furthermore, and given that there are an estimated 2,000 GPCRs in the human genome, the majority of which being orphan receptors, the traditional dogma castigates a creative approach to the discovery of therapeutics to these receptors. Numerous orphan G protein-coupled receptors are constitutively active in their endogenous state.
SUMMARY OF THE INVENTION
The present invention relates to a gene, designated 101P3A11, that has now been found to be over-expressed in the cancer(s) listed in Table I. Northern blot expression analysis of 101P3A11 gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide (FIG. 2) and amino acid (FIG. 2, and FIG. 3) sequences of 101P3A11 are provided. The tissue-related profile of 101P3A11 in normal adult tissues, combined with the over-expression observed in the tissues listed in Table I, shows that 101P3A11 is aberrantly over-expressed in at least some cancers, and thus serves as a useful diagnostic, prophylactic, prognostic, and/or therapeutic target for cancers of the tissue(s) such as those listed in Table I. The endogenous ligand for 101P3A11 is unknown.
The invention provides polynucleotides corresponding or complementary to all or part of the 101P3A11 genes, mRNAs, and/or coding sequences, preferably in isolated form, including polynucleotides encoding 101P3A11-related proteins and fragments of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 contiguous amino acids; at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 317 or 318; or more than 317 or 318 contiguous amino acids of a 101P3A11-related protein, as well as the peptides/proteins themselves; DNA, RNA, DNA/RNA hybrids, and related molecules, polynucleotides or oligonucleotides complementary or having at least a 90% homology to the 101P3A11 genes or mRNA sequences or parts thereof, and polynucleotides or oligonucleotides that hybridize to the 101P3A11 genes, mRNAs, or to 101P3A11-encoding polynucleotides. Also provided are means for isolating cDNAs and the genes encoding 101P3A11. Recombinant DNA molecules containing 101P3A11 polynucleotides, cells transformed or transduced with such molecules, and host-vector systems for the expression of 101P3A11 gene products are also provided. The invention further provides antibodies that bind to 101P3A11 proteins and polypeptide fragments thereof, including polyclonal and monoclonal antibodies, murine and other mammalian antibodies, chimeric antibodies, humanized and fully human antibodies, and antibodies labeled with a detectable marker or therapeutic agent. In certain embodiments there is a proviso that the entire nucleic acid sequence of FIG. 2 is not encoded and/or the entire amino acid sequence of FIG. 2 is not prepared, either of which can be in respective human unit dose forms. In certain embodiments, the entire nucleic acid sequence of FIG. 2 is encoded and/or the entire amino acid sequence of FIG. 2 is prepared, either of which can be in respective human unit dose forms.
The invention further provides methods for detecting the presence and status of 101P3A11 polynucleotides and proteins in various biological samples, as well as methods for identifying cells that express 101P3A11. A typical embodiment of this invention provides methods for monitoring 101P3A11 gene products in a tissue or hematology sample having or suspected of having some form of growth dysregulation such as cancer.
The invention further provides various immunogenic or therapeutic compositions and strategies for treating cancers that express 101P3A11 such as cancers of tissues listed in Table I, including therapies aimed at inhibiting the transcription, translation, processing or function of 101P3A11 as well as cancer vaccines. In one aspect, the invention provides compositions, and methods comprising them, for treating a cancer that expresses 101P3A11 in a human subject wherein the composition comprises a carrier suitable for human use and a human unit dose of one or more than one agent that inhibits the production or function of 101P3A11. Preferably, the carrier is a uniquely human carrier. In another aspect of the invention, the agent is a moiety that is immunoreactive with 101P3A11 protein. Non-limiting examples of such moieties include, but are not limited to, antibodies (such as single chain, monoclonal, polyclonal, humanized, chimeric, or human antibodies), functional equivalents thereof (whether naturally occurring or synthetic), and combinations thereof. The antibodies can be conjugated to a diagnostic or therapeutic moiety. In another aspect, the agent is a small molecule as defined herein.
In another aspect, the agent comprises one or more than one peptide which comprises a cytotoxic T lymphocyte (CTL) epitope that binds an HLA class I molecule in a human to elicit a CTL response to 101P3A11 and/or one or more than one peptide which comprises a helper T lymphocyte (HTL) epitope which binds an HLA class II molecule in a human to elicit an HTL response. The peptides of the invention may be on the same or on one or more separate polypeptide molecules. In a further aspect of the invention, the agent comprises one or more than one nucleic acid molecule that expresses one or more than one of the CTL or HTL response stimulating peptides as described above. In yet another aspect of the invention, the one or more than one nucleic acid molecule may express a moiety that is immunologically reactive with 101P3A11 as described above. The one or more than one nucleic acid molecule may also be, or encodes, a molecule that inhibits production of 101P3A11. Non-limiting examples of such molecules include, but are not limited to, those complementary to a nucleotide sequence essential for production of 101P3A11 (e.g. antisense sequences or molecules that form a triple helix with a nucleotide double helix essential for 101P3A11 production) or a ribozyme effective to lyse 101P3A11 mRNA.
Note: To determine the starting position of any peptide set forth in Tables V-XVIII and XXII to IL (collectively HLA Peptide Tables) respective to its parental protein, e.g., variant 1, variant 2, etc., reference is made to three factors: the particular variant, the length of the peptide in an HLA Peptide Table, and the Search Peptides in Table LII. Generally, a unique Search Peptide is used to obtain HLA peptides of a particular for a particular variant. The position of each Search Peptide relative to its respective parent molecule is listed in Table LII. Accordingly if a Search Peptide begins at position “X”, one must add the value “X−1” to each position in Tables V-XVIII and XXII to IL to obtain the actual position of the HLA peptides in their parental molecule. For example if a particular Search Peptide begins at position 150 of is parental molecule, one must add 150−1, i.e., 149 to each HLA peptide amino acid position to calculate the position of that amino acid in the parent molecule.



BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. The 101P3A11 SSH sequence (SEQ ID NO:26).
FIGS. 2A-2C. The cDNA and amino acid sequence of 101P3A11 variants 1-3 (SEQ ID NOS:27 and 19, SEQ ID NOS: 29 and 30, and SEQ ID NOS: 31 and 32). The start methionine is underlined. The open reading frame for variants 1 and 3 extends from nucleic acid 133 to 1086 including the stop codon. The codon for the initial M in each variant can be omitted as the shorter peptide can have a more favorable Kozak sequence).
FIGS. 3A-C. Amino acid sequences of 101P3A11 variants 1-3 (SEQ ID NOS:19, 30, 32).
FIG. 4. Alignment of 101P3A11 (Sbjct) (SEQ ID NO:143) with mouse olfactory receptor S25 (Query) (SEQ ID NO:144). The transmembrane regions of 101P3A11 and mouse olfactory receptor S25 (ORS25) predicted using the TMHMM algorithm are highlighted in gray. The amino acids of ORS25 predicted (Floriano, W. B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716) to be involved in binding of the ligand hexanol and/or involved in the formation of the ligand binding pocket are italicized and bolded in the Figure, and are: Leu 131, Val 134, Val 135, Gly 138, Thr 139, Ser 193, Ser 197, Phe 225, Ala 230, Ile 231, Gly 234, Thr 284, Phe 287, Gln 300, Lys 302.
FIG. 5. Hydrophilicity amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Hopp and Woods (Hopp T. P., Woods K. R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) accessed on the Protscale website through the ExPasy molecular biology server.
FIG. 6. Hydropathicity amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Kyte and Doolittle (Kyte J., Doolittle R. F., 1982. J. Mol. Biol. 157:105-132) accessed on the ProtScale website through the ExPasy molecular biology server.
FIG. 7. Percent accessible residues amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Janin (Janin J., 1979 Nature 277:491-492) accessed on the ProtScale website through the ExPasy molecular biology server.
FIG. 8. Average flexibility amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Bhaskaran and Ponnuswamy (Bhaskaran R., and Ponnuswamy P. K., 1988. Int. J. Pept. Protein Res. 32:242-255) accessed on the ProtScale website through the ExPasy molecular biology server.
FIG. 9. Beta-turn amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Deleage and Roux (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294) accessed on the ProtScale website through the ExPasy molecular biology server.
FIG. 10A. Expression of 101P3A11 by RT-PCR. First strand cDNA was prepared from vital pool 1 (VP1: liver, lung and kidney), vital pool 2 (VP2, pancreas, colon and stomach), prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 101P3A11, was performed at 30 cycles of amplification. Expression of 101P3A11 was observed in prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool, but not in VP1 and VP2.
FIG. 10B. Expression of 101P3A11 in human cancers demonstrated by dot blot analysis of tumor RNA (T) and normal RNA (N) matched samples using patient-derived amplified cDNAs. Up-regulation of PHOR-1 expression was found in 3 of 3 prostate cancer patients, 6 of 14 kidney cancer patients, 2 of 8 uterine cancer patients, 3 of 8 stomach cancer patients and 7 of 7 rectal cancer patients.
FIG. 11. Expression of 101P3A11 in human patient cancer specimens. RNA was extracted from a pool of three prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, and a cancer metastasis pool derived from cancer patients, as well as from normal prostate (NP), normal bladder (NB), normal kidney (NK) and normal colon (NC). Northern blots with 10 μg of total RNA/lane were probed with a 101P3A11 fragment. Size standards in kilobases (kb) are indicated on the side. The results showed expression of 101P3A11 in prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, cancer metastasis pool, bladder cancer pool, and in the normal prostate but not in the other normal tissues. A picture of the ethidium-bromide staining of the RNA gel is also presented.
FIG. 12A. Expression of 101P3A11 in prostate cancer patient specimens. RNA was extracted from prostate tumors (T) and their normal adjacent tissues (Nat) derived from prostate cancer patients. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequences. Results show upregulated expression of 101P3A11 in 8 of 10 tumor specimens.
FIG. 12B. Photomicrograph showing 101P3A11 expression in prostatic intraepithelial neoplasia (PIN) by in situ hybridization with an anti-sense 101P3A11 riboprobe.
FIG. 12C. Photomicrograph showing 101P3A11 expression in prostate cancer tissue by in situ hybridization with an anti-sense 101P3A11 riboprobe.
FIG. 12D. Photomicrograph showing 101P3A11 expression in prostate cancer by in situ hybridization with an anti-sense 101P3A11 riboprobe. Note up-regulation of expression relative to normal prostate, FIG. 12E.
FIG. 12E. Photomicrograph showing 101P3A11 expression in normal prostate by in situ hybridization with an anti-sense 101P3A11 riboprobe.
FIG. 13. Expression of 101P3A11 in colon cancer patient specimens. RNA was extracted from colon tumors (T) and their normal adjacent tissues (Nat) derived from colon cancer patients. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. Results showed expression of 101P3A11 in colon tumors but not in normal tissues. Expression was also seen in the colon cancer cell line T84. A picture of the ethidium-bromide staining of the RNA gel is also presented.
FIG. 14. Expression of 101P3A11 in kidney cancer patient specimens. RNA was extracted from kidney tumors (T) and their normal adjacent tissues (Nat) derived from kidney cancer patients. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. The results showed expression of 101P3A11 in five of six kidney tumor specimens. The expression detected in normal adjacent tissues (isolated from diseased tissues) but not in normal tissues (isolated from healthy donors) indicates that these tissues are not fully normal and that 101P3A11 is expressed in early stage tumors. A picture of the ethidium-bromide staining of the RNA gel is also presented.
FIGS. 15A-15C. Androgen regulation of 101P3A11 in tissue culture cells. LAPC-9 cells were grown in charcoal-stripped medium and stimulated with the synthetic androgen mibolerone, for either 14 or 24 hours. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequences (FIG. 15A). A picture of the ethidium-bromide staining of the RNA gel is also presented (FIG. 15C). Results showed expression of 101P3A11 was not regulated by androgen. The experimental samples were confirmed by testing for the expression of the androgen-regulated prostate cancer gene PSA (FIG. 15B). This experiment showed that, as expected, PSA levels go down in presence of charcoal-stripped serum, and expression is induced at 14 and 24 hours in presence of mibolerone.
FIG. 16. Androgen regulation of 101P3A11 in vivo. Male mice were injected with LAPC-9AD tumor cells. When tumors reached a palpable size (0.3-0.5 cm in diameter), mice were castrated and tumors harvested at different time points following the castration. RNA was isolated from the xenograft tissues. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. A picture of the ethidium-bromide staining of the RNA gel is also presented. The results showed that expression of 101P3A11 is not androgen regulated.
FIG. 17. Expression and detection of 101P3A11(159-202)-psecFc fusion protein. The 101P3A11(159-202)-psecFc vector was constructed. The recombinant expression vector DNA was transfected into either 293T cells or Cos-7 cells. Cells as well as culture supernatants (media) were harvested 24 hours later. The cells were lysed, and run on SDS-PAGE gel along with the media samples. The gel was transferred to nitrocellulose, stained with HRP-labeled anti-human IgG and developed using the ECL chemiluminescence detection kit. Results showed expression of the 101P3A11(159-202)-psecFc fusion protein in the lysates of both 293T and Cos-7 cells. The 101P3A11(159-202)-psecFc fusion protein was also secreted and detected in the culture supernatants of both cell types.
FIG. 18. Expression of 101P3A11 in 300.19 cells following retroviral-mediated gene delivery. 300.19 cells were transduced with the pSRα retroviral vector encoding the 101P3A11 gene. Following selection with neomycin, the cells were expanded and RNA was extracted. A Northern blot with 10 μg of total RNA/lane was probed with the 101P3A11 sequence. Size standards in kilobases (kb) are indicated on the side. Results showed expression of the 101P3A11 transcript driven from the retroviral LTR. LAPC-4AD and LAPC-9AD showed expression of the endogenous 101P3A11 transcript. The Figure shows results of a short exposure of the autoradiogram.
FIGS. 19A-19C. Secondary structure and transmembrane prediction for 101P3A11. FIG. 19A: The secondary structure of 101P3A11 protein (SEQ ID NO: 28) was predicted using the HNN—Hierarchical Neural Network method, accessed from the ExPasy molecular biology server. This method predicts the presence and location of alpha helices, extended strands, and random coils from the primary protein sequence. The percent of the protein in a given secondary structure is also given. FIG. 19B is a schematic representation of the probability of existence of transmembrane regions and orientation of 101P3A11 based on the TMpred algorithm of Hofmann and Stoffel which utilizes TMBASE (K. Hofmann, W. Stoffel. TMBASE—A database of membrane spanning protein segments Biol. Chem. Hoppe-Seyler 374:166, 1993). FIG. 19C is a schematic representation of the probability of the existence of transmembrane regions and the extracellular and intracellular orientation of 101P3A11 based on the TMHMM algorithm of Sonnhammer, von Heijne, and Krogh (Erik L. L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, Calif.: AAAI Press, 1998). The TMpred and TMHMM algorithms are accessed from the ExPasy molecular biology server. The results of the transmembrane prediction programs presented in FIGS. 19B and 19C depict 101P3A11 as containing 7 transmembrane domains consistent with that of a G-protein coupled receptor.
FIG. 20. Expression of 101P3A11 in NIH-3T3 Tumors. Mice were injected subcutaneously with control 3T3-neo or NIH3T3 cells expressing 101P3A11. Tumors were allowed to grow, the mice were then sacrificed and tumors harvested. RNA was isolated from LAPC-4AD and LAPC-4AI xenografts, 3T3-neo and 3T3-101P3A11 cells grown in culture were used as controls. RNA isolated from six different tumors derived from 3T3-101P3A11 cells (Tumor #1-3) were compared by Northern blotting. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequence. A picture of the ethidium-bromide staining of the RNA gel is also presented. Results showed expression of 101P3A11 in all 3T3-101P3A11 tumors as well as in 3T3/101P3A11 cells used to derive the tumors, but not in the negative control cells 3T3/neo cells.
FIG. 21. 101P3A11 Induces Tumor Formation of 3T3 Cells. Injection of 106 3T3-neo, 3T3-Ras or 3T3-101P3A11 cells (106 of the indicated cells mixed with Matrigel) subcutaneously into 6 male SCID mice (right flank) revealed that 6/6 3T3-v12Ras-injected mice formed tumors, 6/6 3T3-101P3A11-injected mice formed tumors, and 0/6 3T3-neo-injected mice formed tumors. Each data point represents the mean tumor volume (n=6) in each group.
FIG. 22. PTX reduces the in vivo growth of 3T3-101P3A11 Tumors. Pertussis toxin was found to inhibit the sub-cutaneous growth of 3T3-101P3A11 tumors in SCID mice in a dose dependent manner.
FIG. 23. Alignment of 101P3A11-PHOR-1 (Phor) (SEQ ID NO:35) with the rat GPCR RA1C (gil3420759) (SEQ ID NO:36). Identities=179/299 (59%), Positives=231/299 (76%), Gaps=1/299 (0%).
FIG. 24. Alignment of 101P3A11-PHOR-1 (Phor) (SEQ ID NO:37) with the human prostate specific GPCR. (gil13540539) (SEQ ID NO:38). Identities=179/299 (59%), Positives=233/299 (77%), Gaps=1/299 (0%).
FIG. 25. Alignment of 101P3A11-PHOR-1 (Phor) (SEQ ID NO:145) with human olfactory receptor 51I12, HOR5, (gil14423836) (SEQ ID NO:146). Identities=163/304 (53%), Positives=214/304 (69%), Gaps=1/304 (0%).
FIG. 26. 101P3A11 Modulated Tyrosine Phosphorylation in NIH-3T3 Cells. 101P3A11 mediated the de-phosphorylation of proteins at 200, 120-140, 85-90 and 55 kDa. 101P3A11 induced the phosphorylation of proteins at 80 and 29 kDa in NIH-3T3 cells.
FIG. 27. ERK Phosphorylation by PCR ligands in 101P3A11 Expressing Cells. FBS, lipophosphatidic acid, gastrin releasing peptide, leukotriene and platelet activating factor induced the phosphorylation of ERK in 101P3A11 expressing cells.
FIG. 28. Inhibition of 101P3A11-Mediated ERK Activation by PD98059. ERK phosphorylation was inhibited by a MEK specific (PD98059) but not a p38 specific (SB203580) inhibitor in PC3-101P3A11 cells.
FIG. 29. Enhanced ERK Phosphorylation in Sodium Orthovanadate Treated PC3-101P3A11 Cells. Sodium orthovanadate induced increased ERK phosphorylation in PC3-101P3A11 cells relative to PC3-neo cells.
FIG. 30. Inhibition of 101P3A11-Mediated ERK Phosphorylation by AG1517. The EGFR inhibitor, AG1517, inhibits EGF-mediated ERK phosphorylation in control and 101P3A11-expressing PC3 cells. AG1517 partially inhibits 101P3A11 mediated ERK phosphorylation in PC3 cells.
FIGS. 31A-31B. Activation of p38 in PC3-101P3A11 Cells. Expression of 101P3A11 mediates p38 phosphorylation in cells treated with 10% FBS as shown by blotting with antibodies to phospho-p38 (FIG. 31A) compared to p38 (FIG. 31B).
FIG. 32. 101P3A11 Induced Accumulation of cAMP in PC3 Cells. Expression of 101P3A11 increased the accumulation of cAMP in cells treated with 0.1% and 10% FBS. FBS-induced cAMP accumulation in 101P3A11 cells was inhibited by pertussis toxin.
FIG. 33. Pertussis Toxin Inhibits 101P3A11 Mediated ERK Phosphorylation. Pertussis toxin inhibited FBS-mediated ERK phosphorylation in 101P3A11 expressing cells.
FIG. 34. Pertussis Toxin Inhibited ERK Phosphorylation in PC3-101P3A11 Cells. Pertussis toxin inhibited FBS-mediated ERK phosphorylation in 101P3A11 expressing cells. The inhibitory activity of pertussis toxin on ERK phosphorylation was more dramatic in FBS-treated than EGF or GRP-treated PC3-101P3A11 cells
FIG. 35. Inhibition of 101P3A11-mediated signaling by Suranim, a G protein inhibitor. Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence of G protein inhibitors Surinam and NF449. Proliferation was analyzed by Alamar blue after 72 hours. Suranim and NF449 inhibited the proliferation of 101P3A11 expressing but not control cells.
FIGS. 36A-36B. 101P3A11 Mediated ERK Phosphorylation By Conditioned Media. FIG. 36A: blotting with anti-phospho ERK antibodies; FIG. 36B: blotting with anti-ERK antibodies. Supernatants from PC3, PC3-101P3A11, PrEC and LAPC42 cells induce ERK phosphorylation in PC3 101P3A11 but not PC3 cells. Supernatants from 3T3 and 293T cells had little specific effect on ERK phosphorylation.
FIG. 37. 101P3A11 Enhances the Proliferation of 3T3 Cells. Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence 0.5 or 10% FBS. Proliferation was analyzed by Alamar blue after 48 hours. Expression of 101P3A11 induced a 6 fold increase in the proliferation of 3T3 cells grown in 0.5% FBS.
FIG. 38. Inhibition of 101P3A11 Mediated ERK Phosphorylation by 101P3A11 Specific Antibodies. Expression of 101P3A11 induced ERK phosphorylation in 293T cells. Anti-101P3A11 pAb inhibited ERK Phosphorylation in 293T-101P3A11 cells.
FIG. 39. Anti-101P3A11 Ab Mediated cAMP Accumulation in PC3-101P3A11 Cells. Control PC3 cells and cells expressing 101P3A11 were treated with anti-101P3A11 pAb for 2 min and evaluated for intracellular cAMP content. The assay was performed in duplicate.
FIGS. 40A-40F. Photomicrographs showing immunohistochemical analysis using anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (FIG. 40A); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer cell line, LNCaP (FIG. 40B); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (FIG. 40C); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded normal prostate (FIG. 40D); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (FIG. 40E); and anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded normal prostate (FIG. 40F).
FIGS. 41A-41F. Photomicrographs showing immunohistochemical analysis using anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (FIG. 41A); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded bladder cancer tissues (FIG. 41B); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded kidney cancer tissues (FIG. 41C); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded colon cancer tissues (FIG. 41D); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded lung cancer tissues (FIG. 41E); and anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded breast cancer tissues (FIG. 41F).
FIG. 42 shows that 101P3A11 induces orthotopic growth of tumors. 5×105 cells were injected orthotopically into SCID mice, 7 mice per group; tumor weight was evaluated 24-25 days post cell injection.
FIG. 43 shows that 101P3A11 induces colony formation in a soft agar assay.
FIG. 44: Schematic of 101P3A11 Gene Variants
FIG. 45: Schematic of 101P3A11 Proteins Variants
FIG. 46: Exon Map
FIG. 47: Recognition of PHOR-1 protein by PHOR-1 mAbs
FIG. 48: Recognition of PHOR-1 protein in transfected 293T cells by sera from GST-PHOR-1 immunized mice.
FIG. 49: Data showing that four hybridomas reactive to MBP-PHOR-1 exhibited strong specific reactivity to PHOR-1 protein expressed in cells. This was demonstrated by Western analysis of 293T cells transfected with the epitope tagged PHOR-1 cDNA
FIG. 50: Mouse polyclonal antibodies raised to amino acids 1-23 detect PHOR-1 expressed in 293T cells
FIG. 51: Inhibition of ERK Phosphorylation by GPCR Inhibitors
FIG. 52: Inhibition of PC3 Proliferation by GPCR Inhibitors
FIG. 53: Inhibition of PC3-AGS-3 Proliferation by PTX
FIG. 54: AGS-3 Enhances Proliferation of 3T3 and PC3 Cells
FIG. 55: AGS-3 Induces in vivo Tumor Formation of 3T3 Cells
FIG. 56: Inhibition of 3T3-AGS-3 Tumor Formation by PTX
FIG. 57: AGS-3 Induces the Orthotopic Growth of 3T3 Tumors
FIG. 58: AGS-3 Enhances Orthotopic Growth of PC3 Cells
FIG. 59: Partial Inhibition of 3T3-AGS-3 Tumor Formation by Suramin
FIG. 60: AGS-3 Induces Intratibial Tumor Growth of 3T3Cells
FIG. 61: AGS-3 Enhances Intratibial Tumor Growth of PC3 Cells
FIG. 62: Inhibition of AGS-3 Mediated ERK Phosphorylation by AGS-3 Specific Antibodies
FIG. 63: AGS-3 Enhances Cell Cycle Entry of 3T3 and PC3 Cells
FIG. 64: Anti-AGS3 Staining of MDCK Cells
FIG. 65A-65B: Nucleic Acid Alignments (SEQ ID NOS:33-34; 35-36; 37-38)
FIG. 66. Expression and detection of 101P3A11.GFP fusion protein. The pcDNA3.1/101P3A11.GFP vector was constructed. 293T cells were transfected with either the pcDNA3.1/101P3A11.GFP recombinant expression vector (A), pcDNA3.1/GFP vector (B) or control pcDNA3.1 vector (C). Cells were harvested 24 hours later and analyzed by microscopy for detection of green fluorescence. Results show expression of the 101P3A11.GFP fusion protein is localized mostly at the cell membrane, whereas expression of the free GFP is throughout the cells. The control vector did not show any fluorescence. We conclude that the 101P3A11.GFP fusion protein is expressed from the pcDNA3.1/101P3A11.GFP construct, and that the fusion protein is localized at the cell membrane.
FIGS. 67A-67B. The cDNA and amino acid sequence of the open reading frames of codon optimized s101P3A11 v.1 (A) (SEQ ID NOS:27 and 19) and s101P3A11 v.3 (B) (SEQ ID NOS:31-32).
FIG. 68. Expression and detection of codon optimized s101P3A11.GFP fusion protein. The pcDNA3.1/s101P3A11.GFP vector for codon optimized 101P3A11 was constructed. 293T cells were transfected with either pcDNA3.1 vector control (light line), or one of the three different pcDNA3.1/s101P3A11.GFP vector clones, 1G2, 2G3, or 3H5 (dark line). Cells were harvested 24 hours later and either analyzed directly for green fluorescence (A), or stained viably using polyclonal anti-101P3A11 antibody (B) and analyzed by flow cytometry. Results show strong expression of the codon optimized PHOR-1.GFP fusion protein at the cell surface.
FIG. 69A-69E. The nucleotide sequence alignment of 101P3A11 v1 (SEQ ID NO:27) and 101P3A11 v2 (SEQ ID NO:29).
FIG. 70. The peptide sequences of protein coded by 101P3A11 v2 (SEQ ID NO:30)
FIG. 71. The amino acid sequence alignment of 101P3A11 v1 (SEQ ID NO:19) and 101P3A11 v2 (SEQ ID NO:30).



DETAILED DESCRIPTION OF THE INVENTION
Outline of Sections
I.) Definitions
II.) 101P3A11 Polynucleotides
II.A.) Uses of 101P3A11 Polynucleotides
II.A.1.) Monitoring of Genetic Abnormalities
II.A.2.) Antisense Embodiments
II.A.3.) Primers and Primer Pairs
II.A.4.) Isolation of 101P3A11-Encoding Nucleic Acid Molecules
II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems
III.) 101P3A11-related Proteins

    
    
        III.A.) Motif-bearing Protein Embodiments
        III.B.) Expression of 101P3A11-related Proteins
        III.C.) Modifications of 101P3A11-related Proteins
        III.D.) Uses of 101P3A11-related Proteins
    
    


IV.) 101P3A11 Antibodies
V.) 101P3A11 Cellular Immune Responses
VI.) 101P3A11 Transgenic Animals
VII.) Methods for the Detection of 101P3A11
VIII.) Methods for Monitoring the Status of 101P3A11-related Genes and Their Products
IX.) Identification of Molecules That Interact With 101P3A11
X.) Therapeutic Methods and Compositions

    
    
        X.A.) Anti-Cancer Vaccines
        X.B.) 101P3A11 as a Target for Antibody-Based Therapy
        X.C.) 101P3A11 as a Target for Cellular Immune Responses
        
            X.C.1. Minigene Vaccines
            X.C.2. Combinations of CTL Peptides with Helper Peptides
            X.C.3. Combinations of CTL Peptides with T Cell Priming Agents
            X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides
        
        
        X.D.) Adoptive Immunotherapy
        X.E.) Administration of Vaccines for Therapeutic or Prophylactic Purposes
    
    


XI.) Diagnostic and Prognostic Embodiments of 101P3A11.
XII.) Inhibition of 101P3A11 Protein Function

    
    
        XII.A.) Inhibition of 101P3A11 With Intracellular Antibodies
        XII.B.) Inhibition of 101P3A11 with Recombinant Proteins
        XII.C.) Inhibition of 101P3A11 Transcription or Translation
    
    


XII.D.) General Considerations for Therapeutic Strategies
XIII.) KITS/Articles of Manufacture
XIV.) Evaluation of GPCRs and Modulators Thereof
XV.) Screening of Candidate Compounds
XVI.) GPCR Fusion Proteins
I.) DEFINITIONS
Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.
The terms “advanced prostate cancer”, “locally advanced prostate cancer”, “advanced disease” and “locally advanced disease” mean prostate cancers that have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1-C2 disease under the Whitmore-Jewett system, and stage T3-T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, and these patients have substantially less favorable outcomes compared to patients having clinically localized (organ-confined) prostate cancer. Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or induration above the prostate base. Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.
“Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence 101P3A11 (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence 101P3A11. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
The term “analog” refers to a molecule which is structurally similar or shares similar or corresponding attributes with another molecule (e.g. a 101P3A11-related protein). For example an analog of a 101P3A11 protein can be specifically bound by an antibody or T cell that specifically binds to 101P3A11.
The term “antibody” is used in the broadest sense. Therefore an “antibody” can be naturally occurring or man-made such as monoclonal antibodies produced by conventional hybridoma technology. Anti-101P3A11 antibodies comprise monoclonal and polyclonal antibodies as well as fragments containing the antigen-binding domain and/or one or more complementarity determining regions of these antibodies.
An “antibody fragment” is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. In one embodiment it specifically covers single anti-101P3A11 antibodies and clones thereof (including agonist, antagonist and neutralizing antibodies) and anti-101P3A11 antibody compositions with polyepitopic specificity.
The term “codon optimized sequences” refers to nucleotide sequences that have been optimized for a particular host species by replacing any codons having a usage frequency of less than about 20%. Nucleotide sequences that have been optimized for expression in a given host species by elimination of spurious polyadenylation sequences, elimination of exon/intron splicing signals, elimination of transposon-like repeats and/or optimization of GC content in addition to codon optimization are referred to herein as an “expression enhanced sequences.”
The term “cytotoxic agent” refers to a substance that inhibits or prevents the expression activity of cells, function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Examples of cytotoxic agents include, but are not limited to maytansinoids, yttrium, bismuth, ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, restrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32 and radioactive isotopes of Lu. Antibodies may also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting the pro-drug to its active form.
The term “homolog” refers to a molecule which exhibits homology to another molecule, by for example, having sequences of chemical residues that are the same or similar at corresponding positions.
“Human Leukocyte Antigen” or “HLA” is a human class I or class II Major Histocompatibility Complex (MHC) protein (see, e.g., Stites, et al., IMMUNOLOGY, 8TH ED., Lange Publishing, Los Altos, Calif. (1994).
The terms “hybridize”, “hybridizing”, “hybridizes” and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6×SSC/0.1% SDS/100 μg/ml ssDNA, in which temperatures for hybridization are above 37 degrees C. and temperatures for washing in 0.1×SSC/0.1% SDS are above 55 degrees C.
The phrases “isolated” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their in situ environment. For example, a polynucleotide is said to be “isolated” when it is substantially separated from contaminant polynucleotides that correspond or are complementary to genes other than the 101P3A11 genes or that encode polypeptides other than 101P3A11 gene product or fragments thereof. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated 101P3A11 polynucleotide. A protein is said to be “isolated,” for example, when physical, mechanical or chemical methods are employed to remove the 101P3A11 proteins from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated 101P3A11 protein. Alternatively, an isolated protein can be prepared by chemical means.
The term “mammal” refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.
The terms “metastatic prostate cancer” and “metastatic disease” mean prostate cancers that have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage T×N×M+ under the TNM system. As is the case with locally advanced prostate cancer, surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is a preferred treatment modality. Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation. Approximately half of these androgen-refractory patients die within 6 months after developing that status. The most common site for prostate cancer metastasis is bone. Prostate cancer bone metastases are often osteoblastic rather than osteolytic (i.e., resulting in net bone formation). Bone metastases are found most frequently in the spine, followed by the femur, pelvis, rib cage, skull and humerus. Other common sites for metastasis include lymph nodes, lung, liver and brain. Metastatic prostate cancer is typically diagnosed by open or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy.
The term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the antibodies comprising the population are identical except for possible naturally occurring mutations that are present in minor amounts.
A “motif”, as in biological motif of a 101P3A11-related protein, refers to any pattern of amino acids forming part of the primary sequence of a protein, that is associated with a particular function (e.g. protein-protein interaction, protein-DNA interaction, etc) or modification (e.g. that is phosphorylated, glycosylated or amidated), or localization (e.g. secretory sequence, nuclear localization sequence, etc.) or a sequence that is correlated with being immunogenic, either humorally or cellularly. A motif can be either contiguous or capable of being aligned to certain positions that are generally correlated with a certain function or property. In the context of HLA motifs, “motif” refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs for HLA binding are typically different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues.
A “pharmaceutical excipient” comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like.
“Pharmaceutically acceptable” refers to a non-toxic, inert, and/or composition that is physiologically compatible with humans or other mammals.
The term “polynucleotide” means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA and/or RNA. In the art, this term if often used interchangeably with “oligonucleotide”. A polynucleotide can comprise a nucleotide sequence disclosed herein wherein thymidine (T), as shown for example in FIG. 2, can also be uracil (U); this definition pertains to the differences between the chemical structures of DNA and RNA, in particular the observation that one of the four major bases in RNA is uracil (U) instead of thymidine (T).
The term “polypeptide” means a polymer of at least about 4, 5, 6, 7, or 8 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. In the art, this term is often used interchangeably with “peptide” or “protein”.
An HLA “primary anchor residue” is an amino acid at a specific position along a peptide sequence which is understood to provide a contact point between the immunogenic peptide and the HLA molecule. One to three, usually two, primary anchor residues within a peptide of defined length generally defines a “motif” for an immunogenic peptide. These residues are understood to fit in close contact with peptide binding groove of an HLA molecule, with their side chains buried in specific pockets of the binding groove. In one embodiment, for example, the primary anchor residues for an HLA class I molecule are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 8, 9, 10, 11, or 12 residue peptide epitope in accordance with the invention. In another embodiment, for example, the primary anchor residues of a peptide that will bind an HLA class II molecule are spaced relative to each other, rather than to the termini of a peptide, where the peptide is generally of at least 9 amino acids in length. The primary anchor positions for each motif and supermotif are set forth in Table IV. For example, analog peptides can be created by altering the presence or absence of particular residues in the primary and/or secondary anchor positions shown in Table IV. Such analogs are used to modulate the binding affinity and/or population coverage of a peptide comprising a particular HLA motif or supermotif.
A “recombinant” DNA or RNA molecule is a DNA or RNA molecule that has been subjected to molecular manipulation in vitro.
Non-limiting examples of small molecules include compounds that bind or interact with 101P3A11, ligands including hormones, neuropeptides, chemokines, odorants, phospholipids, and functional equivalents thereof that bind and preferably inhibit 101P3A11 protein function. Such non-limiting small molecules preferably have a molecular weight of less than about 10 kDa, more preferably below about 9, about 8, about 7, about 6, about 5 or about 4 kDa. In certain embodiments, small molecules physically associate with, or bind, 101P3A11 protein; are not found in naturally occurring metabolic pathways; and/or are more soluble in aqueous than non-aqueous solutions
“Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured nucleic acid sequences to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
“Stringent conditions” or “high stringency conditions”, as defined herein, are identified by, but not limited to, those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium. citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C. “Moderately stringent conditions” are described by, but not limited to, those in Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37° C. in a solution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1×SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
An HLA “supermotif” is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles.
As used herein “to treat” or “therapeutic” and grammatically related terms, refer to any improvement of any consequence of disease, such as prolonged survival, less morbidity, and/or a lessening of side effects which are the byproducts of an alternative therapeutic modality; full eradication of disease is not required.
A “transgenic animal” (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A “transgene” is a DNA that is integrated into the genome of a cell from which a transgenic animal develops.
As used herein, an HLA or cellular immune response “vaccine” is a composition that contains or encodes one or more peptides of the invention. There are numerous embodiments of such vaccines, such as a cocktail of one or more individual peptides; one or more peptides of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such individual peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The “one or more peptides” can include any whole unit integer from 1-150 or more, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I peptides of the invention can be admixed with, or linked to, HLA class II peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. HLA vaccines can also comprise peptide-pulsed antigen presenting cells, e.g., dendritic cells.
The term “variant” refers to a molecule that exhibits a variation from a described type or norm, such as a protein that has one or more different amino acid residues in the corresponding position(s) of a specifically described protein (e.g. the 101P3A11 protein shown in FIG. 2 or FIG. 3. An analog is an example of a variant protein. Splice isoforms and single nucleotides polymorphisms (SNPs) are further examples of variants.
The “101P3A11-related proteins” of the invention include those specifically identified herein, as well as allelic variants, conservative substitution variants, analogs and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined herein or readily available in the art. Fusion proteins that combine parts of different 101P3A11 proteins or fragments thereof, as well as fusion proteins of a 101P3A11 protein and a heterologous polypeptide are also included. Such 101P3A11 proteins are collectively referred to as the 101P3A11-related proteins, the proteins of the invention, or 101P3A11. The term “101P3A11-related protein” refers to a polypeptide fragment or a 101P3A11 protein sequence of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 317 or 318 or more amino acids.
“Active ingredient” in the context of a “Pharmaceutical Composition” shall mean a component of a Pharmaceutical Composition that provides the primary pharmaceutical benefit, as opposed to an “inactive ingredient” which would generally be recognized as providing no pharmaceutical benefit.
“Agonists” shall mean moieties that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes. In the context of the disclosed invention, a Pharmaceutical Candidate comprising a 101P3A11 Agonist can be utilized for affecting metabolism. “Partial agonists” shall mean moieties that activate the intracellular response when they bind to the receptor to a lesser degree/extent than do agonists, or enhance GTP binding to membranes to a lesser degree/extent than do agonists.
“Antagonist” shall mean moieties that competitively bind to the receptor at the same site as the agonists but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
“Candidate compound,” in the context of the disclosed invention, shall mean a small molecule that is amenable to a screening technique.
“Composition” shall having a meaning in accordance with standard use. For example, a composition can mean a material comprising at least two compounds, components or substituents; for example, and not limitation, a Pharmaceutical Composition comprising at least one Active Ingredient and at least one other component.
“Compound efficacy” shall mean a measurement of the ability of a compound to inhibit or stimulate receptor functionality, as opposed to receptor binding affinity.
“Constitutive receptor activation” shall mean stabilization of a receptor in the active state by means other than binding of the receptor with its endogenous ligand or a chemical equivalent thereof.
“Contact” or “contacting” shall mean bringing at least two moieties together, whether in an in vitro system or an in vivo system.
“Endogenous” shall mean a material that a mammal naturally produces. Endogenous in reference to, for example and not limitation, the term “receptor” shall mean that which is naturally produced by a mammal (for example, and not limitation, a human), yeast, bacterium or a virus. In contrast, the term “non-endogenous” in this context shall mean that which is not naturally produced by a mammal (for example, and not limitation, a human) yeast, bacterium or a virus. For example, and not limitation, a receptor which is not constitutively active in its endogenous form, but when manipulated becomes constitutively active, is most preferably referred to herein as a “non-endogenous, constitutively activated receptor.” Both terms can be utilized to describe both “in vivo” and “in vitro” systems. For example, and not a limitation, in a screening approach, the endogenous or non-endogenous receptor may be in reference to an in vitro screening system. As a further example and not limitation, where the genome of a mammal has been manipulated to include a non-endogenous constitutively activated receptor, screening of a candidate compound by means of an in vivo system is viable.
“G protein coupled receptor fusion protein” and “GPCR fusion protein,” in the context of the invention disclosed herein, each mean a non-endogenous protein comprising an endogenous, constitutively activated orphan GPCR fused to at least one G protein, most preferably, the alpha (a) subunit of such G protein (this being the subunit that binds GTP), with the G protein preferably being of the same type as the G protein that naturally couples with endogenous orphan GPCR. For example, and not limitation, in an endogenous state, the G protein “Gsa” is the predominate G protein that couples with 101P3A11 such that a GPCR Fusion Protein based upon 101P3A11 would be a non-endogenous protein comprising 101P3A 11 fused to Gscc. The G protein can be fused directly to the c-terminus of the endogenous, constitutively active orphan GPCR or there may be spacers between the two.
“Inhibit” or “inhibiting”, in relationship to the term “response” shall mean that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.
“Inverse agonists” shall mean moieties that bind the endogenous form of the receptor, and which inhibit the baseline intracellular response initiated by the active endogenous form of the receptor below the normal base level of activity that is observed in the absence of the endogenous ligand, agonists or partial agonists, or decrease GTP binding to membranes. Preferably, the baseline intracellular response is decreased in the presence of the inverse agonist by at least 30%, more preferably by at least 50%, and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist. Biologically, “101P3A11 inverse agonist” shall mean moieties that can be assessed in vivo by factors other than just determination that the moiety has interacted with 101P3A11.
“Ligand” shall mean an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor.
“Pharmaceutical composition” shall mean a composition comprising at one Active Ingredient and at least one ingredient that is not an Active Ingredient (for example and not limitation, a filler, dye, or a mechanism for slow release), whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal or in cells thereof such as in vitro (e.g., without limitation, the mammal is a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.
“Small molecule”, in the context of the invention disclosed herein, is a non-protein based moiety; for example, and not limitation, NF449 is a small molecule within the context of this invention. In a preferred embodiment, the endogenous ligand for a receptor is not a “small molecule.”
II.) 101P3A11 POLYNUCLEOTIDES
One aspect of the invention provides polynucleotides corresponding or complementary to all or part of a 101P3A11 gene, mRNA, and/or coding sequence, preferably in isolated form, including polynucleotides encoding a 101P3A11-related protein and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to a 101P3A11 gene or mRNA sequence or a part thereof, and polynucleotides or oligonucleotides that hybridize to a 101P3A11 gene, mRNA, or to a 101P3A11 encoding polynucleotide (collectively, “101P3A11 polynucleotides”). In all instances when referred to in this section, T can also be U in FIG. 2.
Embodiments of a 101P3A11 polynucleotide include: a 101P3A11 polynucleotide having the sequence shown in FIG. 2, the nucleotide sequence of 101P3A11 as shown in FIG. 2 wherein T is U; at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in FIG. 2; or, at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in FIG. 2 where T is U. For example, embodiments of 101P3A11 nucleotides comprise, without limitation:
(I) a polynucleotide comprising, consisting essentially of, or consisting of a sequence as shown in FIG. 2, wherein T can also be U;
(II) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2A, from nucleotide residue number 130 through nucleotide residue number 1086, optionally including the last, stop codon, wherein T can also be U;
(III) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2A, from nucleotide residue number 133 through nucleotide residue number 1086, optionally including the last, stop codon, wherein T can also be U;
(IV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2B, from nucleotide residue number 130 through nucleotide residue number 348, optionally including the last, stop codon, wherein T can also be U;
(V) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2B, from nucleotide residue number 133 through nucleotide residue number 348, optionally including the stop codon, wherein T can also be U;
(VI) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2C, from nucleotide residue number 130 through nucleotide residue number 1086, optionally including the last, stop codon, wherein T can also be U;
(VII) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in FIG. 2C, from nucleotide residue number 133 through nucleotide residue number 1086, optionally including the last, stop codon, wherein T can also be U;
(VIII) a polynucleotide that encodes a 101P3A11-related protein that is at least 90% homologous to an entire amino acid sequence shown in FIGS. 2A-C;
(IX) a polynucleotide that encodes a 101P3A11-related protein that is at least 90% identical to an entire amino acid sequence shown in FIGS. 2A-C;
(X) a polynucleotide that encodes at least one peptide set forth in Tables V-XVIII and XXII to IL, optionally with a proviso that the polynucleotide is not a contiguous sequence from a nucleic acid sequence of FIG. 2;
(XI) a polynucleotide that encodes at least two peptides selected from the peptides set forth in Tables V-XVIII and XXII to IL, optionally with a proviso that the polynucleotide is not a contiguous sequence from a nucleic acid sequence of FIG. 2;
(XII) a polynucleotide that encodes at least two peptides selected from the peptides set forth in Tables V-XVIII and XXII to IL, optionally with a proviso that the polynucleotide is not a contiguous sequence from a nucleic acid sequence of FIG. 2;
(XIII) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;
(XIV) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6;
(XV) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;
(XVI) a polynucleotide that encodes a peptide region of at least 5 amino-acids of a peptide of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;
(XVII) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9;
(XVIII) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3B in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;
(XIX) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3B in any whole number increment up to 317 or 318 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6;
(XX) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3B in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;
(XXI) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3B in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;
(XXII) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of FIG. 3B in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9;
(XXIII) a polynucleotide that encodes monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(1)4 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4351 on 15 May 2002;
(XXIV) a polynucleotide that encodes monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(1)10 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4352 on 15 May 2002;
(XXV) a polynucleotide that encodes monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(1)23 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4353 on 15 May 2002;
(XXVI) a polynucleotide that encodes monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(4)7 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4354 on 15 May 2002;
(XXVII) a polynucleotide that is fully complementary to a polynucleotide of any one of (I)-(XXVI); and,
(XXVIII) a peptide that is encoded by any of (I)-(XXVI);
(XXIX) a peptide that occurs at least twice in Tables V-XVIII and XXII to IL collectively, or an oligonucleotide that encodes such HLA peptide;
(XXX) a peptide that occurs at least once in Tables V-XVIII and at least once in tables XXII to IL, or an oligonucleotide that encodes such HLA peptide;
(XXXI) a peptide which comprises peptide regions, or an oligonucleotide encoding the peptide, that has one two, three, four, or five of the following characteristics:

    
    
        i) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Hydrophilicity profile of FIG. 5;
        ii) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equal to 0.0, in the Hydropathicity profile of FIG. 6;
        iii) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Percent Accessible Residues profile of FIG. 7;
        iv) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Average Flexibility profile of FIG. 8;
        v) a peptide region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Beta-turn profile of FIG. 9;
    
    


(XXXII) a polynucleotide of any of (I)-(XXVII) or peptide of (XXVIII)-(XXXI) together with a pharmaceutical excipient and/or in a human unit dose form.
As used herein, a range is understood to specifically disclose all whole unit positions thereof.
Typical embodiments of the invention disclosed herein include 101P3A11 polynucleotides that encode specific portions of 101P3A11 mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:
(a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 375, 300 or 317 or 318 contiguous amino acids of 101P3A11.
For example, representative embodiments of the invention disclosed herein include: polynucleotides and their encoded peptides themselves encoding about amino acid 1 to about amino acid 10 of the 101P3A11 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 10 to about amino acid 20 of the 101P3A11 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 20 to about amino acid 30 of the 101P3A11 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 30 to about amino acid 40 of the 101P3A11 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 40 to about amino acid 50 of the 101P3A11 protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about amino acid 50 to about amino acid 60 of the 101P3A11 protein shown in FIG. 2 or FIG. 3, or polynucleotides encoding about amino acid 60 to about amino acid 70 or amino acid 317 or 318 of the 101P3A11 protein shown in FIG. 2 or FIG. 3. Accordingly polynucleotides encoding portions of the amino acid sequence (of about 10 amino acids), of amino acids 1 through the carboxyl terminal amino acid of the 101P3A11 protein are embodiments of the invention. Wherein it is understood that each particular amino acid position discloses that position plus or minus five amino acid residues.
Polynucleotides encoding relatively long portions of a 101P3A11 protein are also within the scope of the invention. For example, polynucleotides encoding from about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 30, or 40 or 50 etc.) of the 101P3A11 protein “or variant” shown in FIG. 2 or FIG. 3 can be generated by a variety of techniques well known in the art. These polynucleotide fragments can include any portion of the 101P3A11 sequence as shown in FIG. 2.
Additional illustrative embodiments of the invention disclosed herein include 101P3A11 polynucleotide fragments encoding one or more of the biological motifs contained within a 101P3A11 protein “or variant” sequence, including one or more of the motif-bearing subsequences of a 101P3A11 protein “or variant” set forth in Tables V-XVIII and XXII to IL. In another embodiment, typical polynucleotide fragments of the invention encode one or more of the regions of 101P3A11 protein or variant that exhibit homology to a known molecule. In another embodiment of the invention, typical polynucleotide fragments can encode one or more of the 101P3A11 protein or variant N-glycosylation sites, cAMP and cGMP-dependent protein kinase phosphorylation sites, casein kinase II phosphorylation sites or N-myristoylation site and amidation sites.
Note that to determine the starting position of any peptide set forth in Tables V-XVIII and Tables XXII to IL (collectively HLA Peptide Tables) respective to its parental protein, e.g., variant 1, variant 2, etc., reference is made to three factors: the particular variant, the length of the peptide in an HLA Peptide Table, and the Search Peptides listed in Table LVII. Generally, a unique Search Peptide is used to obtain HLA peptides for a particular variant. The position of each Search Peptide relative to its respective parent molecule is listed in Table LLII. Accordingly if a Search Peptide begins at position “X”, one must add the value “X minus 1” to each position in Tables V-XVIII and Tables XXII-IL to obtain the actual position of the HLA peptides in their parental molecule. For example if a particular Search Peptide begins at position 150 of its parental molecule, one must add 150−1, i.e., 149 to each HLA peptide amino acid position to calculate the position of that amino acid in the parent molecule.
II.A.) Uses of 101P3A11 Polynucleotides
II.A.1.) Monitoring of Genetic Abnormalities
The polynucleotides of the preceding paragraphs have a number of different specific uses. The human 101P3A11 gene maps to the chromosomal location set forth in the Example entitled “Chromosomal Mapping of 101P3A11.” For example, because the 101P3A11 gene maps to this chromosome, polynucleotides that encode different regions of the 101P3A11 proteins are used to characterize cytogenetic abnormalities of this chromosomal locale, such as abnormalities that are identified as being associated with various cancers. In certain genes, a variety of chromosomal abnormalities including rearrangements have been identified as frequent cytogenetic abnormalities in a number of different cancers (see e.g. Krajinovic et al., Mutat. Res. 382(3-4): 81-83 (1998); Johansson et al., Blood 86(10): 3905-3914 (1995) and Finger et al., P.N.A.S. 85(23): 9158-9162 (1988)). Thus, polynucleotides encoding specific regions of the 101P3A11 proteins provide new tools that can be used to delineate, with greater precision than previously possible, cytogenetic abnormalities in the chromosomal region that encodes 101P3A11 that may contribute to the malignant phenotype. In this context, these polynucleotides satisfy a need in the art for expanding the sensitivity of chromosomal screening in order to identify more subtle and less common chromosomal abnormalities (see e.g. Evans et al., Am. J. Obstet. Gynecol 171(4): 1055-1057 (1994)).
Furthermore, as 101P3A11 was shown to be highly expressed in bladder and other cancers, 101P3A11 polynucleotides are used in methods assessing the status of 101P3A11 gene products in normal versus cancerous tissues. Typically, polynucleotides that encode specific regions of the 101P3A11 proteins are used to assess the presence of perturbations (such as deletions, insertions, point mutations, or alterations resulting in a loss of an antigen etc.) in specific regions of the 101P3A11 gene, such as regions containing one or more motifs. Exemplary assays include both RT-PCR assays as well as single-strand conformation polymorphism (SSCP) analysis (see, e.g., Marrogi et al, J. Cutan. Pathol. 26(8): 369-378 (1999), both of which utilize polynucleotides encoding specific regions of a protein to examine these regions within the protein.
II.A.2.) Antisense Embodiments
Other specifically contemplated nucleic acid related embodiments of the invention disclosed herein are genomic DNA, cDNAs, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone, or including alternative bases, whether derived from natural sources or synthesized, and include molecules capable of inhibiting the RNA or protein expression of 101P3A11. For example, antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the 101P3A11 polynucleotides and polynucleotide sequences disclosed herein.
Antisense technology entails the administration of exogenous oligonucleotides that bind to a target polynucleotide located within the cells. The term “antisense” refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., 101P3A11. See for example, Jack Cohen, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988). The 101P3A11 antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, supra), which exhibit enhanced cancer cell growth inhibitory action. S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention can be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide, which is a sulfur transfer reagent. See, e.g., Iyer, R. P. et al., J. Org. Chem. 55:4693-4698 (1990); and Iyer, R. P. et al., J. Am. Chem. Soc 112: 1253-1254 (1990). Additional 101P3A11 antisense oligonucleotides of the present invention include morpholino antisense oligonucleotides known in the art (see, e.g., Partridge et al., 1996, Antisense & Nucleic Acid Drug Development 6: 169-175).
The 101P3A11 antisense oligonucleotides of the present invention typically can be RNA or DNA that is complementary to and stably hybridizes with the first 100 5′ codons or last 100 3′ codons of a 101P3A11 genomic sequence or the corresponding mRNA. Absolute complementarity is not required, although high degrees of complementarity are preferred. Use of an oligonucleotide complementary to this region allows for the selective hybridization to 101P3A11 mRNA and not to mRNA specifying other regulatory subunits of protein kinase. In one embodiment, 101P3A11 antisense oligonucleotides of the present invention are 15 to 30-mer fragments of the antisense DNA molecule that have a sequence that hybridizes to 101P3A11 mRNA. Optionally, 101P3A11 antisense oligonucleotide is a 30-mer oligonucleotide that is complementary to a region in the first 10 5′ codons or last 10 3′ codons of 101P3A11. Alternatively, the antisense molecules are modified to employ ribozymes in the inhibition of 101P3A11 expression, see, e.g., L. A. Couture & D. T. Stinchcomb; Trends Genet. 12: 510-515 (1996).
II.A.3.) Primers and Primer Pairs
Further specific embodiments of this nucleotides of the invention include primers and primer pairs, which allow the specific amplification of polynucleotides of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. Probes can be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme. Such probes and primers are used to detect the presence of a 101P3A11 polynucleotide in a sample and as a means for detecting a cell expressing a 101P3A11 protein.
Examples of such probes include polypeptides comprising all or part of the human 101P3A11 cDNA sequence shown in FIG. 2. Examples of primer pairs capable of specifically amplifying 101P3A11 mRNAs are also described in the Examples. As will be understood by the skilled artisan, a great many different primers and probes can be prepared based on the sequences provided herein and used effectively to amplify and/or detect a 101P3A11 mRNA.
The 101P3A11 polynucleotides of the invention are useful for a variety of purposes, including but not limited to their use as probes and primers for the amplification and/or detection of the 101P3A11 gene(s), mRNA(s), or fragments thereof; as reagents for the diagnosis and/or prognosis of prostate cancer and other cancers; as coding sequences capable of directing the expression of 101P3A11 polypeptides; as tools for modulating or inhibiting the expression of the 101P3A11 gene(s) and/or translation of the 101P3A11 transcript(s); and as therapeutic agents.
The present invention includes the use of any probe as described herein to identify and isolate a 101P3A11 or 101P3A11 related nucleic acid sequence from a naturally occurring source, such as humans or other mammals, as well as the isolated nucleic acid sequence per se, which would comprise all or most of the sequences found in the probe used.
II.A.4.) Isolation of 101P3A11-Encoding Nucleic Acid Molecules
The 101P3A11 cDNA sequences described herein enable the isolation of other polynucleotides encoding 101P3A11 gene product(s), as well as the isolation of polynucleotides encoding 101P3A11 gene product homologs, alternatively spliced isoforms, allelic variants, and mutant forms of a 101P3A11 gene product as well as polynucleotides that encode analogs of 101P3A11-related proteins. Various molecular cloning methods that can be employed to isolate full length cDNAs encoding a 101P3A11 gene are well known (see, for example, Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2d edition, Cold Spring Harbor Press, New York, 1989; Current Protocols in Molecular Biology. Ausubel et al., Eds., Wiley and Sons, 1995). For example, lambda phage cloning methodologies can be conveniently employed, using commercially available cloning systems (e.g., Lambda ZAP Express, Stratagene). Phage clones containing 101P3A11 gene cDNAs can be identified by probing with a labeled 101P3A11 cDNA or a fragment thereof. For example, in one embodiment, a 101P3A11 cDNA (e.g., FIG. 2) or a portion thereof can be synthesized and used as a probe to retrieve overlapping and full-length cDNAs corresponding to a 101P3A11 gene. A 101P3A11 gene itself can be isolated by screening genomic DNA libraries, bacterial artificial chromosome libraries (BACs), yeast artificial chromosome libraries (YACs), and the like, with 101P3A11 DNA probes or primers.
II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems
The invention also provides recombinant DNA or RNA molecules containing a 101P3A11 polynucleotide, a fragment, analog or homologue thereof, including but not limited to phages, plasmids, phagemids, cosmids, YACs, BACs, as well as various viral and non-viral vectors well known in the art, and cells transformed or transfected with such recombinant DNA or RNA molecules. Methods for generating such molecules are well known (see, for example, Sambrook et al., 1989, supra).
The invention further provides a host-vector system comprising a recombinant DNA molecule containing a 101P3A11 polynucleotide, fragment, analog or homologue thereof within a suitable prokaryotic or eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 or HighFive cell). Examples of suitable mammalian cells include various prostate cancer cell lines such as DU145 and TsuPr1, other transfectable or transducible prostate cancer cell lines, primary cells (PrEC), as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells). More particularly, a polynucleotide comprising the coding sequence of 101P3A11 or a fragment, analog or homolog thereof can be used to generate 101P3A11 proteins or fragments thereof using any number of host-vector systems routinely used and widely known in the art.
A wide range of host-vector systems suitable for the expression of 101P3A11 proteins or fragments thereof are available, see for example, Sambrook et al., 1989, supra; Current Protocols in Molecular Biology, 1995, supra). Preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSRαtkneo (Muller et al., 1991, MCB 11: 1785). Using these expression vectors, 101P3A11 can be expressed in several prostate cancer and non-prostate cell lines, including for example 293, 293T, rat-1, NIH 3T3 and TsuPr1. The host-vector systems of the invention are useful for the production of a 101P3A11 protein or fragment thereof. Such host-vector systems can be employed to study the functional properties of 101P3A11 and 101P3A11 mutations or analogs.
Recombinant human 101P3A11 protein or an analog or homolog or fragment thereof can be produced by mammalian cells transfected with a construct encoding a 101P3A11-related nucleotide. For example, 293T cells can be transfected with an expression plasmid encoding 101P3A11 or fragment, analog or homolog thereof, a 101P3A11-related protein is expressed in the 293T cells, and the recombinant 101P3A11 protein is isolated using standard purification methods (e.g., affinity purification using anti-101P3A11 antibodies). In another embodiment, a 101P3A11 coding sequence is subcloned into the retroviral vector pSRαMSVtkneo and used to infect various mammalian cell lines, such as NIH 3T3, TsuPr1, 293 and rat-1 in order to establish 101P3A11 expressing cell lines. Various other expression systems well known in the art can also be employed. Expression constructs encoding a leader peptide joined in frame to a 101P3A11 coding sequence can be used for the generation of a secreted form of recombinant 101P3A11 protein.
As discussed herein, redundancy in the genetic code permits variation in 101P3A11 gene sequences. In particular, it is known in the art that specific host species often have specific codon preferences, and thus one can adapt the disclosed sequence as preferred for a desired host. For example, preferred analog codon sequences typically have rare codons (i.e., codons having a usage frequency of less than about 20% in known sequences of the desired host) replaced with higher frequency codons. Codon preferences for a specific species are calculated, for example, by utilizing codon usage tables available on the INTERNET.
Additional sequence modifications are known to enhance protein expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon/intron splice site signals, transposon-like repeats, and/or other such well-characterized sequences that are deleterious to gene expression. The GC content of the sequence is adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. Where possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. Other useful modifications include the addition of a translational initiation consensus sequence at the start of the open reading frame, as described in Kozak, Mol. Cell. Biol., 9:5073-5080 (1989). Skilled artisans understand that the general rule that eukaryotic ribosomes initiate translation exclusively at the 5′ proximal AUG codon is abrogated only under rare conditions (see, e.g., Kozak PNAS 92(7): 2662-2666, (1995) and Kozak NAR 15(20): 8125-8148 (1987)).
III.) 101P3A11-RELATED PROTEINS
Another aspect of the present invention provides 101P3A11-related proteins. Specific embodiments of 101P3A11 proteins comprise a polypeptide having all or part of the amino acid sequence of human 101P3A11 as shown in FIG. 2 or FIG. 3. Alternatively, embodiments of 101P3A11 proteins comprise variant, homolog or analog polypeptides that have alterations in the amino acid sequence of 101P3A11 shown in FIG. 2 or FIG. 3.
Embodiments of a 101P3A11 polynucleotide include: a 101P3A11 polynucleotide having the sequence shown in FIG. 2, the nucleotide sequence of 101P3A11 as shown in FIG. 2 wherein T is U; at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in FIG. 2; or, at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in FIG. 2 where T is U. For example, embodiments of 101P3A11 nucleotides comprise, without limitation:
(I) a protein comprising, consisting essentially of, or consisting of a sequence as shown in FIG. 2;
(II) a 101P3A11-related protein that is at least 90% homologous to an entire amino acid sequence shown in FIGS. 2A-C;
(III) a 101P3A11-related protein that is at least 90% identical to an entire amino acid sequence shown in FIGS. 2A-C;
(IV) a protein that comprises at least one peptide set forth in Tables V-XVIII or Tables XXII to IL, optionally with a proviso that it is not an entire protein of FIG. 2;
(V) a protein that comprises at least one peptide set forth in Tables V-XVIII, collectively, which peptide is also set forth in Tables XXII to IL, collectively, optionally with a proviso that it is not an entire protein of FIG. 2;
(VI) a protein that comprises at least two peptides selected from the peptides set forth in Tables V-XVIII and XXII to IL, optionally with a proviso that it is not an entire protein of FIG. 2;
(VII) a protein that comprises at least two peptides selected from the peptides set forth in Tables V-XVIII and XXII to IL, with a proviso that the protein is not a contiguous sequence from an amino acid sequence of FIG. 2;
(VIII) a protein that comprises at least one peptide selected from the peptides set forth in Tables V-XVIII; and at least one peptide set forth in Tables XXII to IL, with a proviso that the protein is not a contiguous sequence from an amino acid sequence of FIG. 2;
(IX) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;
(X) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6;
(XI) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;
(XII) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;
(XIII) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3A or 3C in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9;
(XIV) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3B in any whole number increment up to 72 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5;
(XV) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3 in any whole number increment up to 72 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6;
(XVI) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3 in any whole number increment up to 72 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;
(XVII) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3 in any whole number increment up to 72 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;
(XVIII) a polypeptide comprising at least 5 amino acids of a protein of FIG. 3 in any whole number increment up to 72 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9;
(XIX) a monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(1)4 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4351 on 15 May 2002;
(XX) a monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(1)10 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4352 on 15 May 2002;
(XXI) a monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(1)23 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4353 on 15 May 2002;
(XXII) a monoclonal antibody or binding region thereof secreted by a hybridoma entitled X18(4)7 deposited with American Type Culture Collection (ATCC; 10801 University Blvd., Manassas, Va. 20110-2209 USA) as Accession No. PTA-4354 on 15 May 2002;
(XXIII) a peptide that occurs at least twice in Tables V-XVIII and XXII to IL, collectively;
(XXIV) a peptide that occurs at least once in Tables V-XVIII, and at least once in tables XXII to IL;
(XXV) a peptide which comprises one two, three, four, or five of the following characteristics, or an oligonucleotide encoding such peptide:

    
    
        i) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Hydrophilicity profile of FIG. 5;
        ii) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equal to 0.0, in the Hydropathicity profile of FIG. 6;
        iii) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Percent Accessible Residues profile of FIG. 7;
        iv) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Average Flexibility profile of FIG. 8; or,
        v) a region of at least 5 amino acids of a particular peptide of FIG. 3, in any whole number increment up to the full length of that protein in FIG. 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Beta-turn profile of FIG. 9;
    
    


(XXVI) a peptide of (I)-(XXV) together with a pharmaceutical excipient and/or in a human unit dose form.
As used herein, a range is understood to specifically disclose all whole unit positions thereof.
Typical embodiments of the invention disclosed herein include 101P3A11 polynucleotides that encode specific portions of 101P3A11 mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:
(a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 317 or 318 contiguous amino acids of 101P3A11.
In general, naturally occurring allelic variants of human 101P3A11 protein share a high degree of structural identity and homology (e.g., 90% or more homology). Typically, allelic variants of a 101P3A11 protein contain conservative amino acid substitutions within the 101P3A11 sequences described herein or contain a substitution of an amino acid from a corresponding position in a homologue of 101P3A11. One class of 101P3A11 allelic variants are proteins that share a high degree of homology with at least a small region of a particular 101P3A11 amino acid sequence, but further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. In comparisons of protein sequences, the terms, similarity, identity, and homology each have a distinct meaning as appreciated in the field of genetics. Moreover, orthology and paralogy can be important concepts describing the relationship of members of a given protein family in one organism to the members of the same family in other organisms.
Amino acid abbreviations are provided in Table II. Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Proteins of the invention can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 conservative substitutions. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered “conservative” in particular environments (see, e.g. Table III herein; pages 13-15 “Biochemistry” 2nd ED. Lubert Stryer ed (Stanford University); Henikoff et al., PNAS 1992 Vol 89 10915-10919; Lei et al., J Biol Chem 1995 May 19; 270(20):11882-6).
Embodiments of the invention disclosed herein include a wide variety of art-accepted variants or analogs of 101P3A11 proteins such as polypeptides having amino acid insertions, deletions and substitutions. 101P3A11 variants can be made using methods known in the art such as site-directed mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)), cassette mutagenesis (Wells et al., Gene, 34:315 (1985)), restriction selection mutagenesis (Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)) or other known techniques can be performed on the cloned DNA to produce the 101P3A11 variant DNA.
Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence that is involved in a specific biological activity such as a protein-protein interaction. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions (Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)). If alanine substitution does not yield adequate amounts of variant, an isosteric amino acid can be used.
As defined herein, 101P3A11 variants, analogs or homologs, have the distinguishing attribute of having at least one epitope that is “cross reactive” with a 101P3A11 protein having an amino acid sequence of FIG. 3. As used in this sentence, “cross reactive” means that an antibody or T cell that specifically binds to a 101P3A11 variant also specifically binds to a 101P3A11 protein having an amino acid sequence set forth in FIG. 3. A polypeptide ceases to be a variant of a protein shown in FIG. 3, when it no longer contains any epitope capable of being recognized by an antibody or T cell that specifically binds to the starting 101P3A11 protein. Those skilled in the art understand that antibodies that recognize proteins bind to epitopes of varying size, and a grouping of the order of about four or five amino acids, contiguous or not, is regarded as a typical number of amino acids in a minimal epitope. See, e.g., Nair et al., J. Immunol. 2000 165(12): 6949-6955; Hebbes et al., Mol Immunol (1989) 26(9):865-73; Schwartz et al., J Immunol (1985) 135(4):2598-608.
Other classes of 101P3A11-related protein variants share 70%, 75%, 80%, 85% or 90% or more similarity with an amino acid sequence of FIG. 3, or a fragment thereof. Another specific class of 101P3A11 protein variants or analogs comprise one or more of the 101P3A11 biological motifs described herein or presently known in the art. Thus, encompassed by the present invention are analogs of 101P3A11 fragments (nucleic or amino acid) that have altered functional (e.g., immunogenic) properties relative to the starting fragment. It is to be appreciated that motifs now or which become part of the art are to be applied to the nucleic or amino acid sequences of FIG. 2 or FIG. 3.
As discussed herein, embodiments of the claimed invention include polypeptides containing less than the full amino acid sequence of a 101P3A11 protein shown in FIG. 2 or FIG. 3. For example, representative embodiments of the invention comprise peptides/proteins having any 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids of a 101P3A11 protein shown in FIG. 2 or FIG. 3.
Moreover, representative embodiments of the invention disclosed herein include polypeptides consisting of about amino acid 1 to about amino acid 10 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 10 to about amino acid 20 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 20 to about amino acid 30 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 30 to about amino acid 40 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 40 to about amino acid 50 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 50 to about amino acid 60 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 60 to about amino acid 70 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 70 to about amino acid 80 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 80 to about amino acid 90 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, polypeptides consisting of about amino acid 90 to about amino acid 100 of a 101P3A11 protein shown in FIG. 2 or FIG. 3, etc. throughout the entirety of a 101P3A11 amino acid sequence. Moreover, polypeptides consisting of about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 130, or 140 or 150 etc.) of a 101P3A11 protein shown in FIG. 2 or FIG. 3 are embodiments of the invention. It is to be appreciated that the starting and stopping positions in this paragraph refer to the specified position as well as that position plus or minus 5 residues.
101P3A11-related proteins are generated using standard peptide synthesis technology or using chemical cleavage methods well known in the art. Alternatively, recombinant methods can be used to generate nucleic acid molecules that encode a 101P3A11-related protein. In one embodiment, nucleic acid molecules provide a means to generate defined fragments of a 101P3A11 protein (or variants, homologs or analogs thereof).
III.A.) Motif-Bearing Protein Embodiments
Additional illustrative embodiments of the invention disclosed herein include 101P3A11 polypeptides comprising the amino acid residues of one or more of the biological motifs contained within a 101P3A11 polypeptide sequence set forth in FIG. 2 or FIG. 3. Various motifs are known in the art, and a protein can be evaluated for the presence of such motifs by a number of publicly available Internet sites (see, e.g., EpimatrixTM and EpimerTM.
Motif bearing subsequences of all 101P3A11 variant proteins are set forth and identified in Tables V-XVIII and XXII TO ILI.
Table XIX sets forth several frequently occurring motifs based on pfam searches. The columns of Table XIX list (1) motif name abbreviation, (2) percent identity found amongst the different member of the motif family, (3) motif name or description and (4) most common function; location information is included if the motif is relevant for location.
Polypeptides comprising one or more of the 101P3A11 motifs discussed above are useful in elucidating the specific characteristics of a malignant phenotype in view of the observation that the 101P3A11 motifs discussed above are associated with growth dysregulation and because 101P3A11 is overexpressed in certain cancers (See, e.g., Table I). Casein kinase II, cAMP and camp-dependent protein kinase, and Protein Kinase C, for example, are enzymes known to be associated with the development of the malignant phenotype (see e.g. Chen et al., Lab Invest., 78(2): 165-174 (1998); Gaiddon et al., Endocrinology 136(10): 4331-4338 (1995); Hall et al., Nucleic Acids Research 24(6): 1119-1126 (1996); Peterziel et al., Oncogene 18(46): 6322-6329 (1999) and O'Brian, Oncol. Rep. 5(2): 305-309 (1998)). Moreover, both glycosylation and myristoylation are protein modifications also associated with cancer and cancer progression (see e.g. Dennis et al., Biochem. Biophys. Acta 1473(1):21-34 (1999); Raju et al., Exp. Cell Res. 235(1): 145-154 (1997)). Amidation is another protein modification also associated with cancer and cancer progression (see e.g. Treston et al., J. Natl. Cancer Inst. Monogr. (13): 169-175 (1992)).
In another embodiment, proteins of the invention comprise one or more of the immunoreactive epitopes identified in accordance with art-accepted methods, such as the peptides set forth in Tables V-XVIII and XXII TO IL. CTL epitopes can be determined using specific algorithms to identify peptides within a 101P3A11 protein that are capable of optimally binding to specified HLA alleles (e.g., Table IV; EpimatrixTM and EpimerTM. Moreover, processes for identifying peptides that have sufficient binding affinity for HLA molecules and which are correlated with being immunogenic epitopes, are well known in the art, and are carried out without undue experimentation. In addition, processes for identifying peptides that are immunogenic epitopes, are well known in the art, and are carried out without undue experimentation either in vitro or in vivo.
Also known in the art are principles for creating analogs of such epitopes in order to modulate immunogenicity. For example, one begins with an epitope that bears a CTL or HTL motif (see, e.g., the HLA Class I and HLA Class II motifs/supermotifs of Table IV). The epitope is analoged by substituting out an amino acid at one of the specified positions, and replacing it with another amino acid specified for that position. For example, one can substitute out a deleterious residue in favor of any other residue, such as a preferred residue as defined in Table IV; substitute a less-preferred residue with a preferred residue as defined in Table IV; or substitute an originally-occurring preferred residue with another preferred residue as defined in Table IV. Substitutions can occur at primary anchor positions or at other positions in a peptide; see, e.g., Table IV.
A variety of references reflect the art regarding the identification and generation of epitopes in a protein of interest as well as analogs thereof. See, for example, WO 97/33602 to Chesnut et al.; Sette, Immunogenetics 1999 50(3-4): 201-212; Sette et al., J. Immunol. 2001 166(2): 1389-1397; Sidney et al., Hum. Immunol. 1997 58(1): 12-20; Kondo et al., Immunogenetics 1997 45(4): 249-258; Sidney et al., J. Immunol. 1996 157(8): 3480-90; and Falk et al., Nature 351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker et al., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol. 152:163-75 (1994)); Kast et al., 1994 152(8): 3904-12; Borras-Cuesta et al., Hum. Immunol. 2000 61(3): 266-278; Alexander et al., J. Immunol. 2000 164(3); 164(3): 1625-1633; Alexander et al., PMID: 7895164, UI: 95202582; O'Sullivan et al., J. Immunol. 1991 147(8): 2663-2669; Alexander et al., Immunity 1994 1(9): 751-761 and Alexander et al., Immunol. Res. 1998 18(2): 79-92.
Related embodiments of the invention include polypeptides comprising combinations of the different motifs set forth in Table XX, and/or, one or more of the predicted CTL epitopes of Tables V-XVII and XXII-XLVII, and/or, one or more of the predicted HTL epitopes of Tables XLVIII-LI, and/or, one or more of the T cell binding motifs known in the art. Preferred embodiments contain no insertions, deletions or substitutions either within the motifs or the intervening sequences of the polypeptides. In addition, embodiments which include a number of either N-terminal and/or C-terminal amino acid residues on either side of these motifs may be desirable (to, for example, include a greater portion of the polypeptide architecture in which the motif is located). Typically the number of N-terminal and/or C-terminal amino acid residues on either side of a motif is between about 1 to about 100 amino acid residues, preferably 5 to about 50 amino acid residues.
101P3A11-related proteins are embodied in many forms, preferably in isolated form. A purified 101P3A11 protein molecule will be substantially free of other proteins or molecules that impair the binding of 101P3A11 to antibody, T cell or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of a 101P3A11-related proteins include purified 101P3A11-related proteins and functional, soluble 101P3A11-related proteins. In one embodiment, a functional, soluble 101P3A11 protein or fragment thereof retains the ability to be bound by antibody, T cell or other ligand.
The invention also provides 101P3A11 proteins comprising biologically active fragments of a 101P3A11 amino acid sequence shown in FIG. 2 or FIG. 3. Such proteins exhibit properties of the starting 101P3A11 protein, such as the ability to elicit the generation of antibodies that specifically bind an epitope associated with the starting 101P3A11 protein; to be bound by such antibodies; to elicit the activation of HTL or CTL; and/or, to be recognized by HTL or CTL that also specifically bind to the starting protein.
101P3A11-related polypeptides that contain particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or on the basis of immunogenicity. Fragments that contain such structures are particularly useful in generating subunit-specific anti-101P3A11 antibodies, or T cells or in identifying cellular factors that bind to 101P3A11. For example, hydrophilicity profiles can be generated, and immunogenic peptide fragments identified, using the method of Hopp, T. P. and Woods, K. R., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828. Hydropathicity profiles can be generated, and immunogenic peptide fragments identified, using the method of Kyte, J. and Doolittle, R. F., 1982, J. Mol. Biol. 157:105-132. Percent (%) Accessible Residues profiles can be generated, and immunogenic peptide fragments identified, using the method of Janin J., 1979, Nature 277:491-492. Average Flexibility profiles can be generated, and immunogenic peptide fragments identified, using the method of Bhaskaran R., Ponnuswamy P. K., 1988, Int. J. Pept. Protein Res. 32:242-255. Beta-turn profiles can be generated, and immunogenic peptide fragments identified, using the method of Deleage, G., Roux B., 1987, Protein Engineering 1:289-294.
CTL epitopes can be determined using specific algorithms to identify peptides within a 101P3A11 protein that are capable of optimally binding to specified HLA alleles (e.g., by using the SYFPEITHI site; the listings in Table IV(A)-(E); EpimatrixTM and EpimerTM). Illustrating this, peptide epitopes from 101P3A11 that are presented in the context of human MHC Class I molecules, e.g., HLA-A1, A2, A3, A11, A24, B7 and B35 were predicted (see, e.g., Tables V-XVIII, XXII TO IL). Specifically, the complete amino acid sequence of the 101P3A11 protein and relevant portions of other variants, i.e., for HLA Class I predictions 9 flanking residues on either side of a point mutation, and for HLA Class II predictions 14 flanking residues on either side of a point mutation, were entered into the HLA Peptide Motif Search algorithm found in the Bioinformatics and Molecular Analysis Section (BIMAS) web site; and the site SYFPEITHI was used.
The HLA peptide motif search algorithm was developed by Dr. Ken Parker based on binding of specific peptide sequences in the groove of HLA Class I molecules, in particular HLA-A2 (see, e.g., Falk et al., Nature 351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker et al., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol. 152:163-75 (1994)). This algorithm allows location and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete protein sequence for predicted binding to HLA-A2 as well as numerous other HLA Class I molecules. Many HLA class I binding peptides are 8-, 9-, 10 or 11-mers. For example, for Class I HLA-A2, the epitopes preferably contain a leucine (L) or methionine (M) at position 2 and a valine (V) or leucine (L) at the C-terminus (see, e.g., Parker et al., J. Immunol. 149:3580-7 (1992)). Selected results of 101P3A11 predicted binding peptides are shown in Tables V-XVIII and XXII TO IL herein. In Tables V-XVIII and XXII TO IL, selected candidates, 9-mers, 10-mers, and 15-mers for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. The binding score corresponds to the estimated half time of dissociation of complexes containing the peptide at 37° C. at pH 6.5. Peptides with the highest binding score are predicted to be the most tightly bound to HLA Class I on the cell surface for the greatest period of time and thus represent the best immunogenic targets for T-cell recognition.
Actual binding of peptides to an HLA allele can be evaluated by stabilization of HLA expression on the antigen-processing defective cell line T2 (see, e.g., Xue et al., Prostate 30:73-8 (1997) and Peshwa et al., Prostate 36:129-38 (1998)). Immunogenicity of specific peptides can be evaluated in vitro by stimulation of CD8+ cytotoxic T lymphocytes (CTL) in the presence of antigen presenting cells such as dendritic cells.
It is to be appreciated that every epitope predicted by the BIMAS site, EpimerTM and EpimatrixTM sites, or specified by the HLA class I or class II motifs available in the art or which become part of the art such as set forth in Table IV (or determined using World Wide Web site for the SYFPEITHI or or BIMAS databases) are to be “applied” to a 101P3A11 protein in accordance with the invention. As used in this context “applied” means that a 101P3A11 protein is evaluated, e.g., visually or by computer-based patterns finding methods, as appreciated by those of skill in the relevant art. Every subsequence of a 101P3A11 protein of 8, 9, 10, or 11 amino acid residues that bears an HLA Class I motif, or a subsequence of 9 or more amino acid residues that bear an HLA Class II motif are within the scope of the invention.
III.B.) Expression of 101P3A11-Related Proteins
In an embodiment described in the examples that follow, 101P3A11 can be conveniently expressed in cells (such as 293T cells) transfected with a commercially available expression vector such as a CMV-driven expression vector encoding 101P3A11 with a C-terminal 6×His and MYC tag (pcDNA3.1/mycHIS, Invitrogen or Tag5, GenHunter Corporation, Nashville Tenn.). The Tag5 vector provides an IgGK secretion signal that can be used to facilitate the production of a secreted 101P3A11 protein in transfected cells. The secreted HIS-tagged 101P3A11 in the culture media can be purified, e.g., using a nickel column using standard techniques.
III.C.) Modifications of 101P3A11-Related Proteins
Modifications of 101P3A11-related proteins such as covalent modifications are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a 101P3A11 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of a 101P3A11 protein. Another type of covalent modification of a 101P3A11 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of a protein of the invention. Another type of covalent modification of 101P3A11 comprises linking a 101P3A11 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. No. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
The 101P3A11-related proteins of the present invention can also be modified to form a chimeric molecule comprising 101P3A11 fused to another, heterologous polypeptide or amino acid sequence. Such a chimeric molecule can be synthesized chemically or recombinantly. A chimeric molecule can have a protein of the invention fused to another tumor-associated antigen or fragment thereof. Alternatively, a protein in accordance with the invention can comprise a fusion of fragments of a 101P3A11 sequence (amino or nucleic acid) such that a molecule is created that is not, through its length, directly homologous to the amino or nucleic acid sequences shown in FIG. 2 or FIG. 3. Such a chimeric molecule can comprise multiples of the same subsequence of 101P3A11. A chimeric molecule can comprise a fusion of a 101P3A11-related protein with a polyhistidine epitope tag, which provides an epitope to which immobilized nickel can selectively bind, with cytokines or with growth factors. The epitope tag is generally placed at the amino- or carboxyl-terminus of a 101P3A11 protein. In an alternative embodiment, the chimeric molecule can comprise a fusion of a 101P3A11-related protein with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an “immunoadhesin”), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a 101P3A11 polypeptide in place of at least one variable region within an Ig molecule. In a preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CHI, CH2 and CH3 regions of an IgGI molecule. For the production of immunoglobulin fusions see, e.g., U.S. Pat. No. 5,428,130 issued Jun. 27, 1995.
III.D.) Uses of 101P3A11-Related Proteins
The proteins of the invention have a number of different specific uses. As 101P3A11 is highly expressed in prostate and other cancers, 101P3A11-related proteins are used in methods that assess the status of 101P3A11 gene products in normal versus cancerous tissues, thereby elucidating the malignant phenotype. Typically, polypeptides from specific regions of a 101P3A11 protein are used to assess the presence of perturbations (such as deletions, insertions, point mutations etc.) in those regions (such as regions containing one or more motifs). Exemplary assays utilize antibodies or T cells targeting 101P3A11-related proteins comprising the amino acid residues of one or more of the biological motifs contained within a 101P3A11 polypeptide sequence in order to evaluate the characteristics of this region in normal versus cancerous tissues or to elicit an immune response to the epitope. Alternatively, 101P3A11-related proteins that contain the amino acid residues of one or more of the biological motifs in a 101P3A11 protein are used to screen for factors that interact with that region of 101P3A11.
101P3A11 protein fragments/subsequences are particularly useful in generating and characterizing domain-specific antibodies (e.g., antibodies recognizing an extracellular or intracellular epitope of a 101P3A11 protein), for identifying agents or cellular factors that bind to 101P3A11 or a particular structural domain thereof, and in various therapeutic and diagnostic contexts, including but not limited to diagnostic assays, cancer vaccines and methods of preparing such vaccines.
Proteins encoded by the 101P3A11 genes, or by analogs, homologs or fragments thereof, have a variety of uses, including but not limited to generating antibodies and in methods for identifying ligands and other agents and cellular constituents that bind to a 101P3A11 gene product. Antibodies raised against a 101P3A11 protein or fragment thereof are useful in diagnostic and prognostic assays, and imaging methodologies in the management of human cancers characterized by expression of 101P3A11 protein, such as those listed in Table I. Such antibodies can be expressed intracellularly and used in methods of treating patients with such cancers. 101P3A11-related nucleic acids or proteins are also used in generating HTL or CTL responses.
Various immunological assays useful for the detection of 101P3A11 proteins are used, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), immunocytochemical methods, and the like. Antibodies can be labeled and used as immunological imaging reagents capable of detecting 101P3A11-expressing cells (e.g., in radioscintigraphic imaging methods). 101P3A11 proteins are also particularly useful in generating cancer vaccines, as further described herein.
IV.) 101P3A11 ANTIBODIES
Another aspect of the invention provides antibodies that bind to 101P3A11-related proteins. Preferred antibodies specifically bind to a 101P3A11-related protein and do not bind (or bind weakly) to peptides or proteins that are not 101P3A11-related proteins. For example, antibodies that bind 101P3A11 can bind 101P3A11-related proteins such as the homologs or analogs thereof.
101P3A11 antibodies of the invention are particularly useful in cancer (see, e.g., Table I) diagnostic and prognostic assays, and imaging methodologies. Similarly, such antibodies are useful in the treatment, diagnosis, and/or prognosis of other cancers, to the extent 101P3A11 is also expressed or overexpressed in these other cancers. Moreover, intracellularly expressed antibodies (e.g., single chain antibodies) are therapeutically useful in treating cancers in which the expression of 101P3A11 is involved, such as advanced or metastatic prostate cancers.
The invention also provides various immunological assays useful for the detection and quantification of 101P3A11 and mutant 101P3A11-related proteins. Such assays can comprise one or more 101P3A11 antibodies capable of recognizing and binding a 101P3A11-related protein, as appropriate. These assays are performed within various immunological assay formats well known in the art, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like.
Immunological non-antibody assays of the invention also comprise T cell immunogenicity assays (inhibitory or stimulatory) as well as major histocompatibility complex (MHC) binding assays.
In addition, immunological imaging methods capable of detecting prostate cancer and other cancers expressing 101P3A11 are also provided by the invention, including but not limited to radioscintigraphic imaging methods using labeled 101P3A11 antibodies. Such assays are clinically useful in the detection, monitoring, and prognosis of 101P3A11 expressing cancers such as prostate cancer.
101P3A11 antibodies are also used in methods for purifying a 101P3A11-related protein and for isolating 101P3A11 homologues and related molecules. For example, a method of purifying a 101P3A11-related protein comprises incubating a 101P3A11 antibody, which has been coupled to a solid matrix, with a lysate or other solution containing a 101P3A11-related protein under conditions that permit the 101P3A11 antibody to bind to the 101P3A11-related protein; washing the solid matrix to eliminate impurities; and eluting the 101P3A11-related protein from the coupled antibody. Other uses of 101P3A11 antibodies in accordance with the invention include generating anti-idiotypic antibodies that mimic a 101P3A11 protein.
Various methods for the preparation of antibodies are well known in the art. For example, antibodies can be prepared by immunizing a suitable mammalian host using a 101P3A11-related protein, peptide, or fragment, in isolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)). In addition, fusion proteins of 101P3A11 can also be used, such as a 101P3A11 GST-fusion protein. In a particular embodiment, a GST fusion protein comprising all or most of the amino acid sequence of FIG. 2 or FIG. 3 is produced, then used as an immunogen to generate appropriate antibodies. In another embodiment, a 101P3A11-related protein is synthesized and used as an immunogen.
In addition, naked DNA immunization techniques known in the art are used (with or without purified 101P3A11-related protein or 101P3A11 expressing cells) to generate an immune response to the encoded immunogen (for review, see Donnelly et al., 1997, Ann. Rev. Immunol. 15: 617-648).
The amino acid sequence of a 101P3A11 protein as shown in FIG. 2 or FIG. 3 can be analyzed to select specific regions of the 101P3A11 protein for generating antibodies. For example, hydrophobicity and hydrophilicity analyses of a 101P3A11 amino acid sequence are used to identify hydrophilic regions in the 101P3A11 structure. Regions of a 101P3A11 protein that show immunogenic structure, as well as other regions and domains, can readily be identified using various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis. Hydrophilicity profiles can be generated using the method of Hopp, T. P. and Woods, K. R., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828. Hydropathicity profiles can be generated using the method of Kyte, J. and Doolittle, R. F., 1982, J. Mol. Biol. 157:105-132. Percent (%) Accessible Residues profiles can be generated using the method of Janin J., 1979, Nature 277:491-492. Average Flexibility profiles can be generated using the method of Bhaskaran R., Ponnuswamy P. K., 1988, Int. J. Pept. Protein Res. 32:242-255. Beta-turn profiles can be generated using the method of Deleage, G., Roux B., 1987, Protein Engineering 1:289-294. Thus, each region identified by any of these programs or methods is within the scope of the present invention. Methods for the generation of 101P3A11 antibodies are further illustrated by way of the examples provided herein. Methods for preparing a protein or polypeptide for use as an immunogen are well known in the art. Also well known in the art are methods for preparing immunogenic conjugates of a protein with a carrier, such as BSA, KLH or other carrier protein. In some circumstances, direct conjugation using, for example, carbodimide reagents are used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, Ill., are effective. Administration of a 101P3A11 immunogen is often conducted by injection over a suitable time period and with use of a suitable adjuvant, as is understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.
101P3A11 monoclonal antibodies can be produced by various means well known in the art. For example, immortalized cell lines that secrete a desired monoclonal antibody are prepared using the standard hybridoma technology of Kohler and Milstein or modifications that immortalize antibody-producing B cells, as is generally known. Immortalized cell lines that secrete the desired antibodies are screened by immunoassay in which the antigen is a 101P3A11-related protein. When the appropriate immortalized cell culture is identified, the cells can be expanded and antibodies produced either from in vitro cultures or from ascites fluid.
The antibodies or fragments of the invention can also be produced, by recombinant means. Regions that bind specifically to the desired regions of a 101P3A11 protein can also be produced in the context of chimeric or complementarity determining region (CDR) grafted antibodies of multiple species origin. Humanized or human 101P3A11 antibodies can also be produced, and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies, by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences, are well known (see for example, Jones et al., 1986, Nature 321: 522-525; Riechmann et al., 1988, Nature 332: 323-327; Verhoeyen et al., 1988, Science 239: 1534-1536). See also, Carter et al., 1993, Proc. Natl. Acad. Sci. USA 89: 4285 and Sims et al., 1993, J. Immunol. 151: 2296.
Methods for producing fully human monoclonal antibodies include phage display and transgenic methods (for review, see Vaughan et al., 1998, Nature Biotechnology 16: 535-539). Fully human 101P3A11 monoclonal antibodies can be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an in vitro immune system: human antibodies from phage display libraries. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, Human Antibodies from combinatorial libraries. Id., pp 65-82). Fully human 101P3A11 monoclonal antibodies can also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Kucherlapati and Jakobovits et al., published Dec. 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4): 607-614; U.S. Pat. Nos. 6,162,963 issued 19 Dec. 2000; 6,150,584 issued 12 Nov. 2000; and, 6,114,598 issued 5 Sep. 2000). This method avoids the in vitro manipulation required with phage display technology and efficiently produces high affinity authentic human antibodies.
Reactivity of 101P3A11 antibodies with a 101P3A11-related protein can be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, 101P3A11-related proteins, 101P3A11-expressing cells or extracts thereof. A 101P3A11 antibody or fragment thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Further, bi-specific antibodies specific for two or more 101P3A11 epitopes are generated using methods generally known in the art. Homodimeric antibodies can also be generated by cross-linking techniques known in the art (e.g., Wolff et al., Cancer Res. 53: 2560-2565).
Thus, the present invention relates to polyclonal and monoclonal antibodies raised in response to either 101P3A11, or biologically active fragments thereof. The polyclonal and/or monoclonal antibodies of the present invention, especially 101P3A11 neutralizing antibodies (antibodies that block 101P3A11 function and/or block its binding with ligands), will also be useful as therapeutics to modulate 101P3A11 expression and/or activity. In addition, the polyclonal and/or monoclonal antibodies of the present invention are useful as (1) diagnostics for qualitative and/or quantitative detection of 101P3A11 expression in a variety of immunoassays, e.g., Western blotting; immunohistochemistry and immunoprecipitation (of samples/biopsies of material such as tissue, serum, blood, urine or semen); and, (ii) as noted above, inhibition of 101P3A11 function using 101P3A11 neutralizing antibodies for the treatment of diseases associated with 101P3A11 overexpression such as cancers of tissues listed in Table I. Antibodies that antagonize the effect of 101P3A11 (for example, inhibition of 101P3A11's ability to protect certain cells from apoptosis, cell death or inhibition of 101P3A11's ability to bind to its ligand) can be administered directly by methods known in the art (see, e.g., Antibodies in Human Diagnosis and Therapy by Raven Press, New York (1977)). Monoclonal antibodies are especially preferred for the treatment of tumors associated with an abnormal 101P3A11 expression. For example, a 101P3A11 monoclonal antibody which slows the progression of a cancer associated with an increase in 101P3A11 expression within cancer cells, and in turn can cause tumor shrinkage over time, will be especially useful.
A useful paradigm is the early success of HerceptinTM, a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor 2 (HER2). The antibody is produced in CHO cells and the final product is available as a lyophilized powder. HER2 has been shown to be overexpressed in 25-30% of primary breast cancers. In turn, administration of HerceptinTM has been shown to inhibit the proliferation of tumor cells which overexpress HER2. A prospective 101P3A11 monoclonal antibody can be “humanized” by methods well known in the art, such as XenomouseTM technology (Abgenix), or antibody phage display, in order to reduce any unwanted immunological effects of human administration of the antibody. Alternatively, the 101P3A11-based antibody can be a chimera, most likely a mouse/human or rat/human chimera. In addition, any such therapeutic 101P3A11-based antibody can be administered alone or within a regime that includes other cancer therapies, such as known chemotherapeutic agents, which can act in concert to reduce tumor growth associated with increased 101P3A11 expression. Another example of the use of monoclonal antibodies to treat various cancers is RituxanTM, a recombinant DNA-based mouse/human chimeric monoclonal antibody which has been shown to be effective in treating patients with low grade B-cell non-Hodgkin's lymphoma (NHL), a cancer of the immune system. Rituxan targets and destroys white blood cells (B cells) involved in the disease, resulting insignificant tumor shrinkage with less severe side-effects than most cancer treatments. Additional monoclonal antibodies currently under development include (i) an anti-CD-20 monoclonal antibody to treat patients with low-grade lymphomas, (ii) a combination anti-EGFr antibody with doxorubicin in patients with hormone refractory prostate cancer as well as a combination anti-EGFr antibody with cisplatin in patients with head and neck and lung cancer. A 101P3A11 anti-idiotype antibody can also be administered so as to stimulate a host immune response to tumors overexpressing 101P3A11. Therefore, it is evident that 101P3A11 antibodies, especially 101P3A11 monoclonal antibodies, are potentially useful tools, along or in combination with other cancer therapies, for direct therapeutic intervention of cancers characterized by an increase in 101P3A11 expression.
Skilled artisans understand that equivalent molecules known in the art which mimic the inhibitory activity of an antibody capable of inhibiting 101P3A11 function are aspects of the presently disclosed methods which employ an antibody capable of inhibiting 101P3A11 function. Examples of such molecules include anti-101P3A11 peptide mimetics which inhibit the growth of at least a comparable or like manner to an antibody capable of inhibiting 101P3A11 function.
Polyclonal Antibodies
The antibodies of the invention also comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent can include a 101P3A11 polypeptide or a fusion protein thereof. It can be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which can be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol can be selected by one skilled in the art without undue experimentation. The mammal can then be bled, and the serum assayed for antibody titer. If desired, the mammal can be boosted until the antibody titer increases or plateaus.
Monoclonal Antibodies
The antibodies of the invention can, alternatively, be monoclonal antibodies. Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.
The immunizing agent will typically include a 101P3A11 polypeptide or a fusion protein thereof.
Generally, either peripheral blood lymphocytes (“PBLs”) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells. Alternatively, SLAM technology can be employed for screening as appreciated by one of skill in the art.
Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Vir. An example of such a murine myeloma cell line is P3X63AgU.1. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).
The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the 101P3A11. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).
After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986)). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium or RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.
The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (see, e.g., U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody. Optionally, chimeric antibodies can be constructed which include at least one variable or hypervariable domain of an anti-101P3A11 antibody selected from the antibodies disclosed herein.
Optionally, the antibody capable of inhibiting 101P3A11 function of the present invention will bind to the same epitope(s) as any of the antibodies disclosed herein. This can be determined by conducting various assays, such as described herein. For instance, to determine whether a monoclonal antibody has the same specificity as the antibodies referred to herein, one can compare its activity in blocking assays or inhibition assays or functional assays.
The antibodies of the invention include “cross-linked” antibodies. The term “cross-linked” as used herein refers to binding of at least two IgG molecules together to form one (or single) molecule. The 101P3A11 antibodies can be cross-linked using various linker molecules and optionally the antibodies are cross-linked using an anti-IgG molecule, complement, chemical modification or molecular engineering. It is appreciated by those skilled in the art that complement has a relatively high affinity to antibody molecules once the antibodies bind to cell surface membrane. Accordingly, complement can be used as a cross-linking molecule to link two or more antibodies bound to cell surface membrane. Among the various murine Ig isotypes, IgM, IgG2a and IgG2b are known to fix complement.
The antibodies of the invention can optionally comprise dimeric antibodies, as well as multivalent forms of antibodies. Those skilled in the art can construct such dimers or multivalent forms by techniques known in the art and using the anti-101P3A11 antibodies herein.
The antibodies of the invention can also comprise monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields an F(ab′)2 fragment that has two antigen combining sites and is still capable of cross-linking antigen.
The Fab fragments produced in the antibody digestion also contain the constant domains of the light chain and the first constant domain (CH1) of the heavy chain. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab′)2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
Single chain Fv fragments can also be produced, such as described in Iliades et al, FEBS Letters, 409:437-441 (1997). Coupling of such single chain fragments using various linkers is described in Kortt et al., Protein Engineering, 10:423-433 (1997).
In addition to the antibodies described herein, it is contemplated that chimeric or hybrid antibodies are prepared using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
The 101P3A11 antibodies of the invention further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).
Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such “humanized” antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Sources of such import residues or import variable domains (or CDRs) include antibodies that specifically bind 101P3A11.
The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important in order to reduce antigenicity. According to the “best-fit” method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol., 151:2296-2308 (1993); Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992); Presta et al., J. Immunol., 151:2623-2632 (1993)).
It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding (see, WO 94/04679 published 3 Mar. 1994).
Human monoclonal antibodies can be made via an adaptation of the hybridoma method first described by Kohler and Milstein by using human B lymphocytes as the fusion partner. Human B lymphocytes producing an antibody of interest can, for example, be isolated from a human individual, after obtaining informed consent. For instance, the individual can be producing antibodies against an autoantigen as occurs with certain disorders such as systemic lupus erythematosus (Shoenfeld et al. J. Clin. Invest., 70:205 (1982)), immune-mediated thrombocytopenic purpura (ITP) (Nugent et al. Blood, 70(1):16-22 (1987)), or cancer. Alternatively, or additionally, lymphocytes can be immunized in vitro. For instance, one can expose isolated human peripheral blood lymphocytes in vitro to a lysomotrophic agent (e.g., L-leucine-O-methyl ester, L-glutamic acid dimethyl ester or L-leucyl-L-leucine-O-methyl ester) (U.S. Pat. No. 5,567,610, Borrebaeck et al.); and/or T-cell depleted human peripheral blood lymphocytes can be treated in vitro with adjuvants such as 8-mercaptoguanosine and cytokines (U.S. Pat. No. 5,229,275, Goroff et al.).
The B lymphocytes recovered from the subject or immunized in vitro, are then generally immortalized in order to generate a human monoclonal antibody. Techniques for immortalizing the B lymphocyte include, but are not limited to: (a) fusion of the human B lymphocyte with human, murine myelomas or mouse-human heteromyeloma cells; (b) viral transformation (e.g. with an Epstein-Barr virus; see Nugent et al., supra, for example); (c) fusion with a lymphoblastoid cell line; or (d) fusion with lymphoma cells.
Lymphocytes can be fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells. Suitable human myeloma and mouse-human heteromyeloma cell lines have been described (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A chromatography, gel electrophoresis, dialysis, or affinity chromatography.
Human antibodies can also be generated using a non-human host, such as a mouse, which is capable of producing human antibodies. As noted above, transgenic mice are now available that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice resulted in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immuno., 7:33 (1993); U.S. Pat. No. 5,591,669; U.S. Pat. No. 5,589,369; and U.S. Pat. No. 5,545,807. Human antibodies can also be prepared using SCID-hu mice (Duchosal et al Nature 355:258-262 (1992)).
In another embodiment, the human antibody can be selected from a human antibody phage display library. The preparation of libraries of antibodies or fragments thereof is well known in the art and any of the known methods can be used to construct a family of transformation vectors which can be introduced into host cells. Libraries of antibody light and heavy chains in phage (Huse et al., Science, 246:1275 (1989)) or of fusion proteins in phage or phagemid can be prepared according to known procedures. See, for example, Vaughan et al, Nature Biotechnology 14:309-314 (1996); Barbas et al., Proc. Natl. Acad. Sci., USA, 88:7978-7982 (1991); Marks et al., J. Mol. Biol., 222:581-597 (1991); Hoogenboom and Winter, J. Mol. Biol., 227:381-388 (1992); Barbas et al., Proc. Natl. Acad. Sci., USA, 89: 4457-4461 (1992); Griffiths et al., EMBO Journal, 13:3245-3260 (1994); de Kruif et al., J. Mol. Biol., 248:97-105 (1995); WO 98/05344; WO 98/15833; WO 97/47314; WO 97/44491; WO 97/35196; WO 95/34648; U.S. Pat. No. 5,712,089; U.S. Pat. No. 5,702,892; U.S. Pat. No. 5,427,908; U.S. Pat. No. 5,403,484; U.S. Pat. No. 5,432,018; U.S. Pat. No. 5,270,170; WO 92/06176; WO 99/06587; U.S. Pat. No. 5,514,548; WO 97/08320; and U.S. Pat. No. 5,702,892. The antigen of interest is panned against the phage library using procedures known in the field for selecting phage-antibodies which bind to the target antigen.
The 101P3A11 antibodies, as described herein, will optionally possess one or more desired biological activities or properties. Such antibodies can include but are not limited to chimeric, humanized, human, and affinity matured antibodies. As described above, the antibodies can be constructed or engineered using various techniques to achieve these desired activities or properties. In one embodiment, the 101P3A11 antibody will have a 101P3A11 binding affinity of at least 10−5 M, preferably at least in the range of 10−6 M to 10−7 M, mote preferably, at least in the range of 10−8 M to 10−12 M and even more preferably, at least in the range of 10−9 M to 10−12 M. The binding affinity of the antibody can be determined without undue experimentation by testing the antibody in accordance with techniques known in the art, including Scatchard analysis (Munson and Pollard, Anal. Biochem., 107:220 (1980)). For example, a 101P3A11 antibody can be assayed for binding affinity to 101P3A11, including constructs or fragments thereof.
In another embodiment, the antibody interacts in such a way to create a steric conformation which prevents binding of an antibody capable of inhibiting or enhancing 101P3A11 function. The epitope binding property of the antibody of the present invention can be determined using techniques known in the art.
Other Modifications
Other modifications of the 101P3A11 antibodies are contemplated herein. The antibodies of the present invention can be modified by conjugating the antibody to a cytotoxic agent (like a toxin molecule) or a prodrug-activating enzyme which converts a prodrug (e.g. a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Pat. No. 4,975,278. This technology is also referred to as “Antibody Dependent Enzyme Mediated Prodrug Therapy” (ADEPT).
The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active, cytotoxic form. Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; caspases such as caspase-3; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as beta-galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; beta-lactamase useful for converting drugs derivatized with beta-lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as “abzymes”, can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328: 457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.
The enzymes can be covalently bound to the antibodies by techniques well known in the art such as the use of heterobifunctional crosslinking reagents. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature, 312: 604-608 (1984).
Further modifications to the polypeptides of the invention are contemplated. For example, the antibodies can be linked to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol. The antibody also can be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980). To increase the serum half life of the antibody, one can incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described, e.g., in U.S. Pat. No. 5,739,277, for example. As used herein, the term “salvage receptor binding epitope” refers to an epitope of the Fc region of an IgG molecule (e.g., IgG1, IgG2, IgG3, or IgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule.
Formulations
The antibody capable of inhibiting 101P3A11 function are preferably administered in a carrier. The molecules can be administered in a single carrier, or alternatively, can be included in separate carriers. Suitable carriers and their formulations are described in Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the carrier to render the formulation isotonic. Examples of the carrier include saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7.4 to about 7.8. It will be apparent to those persons skilled in the art that certain carriers are preferred depending upon, for instance, the route of administration and concentration of agent being administered. The carrier can be in the form of a lyophilized formulation or aqueous solution.
Acceptable carriers, excipients, or stabilizers are preferably nontoxic to cells and/or recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; and/or non-ionic surfactants such as TWEEN®, PLURONICS® or polyethylene glycol (PEG).
The formulation can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities, and preferably that do not adversely affect each other. Alternatively, or in addition, the composition can comprise a cytotoxic agent, cytokine or growth inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
The antibody capable of inhibiting 101P3A11 function can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drag delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Oslo, A. Ed. (1980).
The formulations to be used for in vivo administration should be sterile. This is readily accomplished by filtration through sterile filtration membranes.
Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and (ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
Modes of Administration
An antibody(s) capable of inhibiting 101P3A11 function can be administered in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intrathecal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Optionally, administration can be performed through mini-pump infusion using various commercially available devices.
Effective dosages and schedules for administering an antibody capable of inhibiting 101P3A11 function can be determined empirically, and making such determinations is within the skill in the art. Effective dosage or amount of an antibody capable of inhibiting 101P3A11 function used alone may range from about 1 μg/kg to about 100 mg/kg of body weight or more per day. Interspecies scaling of dosages can be performed in a manner known in the art, e.g., as disclosed in Mordenti et al., Pharmaceut. Res., 8:1351 (1991). Those skilled in the art will understand that the dosage of an antibody capable of inhibiting 101P3A11 function that must be administered will vary depending on, for example, the mammal which will receive the an antibody capable of inhibiting 101P3A11 function, the route of administration, and other drugs or therapies being administered to the mammal.
Depending on the type of cells and/or severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. 0.1-20 mg/kg) of antibody is an initial candidate dosage for administration, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens can be useful.
It is contemplated that yet additional therapies can be employed in the methods. The one or more other therapies can include but are not limited to, other chemotherapies (or chemotherapeutic agents) and/or radiation therapy, immunoadjuvants, growth inhibitory agents, cytokines, and other non-Her-2 antibody-based therapies. Examples include interleukins (e.g., IL-1, IL-2, IL-3, IL-6), leukemia inhibitory factor, interferons, erythropoietin, thrombopoietin, and anti-VEGF antibody. Other agents known to inhibit the growth of mammalian cells—can also be employed, and such agents include TNF-α, CD30 ligand, 4-1BB ligand, and Apo-1 ligand.
Additional chemotherapies contemplated by the invention include chemical substances or drugs which are known in the art and are commercially available, such as Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside (“Ara-C”), Cyclophosphamide, Leucovorin, Thiotepa, Busulfan, Cytoxin, Taxol, Toxotere, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carrainomycin, Amimopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan and other related nitrogen mustards. Also included are agents that act to regulate or inhibit hormone action on tumors such as tamoxifen and onaptistone.
Preparation and dosing schedules for such chemotherapy can be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service Ed., M. C. Perry, Williams & Wins, Baltimore, Md. (1992). The chemotherapeutic agent can precede, or follow administration with the antibody capable of inhibiting 101P3A11 function, or can be given simultaneously therewith.
The chemotherapy is preferably administered in a carrier, such as those described above. The mode of administration of the chemotherapy can be the same as employed for an antibody capable of modulating, such as inhibiting or enhancing, 101P3A11 function, or it can be administered via a different mode.
Radiation therapy can be administered according to protocols commonly employed in the art and known to the skilled artisan. Such therapy can include cesium, iridium, iodine, or cobalt radiation. The radiation therapy can be whole body irradiation, or can be directed locally to a specific site or tissue in or on the body. Typically, radiation therapy is administered in pulses over a period of time from about 1 to about 2 weeks. The radiation therapy can, however, be administered over longer periods of time. Optionally, the radiation therapy can be administered as a single dose or as multiple, sequential doses.
An antibody capable of inhibiting 101P3A11 function (and one or more other therapies) can be administered concurrently or sequentially. Following administration of an antibody capable of inhibiting 101P3A11 function, treated cells in vitro can be analyzed. Where there has been in vivo treatment, a treated mammal can be monitored in various ways well known to the skilled practitioner. For instance, tumor mass can be observed physically, by biopsy or by standard x-ray imaging techniques.
V.) 101P3A11 CELLULAR IMMUNE RESPONSES
The mechanism by which T cells recognize antigens has been delineated. Efficacious peptide epitope vaccine compositions of the invention induce a therapeutic or prophylactic immune responses in very broad segments of the world-wide population. For an understanding of the value and efficacy of compositions of the invention that induce cellular immune responses, a brief review of immunology-related technology is provided.
A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al., Cell 47:1071, 1986; Babbitt, B. P. et al., Nature 317:359, 1985; Townsend, A. and Bodmer, H., Annu. Rev. Immunol. 7:601, 1989; Germain, R. N., Annu. Rev. Immunol. 11:403, 1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified and are set forth in Table IV (see also, e.g., Southwood, et al., J. Immunol. 160:3363, 1998; Rammensee, et al., Immunogenetics 41:178, 1995; Rammensee et al., SYFPEITHI, access via World Wide Web; Sette, A. and Sidney, J. Curr. Opin. Immunol. 10:478, 1998; Engelhard, V. H., Curr. Opin. Immunol. 6:13, 1994; Sette, A. and Grey, H. M., Curr. Opin. Immunol. 4:79, 1992; Sinigaglia, F. and Hammer, J. Curr. Biol. 6:52, 1994; Ruppert et al., Cell 74:929-937, 1993; Kondo et al., J. Immunol. 155:4307-4312, 1995; Sidney et al., J. Immunol. 157:3480-3490, 1996; Sidney et al., Human Immunol. 45:79-93, 1996; Sette, A. and Sidney, J. Immunogenetics 1999 November; 50(3-4):201-12, Review).
Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft/groove of HLA molecules which accommodate, in an allele-specific mode, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D. R. Annu. Rev. Immunol. 13:587, 1995; Smith, et al., Immunity 4:203, 1996; Fremont et al., Immunity 8:305, 1998; Stern et al., Structure 2:245, 1994; Jones, E. Y. Curr. Opin. Immunol. 9:75, 1997; Brown, J. H. et al., Nature 364:33, 1993; Guo, H. C. et al., Proc. Natl. Acad. Sci. USA 90:8053, 1993; Guo, H. C. et al., Nature 360:364, 1992; Silver, M. L. et al., Nature 360:367, 1992; Matsumura, M. et al., Science 257:927, 1992; Madden et al., Cell 70:1035, 1992; Fremont, D. H. et al., Science 257:919, 1992; Saper, M. A., Bjorkman, P. J. and Wiley, D.C., J. Mol. Biol. 219:277, 1991.)
Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that are correlated with binding to particular HLA antigen(s).
Thus, by a process of HLA motif identification, candidates for epitope-based vaccines have been identified; such candidates can be further evaluated by HLA-peptide binding assays to determine binding affinity and/or the time period of association of the epitope and its corresponding HLA molecule. Additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, and/or immunogenicity.
Various strategies can be utilized to evaluate cellular immunogenicity, including:
1) Evaluation of primary T cell cultures from normal individuals (see, e.g., Wentworth, P. A. et al., Mol. Immunol. 32:603, 1995; Celis, E. et al., Proc. Natl. Acad. Sci. USA 91:2105, 1994; Tsai, V. et al., J. Immunol. 158:1796, 1997; Kawashima, I. et al., Human Immunol. 59:1, 1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells in vitro over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a lymphokine- or 51Cr-release assay involving peptide sensitized target cells.
2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P. A. et al., J. Immunol. 26:97, 1996; Wentworth, P. A. et al., Int. Immunol. 8:651, 1996; Alexander, J. et al., J. Immunol. 159:4753, 1997). For example, in such methods peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured in vitro in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a 51Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen.
3) Demonstration of recall T cell responses from immune individuals who have been either effectively vaccinated and/or from chronically ill patients (see, e.g., Rehermann, B. et al., J. Exp. Med. 181:1047, 1995; Doolan, D. L. et al., Immunity 7:97, 1997; Bertoni, R. et al., J. Clin. Invest. 100:503, 1997; Threlkeld, S. C. et al., J. Immunol. 159:1648, 1997; Diepolder, H. M. et al., J. Virol. 71:6011, 1997). Accordingly, recall responses are detected by culturing PBL from subjects that have been exposed to the antigen due to disease and thus have generated an immune response “naturally”, or from patients who were vaccinated against the antigen. PBL from subjects are cultured in vitro for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of “memory” T cells, as compared to “naive” T cells. At the end of the culture period, T cell activity is detected using assays including 51Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.
VI.) 101P3A11 TRANSGENIC ANIMALS
Nucleic acids that encode a 101P3A11-related protein can also be used to generate either transgenic animals or “knock out” animals that, in turn, are useful in the development and screening of therapeutically useful reagents. In accordance with established techniques, cDNA encoding 101P3A11 can be used to clone genomic DNA that encodes 101P3A11. The cloned genomic sequences can then be used to generate transgenic animals containing cells that express DNA that encode 101P3A11. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 issued 12 Apr. 1988, and 4,870,009 issued 26 Sep. 1989. Typically, particular cells would be targeted for 101P3A11 transgene incorporation with tissue-specific enhancers.
Transgenic animals that include a copy of a transgene encoding 101P3A11 can be used to examine the effect of increased expression of DNA that encodes 101P3A11. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this aspect of the invention, an animal is treated with a reagent and a reduced incidence of a pathological condition, compared to untreated animals that bear the transgene, would indicate a potential therapeutic intervention for the pathological condition.
Alternatively, non-human homologues of 101P3A11 can be used to construct a 101P3A11 “knock out” animal that has a defective or altered gene encoding 101P3A11 as a result of homologous recombination between the endogenous gene encoding 101P3A11 and altered genomic DNA encoding 101P3A11 introduced into an embryonic cell of the animal. For example, cDNA that encodes 101P3A11 can be used to clone genomic DNA encoding 101P3A11 in accordance with established techniques. A portion of the genomic DNA encoding 101P3A11 can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see, e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (see, e.g., Li et al., Cell, 69:915 (1992)). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras (see, e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal, and the embryo brought to term to create a “knock out” animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knock out animals can be characterized, for example, for their ability to defend against certain pathological conditions or for their development of pathological conditions due to absence of a 101P3A11 polypeptide.
VII.) METHODS FOR THE DETECTION OF 101P3A11
Another aspect of the present invention relates to methods for detecting 101P3A11 polynucleotides and 101P3A11-related proteins, as well as methods for identifying a cell that expresses 101P3A11. The expression profile of 101P3A11 makes it a diagnostic marker for metastasized disease. Accordingly, the status of 101P3A11 gene products provides information useful for predicting a variety of factors including susceptibility to advanced stage disease, rate of progression, and/or tumor aggressiveness. As discussed in detail herein, the status of 101P3A11 gene products in patient samples can be analyzed by a variety protocols that are well known in the art including immunohistochemical analysis, the variety of Northern blotting techniques including in situ hybridization, RT-PCR analysis (for example on laser capture micro-dissected samples), Western blot analysis and tissue array analysis.
More particularly, the invention provides assays for the detection of 101P3A11 polynucleotides in a biological sample, such as serum, bone, prostate, and other tissues, urine, semen, cell preparations, and the like. Detectable 101P3A11 polynucleotides include, for example, a 101P3A11 gene or fragment thereof, 101P3A11 mRNA, alternative splice variant 101P3A11 mRNAs, and recombinant DNA or RNA molecules that contain a 101P3A11 polynucleotide. A number of methods for amplifying and/or detecting the presence of 101P3A11 polynucleotides are well known in the art and can be employed in the practice of this aspect of the invention.
In one embodiment, a method for detecting a 101P3A11 mRNA in a biological sample comprises producing cDNA from the sample by reverse transcription using at least one primer; amplifying the cDNA so produced using a 101P3A11 polynucleotides as sense and antisense primers to amplify 101P3A11 cDNAs therein; and detecting the presence of the amplified 101P3A11 cDNA. Optionally, the sequence of the amplified 101P3A11 cDNA can be determined.
In another embodiment, a method of detecting a 101P3A11 gene in a biological sample comprises first isolating genomic DNA from the sample; amplifying the isolated genomic DNA using 101P3A11 polynucleotides as sense and antisense primers; and detecting the presence of the amplified 101P3A11 gene. Any number of appropriate sense and antisense probe combinations can be designed from a 101P3A11 nucleotide sequence (see, e.g., FIG. 2) and used for this purpose.
The invention also provides assays for detecting the presence of a 101P3A11 protein in a tissue or other biological sample such as serum, semen, bone, prostate, urine, cell preparations, and the like. Methods for detecting a 101P3A11-related protein are also well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western blot analysis, molecular binding assays, ELISA, ELIFA and the like. For example, a method of detecting the presence of a 101P3A11-related protein in a biological sample comprises first contacting the sample with a 101P3A11 antibody, a 101P3A11-reactive fragment thereof, or a recombinant protein containing an antigen binding region of a 101P3A11 antibody; and then detecting the binding of 101P3A11-related protein in the sample.
Methods for identifying a cell that expresses 101P3A11 are also within the scope of the invention. In one embodiment, an assay for identifying a cell that expresses a 101P3A11 gene comprises detecting the presence of 101P3A11 mRNA in the cell. Methods for the detection of particular mRNAs in cells are well known and include, for example, hybridization assays using complementary DNA probes (such as in situ hybridization using labeled 101P3A11 riboprobes, Northern blot and related techniques) and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific for 101P3A11, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like). Alternatively, an assay for identifying a cell that expresses a 101P3A11 gene comprises detecting the presence of 101P3A11-related protein in the cell or secreted by the cell. Various methods for the detection of proteins are well known in the art and are employed for the detection of 101P3A11-related proteins and cells that express 101P3A11-related proteins.
101P3A11 expression analysis is also useful as a tool for identifying and evaluating agents that modulate 101P3A11 gene expression. For example, 101P3A11 expression is significantly upregulated in prostate cancer, and is expressed in cancers of the tissues listed in Table I. Identification of a molecule or biological agent that inhibits 101P3A11 expression or over-expression in cancer cells is of therapeutic value. For example, such an agent can be identified by using a screen that quantifies 101P3A11 expression by RT-PCR, nucleic acid hybridization or antibody binding.
VIII.) METHODS FOR MONITORING THE STATUS OF 101P3A11-RELATED GENES AND THEIR PRODUCTS
Oncogenesis is known to be a multistep process where cellular growth becomes progressively dysregulated and cells progress from a normal physiological state to precancerous and then cancerous states (see, e.g., Alers et al., Lab Invest. 77(5): 437-438 (1997) and Isaacs et al., Cancer Surv. 23: 19-32 (1995)). In this context, examining a biological sample for evidence of dysregulated cell growth (such as aberrant 101P3A11 expression in cancers) allows for early detection of such aberrant physiology, before a pathologic state such as cancer has progressed to a stage that therapeutic options are more limited and or the prognosis is worse. In such examinations, the status of 101P3A11 in a biological sample of interest can be compared, for example, to the status of 101P3A11 in a corresponding normal sample (e.g. a sample from that individual or alternatively another individual that is not affected by a pathology). An alteration in the status of 101P3A11 in the biological sample (as compared to the normal sample) provides evidence of dysregulated cellular growth. In addition to using a biological sample that is not affected by a pathology as a normal sample, one can also use a predetermined normative value such as a predetermined normal level of mRNA expression (see, e.g., Grever et al., J. Comp. Neurol. 1996 Dec. 9; 376(2): 306-14 and U.S. Pat. No. 5,837,501) to compare 101P3A11 status in a sample.
The term “status” in this context is used according to its art accepted meaning and refers to the condition or state of a gene and its products. Typically, skilled artisans use a number of parameters to evaluate the condition or state of a gene and its products. These include, but are not limited to the location of expressed gene products (including the location of 101P3A11 expressing cells) as well as the level, and biological activity of expressed gene products (such as 101P3A11 mRNA, polynucleotides and polypeptides). Typically, an alteration in the status of 101P3A11 comprises a change in the location of 101P3A11 and/or 101P3A11 expressing cells and/or an increase in 101P3A11 mRNA and/or protein expression.
101P3A11 status in a sample can be analyzed by a number of means well known in the art, including without limitation, immunohistochemical analysis, in situ hybridization, RT-PCR analysis on laser capture micro-dissected samples, Western blot analysis, and tissue array analysis. Typical protocols for evaluating the status of a 101P3A11 gene and gene products are found, for example in Ausubel et al. eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). Thus, the status of 101P3A11 in a biological sample is evaluated by various methods utilized by skilled artisans including, but not limited to genomic Southern analysis (to examine, for example perturbations in a 101P3A11 gene), Northern analysis and/or PCR analysis of 101P3A11 mRNA (to examine, for example alterations in the polynucleotide sequences or expression levels of 101P3A11 mRNAs), and, Western and/or immunohistochemical analysis (to examine, for example alterations in polypeptide sequences, alterations in polypeptide localization within a sample, alterations in expression levels of 101P3A11 proteins and/or associations of 101P3A11 proteins with polypeptide binding partners). Detectable 101P3A11 polynucleotides include, for example, a 101P3A11 gene or fragment thereof, 101P3A11 mRNA, alternative splice variants, 101P3A11 mRNAs, and recombinant DNA or RNA molecules containing a 101P3A11 polynucleotide.
The expression profile of 101P3A11 makes it a diagnostic marker for local and/or metastasized disease, and provides information on the growth or oncogenic potential of a biological sample. In particular, the status of 101P3A11 provides information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining 101P3A11 status and diagnosing cancers that express 101P3A11, such as cancers of the tissues listed in Table I. For example, because 101P3A11 mRNA is so highly expressed in prostate and other cancers relative to normal prostate tissue, assays that evaluate the levels of 101P3A11 mRNA transcripts or proteins in a biological sample can be used to diagnose a disease associated with 101P3A11 dysregulation, and can provide prognostic information useful in defining appropriate therapeutic options.
The expression status of 101P3A11 provides information including the presence, stage and location of dysplastic, precancerous and cancerous cells, predicting susceptibility to various stages of disease, and/or for gauging tumor aggressiveness. Moreover, the expression profile makes it useful as an imaging reagent for metastasized disease. Consequently, an aspect of the invention is directed to the various molecular prognostic and diagnostic methods for examining the status of 101P3A11 in biological samples such as those from individuals suffering from, or suspected of suffering from a pathology characterized by dysregulated cellular growth, such as cancer.
As described above, the status of 101P3A11 in a biological sample can be examined by a number of well-known procedures in the art. For example, the status of 101P3A11 in a biological sample taken from a specific location in the body can be examined by evaluating the sample for the presence or absence of 101P3A11 expressing cells (e.g. those that express 101P3A11 mRNAs or proteins). This examination can provide evidence of dysregulated cellular growth, for example, when 101P3A11-expressing cells are found in a biological sample that does not normally contain such cells (such as a lymph node), because such alterations in the status of 101P3A11 in a biological sample are often associated with dysregulated cellular growth. Specifically, one indicator of dysregulated cellular growth is the metastases of cancer cells from an organ of origin (such as the prostate) to a different area of the body (such as a lymph node). In this context, evidence of dysregulated cellular growth is important for example because occult lymph node metastases can be detected in a substantial proportion of patients with prostate cancer, and such metastases are associated with known predictors of disease progression (see, e.g., Murphy et al., Prostate 42(4): 315-317 (2000); Su et al., Semin. Surg. Oncol. 18(1): 17-28 (2000) and Freeman et al., J Urol 1995 August 154(2 Pt 1):474-8).
In one aspect, the invention provides methods for monitoring 101P3A11 gene products by determining the status of 101P3A11 gene products expressed by cells from an individual suspected of having a disease associated with dysregulated cell growth (such as hyperplasia or cancer) and then comparing the status so determined to the status of 101P3A11 gene products in a corresponding normal sample. The presence of aberrant 101P3A11 gene products in the test sample relative to the normal sample provides an indication of the presence of dysregulated cell growth within the cells of the individual.
In another aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in 101P3A11 mRNA or protein expression in a test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue. The presence of 101P3A11 mRNA can, for example, be evaluated in tissues including but not limited to those listed in Table I. The presence of significant 101P3A11 expression in any of these tissues is useful to indicate the emergence, presence and/or severity of a cancer, since the corresponding normal tissues do not express 101P3A11 mRNA or express it at lower levels.
In a related embodiment, 101P3A11 status is determined at the protein level rather than at the nucleic acid level. For example, such a method comprises determining the level of 101P3A11 protein expressed by cells in a test tissue sample and comparing the level so determined to the level of 101P3A11 expressed in a corresponding normal sample. In one embodiment, the presence of 101P3A11 protein is evaluated, for example, using immunohistochemical methods. 101P3A11 antibodies or binding partners capable of detecting 101P3A11 protein expression are used in a variety of assay formats well known in the art for this purpose.
In a further embodiment, one can evaluate the status of 101P3A11 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules. These perturbations can include insertions, deletions, substitutions and the like. Such evaluations are useful because perturbations in the nucleotide and amino acid sequences are observed in a large number of proteins associated with a growth dysregulated phenotype (see, e.g., Marrogi et al., 1999, J. Cutan. Pathol. 26(8):369-378). For example, a mutation in the sequence of 101P3A11 may be indicative of the presence or promotion of a tumor. Such assays therefore have diagnostic and predictive value where a mutation in 101P3A11 indicates a potential loss of function or increase in tumor growth.
A wide variety of assays for observing perturbations in nucleotide and amino acid sequences are well known in the art. For example, the size and structure of nucleic acid or amino acid sequences of 101P3A11 gene products are observed by the Northern, Southern, Western, PCR and DNA sequencing protocols discussed herein. In addition, other methods for observing perturbations in nucleotide and amino acid sequences such as single strand conformation polymorphism analysis are well known in the art (see, e.g., U.S. Pat. Nos. 5,382,510 issued 7 Sep. 1999, and 5,952,170 issued 17 Jan. 1995).
Additionally, one can examine the methylation status of a 101P3A11 gene in a biological sample. Aberrant demethylation and/or hypermethylation of CpG islands in gene 5′ regulatory regions frequently occurs in immortalized and transformed cells, and can result in altered expression of various genes. For example, promoter hypermethylation of the pi-class glutathione S-transferase (a protein expressed in normal prostate but not expressed in >90% of prostate carcinomas) appears to permanently silence transcription of this gene and is the most frequently detected genomic alteration in prostate carcinomas (De Marzo et al., Am. J. Pathol. 155(6): 1985-1992 (1999)). In addition, this alteration is present in at least 70% of cases of high-grade prostatic intraepithelial neoplasia (PIN) (Brooks et al., Cancer Epidemiol. Biomarkers Prev., 1998, 7:531-536). In another example, expression of the LAGE-I tumor specific gene (which is not expressed in normal prostate but is expressed in 25-50% of prostate cancers) is induced by deoxy-azacytidine in lymphoblastoid cells, suggesting that tumoral expression is due to demethylation (Lethe et al., Int. J. Cancer 76(6): 903-908 (1998)). A variety of assays for examining methylation status of a gene are well known in the art. For example, one can utilize, in Southern hybridization approaches, methylation-sensitive restriction enzymes that cannot cleave sequences that contain methylated CpG sites to assess the methylation status of CpG islands. In addition, MSP (methylation specific PCR) can rapidly profile the methylation status of all the CpG sites present in a CpG island of a given gene. This procedure involves initial modification of DNA by sodium bisulfite (which will convert all unmethylated cytosines to uracil) followed by amplification using primers specific for methylated versus unmethylated DNA. Protocols involving methylation interference can also be found for example in Current Protocols In Molecular Biology, Unit 12, Frederick M. Ausubel et al. eds., 1995.
Gene amplification is an additional method for assessing the status of 101P3A11. Gene amplification is measured in a sample directly, for example, by conventional Southern blotting or Northern blotting to quantitate the transcription of mRNA (Thomas, 1980, Proc. Natl. Acad. Sci. USA, 77:5201-5205), dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies are employed that recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn are labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
Biopsied tissue or peripheral blood can be conveniently assayed for the presence of cancer cells using for example, Northern, dot blot or RT-PCR analysis to detect 101P3A11 expression. The presence of RT-PCR amplifiable 101P3A11 mRNA provides an indication of the presence of cancer. RT-PCR assays are well known in the art. RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik et al., 1997, Urol. Res. 25:373-384; Ghossein et al., 1995, J. Clin. Oncol. 13:1195-2000; Heston et al., 1995, Clin. Chem. 41:1687-1688).
A further aspect of the invention is an assessment of the susceptibility that an individual has for developing cancer. In one embodiment, a method for predicting susceptibility to cancer comprises detecting 101P3A11 mRNA or 101P3A11 protein in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of 101P3A11 mRNA expression correlates to the degree of susceptibility. In a specific embodiment, the presence of 101P3A11 in prostate or other tissue is examined, with the presence of 101P3A11 in the sample providing an indication of prostate cancer susceptibility (or the emergence or existence of a prostate tumor). Similarly, one can evaluate the integrity 101P3A11 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations in 101P3A11 gene products in the sample is an indication of cancer susceptibility (or the emergence or existence of a tumor).
The invention also comprises methods for gauging tumor aggressiveness. In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of 101P3A11 mRNA or 101P3A11 protein expressed by tumor cells, comparing the level so determined to the level of 101P3A11 mRNA or 101P3A11 protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of 101P3A11 mRNA or 101P3A11 protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness. In a specific embodiment, aggressiveness of a tumor is evaluated by determining the extent to which 101P3A11 is expressed in the tumor cells, with higher expression levels indicating more aggressive tumors. Another embodiment is the evaluation of the integrity of 101P3A11 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations indicates more aggressive tumors.
Another embodiment of the invention is directed to methods for observing the progression of a malignancy in an individual over time. In one embodiment, methods for observing the progression of a malignancy in an individual over time comprise determining the level of 101P3A11 mRNA or 101P3A11 protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of 101P3A11 mRNA or 101P3A11 protein expressed in an equivalent tissue sample taken from the same individual at a different time, wherein the degree of 101P3A11 mRNA or 101P3A11 protein expression in the tumor sample over time provides information on the progression of the cancer. In a specific embodiment, the progression of a cancer is evaluated by determining 101P3A11 expression in the tumor cells over time, where increased expression over time indicates a progression of the cancer. Also, one can evaluate the integrity 101P3A11 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like, where the presence of one or more perturbations indicates a progression of the cancer.
The above diagnostic approaches can be combined with any one of a wide variety of prognostic and diagnostic protocols known in the art. For example, another embodiment of the invention is directed to methods for observing a coincidence between the expression of 101P3A11 gene and 101P3A11 gene products (or perturbations in 101P3A11 gene and 101P3A11 gene products) and a factor that is associated with malignancy, as a means for diagnosing and prognosticating the status of a tissue sample. A wide variety of factors associated with malignancy can be utilized, such as the expression of genes associated with malignancy (e.g. PSA, PSCA and PSM expression for prostate cancer etc.) as well as gross cytological observations (see, e.g., Bocking et al., 1984, Anal. Quant. Cytol. 6(2):74-88; Epstein, 1995, Hum. Pathol. 26(2):223-9; Thorson et al., 1998, Mod. Pathol. 11(6):543-51; Baisden et al., 1999, Am. J. Surg. Pathol. 23(8):918-24). Methods for observing a coincidence between the expression of 101P3A11 gene and 101P3A11 gene products (or perturbations in 101P3A11 gene and 101P3A11 gene products) and another factor that is associated with malignancy are useful, for example, because the presence of a set of specific factors that coincide with disease provides information crucial for diagnosing and prognosticating the status of a tissue sample.
In one embodiment, methods for observing a coincidence between the expression of 101P3A11 gene and 101P3A11 gene products (or perturbations in 101P3A11 gene and 101P3A11 gene products) and another factor associated with malignancy entails detecting the overexpression of 101P3A11 mRNA or protein in a tissue sample, detecting the overexpression of PSA mRNA or protein in a tissue sample (or PSCA or PSM expression), and observing a coincidence of 101P3A11 mRNA or protein and PSA mRNA or protein overexpression (or PSCA or PSM expression). In a specific embodiment, the expression of 101P3A11 and PSA mRNA in prostate tissue is examined, where the coincidence of 101P3A11 and PSA mRNA overexpression in the sample indicates the existence of prostate cancer, prostate cancer susceptibility or the emergence or status of a prostate tumor.
Methods for detecting and quantifying the expression of 101P3A11 mRNA or protein are described herein, and standard nucleic acid and protein detection and quantification technologies are well known in the art. Standard methods for the detection and quantification of 101P3A11 mRNA include in situ hybridization using labeled 101P3A11 riboprobes, Northern blot and related techniques using 101P3A11 polynucleotide probes, RT-PCR analysis using primers specific for 101P3A11, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like. In a specific embodiment, semi-quantitative RT-PCR is used to detect and quantify 101P3A11 mRNA expression. Any number of primers capable of amplifying 101P3A11 can be used for this purpose, including but not limited to the various primer sets specifically described herein. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type 101P3A11 protein can be used in an immunohistochemical assay of biopsied tissue.
IX.) IDENTIFICATION OF MOLECULES THAT INTERACT WITH 101P3A11
The 101P3A11 protein and nucleic acid sequences disclosed herein allow a skilled artisan to identify proteins, small molecules and other agents that interact with 101P3A11, as well as pathways activated by 101P3A11 via any one of a variety of art accepted protocols. For example, one can utilize one of the so-called interaction trap systems (also referred to as the “two-hybrid assay”). In such systems, molecules interact and reconstitute a transcription factor which directs expression of a reporter gene, whereupon the expression of the reporter gene is assayed. Other systems identify protein-protein interactions in vivo through reconstitution of a eukaryotic transcriptional activator, see, e.g., U.S. Pat. Nos. 5,955,280 issued 21 Sep. 1999, 5,925,523 issued 20 Jul. 1999, 5,846,722 issued 8 Dec. 1998 and 6,004,746 issued 21 Dec. 1999. Algorithms are also available in the art for genome-based predictions of protein function (see, e.g., Marcotte, et al., Nature 402: 4 Nov. 1999, 83-86).
Alternatively one can screen peptide libraries to identify molecules that interact with 101P3A11 protein sequences. In such methods, peptides that bind to 101P3A11 are identified by screening libraries that encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, the bacteriophage particles are then screened against the 101P3A11 protein(s).
Accordingly, peptides having a wide variety of uses, such as therapeutic, prognostic or diagnostic reagents, are thus identified without any prior information on the structure of the expected ligand or receptor molecule. Typical peptide libraries and screening methods that can be used to identify molecules that interact with 101P3A11 protein sequences are disclosed for example in U.S. Pat. Nos. 5,723,286 issued 3 Mar. 1998 and 5,733,731 issued 31 Mar. 1998.
Alternatively, cell lines that express 101P3A11 are used to identify protein-protein interactions mediated by 101P3A11. Such interactions can be examined using immunoprecipitation techniques (see, e.g., Hamilton B. J., et al. Biochem. Biophys. Res. Commun. 1999, 261:646-51). 101P3A11 protein can be immunoprecipitated from 101P3A11-expressing cell lines using anti-101P3A11 antibodies. Alternatively, antibodies against His-tag can be used in a cell line engineered to express fusions of 101P3A11 and a His-tag (vectors mentioned above). The immunoprecipitated complex can be examined for protein association by procedures such as Western blotting, 35S-methionine labeling of proteins, protein microsequencing, silver staining and two-dimensional gel electrophoresis.
Small molecules and ligands that interact with 101P3A11 can be identified through related embodiments of such screening assays. For example, small molecules can be identified that interfere with protein function, including molecules that interfere with 101P3A11's ability to mediate phosphorylation and de-phosphorylation, interaction with DNA or RNA molecules as an indication of regulation of cell cycles, second messenger signaling or tumorigenesis. Similarly, small molecules that modulate 101P3A11-related ion channel, protein pump, or cell communication functions are identified and used to treat patients that have a cancer that expresses 101P3A11 (see, e.g., Hille, B., Ionic Channels of Excitable Membranes 2nd Ed., Sinauer Assoc., Sunderland, Mass., 1992). Moreover, ligands that regulate 101P3A11 function can be identified based on their ability to bind 101P3A11 and activate a reporter construct. Typical methods are discussed for example in U.S. Pat. No. 5,928,868 issued 27 Jul. 1999, and include methods for forming hybrid ligands in which at least one ligand is a small molecule. In an illustrative embodiment, cells engineered to express a fusion protein of 101P3A11 and a DNA-binding protein are used to co-express a fusion protein of a hybrid ligand/small molecule and a cDNA library transcriptional activator protein. The cells further contain a reporter gene, the expression of which is conditioned on the proximity of the first and second fusion proteins to each other, an event that occurs only if the hybrid ligand binds to target sites on both hybrid proteins. Those cells that express the reporter gene are selected and the unknown small molecule or the unknown ligand is identified. This method provides a means of identifying modulators which activate or inhibit 101P3A11.
An embodiment of this invention comprises a method of screening for a molecule that interacts with a 101P3A11 amino acid sequence shown in FIG. 2 or FIG. 3, comprising the steps of contacting a population of molecules with a 101P3A11 amino acid sequence, allowing the population of molecules and the 101P3A11 amino acid sequence to interact under conditions that facilitate an interaction, determining the presence of a molecule that interacts with the 101P3A11 amino acid sequence, and then separating molecules that do not interact with the 101P3A11 amino acid sequence from molecules that do. In a specific embodiment, the method further comprises purifying, characterizing and identifying a molecule that interacts with the 101P3A11 amino acid sequence. The identified molecule can be used to modulate a function performed by 101P3A11. In a preferred embodiment, the 101P3A11 amino acid sequence is contacted with a library of peptides.
X.) THERAPEUTIC METHODS AND COMPOSITIONS
The identification of 101P3A11 as a protein that is normally expressed in a restricted set of tissues, but which is also expressed in prostate and other cancers, opens a number of therapeutic approaches to the treatment of such cancers. As contemplated herein, 101P3A11 functions as a transcription factor involved in activating tumor-promoting genes or repressing genes that block tumorigenesis.
Accordingly, therapeutic approaches that inhibit the activity of a 101P3A11 protein are useful for patients suffering from a cancer that expresses 101P3A11. These therapeutic approaches generally fall into two classes. One class comprises various methods for inhibiting the binding or association of a 101P3A11 protein with its binding partner or with other proteins. Another class comprises a variety of methods for inhibiting the transcription of a 101P3A11 gene or translation of 101P3A11 mRNA.
X.A.) Anti-Cancer Vaccines
The invention provides cancer vaccines comprising a 101P3A11-related protein or 101P3A11-related nucleic acid. In view of the expression of 101P3A11, cancer vaccines prevent and/or treat 101P3A11-expressing cancers with minimal or no effects on non-target tissues. The use of a tumor antigen in a vaccine that generates humoral and/or cell-mediated immune responses as anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63:231-237; Fong et al., 1997, J. Immunol. 159:3113-3117).
Such methods can be readily practiced by employing a 101P3A11-related protein, or a 101P3A11-encoding nucleic acid molecule and recombinant vectors capable of expressing and presenting the 101P3A11 immunogen (which typically comprises a number of antibody or T cell epitopes). Skilled artisans understand that a wide variety of vaccine systems for delivery of immunoreactive epitopes are known in the art (see, e.g., Heryln et al., Ann Med 1999 February 31(1):66-78; Maruyama et al., Cancer Immunol Immunother 2000 June 49(3):123-32) Briefly, such methods of generating an immune response (e.g. humoral and/or cell-mediated) in a mammal, comprise the steps of: exposing the mammal's immune system to an immunoreactive epitope (e.g. an epitope present in a 101P3A11 protein shown in FIG. 3 or analog or homolog thereof) so that the mammal generates an immune response that is specific for that epitope (e.g. generates antibodies that specifically recognize that epitope). In a preferred method, a 101P3A11 immunogen contains a biological motif, see e.g., Tables V-XVIII and XXII TO IL, or a peptide of a size range from 101P3A11 indicated in FIG. 5, FIG. 6, FIG. 7, FIG. 8, and FIG. 9.
The entire 101P3A11 protein, immunogenic regions or epitopes thereof can be combined and delivered by various means. Such vaccine compositions can include, for example, lipopeptides (e.g., Vitiello, A. et al., J. Clin. Invest. 95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) (“PLG”) microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, 1991: Alonso et al., Vaccine 12:299-306, 1994; Jones et al., Vaccine 13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875, 1990; Hu et al., Clin Exp Immunol. 113:235-243, 1998), multiple antigen peptide systems (MAPs) (see e.g., Tam, J. P., Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413, 1988; Tam, J. P., J. Immunol. Methods 196:17-32, 1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M. E. et al., In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. et al., Nature 320:535, 1986; Hu, S. L. et al., Nature 320:537, 1986; Kieny, M.-P. et al., AIDS Bio/Technology 4:790, 1986; Top, F. H. et al., J. Infect. Dis. 124:148, 1971; Chanda, P. K. et al., Virology 175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. et al., J. Immunol. Methods. 192:25, 1996; Eldridge, J. H. et al., Sem. Hematol. 30:16, 1993; Falo, L. D., Jr. et al., Nature Med. 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. Annu. Rev. Immunol. 4:369, 1986; Gupta, R. K. et al., Vaccine 11:293, 1993), liposomes (Reddy, R. et al., J. Immunol. 148:1585, 1992; Rock, K. L., Immunol. Today 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. et al., Science 259:1745, 1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., Vaccine 11:957, 1993; Shiver, J. W. et al., In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A., Annu. Rev. Immunol. 12:923, 1994 and Eldridge, J. H. et al., Sem. Hematol. 30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Mass.) may also be used.
In patients with 101P3A11-associated cancer, the vaccine compositions of the invention can also be used in conjunction with other treatments used for cancer, e.g., surgery, chemotherapy, drug therapies, radiation therapies, etc. including use in combination with immune adjuvants such as IL-2, IL-12, GM-CSF, and the like.
Cellular Vaccines:
CTL epitopes can be determined using specific algorithms to identify peptides within 101P3A11 protein that bind corresponding HLA alleles (see e.g., Table IV; EpimerTM and EpimatrixTM); and, BIMAS and SYFPEITHI sites. In a preferred embodiment, a 101P3A11 immunogen contains one or more amino acid sequences identified using techniques well known in the art, such as the sequences shown in Tables V-XVIII and XXII TO IL or a peptide of 8, 9, 10 or 11 amino acids specified by an HLA Class I motif/supermotif (e.g., Table IV (A), Table IV (D), or Table IV (E)) and/or a peptide of at least 9 amino acids that comprises an HLA Class II motif/supermotif (e.g., Table IV (B) or Table IV (C)). As is appreciated in the art, the HLA Class I binding groove is essentially closed ended so that peptides of only a particular size range can fit into the groove and be bound, generally HLA Class I epitopes are 8, 9, 10, or 11 amino acids long. In contrast, the HLA Class II binding groove is essentially open ended; therefore a peptide of about 9 or more amino acids can be bound by an HLA Class II molecule. Due to the binding groove differences between HLA Class I and II, HLA Class I motifs are length specific, i.e., position two of a Class I motif is the second amino acid in an amino to carboxyl direction of the peptide. The amino acid positions in a Class II motif are relative only to each other, not the overall peptide, i.e., additional amino acids can be attached to the amino and/or carboxyl termini of a motif-bearing sequence. HLA Class II epitopes are often 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long, or longer than 25 amino acids.
Antibody-Based Vaccines
A wide variety of methods for generating an immune response in a mammal are known in the art (for example as the first step in the generation of hybridomas). Methods of generating an immune response in a mammal comprise exposing the mammal's immune system to an immunogenic epitope on a protein (e.g. a 101P3A11 protein) so that an immune response is generated. A typical embodiment consists of a method for generating an immune response to 101P3A11 in a host, by contacting the host with a sufficient amount of at least one 101P3A11 B cell or cytotoxic T-cell epitope or analog thereof; and at least one periodic interval thereafter re-contacting the host with the 101P3A11 B cell or cytotoxic T-cell epitope or analog thereof. A specific embodiment consists of a method of generating an immune response against a 101P3A11-related protein or a man-made multiepitopic peptide comprising: administering 101P3A11 immunogen (e.g. a 101P3A11 protein or a peptide fragment thereof, a 101P3A11 fusion protein or analog etc.) in a vaccine preparation to a human or another mammal. Typically, such vaccine preparations further contain a suitable adjuvant (see, e.g., U.S. Pat. No. 6,146,635) or a universal helper epitope such as a PADRETM peptide (Epimmune Inc., San Diego, Calif.; see, e.g., Alexander et al., J. Immunol. 2000 164(3); 164(3): 1625-1633; Alexander et al., Immunity 1994 1(9): 751-761 and Alexander et al., Immunol. Res. 1998 18(2): 79-92). An alternative method comprises generating an immune response in an individual against a 101P3A11 immunogen by: administering in vivo to muscle or skin of the individual's body a DNA molecule that comprises a DNA sequence that encodes a 101P3A11 immunogen, the DNA sequence operatively linked to regulatory sequences which control the expression of the DNA sequence; wherein the DNA molecule is taken up by cells, the DNA sequence is expressed in the cells and an immune response is generated against the immunogen (see, e.g., U.S. Pat. No. 5,962,428). Optionally a genetic vaccine facilitator such as anionic lipids; saponins; lectins; estrogenic compounds; hydroxylated lower alkyls; dimethyl sulfoxide; and urea is also administered. In addition, an antiidiotypic antibody can be administered that mimics 101P3A11, in order to generate a response to the target antigen.
Nucleic Acid Vaccines:
Vaccine compositions of the invention include nucleic acid-mediated modalities. DNA or RNA that encode protein(s) of the invention can be administered to a patient. Genetic immunization methods can be employed to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing 101P3A11. Constructs comprising DNA encoding a 101P3A11-related protein/immunogen and appropriate regulatory sequences can be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded 101P3A11 protein/immunogen. Alternatively, a vaccine comprises a 101P3A11-related protein. Expression of the 101P3A11-related protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against cells that bear a 101P3A11 protein. Various prophylactic and therapeutic genetic immunization techniques known in the art can be used. Nucleic acid-based delivery is described, for instance, in Wolff et. al., Science 247:1465 (1990) as well as U.S. Pat. Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720. Examples of DNA-based delivery technologies include “naked DNA”, facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated (“gene gun”) or pressure-mediated delivery (see, e.g., U.S. Pat. No. 5,922,687).
For therapeutic or prophylactic immunization purposes, proteins of the invention can be expressed via viral or bacterial vectors. Various viral gene delivery systems that can be used in the practice of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbis virus (see, e.g., Restifo, 1996, Curr. Opin. Immunol. 8:658-663; Tsang et al. J. Natl. Cancer Inst. 87:982-990 (1995)). Non-viral delivery systems can also be employed by introducing naked DNA encoding a 101P3A11-related protein into the patient (e.g., intramuscularly or intradermally) to induce an anti-tumor response.
Vaccinia virus is used, for example, as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the protein immunogenic peptide, and thereby elicits a host immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Pat. No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein.
Thus, gene delivery systems are used to deliver a 101P3A11-related nucleic acid molecule. In one embodiment, the full-length human 101P3A11 cDNA is employed. In another embodiment, 101P3A11 nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) and/or antibody epitopes are employed.
Ex Vivo Vaccines
Various ex vivo strategies can also be employed to generate an immune response. One approach involves the use of antigen presenting cells (APCs) such as dendritic cells (DC) to present 101P3A11 antigen to a patient's immune system. Dendritic cells express MHC class I and II molecules, B7 co-stimulator, and IL-12, and are thus highly specialized antigen presenting cells. In prostate cancer, autologous dendritic cells pulsed with peptides of the prostate-specific membrane antigen (PSMA) are being used in a Phase I clinical trial to stimulate prostate cancer patients' immune systems (Tjoa et al., 1996, Prostate 28:65-69; Murphy et al., 1996, Prostate 29:371-380). Thus, dendritic cells can be used to present 101P3A11 peptides to T cells in the context of MHC class I or II molecules. In one embodiment, autologous dendritic cells are pulsed with 101P3A11 peptides capable of binding to MHC class I and/or class II molecules. In another embodiment, dendritic cells are pulsed with the complete 101P3A11 protein. Yet another embodiment involves engineering the overexpression of a 101P3A11 gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur et al., 1997, Cancer Gene Ther. 4:17-25), retrovirus (Henderson et al., 1996, Cancer Res. 56:3763-3770), lentivirus, adeno-associated virus, DNA transfection (Ribas et al., 1997, Cancer Res. 57:2865-2869), or tumor-derived RNA transfection (Ashley et al., 1997, J. Exp. Med. 186:1177-1182). Cells that express 101P3A11 can also be engineered to express immune modulators, such as GM-CSF, and used as immunizing agents.
X.B.) 101P3A11 as a Target for Antibody-Based Therapy
101P3A11 is an attractive target for antibody-based therapeutic strategies. A number of antibody strategies are known in the art for targeting both extracellular and intracellular molecules (see, e.g., complement and ADCC mediated killing as well as the use of intrabodies). Because 101P3A11 is expressed by cancer cells of various lineages relative to corresponding normal cells, systemic administration of 101P3A11-immunoreactive compositions are prepared that exhibit excellent sensitivity without toxic, non-specific and/or non-target effects caused by binding of the immunoreactive composition to non-target organs and tissues. Antibodies specifically reactive with domains of 101P3A11 are useful to treat 101P3A11-expressing cancers systemically, either as conjugates with a toxin or therapeutic agent, or as naked antibodies capable of inhibiting cell proliferation or function.
101P3A11 antibodies can be introduced into a patient such that the antibody binds to 101P3A11 and modulates a function, such as an interaction with a binding partner, and consequently mediates destruction of the tumor cells and/or inhibits the growth of the tumor cells. Mechanisms by which such antibodies exert a therapeutic effect can include complement-mediated cytolysis, antibody-dependent cellular cytotoxicity, modulation of the physiological function of 101P3A11, inhibition of ligand binding or signal transduction pathways, modulation of tumor cell differentiation, alteration of tumor angiogenesis factor profiles, and/or apoptosis.
Those skilled in the art understand that antibodies can be used to specifically target and bind immunogenic molecules such as an immunogenic region of a 101P3A11 sequence shown in FIG. 2 or FIG. 3. In addition, skilled artisans understand that it is routine to conjugate antibodies to cytotoxic agents (see, e.g., Slevers et al. Blood 93:11 3678-3684 (Jun. 1, 1999)). When cytotoxic and/or therapeutic agents are delivered directly to cells, such as by conjugating them to antibodies specific for a molecule expressed by that cell (e.g. 101P3A11), the cytotoxic agent will exert its known biological effect (i.e. cytotoxicity) on those cells.
A wide variety of compositions and methods for using antibody-cytotoxic agent conjugates to kill cells are known in the art. In the context of cancers, typical methods entail administering to an animal having a tumor a biologically effective amount of a conjugate comprising a selected cytotoxic and/or therapeutic agent linked to a targeting agent (e.g. an anti-101P3A11 antibody) that binds to a marker (e.g. 101P3A11) expressed, accessible to binding or localized on the cell surfaces. A typical embodiment is a method of delivering a cytotoxic and/or therapeutic agent to a cell expressing 101P3A11, comprising conjugating the cytotoxic agent to an antibody that immunospecifically binds to a 101P3A11 epitope, and, exposing the cell to the antibody-agent conjugate. Another illustrative embodiment is a method of treating an individual suspected of suffering from metastasized cancer, comprising a step of administering parenterally to said individual a pharmaceutical composition comprising a therapeutically effective amount of an antibody conjugated to a cytotoxic and/or therapeutic agent.
Cancer immunotherapy using anti-101P3A11 antibodies can be done in accordance with various approaches that have been successfully employed in the treatment of other types of cancer, including but not limited to colon cancer (Arlen et al., 1998, Crit. Rev. Immunol. 18:133-138), multiple myeloma (Ozaki et al., 1997, Blood 90:3179-3186, Tsunenari et al., 1997, Blood 90:2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res. 52:2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J. Immunother. Emphasis Tumor Immunol. 19:93-101), leukemia (Zhong et al., 1996, Leuk. Res. 20:581-589), colorectal cancer (Moun et al., 1994, Cancer Res. 54:6160-6166; Velders et al., 1995, Cancer Res. 55:4398-4403), and breast cancer (Shepard et al., 1991, J. Clin. Immunol. 11:117-127). Some therapeutic approaches involve conjugation of naked antibody to a toxin or radioisotope, such as the conjugation of Y91 or I131 to anti-CD20 antibodies (e.g., ZevalinTM, IDEC Pharmaceuticals Corp. or BexxarTM, Coulter Pharmaceuticals), while others involve co-administration of antibodies and other therapeutic agents, such as HerceptinTM (trastuzumab) with paclitaxel (Genentech, Inc.). The antibodies can be conjugated to a therapeutic agent. To treat prostate cancer, for example, 101P3A11 antibodies can be administered in conjunction with radiation, chemotherapy or hormone ablation. Also, antibodies can be conjugated to a toxin such as calicheamicin (e.g., MylotargTM, Wyeth-Ayerst, Madison, N.J., a recombinant humanized IgG4 kappa antibody conjugated to antitumor antibiotic calicheamicin) or a maytansinoid (e.g., taxane-based Tumor-Activated Prodrug, TAP, platform, ImmunoGen, Cambridge, Mass., also see e.g., U.S. Pat. No. 5,416,064).
Although 101P3A11 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well. Fan et al. (Cancer Res. 53:4637-4642, 1993), Prewett et al. (International J. of Onco. 9:217-224, 1996), and Hancock et al. (Cancer Res. 51:4575-4580, 1991) describe the use of various antibodies together with chemotherapeutic agents.
Although 101P3A11 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well.
Cancer patients can be evaluated for the presence and level of 101P3A11 expression, preferably using immunohistochemical assessments of tumor tissue, quantitative 101P3A11 imaging, or other techniques that reliably indicate the presence and degree of 101P3A11 expression. Immunohistochemical analysis of tumor biopsies or surgical specimens is preferred for this purpose. Methods for immunohistochemical analysis of tumor tissues are well known in the art.
Anti-101P3A11 monoclonal antibodies that treat prostate and other cancers include those that initiate a potent immune response against the tumor or those that are directly cytotoxic. In this regard, anti-101P3A11 monoclonal antibodies (mAbs) can elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites on complement proteins. In addition, anti-101P3A11 mAbs that exert a direct biological effect on tumor growth are useful to treat cancers that express 101P3A11. Mechanisms by which directly cytotoxic mAbs act include: inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism(s) by which a particular anti-101P3A11 mAb exerts an anti-tumor effect is evaluated using any number of in vitro assays that evaluate cell death such as ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.
In some patients, the use of murine or other non-human monoclonal antibodies, or human/mouse chimeric mAbs can induce moderate to strong immune responses against the non-human antibody. This can result in clearance of the antibody from circulation and reduced efficacy. In the most severe cases, such an immune response can lead to the extensive formation of immune complexes which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the therapeutic methods of the invention are those that are either fully human or humanized and that bind specifically to the target 101P3A11 antigen with high affinity but exhibit low or no antigenicity in the patient.
Therapeutic methods of the invention contemplate the administration of single anti-101P3A11 mAbs as well as combinations, or cocktails, of different mAbs. Such mAb cocktails can have certain advantages inasmuch as they contain mAbs that target different epitopes, exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination can exhibit synergistic therapeutic effects. In addition, anti-101P3A11 mAbs can be administered concomitantly with other therapeutic modalities, including but not limited to various chemotherapeutic agents, androgen-blockers, immune modulators (e.g., IL-2, GM-CSF), surgery or radiation. The anti-101P3A11 mAbs are administered in their “naked” or unconjugated form, or can have a therapeutic agent(s) conjugated to them.
Anti-101P3A11 antibody formulations are administered via any route capable of delivering the antibodies to a tumor cell. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Treatment generally involves repeated administration of the anti-101P3A11 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 mg/kg body weight. In general, doses in the range of 10-1000 mg mAb per week are effective and well tolerated.
Based on clinical experience with the HerceptinTM mAb in the treatment of metastatic breast cancer, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti-101P3A11 mAb preparation represents an acceptable dosing regimen. Preferably, the initial loading dose is administered as a 90 minute or longer infusion. The periodic maintenance dose is administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. As appreciated by those of skill in the art, various factors can influence the ideal dose regimen in a particular case. Such factors include, for example, the binding affinity and half life of the Ab or mAbs used, the degree of 101P3A11 expression in the patient, the extent of circulating shed 101P3A11 antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient.
Optionally, patients should be evaluated for the levels of 101P3A11 in a given sample (e.g. the levels of circulating 101P3A11 antigen and/or 101P3A11 expressing cells) in order to assist in the determination of the most effective dosing regimen, etc. Such evaluations are also used for monitoring purposes throughout therapy, and are useful to gauge therapeutic success in combination with the evaluation of other parameters (for example, urine cytology and/or ImmunoCyt levels in bladder cancer therapy, or by analogy, serum PSA levels in prostate cancer therapy).
Anti-idiotypic anti-101P3A11 antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a 101P3A11-related protein. In particular, the generation of anti-idiotypic antibodies is well known in the art; this methodology can readily be adapted to generate anti-idiotypic anti-101P3A11 antibodies that mimic an epitope on a 101P3A11-related protein (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J. Clin. Invest. 96:334-342; Herlyn et al., 1996, Cancer Immunol. Immunother. 43:65-76). Such an anti-idiotypic antibody can be used in cancer vaccine strategies.
X.C.) 101P3A11 as a Target for Cellular Immune Responses
Vaccines and methods of preparing vaccines that contain an immunogenically effective amount of one or more HLA-binding peptides as described herein are further embodiments of the invention. Furthermore, vaccines in accordance with the invention encompass compositions of one or more of the claimed peptides. A peptide can be present in a vaccine individually. Alternatively, the peptide can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition can be a naturally occurring region of an antigen or can be prepared, e.g., recombinantly or by chemical synthesis.
Carriers that can be used with vaccines of the invention are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (i.e., acceptable) diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine (P3CSS). Moreover, an adjuvant such as a synthetic cytosine-phosphorothiolated-guanine-containing (CpG) oligonucleotides has been found to increase CTL responses 10- to 100-fold. (see, e.g. Davila and Celis, J. Immunol. 165:539-547 (2000))
Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to later development of cells that express or overexpress 101P3A11 antigen, or derives at least some therapeutic benefit when the antigen was tumor-associated.
In some embodiments, it may be desirable to combine the class I peptide components with components that induce or facilitate neutralizing antibody and or helper T cell responses directed to the target antigen. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I and/or class II epitope in accordance with the invention, along with a cross reactive HTL epitope such as PADRETM (Epimmune, San Diego, Calif.) molecule (described e.g., in U.S. Pat. No. 5,736,142).
A vaccine of the invention can also include antigen-presenting cells (APC), such as dendritic cells (DC), as a vehicle to present peptides of the invention. Vaccine compositions can be created in vitro, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs in vitro. For example, dendritic cells are transfected, e.g., with a minigene in accordance with the invention, or are pulsed with peptides. The dendritic cell can then be administered to a patient to elicit immune responses in vivo. Vaccine compositions, either DNA- or peptide-based, can also be administered in vivo in combination with dendritic cell mobilization whereby loading of dendritic cells occurs in vivo.
Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polyepitopic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. It is preferred that each of the following principles be balanced in order to make the selection. The multiple epitopes to be incorporated in a given vaccine composition may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived.
1.) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with tumor clearance. For HLA Class I this includes 3-4 epitopes that come from at least one tumor associated antigen (TAA). For HLA Class II a similar rationale is employed; again 3-4 epitopes are selected from at least one TAA (see, e.g., Rosenberg et al., Science 278:1447-1450). Epitopes from one TAA may be used in combination with epitopes from one or more additional TAAs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TAAs.
2.) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC50 of 500 nM or less, often 200 nM or less; and for Class II an IC50 of 1000 nM or less.
3.) Sufficient supermotif bearing-peptides, or a sufficient array of allele-specific motif-bearing peptides, are selected to give broad population coverage. For example, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage.
4.) When selecting epitopes from cancer-related antigens it is often useful to select analogs because the patient may have developed tolerance to the native epitope.
5.) Of particular relevance are epitopes referred to as “nested epitopes.” Nested epitopes occur where at least two epitopes overlap in a given peptide sequence. A nested peptide sequence can comprise B cell, HLA class I and/or HLA class II epitopes. When providing nested epitopes, a general objective is to provide the greatest number of epitopes per sequence. Thus, an aspect is to avoid providing a peptide that is any longer than the amino terminus of the amino terminal epitope and the carboxyl terminus of the carboxyl terminal epitope in the peptide. When providing a multi-epitopic sequence, such as a sequence comprising nested epitopes, it is generally important to screen the sequence in order to insure that it does not have pathological or other deleterious biological properties.
6.) If a polyepitopic protein is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of interest. This principle is similar, if not the same as that employed when selecting a peptide comprising nested epitopes. However, with an artificial polyepitopic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic protein. Spacer amino acid residues can, for example, be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a “dominant epitope.” A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed.
7.) Where the sequences of multiple variants of the same target protein are present, potential peptide epitopes can also be selected on the basis of their conservancy. For example, a criterion for conservancy may define that the entire sequence of an HLA class I binding peptide or the entire 9-mer core of a class II binding peptide be conserved in a designated percentage of the sequences evaluated for a specific protein antigen.
X.C.1. Minigene Vaccines
A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding a peptide comprising one or multiple epitopes of the invention.
The use of multi-epitope minigenes is described below and in, Ishioka et al., J. Immunol. 162:3915-3925, 1999; An, L. and Whitton, J. L., J. Virol. 71:2292, 1997; Thomson, S. A. et al., J. Immunol. 157:822, 1996; Whitton, J. L. et al., J. Virol. 67:348, 1993; Hanke, R. et al., Vaccine 16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing epitopes derived 101P3A11, the PADRE® universal helper T cell epitope or multiple HTL epitopes from 101P3A11, (see e.g., Tables V-XVIII and XXII to IL), and an endoplasmic reticulum-translocating signal sequence can be engineered. A vaccine may also comprise epitopes that are derived from other TAAs.
The immunogenicity of a multi-epitopic minigene can be confirmed in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA-encoded epitopes in vivo can be correlated with the in vitro responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes.
For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, antibody epitopes, a ubiquitination signal sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL or HTL epitopes; these larger peptides comprising the epitope(s) are within the scope of the invention.
The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector.
Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an E. coli origin of replication; and an E. coli selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Pat. Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.
Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.
Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate E. coli strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.
In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence, if desired to enhance immunogenicity.
In some embodiments, a bi-cistronic expression vector which allows production of both the minigene-encoded epitopes and a second protein (included to enhance or decrease immunogenicity) can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e.g., LeIF), costimulatory molecules, or for HTL responses, pan-DR binding proteins (PADRETM, Epimmune, San Diego, Calif.). Helper (HTL) epitopes can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes; this allows direction of the HTL epitopes to a cell compartment different than that of the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF-β) may be beneficial in certain diseases.
Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in E. coli, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and grown to saturation in shaker flasks or a bioreactor according to well-known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by QIAGEN, Inc. (Valencia, Calif.). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.
Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as “naked DNA,” is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene DNA vaccines, an alternative method for formulating purified plasmid DNA may be desirable. A variety of methods have been described, and new techniques may become available. Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., as described by WO 93/24640; Mannino & Gould-Fogerite, BioTechniques 6(7): 682 (1988); U.S. Pat. No. 5,279,833; WO 91/06309; and Felgner, et al., Proc. Nat'l Acad. Sci. USA 84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.
Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for “naked” DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 (51Cr) labeled and used as target cells for epitope-specific CTL lines; cytolysis, detected by 51Cr release, indicates both production of, and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.
In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (i.p.) for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTL effector cells, assays are conducted for cytolysis of peptide-loaded, 51Cr-labeled target cells using standard techniques. Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, corresponding to minigene-encoded epitopes, demonstrates DNA vaccine function for in vivo induction of CTLs. Immunogenicity of HTL epitopes is confirmed in transgenic mice in an analogous manner.
Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Pat. No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment, DNA can be adhered to particles, such as gold particles.
Minigenes can also be delivered using other bacterial or viral delivery systems well known in the art, e.g., an expression construct encoding epitopes of the invention can be incorporated into a viral vector such as vaccinia.
X.C.2. Combinations of CTL Peptides with Helper Peptides
Vaccine compositions comprising CTL peptides of the invention can be modified, e.g., analoged, to provide desired attributes, such as improved serum half life, broadened population coverage or enhanced immunogenicity.
For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Although a CTL peptide can be directly linked to a T helper peptide, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues and sometimes 10 or more residues. The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated.
In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in a majority of a genetically diverse population. This can be accomplished by selecting peptides that bind to many, most, or all of the HLA class II molecules. Examples of such amino acid bind many HLA Class II molecules include sequences from antigens such as tetanus toxoid at positions 830-843 QYIKANSKFIGITE (SEQ ID NO: 39), Plasmodium falciparum circumsporozoite (CS) protein at positions 378-398 DIEKKIAKMEKASSVFNVVNS (SEQ ID NO: 40), and Streptococcus 18 kD protein at positions 116-131 GAVDSILGGVATYGAA (SEQ ID NO: 41). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.
Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (see, e.g., PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (e.g., PADRETM, Epimmune, Inc., San Diego, Calif.) are designed to most preferably bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVAAWTLKAAa (SEQ ID NO: 42), where “X” is either cyclohexylalanine, phenylalanine, or tyrosine, and a is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding epitope comprises all “L” natural amino acids and can be provided in the form of nucleic acids that encode the epitope.
HTL peptide epitopes can also be modified to alter their biological properties. For example, they can be modified to include D-amino acids to increase their resistance to proteases and thus extend their serum half life, or they can be conjugated to other molecules such as lipids, proteins, carbohydrates, and the like to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or carboxyl termini.
X.C.3. Combinations of CTL Peptides with T Cell Priming Agents
In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes B lymphocytes or T lymphocytes. Lipids have been identified as agents capable of priming CTL in vivo. For example, palmitic acid residues can be attached to the ε- and α-amino groups of a lysine residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be administered either directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment, a particularly effective immunogenic composition comprises palmitic acid attached to ε- and α-amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.
As another example of lipid priming of CTL responses, E. coli lipoproteins, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine (P3CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide (see, e.g., Deres, et al., Nature 342:561, 1989). Peptides of the invention can be coupled to P3CSS, for example, and the lipopeptide administered to an individual to specifically prime an immune response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P3CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses.
X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides
An embodiment of a vaccine composition in accordance with the invention comprises ex vivo administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A pharmaceutical to facilitate harvesting of DC can be used, such as ProgenipoietinTM (Pharmacia-Monsanto, St. Louis, Mo.) or GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces.
The DC can be pulsed ex vivo with a cocktail of peptides, some of which stimulate CTL responses to 101P3A11. Optionally, a helper T cell (HTL) peptide, such as a natural or artificial loosely restricted HLA Class II peptide, can be included to facilitate the CTL response. Thus, a vaccine in accordance with the invention is used to treat a cancer which expresses or overexpresses 101P3A11.
X.D. Adoptive Immunotherapy
Antigenic 101P3A11-related peptides are used to elicit a CTL and/or HTL response ex vivo, as well. The resulting CTL or HTL cells, can be used to treat tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. Ex vivo CTL or HTL responses to a particular antigen are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (e.g., a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells.
X.E. Administration of Vaccines for Therapeutic or Prophylactic Purposes
Pharmaceutical and vaccine compositions of the invention are typically used to treat and/or prevent a cancer that expresses or overexpresses 101P3A11. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective B cell, CTL and/or HTL response to the antigen and to cure or at least partially arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as “therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.
For pharmaceutical compositions, the immunogenic peptides of the invention, or DNA encoding them, are generally administered to an individual already bearing a tumor that expresses 101P3A11. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. Patients can be treated with the immunogenic peptides separately or in conjunction with other treatments, such as surgery, as appropriate.
For therapeutic use, administration should generally begin at the first diagnosis of 101P3A11-associated cancer. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. The embodiment of the vaccine composition (i.e., including, but not limited to embodiments such as peptide cocktails, polyepitopic polypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells) delivered to the patient may vary according to the stage of the disease or the patient's health status. For example, in a patient with a tumor that expresses 101P3A11, a vaccine comprising 101P3A11-specific CTL may be more efficacious in killing tumor cells in patient with advanced disease than alternative embodiments.
It is generally important to provide an amount of the peptide epitope delivered by a mode of administration sufficient to effectively stimulate a cytotoxic T cell response; compositions which stimulate helper T cell responses can also be given in accordance with this embodiment of the invention.
The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. Boosting dosages of between about 1.0 μg to about 50,000 μg of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient's response and condition as determined by measuring the specific activity of CTL and HTL obtained from the patient's blood. Administration should continue until at least clinical symptoms or laboratory tests indicate that the neoplasia, has been eliminated or reduced and for a period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.
In certain embodiments, the peptides and compositions of the present invention are employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides in preferred compositions of the invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts.
The vaccine compositions of the invention can also be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. This is followed by boosting dosages of between about 1.0 μg to about 50,000 μg of peptide administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine can be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood.
The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, nasal, intrathecal, or local (e.g. as a cream or topical ointment) administration. Preferably, the pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.
A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
A human unit dose form of a composition is typically included in a pharmaceutical composition that comprises a human unit dose of an acceptable carrier, in one embodiment an aqueous carrier, and is administered in a volume/quantity that is known by those of skill in the art to be used for administration of such compositions to humans (see, e.g., Remington's Pharmaceutical Sciences, 17th Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pa., 1985). For example a peptide dose for initial immunization can be from about 1 to about 50,000 μg, generally 100-5,000 μg, for a 70 kg patient. For example, for nucleic acids an initial immunization may be performed using an expression vector in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of 5-107 to 5×109 pfu.
For antibodies, a treatment generally involves repeated administration of the anti-101P3A11 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight. In general, doses in the range of 10-500 mg mAb per week are effective and well tolerated. Moreover, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti-101P3A11 mAb preparation represents an acceptable dosing regimen. As appreciated by those of skill in the art, various factors can influence the ideal dose in a particular case. Such factors include, for example, half life of a composition, the binding affinity of an Ab, the immunogenicity of a substance, the degree of 101P3A11 expression in the patient, the extent of circulating shed 101P3A11 antigen, the desired steady-state concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient. Non-limiting preferred human unit doses are, for example, 500 μg-1 mg, 1 mg-50 mg, 50 mg-100 mg, 100 mg-200 mg, 200 mg-300 mg, 400 mg-500 mg, 500 mg-600 mg, 600 mg-700 mg, 700 mg-800 mg, 800 mg-900 mg, 900 mg-1 g, or 1 mg-700 mg. In certain embodiments, the dose is in a range of 2-5 mg/kg body weight, e.g., with follow on weekly doses of 1-3 mg/kg; 0.5 mg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mg/kg body weight followed, e.g., in two, three or four weeks by weekly doses; 0.5-10 mg/kg body weight, e.g., followed in two, three or four weeks by weekly doses; 225, 250, 275, 300, 325, 350, 375, 400 mg m2 of body area weekly; 1-600 mg m2 of body area weekly; 225-400 mg m2 of body area weekly; these does can be followed by weekly doses for 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12 or more weeks.
In one embodiment, human unit dose forms of polynucleotides comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art a therapeutic effect depends on a number of factors, including the sequence of the polynucleotide, molecular weight of the polynucleotide and route of administration. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. Generally, for a polynucleotide of about 20 bases, a dosage range may be selected from, for example, an independently selected lower limit such as about 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or 500 mg/kg up to an independently selected upper limit, greater than the lower limit, of about 60, 80, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10,000 mg/kg. For example, a dose may be about any of the following: 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.1 to 25 mg/kg, 0.1 to 10 mg/kg, 1 to 500 mg/kg, 100 to 400 mg/kg, 200 to 300 mg/kg, 1 to 100 mg/kg, 100 to 200 mg/kg, 300 to 400 mg/kg, 400 to 500 mg/kg, 500 to 1000 mg/kg, 500 to 5000 mg/kg, or 500 to 10,000 mg/kg. Generally, parenteral routes of administration may require higher doses of polynucleotide compared to more direct application to the nucleotide to diseased tissue, as do polynucleotides of increasing length.
In one embodiment, human unit dose forms of T-cells comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art, a therapeutic effect depends on a number of factors. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. A dose may be about 104 cells to about 106 cells, about 106 cells to about 108 cells, about 108 to about 1011 cells, or about 108 to about 5×1010 cells. A dose may also about 106 cells/m2 to about 1010 cells/m2, or about 106 cells/m2 to about 108 cells/m2.
Proteins(s) of the invention, and/or nucleic acids encoding the protein(s), can also be administered via liposomes, which may also serve to: 1) target the proteins(s) to a particular tissue, such as lymphoid tissue; 2) to target selectively to diseases cells; or, 3) to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid liability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
For targeting cells of the immune system, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.
For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.
For aerosol administration, immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are about 0.01%-20% by weight, preferably about 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from about 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute about 0.1%-20% by weight of the composition, preferably about 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.
XI.) DIAGNOSTIC AND PROGNOSTIC EMBODIMENTS OF 101P3A11
As disclosed herein, 101P3A11 polynucleotides, polypeptides, reactive cytotoxic T cells (CTL), reactive helper T cells (HTL) and anti-polypeptide antibodies are used in well known diagnostic, prognostic and therapeutic assays that examine conditions associated with dysregulated cell growth such as cancer, in particular the cancers listed in Table I (see, e.g., both its specific pattern of tissue expression as well as its overexpression in certain cancers as described for example in the Example entitled “Expression analysis of 101P3A11 in normal tissues, and patient specimens”).
101P3A11 can be analogized to a prostate associated antigen PSA, the archetypal marker that has been used by medical practitioners for years to identify and monitor the presence of prostate cancer (see, e.g., Merrill et al., J. Urol. 163(2): 503-5120 (2000); Polascik et al., J. Urol. August; 162(2):293-306 (1999) and Fortier et al., J. Nat. Cancer Inst. 91(19): 1635-1640(1999)). A variety of other diagnostic markers are also used in similar contexts including p53 and K-ras (see, e.g., Tulchinsky et al., Int J Mol Med 1999 July 4(1):99-102 and Minimoto et al., Cancer Detect Prev 2000; 24(1):1-12). Therefore, this disclosure of 101P3A11 polynucleotides and polypeptides (as well as 101P3A11 polynucleotide probes and anti-101P3A11 antibodies used to identify the presence of these molecules) and their properties allows skilled artisans to utilize these molecules in methods that are analogous to those used, for example, in a variety of diagnostic assays directed to examining conditions associated with cancer.
Typical embodiments of diagnostic methods which utilize the 101P3A11 polynucleotides, polypeptides, reactive T cells and antibodies are analogous to those methods from well-established diagnostic assays which employ, e.g., PSA polynucleotides, polypeptides, reactive T cells and antibodies. For example, just as PSA polynucleotides are used as probes (for example in Northern analysis, see, e.g., Sharief et al., Biochem. Mol. Biol. Int. 33(3):567-74(1994)) and primers (for example in PCR analysis, see, e.g., Okegawa et al., J. Urol. 163(4): 1189-1190 (2000)) to observe the presence and/or the level of PSA mRNAs in methods of monitoring PSA overexpression or the metastasis of prostate cancers, the 101P3A11 polynucleotides described herein can be utilized in the same way to detect 101P3A11 overexpression or the metastasis of prostate and other cancers expressing this gene. Alternatively, just as PSA polypeptides are used to generate antibodies specific for PSA which can then be used to observe the presence and/or the level of PSA proteins in methods to monitor PSA protein overexpression (see, e.g., Stephan et al., Urology 55(4):560-3 (2000)) or the metastasis of prostate cells (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3):233-7 (1996)), the 101P3A11 polypeptides described herein can be utilized to generate antibodies for use in detecting 101P3A11 overexpression or the metastasis of prostate cells and cells of other cancers expressing this gene.
Specifically, because metastases involves the movement of cancer cells from an organ of origin (such as the lung or prostate gland etc.) to a different area of the body (such as a lymph node), assays which examine a biological sample for the presence of cells expressing 101P3A11 polynucleotides and/or polypeptides can be used to provide evidence of metastasis. For example, when a biological sample from tissue that does not normally contain 101P3A11-expressing cells (lymph node) is found to contain 101P3A11-expressing cells such as the 101P3A11 expression seen in LAPC4 and LAPC9, xenografts isolated from lymph node and bone metastasis, respectively, this finding is indicative of metastasis.
Alternatively 101P3A11 polynucleotides and/or polypeptides can be used to provide evidence of cancer, for example, when cells in a biological sample that do not normally express 101P3A11 or express 101P3A11 at a different level are found to express 101P3A11 or have an increased expression of 101P3A11 (see, e.g., the 101P3A11 expression in the cancers listed in Table I and in patient samples etc. shown in the accompanying Figures). In such assays, artisans may further wish to generate supplementary evidence of metastasis by testing the biological sample for the presence of a second tissue restricted marker (in addition to 101P3A11) such as PSA, PSCA etc. (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3): 233-237 (1996)).
Just as PSA polynucleotide fragments and polynucleotide variants are employed by skilled artisans for use in methods of monitoring PSA, 101P3A11 polynucleotide fragments and polynucleotide variants are used in an analogous manner. In particular, typical PSA polynucleotides used in methods of monitoring PSA are probes or primers which consist of fragments of the PSA cDNA sequence. Illustrating this, primers used to PCR amplify a PSA polynucleotide must include less than the whole PSA sequence to function in the polymerase chain reaction. In the context of such PCR reactions, skilled artisans generally create a variety of different polynucleotide fragments that can be used as primers in order to amplify different portions of a polynucleotide of interest or to optimize amplification reactions (see, e.g., Caetano-Anolles, G. Biotechniques 25(3): 472-476, 478-480 (1998); Robertson et al., Methods Mol. Biol. 98:121-154 (1998)). An additional illustration of the use of such fragments is provided in the Example entitled “Expression analysis of 101P3A11 in normal tissues, and patient specimens,” where a 101P3A11 polynucleotide fragment is used as a probe to show the expression of 101P3A11 RNAs in cancer cells. In addition, variant polynucleotide sequences are typically used as primers and probes for the corresponding mRNAs in PCR and Northern analyses (see, e.g., Sawai et al., Fetal Diagn. Ther. 1996 November-December 11(6):407-13 and Current Protocols In Molecular Biology, Volume 2, Unit 2, Frederick M. Ausubel et al. eds., 1995)). Polynucleotide fragments and variants are useful in this context where they are capable of binding to a target polynucleotide sequence (e.g., a 101P3A11 polynucleotide shown in FIG. 2 or variant thereof) under conditions of high stringency.
Furthermore, PSA polypeptides which contain an epitope that can be recognized by an antibody or T cell that specifically binds to that epitope are used in methods of monitoring PSA. 101P3A11 polypeptide fragments and polypeptide analogs or variants can also be used in an analogous manner. This practice of using polypeptide fragments or polypeptide variants to generate antibodies (such as anti-PSA antibodies or T cells) is typical in the art with a wide variety of systems such as fusion proteins being used by practitioners (see, e.g., Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubel et al. eds., 1995). In this context, each epitope(s) functions to provide the architecture with which an antibody or T cell is reactive. Typically, skilled artisans create a variety of different polypeptide fragments that can be used in order to generate immune responses specific for different portions of a polypeptide of interest (see, e.g., U.S. Pat. No. 5,840,501 and U.S. Pat. No. 5,939,533). For example it may be preferable to utilize a polypeptide comprising one of the 101P3A11 biological motifs discussed herein or a motif-bearing subsequence which is readily identified by one of skill in the art based on motifs available in the art. Polypeptide fragments, variants or analogs are typically useful in this context as long as they comprise an epitope capable of generating an antibody or T cell specific for a target polypeptide sequence (e.g. a 101P3A11 polypeptide shown in FIG. 3).
As shown herein, the 101P3A11 polynucleotides and polypeptides (as well as the 101P3A11 polynucleotide probes and anti-101P3A11 antibodies or T cells used to identify the presence of these molecules) exhibit specific properties that make them useful in diagnosing cancers such as those listed in Table I. Diagnostic assays that measure the presence of 101P3A11 gene products, in order to evaluate the presence or onset of a disease condition described herein, such as prostate cancer, are used to identify patients for preventive measures or further monitoring, as has been done so successfully with PSA. Moreover, these materials satisfy a need in the art for molecules having similar or complementary characteristics to PSA in situations where, for example, a definite diagnosis of metastasis of prostatic origin cannot be made on the basis of a test for PSA alone (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3): 233-237 (1996)), and consequently, materials such as 101P3A11 polynucleotides and polypeptides (as well as the 101P3A11 polynucleotide probes and anti-101P3A11 antibodies used to identify the presence of these molecules) need to be employed to confirm a metastases of prostatic origin.
Finally, in addition to their use in diagnostic assays, the 101P3A11 polynucleotides disclosed herein have a number of other utilities such as their use in the identification of oncogenetic associated chromosomal abnormalities in the chromosomal region to which the 101P3A11 gene maps (see the Example entitled “Chromosomal Mapping of 101P3A11” below). Moreover, in addition to their use in diagnostic assays, the 101P3A11-related proteins and polynucleotides disclosed herein have other utilities such as their use in the forensic analysis of tissues of unknown origin (see, e.g., Takahama K Forensic Sci Int 1996 Jun. 28; 80(1-2): 63-9).
Additionally, 101P3A11-related proteins or polynucleotides of the invention can be used to treat a pathologic condition characterized by the over-expression of 101P3A11. For example, the amino acid or nucleic acid sequence of FIG. 2 or FIG. 3, or fragments of either, can be used to generate an immune response to a 101P3A11 antigen. Antibodies or other molecules that react with 101P3A11 can be used to modulate the function of this molecule, and thereby provide a therapeutic benefit.
XII.) INHIBITION OF 101P3A11 PROTEIN FUNCTION
The invention includes various methods and compositions for inhibiting the binding of 101P3A11 to its binding partner or its association with other protein(s) as well as methods for inhibiting 101P3A11 function.
XII.A.) Inhibition of 101P3A11 with Intracellular Antibodies
In one approach, a recombinant vector that encodes single chain antibodies that specifically bind to 101P3A11 are introduced into 101P3A11 expressing cells via gene transfer technologies. Accordingly, the encoded single chain anti-101P3A11 antibody is expressed intracellularly, binds to 101P3A11 protein, and thereby inhibits its function. Methods for engineering such intracellular single chain antibodies are well known. Such intracellular antibodies, also known as “intrabodies”, are specifically targeted to a particular compartment within the cell, providing control over where the inhibitory activity of the treatment is focused. This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors (see, e.g., Richardson et al., 1995, Proc. Natl. Acad. Sci. USA 92: 3137-3141; Beerli et al., 1994, J. Biol. Chem. 289: 23931-23936; Deshane et al., 1994, Gene Ther. 1: 332-337).
Single chain antibodies comprise the variable domains of the heavy and light chain joined by a flexible linker polypeptide, and are expressed as a single polypeptide. Optionally, single chain antibodies are expressed as a single chain variable region fragment joined to the light chain constant region. Well-known intracellular trafficking signals are engineered into recombinant polynucleotide vectors encoding such single chain antibodies in order to precisely target the intrabody to the desired intracellular compartment. For example, intrabodies targeted to the endoplasmic reticulum (ER) are engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL (SEQ ID NO: 43) amino acid motif. Intrabodies intended to exert activity in the nucleus are engineered to include a nuclear localization signal. Lipid moieties are joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies can also be targeted to exert function in the cytosol. For example, cytosolic intrabodies are used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.
In one embodiment, intrabodies are used to capture 101P3A11 in the nucleus, thereby preventing its activity within the nucleus. Nuclear targeting signals are engineered into such 101P3A11 intrabodies in order to achieve the desired targeting. Such 101P3A11 intrabodies are designed to bind specifically to a particular 101P3A11 domain. In another embodiment, cytosolic intrabodies that specifically bind to a 101P3A11 protein are used to prevent 101P3A11 from gaining access to the nucleus, thereby preventing it from exerting any biological activity within the nucleus (e.g., preventing 101P3A11 from forming transcription complexes with other factors).
In order to specifically direct the expression of such intrabodies to particular cells, the transcription of the intrabody is placed under the regulatory control of an appropriate tumor-specific promoter and/or enhancer. In order to target intrabody expression specifically to prostate, for example, the PSA promoter and/or promoter/enhancer can be utilized (See, for example, U.S. Pat. No. 5,919,652 issued 6 Jul. 1999).
XII.B.) Inhibition of 101P3A11 with Recombinant Proteins
In another approach, recombinant molecules bind to 101P3A11 and thereby inhibit 101P3A11 function. For example, these recombinant molecules prevent or inhibit 101P3A11 from accessing/binding to its binding partner(s) or associating with other protein(s). Such recombinant molecules can, for example, contain the reactive part(s) of a 101P3A11 specific antibody molecule. In a particular embodiment, the 101P3A11 binding domain of a 101P3A11 binding partner is engineered into a dimeric fusion protein, whereby the fusion protein comprises two 101P3A11 ligand binding domains linked to the Fc portion of a human IgG, such as human IgG1. Such IgG portion can contain, for example, the CH2 and CH3 domains and the hinge region, but not the CH1 domain. Such dimeric fusion proteins are administered in soluble form to patients suffering from a cancer associated with the expression of 101P3A11, whereby the dimeric fusion protein specifically binds to 101P3A11 and blocks 101P3A11 interaction with a binding partner. Such dimeric fusion proteins are further combined into multimeric proteins using known antibody linking technologies.
XII.C.) Inhibition of 101P3A11 Transcription or Translation
The present invention also comprises various methods and compositions for inhibiting the transcription of the 101P3A11 gene. Similarly, the invention also provides methods and compositions for inhibiting the translation of 101P3A11 mRNA into protein.
In one approach, a method of inhibiting the transcription of the 101P3A11 gene comprises contacting the 101P3A11 gene with a 101P3A11 antisense polynucleotide. In another approach, a method of inhibiting 101P3A11 mRNA translation comprises contacting a 101P3A11 mRNA with an antisense polynucleotide. In another approach, a 101P3A11 specific ribozyme is used to cleave a 101P3A11 message, thereby inhibiting translation. Such antisense and ribozyme based methods can also be directed to the regulatory regions of the 101P3A11 gene, such as 101P3A11 promoter and/or enhancer elements. Similarly, proteins capable of inhibiting a 101P3A11 gene transcription factor are used to inhibit 101P3A11 mRNA transcription. The various polynucleotides and compositions useful in the aforementioned methods have been described above. The use of antisense and ribozyme molecules to inhibit transcription and translation is well known in the art.
Other factors that inhibit the transcription of 101P3A11 by interfering with 101P3A11 transcriptional activation are also useful to treat cancers expressing 101P3A11. Similarly, factors that interfere with 101P3A11 processing are useful to treat cancers that express 101P3A11. Cancer treatment methods utilizing such factors are also within the scope of the invention.
XII.D.) General Considerations for Therapeutic Strategies
Gene transfer and gene therapy technologies can be used to deliver therapeutic polynucleotide molecules to tumor cells synthesizing 101P3A11 (i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other 101P3A11 inhibitory molecules). A number of gene therapy approaches are known in the art. Recombinant vectors encoding 101P3A11 antisense polynucleotides, ribozymes, factors capable of interfering with 101P3A11 transcription, and so forth, can be delivered to target tumor cells using such gene therapy approaches.
The above therapeutic approaches can be combined with any one of a wide variety of surgical, chemotherapy or radiation therapy regimens. The therapeutic approaches of the invention can enable the use of reduced dosages of chemotherapy (or other therapies) and/or less frequent administration, an advantage for all patients and particularly for those that do not tolerate the toxicity of the chemotherapeutic agent well.
The anti-tumor activity of a particular composition (e.g., antisense, ribozyme, intrabody), or a combination of such compositions, can be evaluated using various in vitro and in vivo assay systems. In vitro assays that evaluate therapeutic activity include cell growth assays, soft agar assays and other assays indicative of tumor promoting activity, binding assays capable of determining the extent to which a therapeutic composition will inhibit the binding of 101P3A11 to a binding partner, etc.
In vivo, the effect of a 101P3A11 therapeutic composition can be evaluated in a suitable animal model. For example, xenogenic prostate cancer models can be used, wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice (Klein et al., 1997, Nature Medicine 3: 402-408). For example, PCT Patent Application WO98/16628 and U.S. Pat. No. 6,107,540 describe various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease. Efficacy can be predicted using assays that measure inhibition of tumor formation, tumor regression or metastasis, and the like.
In vivo assays that evaluate the promotion of apoptosis are useful in evaluating therapeutic compositions. In one embodiment, xenografts from tumor bearing mice treated with the therapeutic composition can be examined for the presence of apoptotic foci and compared to untreated control xenograft-bearing mice. The extent to which apoptotic foci are found in the tumors of the treated mice provides an indication of the therapeutic efficacy of the composition.
The therapeutic compositions used in the practice of the foregoing methods can be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material that when combined with the therapeutic composition retains the anti-tumor function of the therapeutic composition and is generally non-reactive with the patient's immune system. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16th Edition, A. Osal., Ed., 1980).
Therapeutic formulations can be solubilized and administered via any route capable of delivering the therapeutic composition to the tumor site. Potentially effective routes of administration include, but are not limited to, intravenous, parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, orthotopic, and the like. A preferred formulation for intravenous injection comprises the therapeutic composition in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP. Therapeutic protein preparations can be lyophilized and stored as sterile powders, preferably under vacuum, and then reconstituted in bacteriostatic water (containing for example, benzyl alcohol preservative) or in sterile water prior to injection.
Dosages and administration protocols for the treatment of cancers using the foregoing methods will vary with the method and the target cancer, and will generally depend on a number of other factors appreciated in the art.
XIII.) KITS/ARTICLES OF MANUFACTURE
For use in the diagnostic and therapeutic applications described herein, kits are also within the scope of the invention. Such kits can comprise a carrier, package or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in the method. For example, the container(s) can comprise a probe that is or can be detectably labeled. Such probe can be an antibody or polynucleotide specific for a FIG. 2-related protein or a FIG. 2 gene or message, respectively. Where the method utilizes nucleic acid hybridization to detect the target nucleic acid, the kit can also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, florescent, or radioisotope label. The kit can include all or part of the amino acid sequences in FIG. 2 or FIG. 3 or analogs thereof, or a nucleic acid molecules that encodes such amino acid sequences.
The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.
A label can be present on the container to indicate that the composition is used for a specific therapy or non-therapeutic application, such as a diagnostic or laboratory application, and can also indicate directions for either in vivo or in vitro use, such as those described herein. Directions and or other information can also be included on an insert(s) or label(s) which is included with or on the kit.
The terms “kit” and “article of manufacture” can be used as synonyms.
In another embodiment of the invention, an article(s) of manufacture containing compositions, such as amino acid sequence(s), small molecule(s), nucleic acid sequence(s), and/or antibody(s), e.g., materials useful for the diagnosis, prognosis, prophylaxis and/or treatment of neoplasias of tissues such as those set forth in Table I is provided. The article of manufacture typically comprises at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass or plastic. The container can hold amino acid sequence(s), small molecule(s), nucleic acid sequence(s), and/or antibody(s), in one embodiment the container holds a polynucleotide for use in examining the mRNA expression profile of a cell, together with reagents used for this purpose.
The container can alternatively hold a composition which is effective for treating, diagnosis, prognosing or prophylaxing a condition and can have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agents in the composition can be an antibody capable of specifically binding 101P3A11 and modulating the function of 101P3A11.
The label can be on or associated with the container. A label a can be on a container when letters, numbers or other characters forming the label are molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. The label can indicate that the composition is used for diagnosing, treating, prophylaxing or prognosing a condition, such as a neoplasia of a tissue set forth in Table I. The article of manufacture can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and/ordextrose solution. It can further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, stirrers, needles, syringes, and/or package inserts with indications and/or instructions for use.
XIV.) EVALUATION OF GPCRS AND MODULATORS THEREOF
The traditional study of receptors has always proceeded from the a priori assumption (historically based) that the endogenous ligand must first be identified before discovery could proceed to find antagonists and other molecules that could affect the receptor. Even in cases where an antagonist might have been known first, the search immediately extended to looking for the endogenous ligand. This mode of thinking has persisted in receptor research even after the discovery of constitutively activated receptors. What has not been recognized is that it is the active state of the receptor that is most useful for discovering agonists, partial agonists, and inverse agonists of the receptor. For those diseases that result from an overly active receptor, what is desired in a therapeutic, drug is a compound which acts to diminish the active state of a receptor, not necessarily a drug which is an antagonist to the endogenous ligand. This is because a compound (e.g., therapeutic, prophylactic, diagnostic, prognostic, or laboratory reactant) that reduces the activity of the active receptor state need not bind at the same site as the endogenous ligand. In accordance with the present disclosure, any search for relevant compounds should start by screening compounds against the ligand-independent active state. The search, then, is for an inverse agonist to the active state receptor.
Screening candidate compounds against orphan receptors, for example, including and not limited to, 101P3A11 and 101P3A11 Fusion Protein, allows for the direct identification of candidate compounds which act at the orphan cell surface receptor, without requiring any prior knowledge or use of the receptor's endogenous ligand. By determining areas within the body where such receptors are expressed and/or over-expressed, it is possible to determine related disease/disorder states which are associated with the expression and/or over expression of these receptors; such an approach is disclosed herein.
Disease/Disorder Identification and/or Selection.
Inverse agonists and agonists to 101P3A11 can be identified by the methodologies disclosed herein. Such inverse agonists and agonists are ideal candidates as lead compounds in drug discovery programs for treating diseases related to this receptor. Indeed, an antagonist to such a receptor (even if the ligand were known) may be ineffective given that the receptor is activated even in the absence of ligand-receptor binding. Because of the ability to directly identify inverse agonists and agonists to these receptors, thereby allowing for the development of pharmaceutical compositions, a search for diseases and disorders associated with these receptors is possible. For example, 101P3A11 is expressed in cancers of the tissues set forth in Table I.
XV.) SCREENING OF CANDIDATE COMPOUNDS
General GPCR Screening Assay Techniques
When a G protein receptor becomes constitutively active, it binds to a G protein (for example Gq, Gs, Gi, Go) and stimulates the binding of GTP to the G protein. The G protein then acts as a GTPase and slowly hydrolyzes the GTP to GDP, whereby the receptor, under normal conditions, becomes deactivated. However, constitutively activated receptors continue to exchange GDP to GTP. A non-hydrolyzable analog of GTP, [35S]GTP7S, can be used to monitor enhanced binding to membranes which express constitutively activated receptors. It is reported that [35 S]GTP7S can be used to monitor G protein coupling to membranes in the absence and presence of ligand. An example of this monitoring, among other examples well-known and available to those in the art, was reported by Traynor and Nahorski in 1995 (Mol. Pharmacol. 1995 April; 47(4):848-54). Generally, this preferred use of this assay system is for initial screening of candidate compounds because the system is generically applicable to all G protein-coupled receptors regardless of the particular G protein that interacts with the intracellular domain of the receptor.
Specific GPCR Screening Assay Techniques
Once candidate compounds are identified using the “generic” G protein-coupled receptor assay (i.e. an assay to select compounds that are agonists, partial agonists, or inverse agonists), farther screening to confirm that the compounds have interacted at the receptor site is preferred. For example, a compound identified by the “generic” assay may not bind to the receptor, but may instead merely “uncouple” the G protein from the intracellular domain.
Thus, by screening those candidate compounds, which have been identified using a “generic” assay in an agonist and/or antagonist competitive binding assay, farther refinement in the selection process is provided.
In the case of 101P3A11 it has been determined that this receptor couples the G protein Gs.
Gs stimulates the enzyme adenylyl cyclase (Gi, on the other hand, inhibits this enzyme).
Adenylyl cyclase catalyzes the conversion of ATP to cANT; thus, assays that detect cANT can be utilized, for example and not limitation, cell-based cANT assay, to determine if a candidate compound is an inverse agonist to the receptor (i.e., such a compound which contacts the receptor would decrease the levels of cAMP relative to the uncontacted receptor). As a result, “cyclase-based assays” can be used to further screen those compounds selected from an agonist and/or antagonist competitive binding assay.
XVI.) GPCR FUSION PROTEINS
The use of an endogenous, constitutively activated orphan GPCRs, such as 101P3A11, for use in screening of candidate compounds for the direct identification of inverse agonists, agonists and partial agonists, provides a unique challenge in that, by definition, the endogenous receptor is active even in the absence of an endogenous ligand bound thereto.
Thus, in order to differentiate between, e.g., the endogenous receptor in the presence of a candidate compound and the endogenous receptor in the absence of that compound, with an aim of such a differentiation to allow for an understanding as to whether such compound may be an inverse agonist, agonist, partial agonist or have no affect on such a receptor, it is preferred that an approach be utilized that can enhance such differentiation. A preferred approach is the use of a GPCR Fusion Protein.
Generally, once it is determined that an endogenous orphan GPCR is constitutively activate, using the assay techniques set forth herein (as well as others known in the art), it is possible to determine the predominant G protein that couples with the endogenous GPCR. Coupling of the G protein to the GPCR provides a signaling pathway that can be assessed. Because it is most preferred that screening take place by use of a mammalian expression system, such a system will be expected to have endogenous G protein therein. Thus, by definition, in such a system, the endogenous, constitutively active orphan GPCR will continuously signal. In this regard, it is preferred that this signal be enhanced such that in the presence of, e.g., an inverse agonist to the receptor, it is more likely that one will be able to more readily differentiate, particularly in the context of screening, between the receptor when it is contacted with the inverse agonist.
A GPCR Fusion Protein is intended to enhance the efficacy of G protein coupling with the endogenous GPCR. The GPCR Fusion Protein appears to be important for screening with an endogenous, constitutively activated GPCR because such an approach increases the signal that is most preferably utilized in such screening techniques. This is important in facilitating a significant “signal to noise” ratio. A significant ratio is preferred for the screening of candidate compounds as disclosed herein.
The construction of a construct useful for expression of a GPCR Fusion Protein is within the purview of those having ordinary skill in the art. Commercially available expression vectors and systems offer a variety of approaches that can fit the particular needs of an investigator. The criteria of importance for such a GPCR Fusion Protein construct is that the endogenous GPCR sequence and the G protein sequence both be in-frame (preferably, the sequence for the endogenous GPCR is upstream of the G protein sequence) and that the “stop” codon of the GPCR must be deleted or replaced such that upon expression of the GPCR, the G protein can also be expressed. The GPCR can be linked directly to the G protein, or there can be spacer residues between the two (preferably, no more than about 12, although this number can be readily ascertained by one of ordinary skill in the art). Both approaches have been evaluated, and in terms of measurement of the activity of the GPCR, the results are substantially the same; however, there is a preference (based upon convenience) for use of a spacer in that some restriction sites that are not used will, upon expression, effectively, become a spacer. Most preferably, the G protein that couples to the endogenous GPCR will have been identified prior to the creation of the GPCR Fusion Protein construct. Because there are only a few G proteins that have been identified, it is preferred that a construct comprising the sequence of the G protein (i.e., a universal G protein construct) be available for insertion of an endogenous GPCR sequence therein; this provides for efficiency in the context of large-scale screening of a variety of different endogenous GPCRs having different sequences.
Pharmaceutical Compositions Candidate compounds selected for further development as active ingredients can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically-acceptable carriers are available to those in the art; for example, see Remington's Pharmaceutical Sciences, 16th Edition, 1980, Mack Publishing Co., (Oslo et al., eds.).
EXAMPLES
Various aspects of the invention are further described and illustrated by way of the several examples that follow, none of which are intended to limit the scope of the invention.
Example 1
Expression Analysis of 101P3A11 in Normal Tissues and Patient Specimens
Analysis of 101P3A11 by RT-PCR is shown in FIG. 10A. First strand cDNA was prepared from vital pool 1 (VP1: liver, lung and kidney), vital pool 2 (VP2, pancreas, colon and stomach), prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 101P3A11, was performed at 30 cycles of amplification. Expression of 101P3A11 was observed in prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool, but not in VP1 and VP2. Dot blots using patient-derived amplified cDNAs (Clontech, CA) show upregulation of PHOR-1 in 3/3 prostate cancer patients, 6/14 kidney cancer patients, 2/8 uterine cancer, 1/1 cervical cancer, 3/8 stomach cancer, and in 7/7 rectal cancer patients (FIG. 10B).
Expression of 101P3A11 was assayed in a panel of human patient cancer specimens (FIG. 11). RNA was extracted from a pool of three prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, and cancer metastasis pool derived from cancer patients, as well as from normal prostate (NP), normal bladder (NB), normal kidney (NK) and normal colon (NC). Northern blots with 10 μg of total RNA/lane were probed with a 101P3A11 sequence fragment. Size standards in kilobases (kb) are indicated on the side. The results show expression of 101P3A11 in prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, cancer metastasis pool, bladder cancer pool, and in the normal prostate but not in the other normal tissues.
Northern blot analysis on individual prostate patient tumor specimens is shown in FIG. 12A. RNA was extracted from prostate tumors (T) and their normal adjacent tissues (Nat) derived from prostate cancer patients. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequence. Results showed expression of 101P3A11 in all three patient specimens, and expression is especially upregulated in one of the three prostate tumor tissues.
RNA in situ analysis using anti-sense 101P3A11 riboprobe showed significant glandular epithelial and basal cell expression in normal prostate (4/4), PIN (1/1), and prostate cancer (6/6) patients. 101P3A11 sense riboprobe had little to no staining. The RNA in situ staining in PIN and prostate cancer is shown in FIG. 12B and FIG. 12C. The staining intensity in the cancer cells was generally higher than that observed in normal glands (FIGS. 12D and 12E). The RNA in situ results also demonstrate that the expression observed in the prostate tissues is in the glandular epithelia, basal cells, and cancer cells.
Endogenous expression of the 101P3A11 protein is demonstrated in the immunohistochemistry analysis of the anti-101P3A11 (PEPTIDE 1: amino acids 1-14) rabbit polyclonal antibody (FIG. 40A-40F). Staining in prostate cancer is greater than the staining observed in normal prostate. The staining is localized apically within the luminal epithelia of the normal prostate (FIGS. 40E and 40F). The staining observed in prostate cancer is also localized apically in low to intermediate grade cancer (FIGS. 40B and 40C) and throughout all cells of more advanced prostate cancer (FIG. 40A). Staining was observed in 19/20 normal prostate patients and in all of the nineteen prostate cancer patients analyzed. The prostate cancer cell line, LNCaP also shows similar staining (FIGS. 40D and 40F) in almost all cells.
In addition, the present protocol was used to identify endogenous expression of the 101P3A11 protein in prostate cancer, bladder cancer, kidney cancer, colon cancer, lung cancer, and breast cancer. Immunohistochemical analysis was performed with the anti-101P3A11 (PEPTIDE 1: amino acids 1-14) rabbit polyclonal antibody (prostate cancer, FIG. 41A; bladder cancer, FIG. 41B; kidney cancer, FIG. 41C; colon cancer, FIG. 41D; lung cancer, FIG. 41E; and breast cancer, FIG. 41F). Specific staining is observed in tumor cells of the six cancers analyzed.
Expression of 101P3A11 was also detected in the tumors of two colon cancer patients but not in normal colon tissues (FIG. 13), and in five out of six kidney tumors isolated from kidney cancer patients (FIG. 14). The expression detected in normal adjacent tissues (isolated from diseased tissues) but not in normal tissues of the kidney (isolated from healthy donors) indicates that these tissues are not fully normal and that 101P3A11 is expressed in early stage tumors.
In order to assay for androgen regulation of 101P3A11 expression, LAPC-9 cells were grown in charcoal-stripped medium and stimulated with the synthetic androgen mibolerone, for either 14 or 24 hours (FIG. 15A, FIG. 15B, and FIG. 15C). Northern blots with 10 μg of total RNA/lane were probed with the 101P3A11 sequences (FIG. 15A). A picture of the ethidium-bromide staining of the RNA gel is also presented (FIG. 15C). Results showed expression of 101P3A11 is not regulated by androgen. The experimental samples were confirmed by testing for the expression of the androgen-regulated prostate cancer gene PSA (FIG. 15B). This experiment showed that, as expected, PSA levels go down in presence of charcoal-stripped serum, and expression is induced at 14 and 24 hours in presence of mibolerone.
Analysis of androgen regulation of 101P3A11 in vivo is shown in FIG. 16. Male mice were injected with LAPC-9AD tumor cells. When tumors reached a palpable size, mice were castrated and tumors harvested at different time points following castration. RNA was isolated from the xenograft tissues. Northern blots with 10 μg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. A picture of the ethidium-bromide staining of the RNA gel is also presented in FIG. 16. The results showed that expression of 101P3A11 was not affected by androgen deprivation, and therefore, is not androgen regulated.
Example 2
Splice Variants/Transcript Variants of 101P3A11
Transcript variants are variants of mature mRNA from the same gene which arise by alternative transcription or alternative splicing. Alternative transcripts are transcripts from the same gene but start transcription at different points. Splice variants are mRNA variants spliced differently from the same transcript. In eukaryotes, when a multi-exon gene is transcribed from genomic DNA, the initial RNA is spliced to produce functional mRNA, which has only exons and is used for translation into an amino acid sequence. Accordingly, a given gene can have zero to many alternative transcripts and each transcript can have zero to many splice variants. Each transcript variant has a unique exon makeup, and can have different coding and/or non-coding (5′ or 3′ end) portions, from the original transcript. Transcript variants can code for similar or different proteins with the same or a similar function or can encode proteins with different functions, and can be expressed in the same tissue at the same time, or in different tissues at the same time, or in the same tissue at different times, or in different tissues at different times. Proteins encoded by transcript variants can have similar or different cellular or extracellular localizations, e.g., secreted versus intracellular.
Transcript variants are identified by a variety of art-accepted methods. For example, alternative transcripts and splice variants are identified by full-length cloning experiment, or by use of full-length transcript and EST sequences. First, all human ESTs were grouped into clusters which show direct or indirect identity with each other. Second, ESTs in the same cluster were further grouped into sub-clusters and assembled into a consensus sequence. The original gene sequence is compared to the consensus sequence(s) or other full-length sequences. Each consensus sequence is a potential splice variant for that gene. Even when a variant is identified that is not a full-length clone, that portion of the variant is very useful for antigen generation and for further cloning of the full-length splice variant, using techniques known in the art.
Moreover, computer programs are available in the art that identify transcript variants based on genomic sequences. Genomic-based transcript variant identification programs include FgenesH (A. Salamov and V. Solovyev, “Ab initio gene finding in Drosophila genomic DNA,” Genome Research. 2000 April; 10(4):516-22); Grail and GenScan. For a general discussion of splice variant identification protocols see, e.g., Southan, C., A genomic perspective on human proteases, FEBS Lett. 2001 Jun. 8; 498(2-3):214-8; de Souza, S. J., et al., Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags, Proc. Natl. Acad Sci USA. 2000 Nov. 7; 97(23):12690-3.
To further confirm the parameters of a transcript variant, a variety of techniques are available in the art, such as full-length cloning, proteomic validation, PCR-based validation, and 5′ RACE validation, etc. (see e.g., Proteomic Validation: Brennan, S. O., et al., Albumin banks peninsula: a new termination variant characterized by electrospray mass spectrometry, Biochem Biophys Acta. 1999 Aug. 17; 1433(1-2):321-6; Ferranti P, et al., Differential splicing of pre-messenger RNA produces multiple forms of mature caprine alpha(s1)-casein, Eur J Biochem. 1997 Oct. 1; 249(1):1-7. For PCR-based Validation: Wellmann S, et al., Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology, Clin Chem. 2001 April; 47(4):654-60; Jia, H. P., et al., Discovery of new human beta-defensins using a genomics-based approach, Gene. 2001 Jan. 24; 263(1-2):211-8. For PCR-based and 5′ RACE Validation: Brigle, K. E., et al., Organization of the murine reduced folate carrier gene and identification of variant splice forms, Biochem Biophys Acta. 1997 Aug. 7; 1353(2): 191-8).
It is known in the art that genomic regions are modulated in cancers. When the genomic region to which a gene maps is modulated in a particular cancer, the alternative transcripts or splice variants of the gene are modulated as well. Disclosed herein is that 101P3A11 has a particular expression profile related to cancer. Alternative transcripts and splice variants of 101P3A11 may also be involved in cancers in the same or different tissues, thus serving as tumor-associated markers/antigens.
The exon composition of the original transcript, designated as 101P3A11 v.1, are:












Exon number
Start
End







1
1
90


2
91
3136









Using the full-length gene and EST sequences, one transcript variant was identified, designated as 101P3A11 v.2. Compared with 101P3A11 v.1, transcript variant 101P3A11 v.2 has spliced out a fragment from the second exon of variant 1, as shown in FIG. 46. All other exons are the same corresponding exons of 101P3A11 v.1. Theoretically, each different combination of exons in spatial order, e.g. exons 2 and 3, is a potential splice variant. FIG. 46 shows the schematic alignment of exons of the two transcript variants.
FIG. 2 shows nucleotide sequence of the transcript variant (101P3A11 v.2). FIG. 69 shows the alignment of the transcript variant with nucleic acid sequence of 101P3A11 v.1. FIG. 70 lays out amino acid translation of the transcript variant for the identified reading frame orientation. FIG. 71 displays alignments of the amino acid sequence encoded by the splice variant with that of 101P3A11 v.1.
Example 3
Single Nucleotide Polymorphisms (SNPs) of 101P3A11
A Single Nucleotide Polymorphism (SNP) is a single base pair variation in a nucleotide sequence at a specific location. At any given point of the genome, there are four possible nucleotide base pairs: A/T, C/G, G/C and T/A. Genotype refers to the specific base pair sequence of one or more locations in the genome of an individual. Haplotype refers to the base pair sequence of more than one location on the same DNA molecule (or the same chromosome in higher organisms), often in the context of one gene or in the context of several tightly linked genes. SNPs that occur on a cDNA are called cSNPs. These cSNPs may change amino acids of the protein encoded by the gene and thus change the functions of the protein. Some SNPs cause inherited diseases; others contribute to quantitative variations in phenotype and reactions to environmental factors including diet and drugs among individuals. Therefore, SNPs and/or combinations of alleles (called haplotypes) have many applications, including diagnosis of inherited diseases, determination of drug reactions and dosage, identification of genes responsible for diseases, and analysis of the genetic relationship between individuals (P. Nowotny, J. M. Kwon and A. M. Goate, “SNP analysis to dissect human traits,” Curr. Opin. Neurobiol. 2001 October; 11(5):637-641; M. Pirmohamed and B. K. Park, “Genetic susceptibility to adverse drug reactions,” Trends Pharmacol. Sci. 2001 June; 22(6):298-305; J. H. Riley, C. J. Allan, E. Lai and A. Roses, “The use of single nucleotide polymorphisms in the isolation of common disease genes,” Pharmacogenomics. 2000 February; 1(1):39-47; R. Judson, J. C. Stephens and A. Windemuth, “The predictive power of haplotypes in clinical response,” Pharmacogenomics. 2000 February; 1(1):15-26).
SNPs are identified by a variety of art-accepted methods (P. Bean, “The promising voyage of SNP target discovery,” Am. Clin. Lab. 2001 October-November; 20(9):18-20; K. M. Weiss, “In search of human variation,” Genome Res. 1998 July; 8(7):691-697; M. M. She, “Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies,” Clin. Chem. 2001 February; 47(2): 164-172). For example, SNPs are identified by sequencing DNA fragments that show polymorphism by gel-based methods such as restriction fragment length polymorphism (RFLP) and denaturing gradient gel electrophoresis (DGGE). They can also be discovered by direct sequencing of DNA samples pooled from different individuals or by comparing sequences from different DNA samples. With the rapid accumulation of sequence data in public and private databases, one can discover SNPs by comparing sequences using computer programs (Z. Gu, L. Hillier and P. Y. Kwok, “Single nucleotide polymorphism hunting in cyberspace,” Hum. Mutat. 1998; 12(4):221-225). SNPs can be verified and genotype or haplotype of an individual can be determined by a variety of methods including direct sequencing and high throughput microarrays (P. Y. Kwok, “Methods for genotyping single nucleotide polymorphisms,” Annu. Rev. Genomics Hum. Genet. 2001; 2:235-258; M. Kokoris, K. Dix, K. Moynihan, J. Mathis, B. Erwin, P. Grass, B. Hines and A. Duesterhoeft, “High-throughput SNP genotyping with the Masscode system,” Mol. Diagn. 2000 December; 5(4):329-340).
Using the methods described above, five SNPs were identified in the original transcript, 101P3A11 v.1, at positions 441 (T/G), 1430 (G/A), 1532 (G/A), 2774 (C/G), and 2833 (G/A). The transcripts or proteins with alternative alleles were designated as variants 101P3A11 v.3, v.4, v.5, v.6 and v.7, respectively. FIG. 44 shows the schematic alignment of the SNP variants. FIG. 45 shows the schematic alignment of protein variants, corresponding to nucleotide variants. Nucleotide variants that code for the same amino acid sequence as variant 1 are not shown in FIG. 11. These alleles of the SNPs, though shown separately here, can occur in different combinations (haplotypes) and in any one of the transcript variants (such as 101P3A11 v.2) that contains the sequence context of the SNPs.
Example 4
Production of Recombinant 101P3A11 in Prokaryotic and Yeast Systems
To express recombinant 101P3A11 in prokaryotic cells, the full or partial length 101P3A11 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 101P3A11 are expressed in these constructs, amino acids 1 to 317; or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 101P3A11, variants, or analogs thereof.
A. In Vitro Transcription and Translation Constructs:
pCRII: To generate 101P3A11 sense and anti-sense RNA probes for RNA in situ investigations, pCRII constructs (Invitrogen, Carlsbad, Calif.) are generated encoding either all or fragments of the 101P3A11 cDNA. The pCRII vector has Sp6 and T7 promoters flanking the insert to drive the transcription of 101P3A11 RNA for use as probes in RNA in situ hybridization experiments. These probes are used to analyze the cell and tissue expression of 101P3A11 at the RNA level. Transcribed 101P3A11 RNA representing the cDNA amino acid coding region of the 101P3A11 gene is used in in vitro translation systems such as the TnTTM Coupled Reticulolysate System (Promega, Corp., Madison, Wis.) to synthesize 101P3A11 protein.
B. Bacterial Constructs:
pGEX Constructs: To generate recombinant 101P3A11 proteins in bacteria that are fused to the Glutathione S-transferase (GST) protein, all or parts of the 101P3A11 cDNA protein coding sequence are fused to the GST gene by cloning into pGEX-6P-1 or any other GST-fusion vector of the pGEX family (Amersham Pharmacia Biotech, Piscataway, N.J.). These constructs allow controlled expression of recombinant 101P3A11 protein sequences with GST fused at the amino-terminus and a six histidine epitope (6×His) at the carboxyl-terminus. The GST and 6×His tags permit purification of the recombinant fusion protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-GST and anti-His antibodies. The 6×His tag is generated by adding 6 histidine codons to the cloning primer at the 3′ end, e.g., of the open reading frame (ORF). A proteolytic cleavage site, such as the PreScissionTM recognition site in pGEX-6P-1, can be employed that permits cleavage of the GST tag from 101P3A11-related protein. The ampicillin resistance gene and pBR322 origin permit selection and maintenance of the pGEX plasmids in E. coli. In one embodiment, amino acids 86-317 are cloned into the pGEX-2T expression vector, the protein is expressed and purified.
pMAL Constructs: To generate, in bacteria, recombinant 101P3A11 proteins that are fused to maltose-binding protein (MBP), all or parts of the 101P3A11 cDNA protein coding sequence are fused to the MBP gene by cloning into the pMAL-c2X and pMAL-p2X vectors (New England Biolabs, Beverly, Mass.). These constructs allow controlled expression of recombinant 101P3A11 protein sequences with MBP fused at the amino-terminus and a 6×His epitope tag at the carboxyl-terminus. The MBP and 6×His tags permit purification of the recombinant protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-MBP and anti-His antibodies. The 6×His epitope tag is generated by adding 6 histidine codons to the 3′ cloning primer. A Factor Xa recognition site permits cleavage of the pMAL tag from 101P3A11. The pMAL-c2X and pMAL-p2X vectors are optimized to express the recombinant protein in the cytoplasm or periplasm respectively. Periplasm expression enhances folding of proteins with disulfide bonds. In one embodiment, amino acids 86-310 is cloned into the pMAL-c2X expression vector, the protein is expressed and purified.
pET Constructs: To express 101P3A11 in bacterial cells, all or parts of the 101P3A11 cDNA protein coding sequence are cloned into the pET family of vectors (Novagen, Madison, Wis.). These vectors allow tightly controlled expression of recombinant 101P3A11 protein in bacteria with and without fusion to proteins that enhance solubility, such as NusA and thioredoxin (Trx), and epitope tags, such as 6×His and S-TagTM that aid purification and detection of the recombinant protein. For example, constructs are made utilizing pET NusA fusion system 43.1 such that regions of the 101P3A11 protein are expressed as amino-terminal fusions to NusA.
C. Yeast Constructs:
pESC Constructs: To express 101P3A11 in the yeast species Saccharomyces cerevisiae for generation of recombinant protein and functional studies, all or parts of the 101P3A11 cDNA protein coding sequence are cloned into the pESC family of vectors each of which contain 1 of 4 selectable markers, HIS3, TRP1, LEU2, and URA3 (Stratagene, La Jolla, Calif.). These vectors allow controlled expression from the same plasmid of up to 2 different genes or cloned sequences containing either FlagTM or Myc epitope tags in the same yeast cell. This system is used to confirm protein-protein interactions of 101P3A11. In addition, expression in yeast yields similar post-translational modifications, such as glycosylations and phosphorylations, that are found when expressed in eukaryotic cells.
pESP Constructs: To express 101P3A11 in the yeast species Saccharomyces pombe, all or parts of the 101P3A11 cDNA protein coding sequence are cloned into the pESP family of vectors. These vectors allow controlled high level expression of a 101P3A11 protein sequence that is fused at either the amino terminus or at the carboxyl terminus to GST which aids purification of the recombinant protein. A FlagTM epitope tag allows detection of the recombinant protein with anti-FlagTM antibody.
Example 5
Production of Recombinant 101P3A11 in Higher Eukaryotic Systems
A. Mammalian Constructs:
To express recombinant 101P3A11 in eukaryotic cells, full or partial length 101P3A11 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 101P3A11 are expressed in these constructs, amino acids 1 to 318 of v.1 and v.3, amino acids to 72 of v.2; or any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 101P3A11, variants, or analogs thereof.
The constructs can be transfected into any one of a wide variety of mammalian cells such as 293T cells. Transfected 293T cell lysates can be probed with the anti-101P3A11 polyclonal serum, described herein.
pcDNA4/HisMax Constructs: To express 101P3A11 in mammalian cells, the 101P3A11 ORF was cloned into pcDNA4/HisMax Version A (Invitrogen, Carlsbad, Calif.). Protein expression is driven from the cytomegalovirus (CMV) promoter and the SP16 translational enhancer. The recombinant protein has XpressTM and six histidine (6×His) epitopes fused to the amino-terminus. The pcDNA4/HisMax vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Zeocin resistance gene allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in E. coli. 
pcDNA3.1/MycHis Constructs: To express 101P3A11 in mammalian cells, the 101P3A11 ORF, with a consensus Kozak translation initiation site, was cloned into pcDNA3.1/MycHis Version A (Invitrogen, Carlsbad, Calif.). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the myc epitope and 6×His epitope fused to the carboxyl-terminus. The pcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability, along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene can be used, as it allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in E. coli. 
pcDNA3.1/GFP Construct: To express 101P3A11 in mammalian cells and to allow detection of the recombinant proteins using fluorescence, the 101P3A11 ORF, with a consensus Kozak translation initiation site, was cloned into pcDNA3.1/GFP. Protein expression was driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the Green Fluorescent Protein (GFP) fused to the carboxyl-terminus facilitating non-invasive, in vivo detection and cell biology studies. The pcDNA3.1/GFP vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in E. coli. FIG. 66 shows expression and detection of 101P3A11.GFP fusion protein. 293T cells were transfected with either pcDNA3.1/101P3A11.GFP recombinant expression vector (A), pcDNA3.1/GFP vector (B) or control pcDNA3.1 vector (C). Cells were harvested 24 hours later and analyzed by microscopy for detection of green fluorescence. Results show expression of the 101P3A11.GFP fusion protein is localized mostly at the cell membrane, whereas expression of the free GFP is throughout the cells. The control vector did not show any fluorescence. We conclude that the 101P3A11.GFP fusion protein is expressed from the pcDNA3.1/101P3A11.GFP construct, and that the fusion protein is localized at the cell membrane.
Additional constructs with an amino-terminal GFP fusion are made in pcDNA3.1/NT-GFP-TOPO spanning the entire length of the 101P3A11 proteins.
Codon optimized 101P3A11: To enhance protein translation of 101P3A11, the nucleic acid sequence of 101P3A11 was codon optimized (s101P3A11). The sequence of codon optimized s101P3A11 is listed in FIG. 67. The s101P3A11 was cloned into the pcDNA3.1/GFP construct and into the pSRa retroviral vector, to generate the s101P3A11.GFP fusion protein. The recombinant protein has the Green Fluorescent Protein (GFP) fused to the carboxyl-terminus facilitating non-invasive, in vivo detection and cell biology studies. FIG. 68 shows expression and detection of the codon optimized s101P3A1.GFP fusion protein. 293T cells were transfected with either pcDNA3.1 vector control (light line), or one of the three different pcDNA3.1/s101P3A11.GFP vector clones, 1G2, 2G3, or 3H5 (dark line). Cells were harvested 24 hours later and either analyzed directly for green fluorescence (A), or stained viably using polyclonal anti-101P3A11 antibody (B) and analyzed by flow cytometry. Results show strong expression of the codon optimized s101P3A11.GFP fusion protein at the cell surface of transfected cells.
PAPtag: The 101P3A11 ORF, or portions thereof, of 101P3A11 are cloned into pAPtag-5 (GenHunter Corp. Nashville, Tenn.). This construct generates an alkaline phosphatase fusion at the carboxyl-terminus of the 101P3A11 proteins while fusing the IgGκ signal sequence to the amino-terminus. Constructs are also generated in which alkaline phosphatase with an amino-terminal IgGκ signal sequence is fused to the amino-terminus of 101P3A11 proteins. The resulting recombinant 101P3A11 proteins are optimized for secretion into the media of transfected mammalian cells and can be used to identify proteins such as ligands or receptors that interact with the 101P3A11 proteins. Protein expression is driven from the CMV promoter and the recombinant proteins also contain myc and 6×His epitopes fused at the carboxyl-terminus that facilitates detection and purification. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the recombinant protein and the ampicillin resistance gene permits selection of the plasmid in E. coli. 
ptag5: The 101P3A11 ORF, or portions thereof, of 101P3A11 are cloned into pTag-5. This vector is similar to pAPtag but without the alkaline phosphatase fusion. This construct generated 101P3A11 protein with an amino-terminal IgGκ signal sequence and myc and 6×His epitope tags at the carboxyl-terminus that facilitate detection and affinity purification. The resulting recombinant 101P3A11 protein was optimized for secretion into the media of transfected mammalian cells, and was used as immunogen or ligand to identify proteins such as ligands or receptors that interact with the 101P3A11 proteins. Protein expression is driven from the CMV promoter. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the protein, and the ampicillin resistance gene permits selection of the plasmid in E. coli. 
PsecFc: The 101P3A11 ORF, or portions thereof, of 101P3A11 are also cloned into psecFc. The psecFc vector was assembled by cloning the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen, California). This construct generates an IgG1 Fc fusion at the carboxyl-terminus of the 101P3A11 proteins, while fusing the IgGκ signal sequence to N-terminus. 101P3A11 fusions utilizing the murine IgG1 Fc region are also used. The resulting recombinant 101P3A11 proteins are optimized for secretion into the media of transfected mammalian cells, and can be used as immunogens or to identify proteins such as ligands or receptors that interact with the 101P3A11 protein. Protein expression is driven from the CMV promoter. The hygromycin resistance gene present in the vector allows for selection of mammalian cells that express the recombinant protein, and the ampicillin resistance gene permits selection of the plasmid in E. coli. 
The amino acid region 159-202 of the 101P3A11 ORF was cloned into psecFc. The resulting recombinant 101P3A11(159-202)-psecFc construct was transfected into 293T and Cos-7 cells, and the expression of recombinant 101P3A11(159-202)-psecFc protein assayed by Western blotting (FIG. 17). Results show that 101P3A11(159-202)-psecFc fusion protein was expressed in the lysates of both 293T and Cos-7 cells. The 101P3A11(159-202)-psecFc fusion protein was also secreted and detected in the culture supernatants of both cell types.
pSRα Constructs: To generate mammalian cell lines that express 101P3A11, constitutively, the ORF of 101P3A11 was cloned into pSRα constructs. Amphotropic and ecotropic retroviruses were generated by transfection of pSRα constructs into the 293T-10A1 packaging line or co-transfection of pSRα and a helper plasmid (containing deleted packaging sequences) into the 293 cells, respectively. The retrovirus was used to infect a variety of mammalian cell lines, resulting in the integration of the cloned gene, 101P3A11, into the host cell lines. Protein expression is driven from a long terminal repeat (LTR). The Neomycin resistance gene present in the vector allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permit selection and maintenance of the plasmid in E. coli. FIG. 18 shows that 101P3A11 was expressed using the pSRα retroviral vector in the cell line 300.19. The retroviral vectors can thereafter be used for infection and generation of various cell lines using, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells.
Additional pSRα constructs are made that fuse an epitope tag such as the FLAGTM tag to the carboxyl-terminus of 101P3A11 sequences to allow detection using anti-Flag antibodies. For example, the FLAGTM sequence 5′ gat tac aag gat gac gac gat aag 3′ (SEQ ID NO: 44) is added to cloning primer at the 3′ end of the ORF. Additional pSRα constructs are made to produce both amino-terminal and carboxyl-terminal GFP and myc/6×His fusion proteins of the full-length 101P3A11 proteins.
Additional Viral Vectors: Additional constructs are made for viral-mediated delivery and expression of 101P3A11. High virus titer leading to high level expression of 101P3A11 is achieved in viral delivery systems such as adenoviral vectors and herpes amplicon vectors. The 101P3A11 coding sequences or fragments thereof are amplified by PCR and subcloned into the AdEasy shuttle vector (Stratagene). Recombination and virus packaging are performed according to the manufacturer's instructions to generate adenoviral vectors. Alternatively, 101P3A11 coding sequences or fragments thereof are cloned into the HSV-1 vector (Imgenex) to generate herpes viral vectors. The viral vectors are thereafter used for infection of various cell lines such as SCaBER, NIH 3T3, 293 or rat-1 cells.
Regulated Expression Systems: To control expression of 101P3A11 in mammalian cells, coding sequences of 101P3A11, or portions thereof, are cloned into regulated mammalian expression systems such as the T-Rex System (Invitrogen), the GeneSwitch System (Invitrogen) and the tightly-regulated Ecdysone System (Sratagene). These systems allow the study of the temporal and concentration dependent effects of recombinant 101P3A11. These vectors are thereafter used to control expression of 101P3A11 in various cell lines such as SCaBER, NIH 3T3, 293 or rat-1 cells.
B. Baculovirus Expression Systems
To generate recombinant 101P3A11 proteins in a baculovirus expression system, 101P3A11 ORF, or portions thereof, are cloned into the baculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides a His-tag at the N-terminus. Specifically, pBlueBac-101P3A11 is co-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9 (Spodoptera frugiperda) insect cells to generate recombinant baculovirus (see Invitrogen instruction manual for details). Baculovirus is then collected from cell supernatant and purified by plaque assay.
Recombinant 101P3A11 protein is then generated by infection of HighFive insect cells (Invitrogen) with purified baculovirus. Recombinant 101P3A11 protein can be detected using anti-101P3A11 or anti-His-tag antibody. 101P3A11 protein can be purified and used in various cell-based assays or as immunogen to generate polyclonal and monoclonal antibodies specific for 101P3A11.
Example 5
Production of Recombinant 101P3A11 in Higher Eukaryotic Systems
A. Mammalian Constructs:
To express recombinant 101P3A11 in eukaryotic cells, full or partial length 101P3A11 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 101P3A11 are expressed in these constructs, amino acids 1 to 317 or 318; or any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 101P3A11, variants, or analogs thereof.
The constructs can be transfected into any one of a wide variety of mammalian cells such as 293T cells. Transfected 293T cell lysates can be probed with the anti-101P3A11 polyclonal serum, described herein.
pcDNA4/HisMax Constructs: To express 101P3A11 in mammalian cells, the 101P3A11 ORF was cloned into pcDNA4/HisMax Version A (Invitrogen, Carlsbad, Calif.). Protein expression is driven from the cytomegalovirus (CMV) promoter and the SP16 translational enhancer. The recombinant protein has XpressTM and six histidine (6×His) epitopes fused to the amino-terminus. The pcDNA4/HisMax vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Zeocin resistance gene allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in E. coli. 
pcDNA3.1/MycHis Constructs: To express 101P3A11 in mammalian cells, the 101P3A11 ORF, with a consensus Kozak translation initiation site, was cloned into pcDNA3.1/MycHis Version A (Invitrogen, Carlsbad, Calif.). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the myc epitope and 6×His epitope fused to the carboxyl-terminus. The pcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability, along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene can be used, as it allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in E. coli. 
pcDNA3.1/CT-GFP-TOPO Construct: To express 101P3A11 in mammalian cells and to allow detection of the recombinant proteins using fluorescence, the 101P3A11 ORF, with a consensus Kozak translation initiation site, was cloned into pcDNA3.1/CT-GFP-TOPO (Invitrogen, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the Green Fluorescent Protein (GFP) fused to the carboxyl-terminus facilitating non-invasive, in vivo detection and cell biology studies. The pcDNA3.1CT-GFP-TOPO vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in E. coli. Additional constructs with an amino-terminal GFP fusion are made in pcDNA3.1/NT-GFP-TOPO spanning the entire length of the 101P3A11 proteins.
PAPtag: The 101P3A11 ORF, or portions thereof, of 101P3A11 are cloned into pAPtag-5 (GenHunter Corp. Nashville, Tenn.). This construct generates an alkaline phosphatase fusion at the carboxyl-terminus of the 101P3A11 proteins while fusing the IgGκ signal sequence to the amino-terminus. Constructs are also generated in which alkaline phosphatase with an amino-terminal IgGκ signal sequence is fused to the amino-terminus of 101P3A11 proteins. The resulting recombinant 101P3A11 proteins are optimized for secretion into the media of transfected mammalian cells and can be used to identify proteins such as ligands or receptors that interact with the 101P3A11 proteins. Protein expression is driven from the CMV promoter and the recombinant proteins also contain myc and 6×His epitopes fused at the carboxyl-terminus that facilitates detection and purification. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the recombinant protein and the ampicillin resistance gene permits selection of the plasmid in E. coli. 
ptag5: The 101P3A11 ORF, or portions thereof, of 101P3A11 are cloned into pTag-5. This vector is similar to pAPtag but without the alkaline phosphatase fusion. This construct generated 101P3A11 protein with an amino-terminal IgGκ signal sequence and myc and 6×His epitope tags at the carboxyl-terminus that facilitate detection and affinity purification. The resulting recombinant 101P3A11 protein was optimized for secretion into the media of transfected mammalian cells, and was used as immunogen or ligand to identify proteins such as ligands or receptors that interact with the 101P3A11 proteins. Protein expression is driven from the CMV promoter. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the protein, and the ampicillin resistance gene permits selection of the plasmid in E. coli. 
PsecFc: The 101P3A11 ORF, or portions thereof, of 101P3A11 are also cloned into psecFc. The psecFc vector was assembled by cloning the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen, California). This construct generates an IgG1 Fc fusion at the carboxyl-terminus of the 101P3A11 proteins, while fusing the IgGκ signal sequence to N-terminus. 101P3A11 fusions utilizing the murine IgG1 Fc region are also used. The resulting recombinant 101P3A11 proteins are optimized for secretion into the media of transfected mammalian cells, and can be used as immunogens or to identify proteins such as ligands or receptors that interact with the 101P3A11 protein. Protein expression is driven from the CMV promoter. The hygromycin resistance gene present in the vector allows for selection of mammalian cells that express the recombinant protein, and the ampicillin resistance gene permits selection of the plasmid in E. coli. 
The amino acid region 159-202 of the 101P3A11 ORF was cloned into psecFc. The resulting recombinant 101P3A11(159-202)-psecFc construct was transfected into 293T and Cos-7 cells, and the expression of recombinant 101P3A11(159-202)-psecFc protein assayed by Western blotting (FIG. 17). Results show that 101P3A11(159-202)-psecFc fusion protein was expressed in the lysates of both 293T and Cos-7 cells. The 101P3A11(159-202)-psecFc fusion protein was also secreted and detected in the culture supernatants of both cell types.
pSRα Constructs: To generate mammalian cell lines that express 101P3A11, constitutively, the ORF of 101P3A11 was cloned into pSRα constructs. Amphotropic and ecotropic retroviruses were generated by transfection of pSRα constructs into the 293T-10A1 packaging line or co-transfection of pSRα and a helper plasmid (containing deleted packaging sequences) into the 293 cells, respectively. The retrovirus was used to infect a variety of mammalian cell lines, resulting in the integration of the cloned gene, 101P3A11, into the host cell lines. Protein expression is driven from a long terminal repeat (LTR). The Neomycin resistance gene present in the vector allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permit selection and maintenance of the plasmid in E. coli. FIG. 18 shows that 101P3A11 was expressed using the pSRα retroviral vector in the cell line 300.19. The retroviral vectors can thereafter be used for infection and generation of various cell lines using, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells.
Additional pSRα constructs are made that fuse an epitope tag such as the FLAGTM tag to the carboxyl-terminus of 101P3A11 sequences to allow detection using anti-Flag antibodies. For example, the FLAGTM sequence 5′ gat tac aag gat gac gac gat aag 3′ (SEQ ID NO: 45) is added to cloning primer at the 3′ end of the ORF. Additional pSRα constructs are made to produce both amino-terminal and carboxyl-terminal GFP and myc/6×His fusion proteins of the full-length 101P3A11 proteins.
Additional Viral Vectors: Additional constructs are made for viral-mediated delivery and expression of 101P3A11. High virus titer leading to high level expression of 101P3A11 is achieved in viral delivery systems such as adenoviral vectors and herpes amplicon vectors. The 101P3A11 coding sequences or fragments thereof are amplified by PCR and subcloned into the AdEasy shuttle vector (Stratagene). Recombination and virus packaging are performed according to the manufacturer's instructions to generate adenoviral vectors. Alternatively, 101P3A11 coding sequences or fragments thereof are cloned into the HSV-1 vector (Imgenex) to generate herpes viral vectors. The viral vectors are thereafter used for infection of various cell lines such as SCaBER, NIH 3T3, 293 or rat-1 cells.
Regulated Expression Systems: To control expression of 101P3A11 in mammalian cells, coding sequences of 101P3A11, or portions thereof, are cloned into regulated mammalian expression systems such as the T-Rex System (Invitrogen), the GeneSwitch System (Invitrogen) and the tightly-regulated Ecdysone System (Sratagene). These systems allow the study of the temporal and concentration dependent effects of recombinant 101P3A11. These vectors are thereafter used to control expression of 101P3A11 in various cell lines such as SCaBER, NIH 3T3, 293 or rat-1 cells.
B. Baculovirus Expression Systems
To generate recombinant 101P3A11 proteins in a baculovirus expression system, 101P3A11 ORF, or portions thereof, are cloned into the baculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides a His-tag at the N-terminus. Specifically, pBlueBac-101P3A11 is co-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9 (Spodoptera frugiperda) insect cells to generate recombinant baculovirus (see Invitrogen instruction manual for details). Baculovirus is then collected from cell supernatant and purified by plaque assay.
Recombinant 101P3A11 protein is then generated by infection of HighFive insect cells (Invitrogen) with purified baculovirus. Recombinant 101P3A11 protein can be detected using anti-101P3A11 or anti-His-tag antibody. 101P3A11 protein can be purified and used in various cell-based assays or as immunogen to generate polyclonal and monoclonal antibodies specific for 101P3A11.
Example 6
Antigenicity Profiles and Secondary Structure
FIG. 5, FIG. 6, FIG. 7, FIG. 8, and FIG. 9 depict graphically five amino acid profiles of the 101P3A11 amino acid sequence, each assessment available by accessing the ProtScale website located on the World Wide Web at (expasy.ch/cgi-bin/protscale.pl) on the ExPasy molecular biology server.
These profiles: FIG. 5, Hydrophilicity, (Hopp T. P., Woods K. R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); FIG. 6, Hydropathicity, (Kyte J., Doolittle R. F., 1982. J. Mol. Biol. 157:105-132); FIG. 7, Percentage Accessible Residues (Janin J., 1979 Nature 277:491-492); FIG. 8, Average Flexibility, (Bhaskaran R., and Ponnuswamy P. K., 1988. Int. J. Pept. Protein Res. 32:242-255); FIG. 9, Beta-turn (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294); and optionally others available in the art, such as on the ProtScale website, were used to identify antigenic regions of the 101P3A11 protein. Each of the above amino acid profiles of 101P3A11 were generated using the following ProtScale parameters for analysis: 1) A window size of 9; 2) 100% weight of the window edges compared to the window center; and, 3) amino acid profile values normalized to lie between 0 and 1.
Hydrophilicity (FIG. 5), Hydropathicity (FIG. 6) and Percentage Accessible Residues (FIG. 7) profiles were used to determine stretches of hydrophilic amino acids (i.e., values greater than 0.5 on the Hydrophilicity and Percentage Accessible Residues profile, and values less than 0.5 on the Hydropathicity profile). Such regions are likely to be exposed to the aqueous environment, be present on the surface of the protein, and thus are available for immune recognition, such as by antibodies.
Average Flexibility (FIG. 8) and Beta-turn (FIG. 9) profiles determine stretches of amino acids (i.e., values greater than 0.5 on the Beta-turn profile and the Average Flexibility profile) that are not constrained in secondary structures such as beta sheets and alpha helices. Such regions are also more likely to be exposed portions of the protein and thus are accessible to immune recognition, such as by antibodies.
Antigenic sequences of the 101P3A11 protein indicated, e.g., by the profiles set forth in FIG. 5, FIG. 6, FIG. 7, FIG. 8, and/or FIG. 9 are used to prepare immunogens, either peptides or nucleic acids that encode them, to generate anti-101P3A11 antibodies. The immunogen can be any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more than 50 contiguous amino acids, or the corresponding nucleic acids that encode them, from the 101P3A11 protein. In particular, peptide immunogens of the invention can comprise, a peptide region of at least 5 amino acids of FIG. 2 in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5; a peptide region of at least 5 amino acids of FIG. 2 in any whole number increment up to 317 or 318 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6; a peptide region of at least 5 amino acids of FIG. 2 in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7; a peptide region of at least 5 amino acids of FIG. 2 in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile on FIG. 8; and, a peptide region of at least 5 amino acids of FIG. 2 in any whole number increment up to 317 or 318 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9. Peptide immunogens of the invention can also comprise nucleic acids that encode any of the forgoing.
All immunogens of the invention, peptide or nucleic acid, can be embodied in human unit dose form, or comprised by a composition that includes a pharmaceutical excipient compatible with human physiology.
The secondary structure of 101P3A11, namely the predicted presence and location of alpha helices, extended strands, and random coils, is predicted from the primary amino acid sequence using the HNN—Hierarchical Neural Network method (Guermeur, 1997, accessed from the ExPasy molecular biology server). The analysis indicates that 101P3A11 is composed 47.95% alpha helix, 21.45% extended strand, and 30.60% random coil (FIG. 19A).
Analysis for the potential presence of transmembrane domains in 101P3A11 was carried out using a variety of transmembrane prediction algorithms accessed from the ExPasy molecular biology server. The programs predict the presence of 7 transmembrane domains in 101P3A11, consistent with the structure of a G-protein coupled receptor. Shown graphically in FIG. 19A are the results of analysis using the TMpred (FIG. 19B) and TMHMM (FIG. 19C) prediction programs depicting the location of the 7 transmembrane domains. The results of each program, namely the amino acids encoding the transmembrane domains are summarized in Table XXI.
Example 7
Generation of 101P3A11 Polyclonal Antibodies
Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. In addition to immunizing with the full length 101P3A11 protein, computer algorithms are employed in design of immunogens that, based on amino acid sequence analysis are antigenic and available for recognition by the immune system of the immunized host (see the Example entitled “Antigenicity Profiles and Secondary Structure”). Such regions would generally be hydrophilic, flexible, in beta-turn conformations, and/or exposed on the surface of the protein (see, e.g., FIG. 5, FIG. 6, FIG. 7, FIG. 8, or FIG. 9 for amino acid profiles that indicate such regions of 101P3A11).
For example, 101P3A11 recombinant bacterial fusion proteins or peptides containing hydrophilic, flexible, beta-turn regions of the 101P3A11 amino acid sequence, such as amino acids 1-23, plus or minus 1-10 amino acids at available termini, and amino acids 159-202, plus or minus 1-10 amino acids at available termini, are used as antigens to generate polyclonal antibodies in New Zealand White rabbits. It is useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. In one embodiment, a peptide encoding amino acids 1-23 of 101P3A11 is conjugated to KLH and used to immunize the rabbit. Alternatively the immunizing agent may include all or portions of the 101P3A11 protein, analogs or fusion proteins thereof. For example, the 101P3A11 amino acid sequence can be fused using recombinant DNA techniques to any one of a variety of fusion protein partners that are well known in the art, such as glutathione-S-transferase (GST) and HIS tagged fusion proteins. Such fusion proteins are purified from induced bacteria using the appropriate affinity matrix.
In one embodiment, a GST-fusion protein encoding amino acids 86-317, plus or minus 1-10 amino acids at available termini, is produced and purified and used as immunogen. Other recombinant bacterial fusion proteins that may be employed include maltose binding protein, LacZ, thioredoxin, NusA, or an immunoglobulin constant region (see the section entitled “Production of 101P3A11 in Prokaryotic Systems” and Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubul et al. eds., 1995; Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L., Damle, N., and Ledbetter, L. (1991) J. Exp. Med. 174, 561-566).
In addition to bacterial derived fusion proteins, mammalian expressed protein antigens are also used. These antigens are expressed from mammalian expression vectors such as the Tag5 and Fc-fusion vectors (see the section entitled “Production of Recombinant 101P3A11 in Eukaryotic Systems”), and retain post-translational modifications such as glycosylations found in native protein. In one embodiment, amino acids 159-202 is cloned into the Tag5 mammalian secretion vector. The recombinant protein is purified by metal chelate chromatography from tissue culture supernatants of 293T cells stably expressing the recombinant vector. The purified Tag5 101P3A11 protein is then used as immunogen.
During the immunization protocol, it is useful to mix or emulsify the antigen in adjuvants that enhance the immune response of the host animal. Examples of adjuvants include, but are not limited to, complete Freund's adjuvant (CFA) and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).
In a typical protocol, rabbits are initially immunized subcutaneously with up to 200 μg, typically 100-200 μg, of fusion protein or peptide conjugated to KLH mixed in complete Freund's adjuvant (CFA). Rabbits are then injected subcutaneously every two weeks with up to 200 μg, typically 100-200 μg, of the immunogen in incomplete Freund's adjuvant (IFA). Test bleeds are taken approximately 7-10 days following each immunization and used to monitor the titer of the antiserum by ELISA.
To test reactivity and specificity of immune serum, such as the rabbit serum derived from immunization with Tag5 101P3A11 encoding amino acids 159-202, the full-length 101P3A11 cDNA is cloned into pcDNA 3.1 myc-his expression vector (Invitrogen, see the Example entitled “Production of Recombinant 101P3A11 in Eukaryotic Systems”). After transfection of the constructs into 293T cells, cell lysates are probed with the anti-101P3A11 serum and with anti-His antibody (Santa Cruz Biotechnologies, Santa Cruz, Calif.) to determine specific reactivity to denatured 101P3A11 protein using the Western blot technique. Immunoprecipitation and flow cytometric analyses of 293T and other recombinant 101P3A11-expressing cells determine recognition of native protein by the antiserum. In addition, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometric techniques using cells that endogenously express 101P3A11 are carried out to test specificity.
The anti-serum from the Tag5 101P3A11 immunized rabbit is affinity purified by passage over a column composed of the Tag5 antigen covalently coupled to Affigel matrix (BioRad, Hercules, Calif.). The serum is then further purified by protein G affinity chromatography to isolate the IgG fraction. Serum from rabbits immunized with fusion proteins, such as GST and MBP fusion proteins, are purified by depletion of antibodies reactive to the fusion partner sequence by passage over an affinity column containing the fusion partner either alone or in the context of an irrelevant fusion protein. Sera from other His-tagged antigens and peptide immunized rabbits as well as fusion partner depleted sera are affinity purified by passage over a column matrix composed of the original protein immunogen or free peptide.
Example 8
Generation of 101P3A11 Monoclonal Antibodies (mAbs)
In one embodiment, therapeutic mAbs to 101P3A11 comprise those that react with epitopes of the protein that would disrupt or modulate the biological function of 101P3A11, for example those that would disrupt its interaction with ligands or proteins that mediate or are involved in its biological activity. Therapeutic mAbs also comprise those that specifically bind epitopes of 101P3A11 exposed on the cell surface and thus are useful in targeting mAb-toxin conjugates. Monoclonal antibodies may also be raised to other antigenic epitopes of 101P3A11 including amino acid sequences predicted to be in intracellular regions. These monoclonal antibodies are useful as intrabodies if they disrupt the signaling mechanisms of 101P3A11, such as the interaction with heterotrimeric G proteins. Such antibodies are also useful as diagnostic agents for techniques such as immunohistochemistry. Immunogens for generation of such mAbs include those designed to encode or contain the entire 101P3A11 protein or regions of the 101P3A11 protein predicted to be exposed to the extracellular environment or hydrophilic cytoplasmic environment, and/antigenic from computer analysis of the amino acid sequence (see, e.g., FIG. 5, FIG. 6, FIG. 7, FIG. 8, or FIG. 9, and the Example entitled “Antigenicity Profiles and Secondary Structure”). Immunogens include peptides, recombinant bacterial proteins, and mammalian expressed Tag 5 proteins and human and murine IgG FC fusion proteins. In addition, cells expressing high levels of 101P3A11, such as 293T-101P3A11 or 300.19-101P3A11 murine Pre-B cells, are used to immunize mice.
To generate mAbs to 101P3A11, mice are first immunized intraperitoneally (IP) with, typically, 10-50 μg of protein immunogen or 107 101P3A11-expressing cells mixed in complete Freund's adjuvant. Alternatively, mice are immunized intradermally. Mice are then subsequently immunized IP every 2-4 weeks with, typically, 10-50 μg of protein immunogen or 107 cells mixed in incomplete Freund's adjuvant. Alternatively, MPL-TDM adjuvant is used in immunizations. In addition to the above protein and cell-based immunization strategies, a DNA-based immunization protocol is employed in which a mammalian expression vector encoding 101P3A11 sequence is used to immunize mice by direct injection of the plasmid DNA. For example, the predicted first extracellular loop, amino acids 82-104, or second extracellular loop of 101P3A11, amino acids 159-202, or the third extracellular loop, amino acids 258-275 (in each instance plus or minus 10 amino acids) is cloned into the Tag5 mammalian secretion vector and the recombinant vector is used as immunogen. In another example the same amino acids are cloned into an Fc-fusion secretion vector in which the 101P3A11 sequence is fused at the amino-terminus to an IgK leader sequence and at the carboxyl-terminus to the coding sequence of the human IgG Fc region. This recombinant vector is then used as immunogen. Amino acid sequences from intracellular regions may also be used as antigens using similar strategies. These regions include amino acids 50-63, amino acids 121-146, amino acids 261-275, and amino acids 295-318 (in each instance plus or minus 10 amino acids, except for the C-terminus residue). The plasmid immunization protocols are used in combination with purified proteins expressed from the same vector and with cells expressing 101P3A11.
During the immunization protocol, test bleeds are taken 7-10 days following an injection to monitor titer and specificity of the immune response. Once appropriate reactivity and specificity is obtained as determined by ELISA, Western blotting, immunoprecipitation, fluorescence microscopy, and flow cytometric analyses, fusion and hybridoma generation is then carried out with established procedures well known in the art (see, e.g., Harlow and Lane, 1988).
In one embodiment for generating 101P3A11 monoclonal antibodies, a Tag5-101P3A11 antigen encoding amino acids 159-202 is expressed and purified from stably transfected 293T cells. Balb C mice are initially immunized intraperitoneally with 25 μg of the Tag5-101P3A11 protein mixed in complete Freund's adjuvant. Mice are subsequently immunized every two weeks with 25 μg of the antigen mixed in incomplete Freund's adjuvant for a total of three immunizations. ELISA using the Tag5 antigen determines the titer of serum from immunized mice. Reactivity and specificity of serum to full length 101P3A11 protein is monitored by Western blotting, immunoprecipitation and flow cytometry using 293T cells transfected with an expression vector encoding the 101P3A11 cDNA (see e.g., the Example entitled “Production of Recombinant 101P3A11 in Eukaryotic Systems”). Other recombinant 101P3A11-expressing cells or cells endogenously expressing 101P3A11 are also used. Mice showing the strongest reactivity are rested and given a final injection of Tag5 antigen in PBS and then sacrificed four days later. The spleens of the sacrificed mice are harvested and fused to SPO/2 myeloma cells using standard procedures (Harlow and Lane, 1988). Supernatants from HAT selected growth wells are screened by ELISA, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometry to identify 101P3A11 specific antibody-producing clones.
The binding affinity of a 101P3A11 monoclonal antibody is determined using standard technologies. Affinity measurements quantify the strength of antibody to epitope binding and are used to help define which 101P3A11 monoclonal antibodies preferred, e.g., for diagnostic or therapeutic use, as appreciated by one of skill in the art. The BIAcore system (Uppsala, Sweden) is a preferred method for determining binding affinity. The BIAcore system uses surface plasmon resonance (SPR, Welford K. 1991, Opt. Quant. Elect. 23: 1; Morton and Myszka, 1998, Methods in Enzymology 295: 268) to monitor biomolecular interactions in real time. BIAcore analysis conveniently generates association rate constants, dissociation rate constants, equilibrium dissociation constants, and affinity constants.
Example 9
HLA Class I and Class II Binding Assays
HLA class I and class II binding assays using purified HLA molecules are performed in accordance with disclosed protocols (e.g., PCT publications WO 94/20127 and WO 94/03205; Sidney et al., Current Protocols in Immunology 18.3.1 (1998); Sidney, et al., J. Immunol. 154:247 (1995); Sette, et al., Mol. Immunol. 31:813 (1994)). Briefly, purified MHC molecules (5 to 500 nM) are incubated with various unlabeled peptide inhibitors and 1-10 nM 125I-radiolabeled probe peptides as described. Following incubation, MHC-peptide complexes are separated from free peptide by gel filtration and the fraction of peptide bound is determined. Typically, in preliminary experiments, each MHC preparation is titered in the presence of fixed amounts of radiolabeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays are performed using these HLA concentrations.
Since under these conditions [label]<[HLA] and IC50≧[HLA], the measured IC50 values are reasonable approximations of the true KD values. Peptide inhibitors are typically tested at concentrations ranging from 120 μg/ml to 1.2 ng/ml, and are tested in two to four completely independent experiments. To allow comparison of the data obtained in different experiments, a relative binding Figure is calculated for each peptide by dividing the IC50 of a positive control for inhibition by the IC50 for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For database purposes, and inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into IC50 nM values by dividing the IC50 nM of the positive controls for inhibition by the relative binding of the peptide of interest. This method of data compilation is accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC.
Binding assays as outlined above may be used to analyze HLA supermotif and/or HLA motif-bearing peptides (see Table IV).
Example 10
Identification of HLA Supermotif- and Motif-Bearing CTL Candidate Epitopes
HLA vaccine compositions of the invention can include multiple epitopes. The multiple epitopes can comprise multiple HLA supermotifs or motifs to achieve broad population coverage. This example illustrates the identification and confirmation of supermotif- and motif-bearing epitopes for the inclusion in such a vaccine composition. Calculation of population coverage is performed using the strategy described below.
Computer Searches and Algorithms for Identification of Supermotif and/or Motif-Bearing Epitopes
The searches performed to identify the motif-bearing peptide sequences in the Example entitled “Antigenicity Profiles” and Tables V-XVIII and XXII TO IL employ the protein sequence data from the gene product of 101P3A11 set forth in FIGS. 2 and 3; the specific peptides used to generate the tables are listed in Table LII.
Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs are performed as follows. All translated 101P3A11 protein sequences are analyzed using a text string search software program to identify potential peptide sequences containing appropriate HLA binding motifs; such programs are readily produced in accordance with information in the art in view of known motif/supermotif disclosures. Furthermore, such calculations can be made mentally.
Identified A2-, A3-, and DR-supermotif sequences are scored using polynomial algorithms to predict their capacity to bind to specific HLA-Class I or Class II molecules. These polynomial algorithms account for the impact of different amino acids at different positions, and are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA molecule interactions can be approximated as a linear polynomial function of the type:

“ΔG”=a1i×a2i×a3i . . . ×ani 

where aji is a coefficient which represents the effect of the presence of a given amino acid (j) at a given position (i) along the sequence of a peptide of n amino acids. The crucial assumption of this method is that the effects at each position are essentially independent of each other (i.e., independent binding of individual side-chains). When residue j occurs at position i in the peptide, it is assumed to contribute a constant amount ji to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide.
The method of derivation of specific algorithm coefficients has been described in Gulukota et al., J. Mol. Biol. 267:1258-126, 1997; (see also Sidney et al., Human Immunol. 45:79-93, 1996; and Southwood et al., J. Immunol. 160:3363-3373, 1998). Briefly, for all i positions, anchor and non-anchor alike, the geometric mean of the average relative binding (ARB) of all peptides carrying j is calculated relative to the remainder of the group, and used as the estimate of ji. For Class II peptides, if multiple alignments are possible, only the highest scoring alignment is utilized, following an iterative procedure. To calculate an algorithm score of a given peptide in a test set, the ARB values corresponding to the sequence of the peptide are multiplied. If this product exceeds a chosen threshold, the peptide is predicted to bind. Appropriate thresholds are chosen as a function of the degree of stringency of prediction desired.
Selection of HLA-A2 Supertype Cross-Reactive Peptides
Protein sequences from 101P3A11 are scanned utilizing motif identification software, to identify 8-, 9- 10- and 11-mer sequences containing the HLA-A2-supermotif main anchor specificity. Typically, these sequences are then scored using the protocol described above and the peptides corresponding to the positive-scoring sequences are synthesized and tested for their capacity to bind purified HLA-A*0201 molecules in vitro (HLA-A*0201 is considered a prototype A2 supertype molecule).
These peptides are then tested for the capacity to bind to additional A2-supertype molecules (A*0202, A*0203, A*0206, and A*6802). Peptides that bind to at least three of the five A2-supertype alleles tested are typically deemed A2-supertype cross-reactive binders. Preferred peptides bind at an affinity equal to or less than 500 nM to three or more HLA-A2 supertype molecules.
Selection of HLA-A3 Supermotif-Bearing Epitopes
The 101P3A11 protein sequence(s) scanned above is also examined for the presence of peptides with the HLA-A3-supermotif primary anchors. Peptides corresponding to the HLA A3 supermotif-bearing sequences are then synthesized and tested for binding to HLA-A*0301 and HLA-A*1101 molecules, the molecules encoded by the two most prevalent A3-supertype alleles. The peptides that bind at least one of the two alleles with binding affinities of ≦500 nM, often ≦200 nM, are then tested for binding cross-reactivity to the other common A3-supertype alleles (e.g., A*3101, A*3301, and A*6801) to identify those that can bind at least three of the five HLA-A3-supertype molecules tested.
Selection of HLA-B7 Supermotif Bearing Epitopes
The 101P3A11 protein(s) scanned above is also analyzed for the presence of 8-, 9-10-, or 11-mer peptides with the HLA-B7-supermotif. Corresponding peptides are synthesized and tested for binding to HLA-B*0702, the molecule encoded by the most common B7-supertype allele (i.e., the prototype B7 supertype allele). Peptides binding B*0702 with IC50 of ≦500 nM are identified using standard methods. These peptides are then tested for binding to other common B7-supertype molecules (e.g., B*3501, B*5101, B*5301, and B*5401). Peptides capable of binding to three or more of the five B7-supertype alleles tested are thereby identified.
Selection of A1 and A24 Motif-Bearing Epitopes
To further increase population coverage, HLA-A1 and -A24 epitopes can also be incorporated into vaccine compositions. An analysis of the 101P3A11 protein can also be performed to identify HLA-A1- and A24-motif-containing sequences.
High affinity and/or cross-reactive binding epitopes that bear other motif and/or supermotifs are identified using analogous methodology.
Example 11
Confirmation of Immunogenicity
Cross-reactive candidate CTL A2-supermotif-bearing peptides that are identified as described herein are selected to confirm in vitro immunogenicity. Confirmation is performed using the following methodology:
Target Cell Lines for Cellular Screening:
The 0.221A2.1 cell line, produced by transferring the HLA-A2.1 gene into the HLA-A, -B, -C null mutant human B-lymphoblastoid cell line 721.221, is used as the peptide-loaded target to measure activity of HLA-A2.1-restricted CTL. This cell line is grown in RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, nonessential amino acids and 10% (v/v) heat inactivated FCS. Cells that express an antigen of interest, or transfectants comprising the gene encoding the antigen of interest, can be used as target cells to confirm the ability of peptide-specific CTLs to recognize endogenous antigen.
Primary CTL Induction Cultures:
Generation of Dendritic Cells (DC): PBMCs are thawed in RPMI with 30 μg/ml DNAse, washed twice and resuspended in complete medium (RPMI-1640 plus 5% AB human serum, non-essential amino acids, sodium pyruvate, L-glutamine and penicillin/streptomycin). The monocytes are purified by plating 10×106 PBMC/well in a 6-well plate. After 2 hours at 37° C., the non-adherent cells are removed by gently shaking the plates and aspirating the supernatants. The wells are washed a total of three times with 3 ml RPMI to remove most of the non-adherent and loosely adherent cells. Three ml of complete medium containing 50 ng/ml of GM-CSF and 1,000 U/ml of IL-4 are then added to each well. TNFα is added to the DCs on day 6 at 75 ng/ml and the cells are used for CTL induction cultures on day 7.
Induction of CTL with DC and Peptide: CD8+ T-cells are isolated by positive selection with Dynal immunomagnetic beads (Dynabeads® M-450) and the Detacha-Bead® reagent. Typically about 200-250×106 PBMC are processed to obtain 24×106 CD8+ T-cells (enough for a 48-well plate culture). Briefly, the PBMCs are thawed in RPMI with 30 μg/ml DNAse, washed once with PBS containing 1% human AB serum and resuspended in PBS/1% AB serum at a concentration of 20×106 cells/ml. The magnetic beads are washed 3 times with PBS/AB serum, added to the cells (140 μl beads/20×106 cells) and incubated for 1 hour at 4° C. with continuous mixing. The beads and cells are washed 4× with PBS/AB serum to remove the nonadherent cells and resuspended at 100×106 cells/ml (based on the original cell number) in PBS/AB serum containing 100 μl/ml Detacha-Bead® reagent and 30 μg/ml DNAse. The mixture is incubated for 1 hour at room temperature with continuous mixing. The beads are washed again with PBS/AB/DNAse to collect the CD8+ T-cells. The DC are collected and centrifuged at 1300 rpm for 5-7 minutes, washed once with PBS with 1% BSA, counted and pulsed with 40 μg/ml of peptide at a cell concentration of 1-2×106/ml in the presence of 3 μg/ml β2-microglobulin for 4 hours at 20° C. The DC are then irradiated (4,200 rads), washed 1 time with medium and counted again.
Setting up induction cultures: 0.25 ml cytokine-generated DC (at 1×105 cells/ml) are co-cultured with 0.25 ml of CD8+ T-cells (at 2×106 cell/ml) in each well of a 48-well plate in the presence of 10 ng/ml of IL-7. Recombinant human IL-10 is added the next day at a final concentration of 10 ng/ml and rhuman IL-2 is added 48 hours later at 10 IU/ml.
Restimulation of the induction cultures with peptide-pulsed adherent cells: Seven and fourteen days after the primary induction, the cells are restimulated with peptide-pulsed adherent cells. The PBMCs are thawed and washed twice with RPMI and DNAse. The cells are resuspended at 5×106 cells/ml and irradiated at  ̃4200 rads. The PBMCs are plated at 2×106 in 0.5 ml complete medium per well and incubated for 2 hours at 37° C. The plates are washed twice with RPMI by tapping the plate gently to remove the nonadherent cells and the adherent cells pulsed with 10 μg/ml of peptide in the presence of 3 μg/ml β2 microglobulin in 0.25 ml RPMI/5% AB per well for 2 hours at 37° C. Peptide solution from each well is aspirated and the wells are washed once with RPMI. Most of the media is aspirated from the induction cultures (CD8+ cells) and brought to 0.5 ml with fresh media. The cells are then transferred to the wells containing the peptide-pulsed adherent cells. Twenty four hours later recombinant human IL-10 is added at a final concentration of 10 ng/ml and recombinant human IL2 is added the next day and again 2-3 days later at 50 IU/ml (Tsai et al., Critical Reviews in Immunology 18(1-2):65-75, 1998). Seven days later, the cultures are assayed for CTL activity in a 51Cr release assay. In some experiments the cultures are assayed for peptide-specific recognition in the in situ IFNγ ELISA at the time of the second restimulation followed by assay of endogenous recognition 7 days later. After expansion, activity is measured in both assays for a side-by-side comparison.
Measurement of CTL Lytic Activity by 51Cr Release.
Seven days after the second restimulation, cytotoxicity is determined in a standard (5 hr) 51Cr release assay by assaying individual wells at a single E:T. Peptide-pulsed targets are prepared by incubating the cells with 10 μg/ml peptide overnight at 37° C.
Adherent target cells are removed from culture flasks with trypsin-EDTA. Target cells are labeled with 200 μCi of 51Cr sodium chromate (Dupont, Wilmington, Del.) for 1 hour at 37° C. Labeled target cells are resuspended at 106 per ml and diluted 1:10 with K562 cells at a concentration of 3.3×106/ml (an NK-sensitive erythroblastoma cell line used to reduce non-specific lysis). Target cells (100 μl) and effectors (100 μl) are plated in 96 well round-bottom plates and incubated for 5 hours at 37° C. At that time, 100 μl of supernatant are collected from each well and percent lysis is determined according to the formula:

[(cpm of the test sample−cpm of the spontaneous 51Cr release sample)/(cpm of the maximal 51Cr release sample−cpm of the spontaneous 51Cr release sample)]×100.

Maximum and spontaneous release are determined by incubating the labeled targets with 1% Triton X-100 and media alone, respectively. A positive culture is defined as one in which the specific lysis (sample-background) is 10% or higher in the case of individual wells and is 15% or more at the two highest E:T ratios when expanded cultures are assayed.
In Situ Measurement of Human IFNγ Production as an Indicator of Peptide-Specific and Endogenous Recognition
Immulon 2 plates are coated with mouse anti-human IFNγ monoclonal antibody (4 μg/ml 0.1M NaHCO3, pH8.2) overnight at 4° C. The plates are washed with Ca2+, Mg2+-free PBS/0.05% Tween 20 and blocked with PBS/10% FCS for two hours, after which the CTLs (100 μl/well) and targets (100 μl/well) are added to each well, leaving empty wells for the standards and blanks (which received media only). The target cells, either peptide-pulsed or endogenous targets, are used at a concentration of 1×106 cells/ml. The plates are incubated for 48 hours at 37° C. with 5% CO2.
Recombinant human IFN-gamma is added to the standard wells starting at 400 pg or 1200 pg/100 microliter/well and the plate incubated for two hours at 37° C. The plates are washed and 100 μl of biotinylated mouse anti-human IFN-gamma monoclonal antibody (2 microgram/ml in PBS/3% FCS/0.05% Tween 20) are added and incubated for 2 hours at room temperature. After washing again, 100 microliter HRP-streptavidin (1:4000) are added and the plates incubated for one hour at room temperature. The plates are then washed 6× with wash buffer, 100 microliter/well developing solution (TMB 1:1) are added, and the plates allowed to develop for 5-15 minutes. The reaction is stopped with 50 microliter/well 1M H3PO4 and read at OD450. A culture is considered positive if it measured at least 50 pg of IFN-gamma/well above background and is twice the background level of expression.
CTL Expansion.
Those cultures that demonstrate specific lytic activity against peptide-pulsed targets and/or tumor targets are expanded over a two week period with anti-CD3. Briefly, 5×104 CD8+ cells are added to a T25 flask containing the following: 1×106 irradiated (4,200 rad) PBMC (autologous or allogeneic) per ml, 2×105 irradiated (8,000 rad) EBV-transformed cells per ml, and OKT3 (anti-CD3) at 30 ng per ml in RPMI-1640 containing 10% (v/v) human AB serum, non-essential amino acids, sodium pyruvate, 25 μM 2-mercaptoethanol, L-glutamine and penicillin/streptomycin. Recombinant human IL2 is added 24 hours later at a final concentration of 2001 U/ml and every three days thereafter with fresh media at 50 IU/ml. The cells are split if the cell concentration exceeds 1×106/ml and the cultures are assayed between days 13 and 15 at E:T ratios of 30, 10, 3 and 1:1 in the 51Cr release assay or at 1×106/ml in the in situ IFNγ assay using the same targets as before the expansion.
Cultures are expanded in the absence of anti-CD3+ as follows. Those cultures that demonstrate specific lytic activity against peptide and endogenous targets are selected and 5×104 CD8+ cells are added to a T25 flask containing the following: 1×106 autologous PBMC per ml which have been peptide-pulsed with 10 μg/ml peptide for two hours at 37° C. and irradiated (4,200 rad); 2×105 irradiated (8,000 rad) EBV-transformed cells per ml RPMI-1640 containing 10% (v/v) human AB serum, non-essential AA, sodium pyruvate, 25 mM 2-ME, L-glutamine and gentamicin.
Immunogenicity of A2 Supermotif-Bearing Peptides
A2-supermotif cross-reactive binding peptides are tested in the cellular assay for the ability to induce peptide-specific CTL in normal individuals. In this analysis, a peptide is typically considered to be an epitope if it induces peptide-specific CTLs in at least individuals, and preferably, also recognizes the endogenously expressed peptide.
Immunogenicity can also be confirmed using PBMCs isolated from patients bearing a tumor that expresses 101P3A11. Briefly, PBMCs are isolated from patients, re-stimulated with peptide-pulsed monocytes and assayed for the ability to recognize peptide-pulsed target cells as well as transfected cells endogenously expressing the antigen.
Evaluation of A*03/A11 Immunogenicity
HLA-A3 supermotif-bearing cross-reactive binding peptides are also evaluated for immunogenicity using methodology analogous for that used to evaluate the immunogenicity of the HLA-A2 supermotif peptides.
Evaluation of B7 Immunogenicity
Immunogenicity screening of the B7-supertype cross-reactive binding peptides identified as set forth herein are confirmed in a manner analogous to the confirmation of A2- and A3-supermotif-bearing peptides.
Peptides bearing other supermotifs/motifs, e.g., HLA-A1, HLA-A24 etc. are also confirmed using similar methodology
Example 12
Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs
HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herein. Moreover, the definition of HLA motifs and supermotifs also allows one to engineer highly cross-reactive epitopes by identifying residues within a native peptide sequence which can be analoged to confer upon the peptide certain characteristics, e.g. greater cross-reactivity within the group of HLA molecules that comprise a supertype, and/or greater binding affinity for some or all of those HLA molecules. Examples of analoging peptides to exhibit modulated binding affinity are set forth in this example.
Analoging at Primary Anchor Residues
Peptide engineering strategies are implemented to further increase the cross-reactivity of the epitopes. For example, the main anchors of A2-supermotif-bearing peptides are altered, for example, to introduce a preferred L, I, V, or M at position 2, and I or V at the C-terminus.
To analyze the cross-reactivity of the analog peptides, each engineered analog is initially tested for binding to the prototype A2 supertype allele A*0201, then, if A*0201 binding capacity is maintained, for A2-supertype cross-reactivity.
Alternatively, a peptide is confirmed as binding one or all supertype members and then analoged to modulate binding affinity to any one (or more) of the supertype members to add population coverage.
The selection of analogs for immunogenicity in a cellular screening analysis is typically further restricted by the capacity of the parent wild type (WT) peptide to bind at least weakly, i.e., bind at an IC50 of 5000 nM or less, to three of more A2 supertype alleles. The rationale for this requirement is that the WT peptides must be present endogenously in sufficient quantity to be biologically relevant. Analoged peptides have been shown to have increased immunogenicity and cross-reactivity by T cells specific for the parent epitope (see, e.g., Parkhurst et al., J. Immunol. 157:2539, 1996; and Pogue et al., Proc. Natl. Acad. Sci. USA 92:8166, 1995).
In the cellular screening of these peptide analogs, it is important to confirm that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, target cells that endogenously express the epitope.
Analoging of HLA-A3 and B7-Supermotif-Bearing Peptides
Analogs of HLA-A3 supermotif-bearing epitopes are generated using strategies similar to those employed in analoging HLA-A2 supermotif-bearing peptides. For example, peptides binding to 3/5 of the A3-supertype molecules are engineered at primary anchor residues to possess a preferred residue (V, S, M, or A) at position 2.
The analog peptides are then tested for the ability to bind A*03 and A*11 (prototype A3 supertype alleles). Those peptides that demonstrate ≦500 nM binding capacity are then confirmed as having A3-supertype cross-reactivity.
Similarly to the A2- and A3-motif bearing peptides, peptides binding 3 or more B7-supertype alleles can be improved, where possible, to achieve increased cross-reactive binding or greater binding affinity or binding half life. B7 supermotif-bearing peptides are, for example, engineered to possess a preferred residue (V, I, L, or F) at the C-terminal primary anchor position, as demonstrated by Sidney et al. (J. Immunol. 157:3480-3490, 1996).
Analoging at primary anchor residues of other motif and/or supermotif-bearing epitopes is performed in a like manner.
The analog peptides are then be confirmed for immunogenicity, typically in a cellular screening assay. Again, it is generally important to demonstrate that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, targets that endogenously express the epitope.
Analoging at Secondary Anchor Residues
Moreover, HLA supermotifs are of value in engineering highly cross-reactive peptides and/or peptides that bind HLA molecules with increased affinity by identifying particular residues at secondary anchor positions that are associated with such properties. For example, the binding capacity of a B7 supermotif-bearing peptide with an F residue at position 1 is analyzed. The peptide is then analoged to, for example, substitute L for F at position 1. The analoged peptide is evaluated for increased binding affinity, binding half life and/or increased cross-reactivity. Such a procedure identifies analoged peptides with enhanced properties.
Engineered analogs with sufficiently improved binding capacity or cross-reactivity can also be tested for immunogenicity in HLA-B7-transgenic mice, following for example, IFA immunization or lipopeptide immunization. Analoged peptides are additionally tested for the ability to stimulate a recall response using PBMC from patients with 101P3A11-expressing tumors.
Other Analoging Strategies
Another form of peptide analoging, unrelated to anchor positions, involves the substitution of a cysteine with α-amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substitution of α-amino butyric acid for cysteine not only alleviates this problem, but has been shown to improve binding and crossbinding capabilities in some instances (see, e.g., the review by Sette et al., In: Persistent Viral Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999).
Thus, by the use of single amino acid substitutions, the binding properties and/or cross-reactivity of peptide ligands for HLA supertype molecules can be modulated.
Example 13
Identification and Confirmation of 101P3A11-Derived Sequences with HLA-DR Binding Motifs
Peptide epitopes bearing an HLA class II supermotif or motif are identified and confirmed as outlined below using methodology similar to that described for HLA Class I peptides.
Selection of HLA-DR-Supermotif-Bearing Epitopes.
To identify 101P3A11-derived, HLA class II HTL epitopes, a 101P3A11 antigen is analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif. Specifically, 15-mer sequences are selected comprising a DR-supermotif, comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total).
Protocols for predicting peptide binding to DR molecules have been developed (Southwood et al., J. Immunol. 160:3363-3373, 1998). These protocols, specific for individual DR molecules, allow the scoring, and ranking, of 9-mer core regions. Each protocol not only scores peptide sequences for the presence of DR-supermotif primary anchors (i.e., at position I and position 6) within a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors. Using allele-specific selection tables (see, e.g., Southwood et al., ibid.), it has been found that these protocols efficiently select peptide sequences with a high probability of binding a particular DR molecule. Additionally, it has been found that performing these protocols in tandem, specifically those for DR1, DR4w4, and DR7, can efficiently select DR cross-reactive peptides.
The 101P3A11-derived peptides identified above are tested for their binding capacity for various common HLA-DR molecules. All peptides are initially tested for binding to the DR molecules in the primary panel: DR1, DR4w4, and DR7. Peptides binding at least two of these three DR molecules are then tested for binding to DR2w2 β1, DR2w2 β2, DR6w19, and DR9 molecules in secondary assays. Finally, peptides binding at least two of the four secondary panel DR molecules, and thus cumulatively at least four of seven different DR molecules, are screened for binding to DR4w15, DR5w11, and DR8w2 molecules in tertiary assays. Peptides binding at least seven of the ten DR molecules comprising the primary, secondary, and tertiary screening assays are considered cross-reactive DR binders. 101P3A11-derived peptides found to bind common HLA-DR alleles are of particular interest.
Selection of DR3 Motif Peptides
Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, and Hispanic populations, DR3 binding capacity is a relevant criterion in the selection of HTL epitopes. Thus, peptides shown to be candidates may also be assayed for their DR3 binding capacity. However, in view of the binding specificity of the DR3 motif, peptides binding only to DR3 can also be considered as candidates for inclusion in a vaccine formulation.
To efficiently identify peptides that bind DR3, target 101P3A11 antigens are analyzed for sequences carrying one of the two DR3-specific binding motifs reported by Geluk et al. (J. Immunol. 152:5742-5748, 1994). The corresponding peptides are then synthesized and confirmed as having the ability to bind DR3 with an affinity of 1 μM or better, i.e., less than 1 μM. Peptides are found that meet this binding criterion and qualify as HLA class II high affinity binders.
DR3 binding epitopes identified in this manner are included in vaccine compositions with DR supermotif-bearing peptide epitopes.
Similarly to the case of HLA class I motif-bearing peptides, the class II motif-bearing peptides are analoged to improve affinity or cross-reactivity. For example, aspartic acid at position 4 of the 9-mer core sequence is an optimal residue for DR3 binding, and substitution for that residue often improves DR 3 binding.
Example 14
Immunogenicity of 101P3A11-Derived HTL Epitopes
This example determines immunogenic DR supermotif- and DR3 motif-bearing epitopes among those identified using the methodology set forth herein.
Immunogenicity of HTL epitopes are confirmed in a manner analogous to the determination of immunogenicity of CTL epitopes, by assessing the ability to stimulate HTL responses and/or by using appropriate transgenic mouse models. Immunogenicity is determined by screening for: 1.) in vitro primary induction using normal PBMC or 2.) recall responses from patients who have 101P3A11-expressing tumors.
Example 15
Calculation of Phenotypic Frequencies of HLA-Supertypes in Various Ethnic Backgrounds to Determine Breadth of Population Coverage
This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes comprising multiple supermotifs and/or motifs.
In order to analyze population coverage, gene frequencies of HLA alleles are determined. Gene frequencies for each HLA allele are calculated from antigen or allele frequencies utilizing the binomial distribution formulae gf=1−(SQRT(1−af)) (see, e.g., Sidney et al., Human Immunol. 45:79-93, 1996). To obtain overall phenotypic frequencies, cumulative gene frequencies are calculated, and the cumulative antigen frequencies derived by the use of the inverse formula [af=1−(1−Cgf)2].
Where frequency data is not available at the level of DNA typing, correspondence to the serologically defined antigen frequencies is assumed. To obtain total potential supertype population coverage no linkage disequilibrium is assumed, and only alleles confirmed to belong to each of the supertypes are included (minimal estimates). Estimates of total potential coverage achieved by inter-loci combinations are made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e.g., total=A+B*(1−A)). Confirmed members of the A3-like supertype are A3, A1, A31, A*3301, and A*6801. Although the A3-like supertype may also include A34, A66, and A*7401, these alleles were not included in overall frequency calculations. Likewise, confirmed members of the A2-like supertype family are A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*6802, and A*6901. Finally, the B7-like supertype-confirmed alleles are: B7, B*3501-03, B51, B*5301, B*5401, B*5501-2, B*5601, B*6701, and B*7801 (potentially also B*1401, B*3504-06, B*4201, and B*5602).
Population coverage achieved by combining the A2-, A3- and B7-supertypes is approximately 86% in five major ethnic groups. Coverage may be extended by including peptides bearing the A1 and A24 motifs. On average, A1 is present in 12% and A24 in 29% of the population across five different major ethnic groups (Caucasian, North American Black, Chinese, Japanese, and Hispanic). Together, these alleles are represented with an average frequency of 39% in these same ethnic populations. The total coverage across the major ethnicities when A1 and A24 are combined with the coverage of the A2-, A3- and B7-supertype alleles is >95%. An analogous approach can be used to estimate population coverage achieved with combinations of class II motif-bearing epitopes.
Immunogenicity studies in humans (e.g., Bertoni et al., J. Clin. Invest 100:503, 1997; Doolan et al., Immunity 7:97, 1997; and Threlkeld et al., J. Immunol. 159: 1648, 1997) have shown that highly cross-reactive binding peptides are almost always recognized as epitopes. The use of highly cross-reactive binding peptides is an important selection criterion in identifying candidate epitopes for inclusion in a vaccine that is immunogenic in a diverse population.
With a sufficient number of epitopes (as disclosed herein and from the art), an average population coverage is predicted to be greater than 95% in each of five major ethnic populations. The game theory Monte Carlo simulation analysis, which is known in the art (see e.g., Osborne, M. J. and Rubinstein, A. “A course in game theory” MIT Press, 1994), can be used to estimate what percentage of the individuals in a population comprised of the Caucasian, North American Black, Japanese, Chinese, and Hispanic ethnic groups would recognize the vaccine epitopes described herein. A preferred percentage is 90%. A more preferred percentage is 95%.
Example 16
CTL Recognition of Endogenously Processed Antigens after Priming
This example confirms that CTL induced by native or analoged peptide epitopes identified and selected as described herein recognize endogenously synthesized, i.e., native antigens.
Effector cells isolated from transgenic mice that are immunized with peptide epitopes, for example HLA-A2 supermotif-bearing epitopes, are re-stimulated in vitro using peptide-coated stimulator cells. Six days later, effector cells are assayed for cytotoxicity and the cell lines that contain peptide-specific cytotoxic activity are further re-stimulated. An additional six days later, these cell lines are tested for cytotoxic activity on 51Cr labeled Jurkat-A2.1/Kb target cells in the absence or presence of peptide, and also tested on 51Cr labeled target cells bearing the endogenously synthesized antigen, i.e. cells that are stably transfected with 101P3A11 expression vectors.
The results demonstrate that CTL lines obtained from animals primed with peptide epitope recognize endogenously synthesized 101P3A11 antigen. The choice of transgenic mouse model to be used for such an analysis depends upon the epitope(s) that are being evaluated. In addition to HLA-A*0201/Kb transgenic mice, several other transgenic mouse models including mice with human A11, which may also be used to evaluate A3 epitopes, and B7 alleles have been characterized and others (e.g., transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes.
Example 17
Activity of CTL-HTL Conjugated Epitopes in Transgenic Mice
This example illustrates the induction of CTLs and HTLs in transgenic mice, by use of a 101P3A11-derived CTL and HTL peptide vaccine compositions. The vaccine composition used herein comprise peptides to be administered to a patient with a 101P3A11-expressing tumor. The peptide composition can comprise multiple CTL and/or HTL epitopes. The epitopes are identified using methodology as described herein. This example also illustrates that enhanced immunogenicity can be achieved by inclusion of one or more HTL epitopes in a CTL vaccine composition; such a peptide composition can comprise an HTL epitope conjugated to a CTL epitope. The CTL epitope can be one that binds to multiple HLA family members at an affinity of 500 nM or less, or analogs of that epitope. The peptides may be lipidated, if desired.
Immunization procedures: Immunization of transgenic mice is performed as described (Alexander et al., J. Immunol. 159:4753-4761, 1997). For example, A2/Kb mice, which are transgenic for the human HLA A2.1 allele and are used to confirm the immunogenicity of HLA-A*0201 motif- or HLA-A2 supermotif-bearing epitopes, and are primed subcutaneously (base of the tail) with a 0.1 ml of peptide in Incomplete Freund's Adjuvant, or if the peptide composition is a lipidated CTL/HTL conjugate, in DMSO/saline, or if the peptide composition is a polypeptide, in PBS or Incomplete Freund's Adjuvant. Seven days after priming, splenocytes obtained from these animals are restimulated with syngenic irradiated LPS-activated lymphoblasts coated with peptide.
Cell lines: Target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA-A2.1/Kb chimeric gene (e.g., Vitiello et al., J. Exp. Med. 173:1007, 1991)
In vitro CTL activation: One week after priming, spleen cells (30×106 cells/flask) are co-cultured at 37° C. with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10×106 cells/flask) in 10 ml of culture medium/T25 flask. After six days, effector cells are harvested and assayed for cytotoxic activity.
Assay for cytotoxic activity: Target cells (1.0 to 1.5×106) are incubated at 37° C. in the presence of 200 μl of 51Cr. After 60 minutes, cells are washed three times and resuspended in R10 medium. Peptide is added where required at a concentration of 1 μg/ml. For the assay, 104 51Cr-labeled target cells are added to different concentrations of effector cells (final volume of 200 μl) in U-bottom 96-well plates. After a six hour incubation period at 37° C., a 0.1 ml aliquot of supernatant is removed from each well and radioactivity is determined in a Micromedic automatic gamma counter. The percent specific lysis is determined by the formula: percent specific release=100×(experimental release−spontaneous release)/(maximum release−spontaneous release). To facilitate comparison between separate CTL assays run under the same conditions, % 51Cr release data is expressed as lytic units/106 cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a six hour 51Cr release assay. To obtain specific lytic units/106, the lytic units/106 obtained in the absence of peptide is subtracted from the lytic units/106 obtained in the presence of peptide. For example, if 30% 51Cr release is obtained at the effector (E):target (T) ratio of 50:1 (i.e., 5×105 effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e., 5×104 effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be: [(1/50,000)−(1/500,000)]×106=18 LU.
The results are analyzed to assess the magnitude of the CTL responses of animals injected with the immunogenic CTL/HTL conjugate vaccine preparation and are compared to the magnitude of the CTL response achieved using, for example, CTL epitopes as outlined above in the Example entitled “Confirmation of Immunogenicity.” Analyses similar to this may be performed to confirm the immunogenicity of peptide conjugates containing multiple CTL epitopes and/or multiple HTL epitopes. In accordance with these procedures, it is found that a CTL response is induced, and concomitantly that an HTL response is induced upon administration of such compositions.
Example 18
Selection of CTL and HTL Epitopes for Inclusion in a 101P3A11-Specific Vaccine
This example illustrates a procedure for selecting peptide epitopes for vaccine compositions of the invention. The peptides in the composition can be in the form of a nucleic acid sequence, either single or one or more sequences (i.e., minigene) that encodes peptide(s), or can be single and/or polyepitopic peptides.
The following principles are utilized when selecting a plurality of epitopes for inclusion in a vaccine composition. Each of the following principles is balanced in order to make the selection.
Epitopes are selected which, upon administration, mimic immune responses that are correlated with 101P3A11 clearance. The number of epitopes used depends on observations of patients who spontaneously clear 101P3A11. For example, if it has been observed that patients who spontaneously clear 101P3A11-expressing cells generate an immune response to at least three (3) epitopes from 101P3A11 antigen, then at least three epitopes should be included for HLA class I. A similar rationale is used to determine HLA class II epitopes.
Epitopes are often selected that have a binding affinity of an IC50 of 500 nM or less for an HLA class I molecule, or for class II, an IC50 of 1000 nM or less; or HLA Class I peptides with high binding scores from the BIMAS web site.
In order to achieve broad coverage of the vaccine through out a diverse population, sufficient supermotif bearing peptides, or a sufficient array of allele-specific motif bearing peptides, are selected to give broad population coverage. In one embodiment, epitopes are selected to provide at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess breadth, or redundancy, of population coverage.
When creating polyepitopic compositions, or a minigene that encodes same, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of interest. The principles employed are similar, if not the same, as those employed when selecting a peptide comprising nested epitopes. For example, a protein sequence for the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, i.e., it has a high concentration of epitopes. Epitopes may be nested or overlapping (i.e., frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. A multi-epitopic, peptide can be generated synthetically, recombinantly, or via cleavage from the native source. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes. This embodiment provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (absent the creating of any analogs) directs the immune response to multiple peptide sequences that are actually present in 101P3A11 thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing nucleic acid vaccine compositions. Related to this embodiment, computer programs can be derived in accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length.
A vaccine composition comprised of selected peptides, when administered, is safe, efficacious, and elicits an immune response similar in magnitude to an immune response that controls or clears cells that bear or overexpress 101P3A11.
Example 19
Construction of “Minigene” Multi-Epitope DNA Plasmids
This example discusses the construction of a minigene expression plasmid. Minigene plasmids may, of course, contain various configurations of B cell, CTL and/or HTL epitopes or epitope analogs as described herein.
A minigene expression plasmid typically includes multiple CTL and HTL peptide epitopes. In the present example, HLA-A2, -A3, -B7 supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearing peptide epitopes are used in conjunction with DR supermotif-bearing epitopes and/or DR3 epitopes. HLA class I supermotif or motif-bearing peptide epitopes derived 101P3A11, are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage. Similarly, HLA class II epitopes are selected from 101P3A11 to provide broad population coverage, i.e. both HLA DR-1-4-7 supermotif-bearing epitopes and HLA DR-3 motif-bearing epitopes are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into a minigene for expression in an expression vector.
Such a construct may additionally include sequences that direct the HTL epitopes to the endoplasmic reticulum. For example, the Ii protein may be fused to one or more HTL epitopes as described in the art, wherein the CLIP sequence of the Ii protein is removed and replaced with an HLA class II epitope sequence so that HLA class II epitope is directed to the endoplasmic reticulum, where the epitope binds to an HLA class II molecules.
This example illustrates the methods to be used for construction of a minigene-bearing expression plasmid. Other expression vectors that may be used for minigene compositions are available and known to those of skill in the art.
The minigene DNA plasmid of this example contains a consensus Kozak sequence and a consensus murine kappa Ig-light chain signal sequence followed by CTL and/or HTL epitopes selected in accordance with principles disclosed herein. The sequence encodes an open reading frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1 Myc-His vector.
Overlapping oligonucleotides that can, for example, average about 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-purified. The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence. The final multiepitope minigene is assembled by extending the overlapping oligonucleotides in three sets of reactions using PCR. A Perkin/Elmer 9600 PCR machine is used and a total of 30 cycles are performed using the following conditions: 95° C. for 15 sec, annealing temperature (5° below the lowest calculated Tm of each primer pair) for 30 sec, and 72° C. for 1 min.
For example, a minigene is prepared as follows. For a first PCR reaction, 5 μg of each of two oligonucleotides are annealed and extended: In an example using eight oligonucleotides, i.e., four pairs of primers, oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100 μl reactions containing Pfu polymerase buffer (1×=10 mM KCL, 10 mM (NH4)2SO4, 20 mM Tris-chloride, pH 8.75, 2 mM MgSO4, 0.1% Triton X-100, 100 μg/ml BSA), 0.25 mM each dNTP, and 2.5 U of Pfu polymerase. The full-length dimer products are gel-purified, and two reactions containing the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles. Half of the two reactions are then mixed, and 5 cycles of annealing and extension carried out before flanking primers are added to amplify the full length product. The full-length product is gel-purified and cloned into pCR-blunt (Invitrogen) and individual clones are screened by sequencing.
Example 20
The Plasmid Construct and the Degree to which it Induces Immunogenicity
The degree to which a plasmid construct, for example a plasmid constructed in accordance with the previous Example, is able to induce immunogenicity is confirmed in vitro by determining epitope presentation by APC following transduction or transfection of the APC with an epitope-expressing nucleic acid construct. Such a study determines “antigenicity” and allows the use of human APC. The assay determines the ability of the epitope to be presented by the APC in a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface. Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (see, e.g., Sijts et al., J. Immunol. 156:683-692, 1996; Demotz et al., Nature 342:682-684, 1989); or the number of peptide-HLA class I complexes can be estimated by measuring the amount of lysis or lymphokine release induced by diseased or transfected target cells, and then determining the concentration of peptide necessary to obtain equivalent levels of lysis or lymphokine release (see, e.g., Kageyama et al., J. Immunol. 154:567-576, 1995).
Alternatively, immunogenicity is confirmed through in vivo injections into mice and subsequent in vitro assessment of CTL and HTL activity, which are analyzed using cytotoxicity and proliferation assays, respectively, as detailed e.g., in Alexander et al., Immunity 1:751-761, 1994.
For example, to confirm the capacity of a DNA minigene construct containing at least one HLA-A2 supermotif peptide to induce CTLs in vivo, HLA-A2.1/Kb transgenic mice, for example, are immunized intramuscularly with 100 μg of naked cDNA. As a means of comparing the level of CTLs induced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the minigene.
Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded in the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a 51Cr release assay. The results indicate the magnitude of the CTL response directed against the A2-restricted epitope, thus indicating the in vivo immunogenicity of the minigene vaccine and polyepitopic vaccine.
It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A2 supermotif peptide epitopes as does the polyepitopic peptide vaccine. A similar analysis is also performed using other HLA-A3 and HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 and HLA-B7 motif or supermotif epitopes, whereby it is also found that the minigene elicits appropriate immune responses directed toward the provided epitopes.
To confirm the capacity of a class II epitope-encoding minigene to induce HTLs in vivo, DR transgenic mice, or for those epitopes that cross react with the appropriate mouse MHC molecule, I-Ab-restricted mice, for example, are immunized intramuscularly with 100 μg of plasmid DNA. As a means of comparing the level of HTLs induced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified in complete Freund's adjuvant. CD4+ T cells, i.e. HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded in the minigene). The HTL response is measured using a 3H-thymidine incorporation proliferation assay, (see, e.g., Alexander et al. Immunity 1:751-761, 1994). The results indicate the magnitude of the HTL response, thus demonstrating the in vivo immunogenicity of the minigene.
DNA minigenes, constructed as described in the previous Example, can also be confirmed as a vaccine in combination with a boosting agent using a prime boost protocol. The boosting agent can consist of recombinant protein (e.g., Barnett et al., Aids Res. and Human Retroviruses 14, Supplement 3:S299-S309, 1998) or recombinant vaccinia, for example, expressing a minigene or DNA encoding the complete protein of interest (see, e.g., Hanke et al., Vaccine 16:439-445, 1998; Sedegah et al., Proc. Natl. Acad. Sci. USA 95:7648-53, 1998; Hanke and McMichael, Immunol. Letters 66: 177-181, 1999; and Robinson et al., Nature Med. 5:526-34, 1999).
For example, the efficacy of the DNA minigene used in a prime boost protocol is initially evaluated in transgenic mice. In this example, A2.1/Kb transgenic mice are immunized IM with 100 μg of a DNA minigene encoding the immunogenic peptides including at least one HLA-A2 supermotif-bearing peptide. After an incubation period (ranging from 3-9 weeks), the mice are boosted IP with 107 pfu/mouse of a recombinant vaccinia virus expressing the same sequence encoded by the DNA minigene. Control mice are immunized with 100 μg of DNA or recombinant vaccinia without the minigene sequence, or with DNA encoding the minigene, but without the vaccinia boost. After an additional incubation period of two weeks, splenocytes from the mice are immediately assayed for peptide-specific activity in an ELISPOT assay. Additionally, splenocytes are stimulated in vitro with the A2-restricted peptide epitopes encoded in the minigene and recombinant vaccinia, then assayed for peptide-specific activity in an alpha, beta and/or gamma IFN ELISA.
It is found that the minigene utilized in a prime-boost protocol elicits greater immune responses toward the HLA-A2 supermotif peptides than with DNA alone. Such an analysis can also be performed using HLA-A11 or HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 or HLA-B7 motif or supermotif epitopes. The use of prime boost protocols in humans is described below in the Example entitled “Induction of CTL Responses Using a Prime Boost Protocol.”
Example 21
Peptide Compositions for Prophylactic Uses
Vaccine compositions of the present invention can be used to prevent 101P3A11 expression in persons who are at risk for tumors that bear this antigen. For example, a polyepitopic peptide epitope composition (or a nucleic acid comprising the same) containing multiple CTL and HTL epitopes such as those selected in the above Examples, which are also selected to target greater than 80% of the population, is administered to individuals at risk for a 101P3A11-associated tumor.
For example, a peptide-based composition is provided as a single polypeptide that encompasses multiple epitopes. The vaccine is typically administered in a physiological solution that comprises an adjuvant, such as Incomplete Freunds Adjuvant. The dose of peptide for the initial immunization is from about 1 to about 50,000 μg, generally 100-5,000 μg, for a 70 kg patient. The initial administration of vaccine is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determine the presence of epitope-specific CTL populations in a PBMC sample. Additional booster doses are administered as required. The composition is found to be both safe and efficacious as a prophylaxis against 101P3A11-associated disease.
Alternatively, a composition typically comprising transfecting agents is used for the administration of a nucleic acid-based vaccine in accordance with methodologies known in the art and disclosed herein.
Example 22
Polyepitopic Vaccine Compositions Derived from Native 101P3A11 Sequences
A native 101P3A11 polyprotein sequence is analyzed, preferably using computer algorithms defined for each class I and/or class II supermotif or motif, to identify “relatively short” regions of the polyprotein that comprise multiple epitopes. The “relatively short” regions are preferably less in length than an entire native antigen. This relatively short sequence that contains multiple distinct or overlapping, “nested” epitopes can be used to generate a minigene construct. The construct is engineered to express the peptide, which corresponds to the native protein sequence. The “relatively short” peptide is generally less than 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length. The protein sequence of the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, i.e., it has a high concentration of epitopes. As noted herein, epitope motifs may be nested or overlapping (i.e., frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes.
The vaccine composition will include, for example, multiple CTL epitopes from 101P3A11 antigen and at least one HTL epitope. This polyepitopic native sequence is administered either as a peptide or as a nucleic acid sequence which encodes the peptide. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide.
The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally, such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup(s) that is presently unknown. Furthermore, this embodiment (excluding an analoged embodiment) directs the immune response to multiple peptide sequences that are actually present in native 101P3A11, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing peptide or nucleic acid vaccine compositions.
Related to this embodiment, computer programs are available in the art which can be used to identify in a target sequence, the greatest number of epitopes per sequence length.
Example 23
Polyepitopic Vaccine Compositions from Multiple Antigens
The 101P3A11 peptide epitopes of the present invention are used in conjunction with epitopes from other target tumor-associated antigens, to create a vaccine composition that is useful for the prevention or treatment of cancer that expresses 101P3A11 and such other antigens. For example, a vaccine composition can be provided as a single polypeptide that incorporates multiple epitopes from 101P3A11 as well as tumor-associated antigens that are often expressed with a target cancer associated with 101P3A11 expression, or can be administered as a composition comprising a cocktail of one or more discrete epitopes. Alternatively, the vaccine can be administered as a minigene construct or as dendritic cells which have been loaded with the peptide epitopes in vitro.
Example 24
Use of Peptides to Evaluate an Immune Response
Peptides of the invention may be used to analyze an immune response for the presence of specific antibodies, CTL or HTL directed to 101P3A11. Such an analysis can be performed in a manner described by Ogg et al., Science 279:2103-2106, 1998. In this Example, peptides in accordance with the invention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen.
In this example highly sensitive human leukocyte antigen tetrameric complexes (“tetramers”) are used for a cross-sectional analysis of, for example, 101P3A11 HLA-A*0201-specific CTL frequencies from HLA A*0201-positive individuals at different stages of disease or following immunization comprising a 101P3A11 peptide containing an A*0201 motif. Tetrameric complexes are synthesized as described (Musey et al., N. Engl. J. Med. 337:1267, 1997). Briefly, purified HLA heavy chain (A*0201 in this example) and β2-microglobulin are synthesized by means of a prokaryotic expression system. The heavy chain is modified by deletion of the transmembrane-cytosolic tail and COOH-terminal addition of a sequence containing a BirA enzymatic biotinylation site. The heavy chain, β2-microglobulin, and peptide are refolded by dilution. The 45-kD refolded product is isolated by fast protein liquid chromatography and then biotinylated by BirA in the presence of biotin (Sigma, St. Louis, Mo.), adenosine 5′ triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added in a 1:4 molar ratio, and the tetrameric product is concentrated to 1 mg/ml. The resulting product is referred to as tetramer-phycoerythrin.
For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300 g for 5 minutes and resuspended in 50 μl of cold phosphate-buffered saline. Tri-color analysis is performed with the tetramer-phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. The PBMCs are incubated with tetramer and antibodies on ice for 30 to 60 min and then washed twice before formaldehyde fixation. Gates are applied to contain >99.98% of control samples. Controls for the tetramers include both A*0201-negative individuals and A*0201-positive non-diseased donors. The percentage of cells stained with the tetramer is then determined by flow cytometry. The results indicate the number of cells in the PBMC sample that contain epitope-restricted CTLs, thereby readily indicating the extent of immune response to the 101P3A11 epitope, and thus the status of exposure to 101P3A11, or exposure to a vaccine that elicits a protective or therapeutic response.
Example 25
Use of Peptide Epitopes to Evaluate Recall Responses
The peptide epitopes of the invention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients. Such an analysis may be performed on patients who have recovered from 101P3A11-associated disease or who have been vaccinated with a 101P3A11 vaccine.
For example, the class I restricted CTL response of persons who have been vaccinated may be analyzed. The vaccine may be any 101P3A11 vaccine. PBMC are collected from vaccinated individuals and HLA typed. Appropriate peptide epitopes of the invention that, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type.
PBMC from vaccinated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co., St. Louis, Mo.), washed three times in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCO Laboratories) supplemented with L-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 μg/ml), and Hepes (10 mM) containing 10% heat-inactivated human AB serum (complete RPMI) and plated using microculture formats. A synthetic peptide comprising an epitope of the invention is added at 10 μg/ml to each well and HBV core 128-140 epitope is added at 1 μg/ml to each well as a source of T cell help during the first week of stimulation.
In the microculture format, 4×105 PBMC are stimulated with peptide in 8 replicate cultures in 96-well round bottom plate in 100 μl/well of complete RPMI. On days 3 and 10, 100 μl of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well. On day 7 the cultures are transferred into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and 105 irradiated (3,000 rad) autologous feeder cells. The cultures are tested for cytotoxic activity on day 14. A positive CTL response requires two or more of the eight replicate cultures to display greater than 10% specific 51Cr release, based on comparison with non-diseased control subjects as previously described (Rehermann, et al., Nature Med. 2:1104, 1108, 1996; Rehermann et al., J. Clin. Invest. 97:1655-1665, 1996; and Rehermann et al. J. Clin. Invest. 98:1432-1440, 1996).
Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, Mass.) or established from the pool of patients as described (Guilhot, et al. J. Virol. 66:2670-2678, 1992).
Cytotoxicity assays are performed in the following manner. Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell line that are incubated overnight with the synthetic peptide epitope of the invention at 10 μM, and labeled with 100 μCi of 51Cr (Amersham Corp., Arlington Heights, Ill.) for 1 hour after which they are washed four times with HBSS.
Cytolytic activity is determined in a standard 4-h, split well 51Cr release assay using U-bottomed 96 well plates containing 3,000 targets/well. Stimulated PBMC are tested at effector/target (E/T) ratios of 20-50:1 on day 14. Percent cytotoxicity is determined from the formula: 100×[(experimental release−spontaneous release)/maximum release−spontaneous release)]. Maximum release is determined by lysis of targets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis, Mo.). Spontaneous release is <25% of maximum release for all experiments.
The results of such an analysis indicate the extent to which HLA-restricted CTL populations have been stimulated by previous exposure to 101P3A11 or a 101P3A11 vaccine.
Similarly, Class II restricted HTL responses may also be analyzed. Purified PBMC are cultured in a 96-well flat bottom plate at a density of 1.5×105 cells/well and are stimulated with 10 μg/ml synthetic peptide of the invention, whole 101P3A11 antigen, or PHA. Cells are routinely plated in replicates of 4-6 wells for each condition. After seven days of culture, the medium is removed and replaced with fresh medium containing 10 U/ml IL-2. Two days later, 1 μCi 3H-thymidine is added to each well and incubation is continued for an additional 18 hours. Cellular DNA is then harvested on glass fiber mats and analyzed for 3H-thymidine incorporation. Antigen-specific T cell proliferation is calculated as the ratio of 3H-thymidine incorporation in the presence of antigen divided by the 3H-thymidine incorporation in the absence of antigen.
Example 26
Induction of Specific CTL Response in Humans
A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows:
A total of about 27 individuals are enrolled and divided into 3 groups:
Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5 μg of peptide composition;
Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50 μg peptide composition;
Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500 μg of peptide composition.
After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage.
The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints.
Safety: The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility.
Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.
The vaccine is found to be both safe and efficacious.
Example 27
Phase II Trials in Patients Expressing 101P3A11
Phase II trials are performed to study the effect of administering the CTL-HTL peptide compositions to patients having cancer that expresses 101P3A11. The main objectives of the trial are to determine an effective dose and regimen for inducing CTLs in cancer patients that express 101P3A11, to establish the safety of inducing a CTL and HTL response in these patients, and to see to what extent activation of CTLs improves the clinical picture of these patients, as manifested, e.g., by the reduction and/or shrinking of lesions. Such a study is designed, for example, as follows:
The studies are performed in multiple centers. The trial design is an open-label, uncontrolled, dose escalation protocol wherein the peptide composition is administered as a single dose followed six weeks later by a single booster shot of the same dose. The dosages are 50, 500 and 5,000 micrograms per injection. Drug-associated adverse effects (severity and reversibility) are recorded.
There are three patient groupings. The first group is injected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively. The patients within each group range in age from 21-65 and represent diverse ethnic backgrounds. All of them have a tumor that expresses 101P3A11.
Clinical manifestations or antigen-specific T-cell responses are monitored to assess the effects of administering the peptide compositions. The vaccine composition is found to be both safe and efficacious in the treatment of 101P3A11-associated disease.
Example 28
Induction of CTL Responses Using a Prime Boost Protocol
A prime boost protocol similar in its underlying principle to that used to confirm the efficacy of a DNA vaccine in transgenic mice, such as described above in the Example entitled “The Plasmid Construct and the Degree to Which It Induces Immunogenicity,” can also be used for the administration of the vaccine to humans. Such a vaccine regimen can include an initial administration of, for example, naked DNA followed by a boost using recombinant virus encoding the vaccine, or recombinant protein/polypeptide or a peptide mixture administered in an adjuvant.
For example, the initial immunization may be performed using an expression vector, such as that constructed in the Example entitled “Construction of “Minigene” Multi-Epitope DNA Plasmids” in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of 5-107 to 5×109 pfu. An alternative recombinant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polyepitopic protein or a mixture of the peptides can be administered. For evaluation of vaccine efficacy, patient blood samples are obtained before immunization as well as at intervals following administration of the initial vaccine and booster doses of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.
Analysis of the results indicates that a magnitude of response sufficient to achieve a therapeutic or protective immunity against 101P3A11 is generated.
Example 29
Administration of Vaccine Compositions Using Dendritic Cells (DC)
Vaccines comprising peptide epitopes of the invention can be administered using APCs, or “professional” APCs such as DC. In this example, peptide-pulsed DC are administered to a patient to stimulate a CTL response in vivo. In this method, dendritic cells are isolated, expanded, and pulsed with a vaccine comprising peptide CTL and HTL epitopes of the invention. The dendritic cells are infused back into the patient to elicit CTL and HTL responses in vivo. The induced CTL and HTL then destroy or facilitate destruction, respectively, of the target cells that bear the 101P3A11 protein from which the epitopes in the vaccine are derived.
For example, a cocktail of epitope-comprising peptides is administered ex vivo to PBMC, or isolated DC therefrom. A pharmaceutical to facilitate harvesting of DC can be used, such as ProgenipoietinTM (Monsanto, St. Louis, Mo.) or GM-CSF/IL-4. After pulsing the DC with peptides, and prior to reinfusion into patients, the DC are washed to remove unbound peptides.
As appreciated clinically, and readily determined by one of skill based on clinical outcomes, the number of DC reinfused into the patient can vary (see, e.g., Nature Med. 4:328, 1998; Nature Med. 2:52, 1996 and Prostate 32:272, 1997). Although 2-50×106 DC per patient are typically administered, larger number of DC, such as 107 or 108 can also be provided. Such cell populations typically contain between 50-90% DC.
In some embodiments, peptide-loaded PBMC are injected into patients without purification of the DC. For example, PBMC generated after treatment with an agent such as ProgenipoietinTM are injected into patients without purification of the DC. The total number of PBMC that are administered often ranges from 108 to 1010. Generally, the cell doses injected into patients is based on the percentage of DC in the blood of each patient, as determined, for example, by immunofluorescence analysis with specific anti-DC antibodies. Thus, for example, if ProgenipoietinTM mobilizes 2% DC in the peripheral blood of a given patient, and that patient is to receive 5×106 DC, then the patient will be injected with a total of 2.5×108 peptide-loaded PBMC. The percent DC mobilized by an agent such as ProgenipoietinTM is typically estimated to be between 2-10%, but can vary as appreciated by one of skill in the art.
Ex Vivo Activation of CTL/HTL Responses
Alternatively, ex vivo CTL or HTL responses to 101P3A11 antigens can be induced by incubating, in tissue culture, the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of APC, such as DC, and immunogenic peptides. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, i.e., tumor cells.
Example 30
An Alternative Method of Identifying and Confirming Motif-Bearing Peptides
Another method of identifying and confirming motif-bearing peptides is to elute them from cells bearing defined MHC molecules. For example, EBV transformed B cell lines used for tissue typing have been extensively characterized to determine which HLA molecules they express. In certain cases these cells express only a single type of HLA molecule. These cells can be transfected with nucleic acids that express the antigen of interest, e.g. 101P3A11. Peptides produced by endogenous antigen processing of peptides produced as a result of transfection will then bind to HLA molecules within the cell and be transported and displayed on the cell's surface. Peptides are then eluted from the HLA molecules by exposure to mild acid conditions and their amino acid sequence determined, e.g., by mass spectral analysis (e.g., Kubo et al., J. Immunol. 152:3913, 1994). Because the majority of peptides that bind a particular HLA molecule are motif-bearing, this is an alternative modality for obtaining the motif-bearing peptides correlated with the particular HLA molecule expressed on the cell.
Alternatively, cell lines that do not express endogenous HLA molecules can be transfected with an expression construct encoding a single HLA allele. These cells can then be used as described, i.e., they can then be transfected with nucleic acids that encode 101P3A11 to isolate peptides corresponding to 101P3A11 that have been presented on the cell surface. Peptides obtained from such an analysis will bear motif(s) that correspond to binding to the single HLA allele that is expressed in the cell.
As appreciated by one in the art, one can perform a similar analysis on a cell bearing more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than transfection, such as loading with a protein antigen, can be used to provide a source of antigen to the cell.
Example 31
Complementary Polynucleotides
Sequences complementary to the 101P3A11-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring 101P3A11. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using, e.g., OLIGO 4.06 software (National Biosciences) and the coding sequence of 101P3A11. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to a 101P3A11-encoding transcript.
Example 32
Purification of Naturally-Occurring or Recombinant 101P3A11 Using 101P3A11-Specific Antibodies
Naturally occurring or recombinant 101P3A11 is substantially purified by immunoaffinity chromatography using antibodies specific for 101P3A11. An immunoaffinity column is constructed by covalently coupling anti-101P3A11 antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.
Media containing 101P3A11 are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of 101P3A11 (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/101P3A11 binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCR.P is collected.
Example 33
Identification of Molecules which Interact with 101P3A11
101P3A11, or biologically active fragments thereof, are labeled with 121 1 Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled 101P3A11, washed, and any wells with labeled 101P3A11 complex are assayed. Data obtained using different concentrations of 101P3A11 are used to calculate values for the number, affinity, and association of 101P3A11 with the candidate molecules.
Example 34
In Vivo Assay for 101P3A11 Tumor Growth Promotion
The effect of the 101P3A11 protein on tumor cell growth can be confirmed in vivo by gene overexpression in a variety of cancer cells, including prostate, kidney, colon and bladder. For example, SCID mice can be injected subcutaneously on one flank with 1×106 prostate, kidney, colon or bladder cancer cells (such as PC3, LNCaP, SCaBER, UM-UC-3, SK-CO, Caco, RT4, T24, Caki, A-498 and SW839 cells) containing tkNeo empty vector or 101P3A11.
At least two strategies can be used:
(1) Constitutive 101P3A11 expression under regulation of a promoter such as a constitutive promoter obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, provided such promoters are compatible with the host cell systems.
(2) Regulated expression under control of an inducible vector system, such as ecdysone, tet, etc., can be used provided such promoters are compatible with the host cell systems. Tumor volume is then monitored at the appearance of palpable tumors and is followed over time to validate that 101P3A11-expressing cells grow at a faster rate and that tumors produced by 101P3A11-expressing cells demonstrate characteristics of altered aggressiveness (e.g., enhanced metastasis, vascularization, reduced responsiveness to chemotherapeutic drugs). FIG. 21 compares subcutaneous growth of control 3T3-neo and 3T3-101P3A11 cells. One million cells stably expressing neo or 101P3A11 were injected subcutaneously in SCID mice along with matrigel. Tumor volume was evaluated by caliper measurements. This experiment demonstrates that expression of 101P3A11 in NIH 3T3 cells is induces tumor formation in 6/6 mice. In an experiment comparing the effect of a strong oncogene such as Ras to that of 101P3A11, we showed that 101P3A11 induced tumor growth of 3T3 cells in a more rapid and aggressive manner that 12V-Ras (FIG. M8). The results indicated that expression of 101P3A11 is sufficient to induce tumor formation in vivo. FIG. 42 shows demonstrates that 101P3A11 induces orthotopic growth of tumors. Additionally, SCID mice were implanted with the same 3T3-101P3A11 cells orthotopically in the prostate to determine if 101P3A11 has an effect on local growth in the prostate or on the ability of the cells to metastasize, specifically to lungs or lymph nodes. This experiment (Figure M10) shows that while control 3T3-neo cells fail to induce tumor formation in the prostate of SCID mice, significant tumor growth was seen in cells expressing 101P3A11. In an analogous manner, cells can be implanted orthotopically in the bladder, colon or kidney. (Saffran, D., et al., PNAS 10:1073-1078; Fu, X., et al., Int. J. Cancer, 1991, 49: p. 938-939; Chang, S., et al., Anticancer Res., 1997, 17: p. 3239-3242; Peralta, E. A., et al., J. Urol., 1999, 162: p. 1806-1811). The tumor enhancing effect of 101P3A11 was also observed when 101P3A11 is expressed in prostate cancer cells such as PC3 and introduced into the prostate of SCID mice (Figure M11). A 2.5 fold increase in tumor weight is observed in tumors expressing 101P3A11 relative to control cells.
Expression od 101P3A11 also enhances tumor growth and progression in the tibia os SCID mice. Clinical studies have repeatedly shown that prostate cancer may become metastatic to the bone. In order to investigate the contribution of 101P3A11 to bone tropism and tumor growth in the bone, control and 101P3A11-expressing cells were compared for their ability to induce tumor growth in the tibia of SCID mice. Experiments in Figures M14 and M15 show that injection of 101P3A11 expressing 3T3 or PC3 cells into the bone of SCID mice results in increase tumor growth and tumor formation relative to control cells.
Furthermore, these assays is useful to confirm the anti-101P3A11 inhibitory effects of candidate therapeutic compositions, such as for example, 101P3A11 antibodies or intrabodies, and 101P3A11 antisense molecules or ribozymes, or 101P3A11 directed small molecules. In FIG. 22, we depict the effect of a small molecule, pertussis toxin (PTX) on tumor formation by 3T3-101P3A11 cells. In this experiment, SCID mice were injected with 3T3-101P3A11 alone or in conjunction with PTX. Each mouse was given 5 doses of PTX at 3-4 days interval. Tumor volume was evaluated by caliper measurements. FIG. 22 shows that PTX inhibits tumor growth in a dose dependent manner. Delivery of PTX at shorter intervals, such as 5 time per week, resulted in a larger rate of inhibition of tumor growth, with 70% inhibition of tumor growth observed after 25 days (Figure M9). Similarly, treatment with the G-protein inhibitor suramin inhibits the growth of 3T3-101P3A11 tumors (Figure M13). In addition to demonstrating that 101A3P11 plays an important role in tumor growth, FIGS. 21 22 and M9 identify a signaling pathway associated with 101P3A11 and indicate that 101P3A11 produced its effect on tumor growth by activating an adenylate cyclase dependent pathway.
Example 35
101P3A11 Monoclonal Antibody-Mediated Inhibition of Tumors In Vivo
The significant expression of 101P3A11 in cancer tissues, together with its restricted expression in normal tissues, makes 101P3A11 an excellent target for antibody therapy. In cases where the monoclonal antibody target is a cell surface protein, as is 101P3A11, antibodies have been shown to be efficacious at inhibiting tumor growth (See, e.g., Saffran, D., et al., PNAS 10:1073-1078). In cases where the target is not on the cell surface, such as PSA and PAP in prostate cancer, antibodies have also been shown to recognize and inhibit growth of cells expressing those proteins (Saffran, D.C., et al., Cancer and Metastasis Reviews, 1999. 18: 437-449). As with any cellular protein with a restricted expression profile, 101P3A11 is a target for T cell-based immunotherapy.
Accordingly, the therapeutic efficacy of anti-101P3A11 mAbs in human colon, kidney, bladder and prostate cancer mouse models is modeled in 101P3A11-expressing kidney, colon, bladder or prostate cancer xenografts or cancer cell lines, such as those described in the Example entitled “In vivo Assay for 101P3A11 Tumor Growth Promotion”, that have been engineered to express 101P3A11.
Antibody efficacy on tumor growth and metastasis formation is confirmed, e.g., in a mouse orthotopic prostate, colon, bladder or kidney cancer xenograft model. The antibodies can be unconjugated, or can be conjugated to a therapeutic modality, as appreciated in the art. It is confirmed that anti-101P3A11 mAbs inhibit formation of 101P3A11-expressing kidney, colon, bladder and prostate tumors. Anti-101P3A11 mAbs also retard the growth of established orthotopic tumors and prolong survival of tumor-bearing mice. These results indicate the utility of anti-101P3A11 mAbs in the treatment of local and advanced stages of cancer. (See, e.g., Saffran, D., et al., PNAS 10:1073-1078).
Administration of anti-101P3A11 mAbs retard established orthotopic tumor growth and inhibit metastasis to distant sites, resulting in a significant prolongation in the survival of tumor-bearing mice. These studies indicate that 101P3A11 is an attractive target for immunotherapy and demonstrate the therapeutic potential of anti-101P3A11 mAbs for the treatment of local and metastatic kidney, colon, bladder and prostate cancer. Similar studies manifest that 101P3A11 is safe and effective when used in combination with other therapeutic modalities such as surgery, radiation therapy, hormone therapy or chemotherapy.
This example demonstrates that unconjugated 101P3A11 monoclonal antibodies effectively to inhibit the growth of human bladder tumors grown in SCID mice; accordingly a combination of such efficacious monoclonal antibodies is also effective.
Tumor Inhibition Using Multiple Unconjugated 101P3A11 mAbs
Materials and Methods
101P3A11 Monoclonal Antibodies:
Monoclonal antibodies are raised against 101P3A11 as described in the Example entitled “Generation of 101P3A11 Monoclonal Antibodies (mAbs).” The antibodies are characterized by ELISA, Western blot, FACS, and immunoprecipitation for their capacity to bind 101P3A11. Epitope mapping data for the anti-101P3A11 mAbs, as determined by ELISA and Western analysis, recognize epitopes on the 101P3A11 protein. Immunohistochemical analysis of prostate cancer tissues and cells with these antibodies is performed.
The monoclonal antibodies are purified from ascites or hybridoma tissue culture supernatants by Protein-G Sepharose chromatography, dialyzed against PBS, filter sterilized, and stored at −20° C. Protein determinations are performed by a Bradford assay (Bio-Rad, Hercules, Calif.). A therapeutic monoclonal antibody or a cocktail comprising a mixture of individual monoclonal antibodies is prepared and used for the treatment of mice receiving subcutaneous or orthotopic injections of UM-UC3, J82, CaKi1, 769P, CaOv1 or PA1 tumor xenografts.
Cell Lines
The bladder, kidney and ovary carcinoma cell lines, UM-UC3, J82, CaKi1, 769P, CaOv1 and PA1 as well as the fibroblast line NIH 3T3 (American Type Culture Collection) are maintained in DMEM supplemented with L-glutamine and 10% FBS.
A UM-UC3-101P3A11, J82-101P3A11, CaKi1-101P3A11, 769P-101P3A11, CaOv1-101P3A11, PA1-101P3A and 3T3-101P3A11 cell populations are generated by retroviral gene transfer as described in Hubert, R. S., et al., Proc Natl Acad Sci USA, 1999, 96(25): 14523.
Xenograft Mouse Models.
Subcutaneous (s.c.) tumors are generated by injection of 1×106 cancer cells mixed at a 1:1 dilution with Matrigel (Collaborative Research) in the right flank of male SCID mice. To test antibody efficacy on tumor formation, i.p. antibody injections are started on the same day as tumor-cell injections. As a control, mice are injected with either purified mouse IgG (ICN) or PBS; or a purified monoclonal antibody that recognizes an irrelevant antigen not expressed in human cells. In preliminary studies, no difference is found between mouse IgG or PBS on tumor growth. Tumor sizes are determined by caliper measurements, and the tumor volume is calculated as length×width×height. Mice with s.c. tumors greater than 1.5 cm in diameter are sacrificed.
Orthotopic injections are performed under anesthesia by using ketamine/xylazine. For bladder orthotopic studies, an incision is made through the abdomen to expose the bladder, and tumor cells (5×105) mixed with Matrigel are injected into the bladder wall in a 10-μl volume. To monitor tumor growth, mice are palpated and blood is collected on a weekly basis to measure BTA levels. For kidney and ovary orthopotic models, an incision is made through the abdominal muscles to expose the kidney or the ovary. Tumor cells mixed with Matrigel are injected under the kidney capsule or into the ovary in a 10-μl volume (Yoshida Y et al, Anticancer Res. 1998, 18:327; Ahn et al, Tumour Biol. 2001, 22:146). To monitor tumor growth, blood is collected on a weekly basis measuring G250 and SM047 levels. The mice are segregated into groups for the appropriate treatments, with anti-101P3A11 or control mAbs being injected i.p.
Anti-101P3A11 mAbs Inhibit Growth of 101P3A11-Expressing Xenograft-Cancer Tumors
The effect of anti-101P3A11 mAbs on tumor formation is tested on the growth and progression of bladder, kidney and ovarian cancer xenografts using UC3-101P3A11, J82-101P3A11, CaKi1-101P3A11, 769P-101P3A11, CaOv1-101P3A11 and PA1-101P3A11 orthotopic models. As compared with the s.c. tumor model, the orthotopic model, which requires injection of tumor cells directly in the mouse bladder, kidney and ovary, respectively, results in a local tumor growth, development of metastasis in distal sites, deterioration of mouse health, and subsequent death (Saffran, D., et al., PNAS supra; Fu, X., et al., Int J Cancer, 1992, 52(6): p. 987-90; Kubota, T., J Cell Biochem, 1994, 56(1): p. 4-8). The features make the orthotopic model more representative of human disease progression and allowed us to follow the therapeutic effect of mAbs on clinically relevant end points.
Accordingly, tumor cells are injected into the mouse bladder, kidney or ovary, and 2 days later, the mice are segregated into two groups and treated with either: a) 200-500 μg, of anti-101P3A11 Ab, or b) PBS three times per week for two to five weeks.
A major advantage of the orthotopic cancer models is the ability to study the development of metastases. Formation of metastasis in mice bearing established orthotopic tumors is studies by IHC analysis on lung sections using an antibody against a tumor-specific cell-surface protein such as anti-CK20 for bladder cancer, anti-G250 for kidney cancer and SM047 antibody for ovarian cancer models (Lin S et al, Cancer Detect Prev. 2001; 25:202; McCluggage W et al, Histopathol 2001, 38:542).
Mice bearing established orthotopic tumors are administered 1000 μg injections of either anti-101P3A11 mAb or PBS over a 4-week period. Mice in both groups are allowed to establish a high tumor burden, to ensure a high frequency of metastasis formation in mouse lungs. Mice then are killed and their bladders, livers, bone and lungs are analyzed for the presence of tumor cells by IHC analysis.
These studies demonstrate a broad anti-tumor efficacy of anti-101P3A11 antibodies on initiation and progression of prostate and kidney cancer in xenograft mouse models. Anti-101P3A11 antibodies inhibit tumor formation of tumors as well as retarding the growth of already established tumors and prolong the survival of treated mice. Moreover, anti-101P3A11 mAbs demonstrate a dramatic inhibitory effect on the spread of local bladder, kidney and ovarian tumor to distal sites, even in the presence of a large tumor burden. Thus, anti-101P3A11 mAbs are efficacious on major clinically relevant end points (tumor growth), prolongation of survival, and health.
Example 36
Therapeutic and Diagnostic Use of Anti-101P3A11 Antibodies in Humans
Anti-101P3A11 monoclonal antibodies are safely and effectively used for diagnostic, prophylactic, prognostic and/or therapeutic purposes in humans. Western blot and immunohistochemical analysis of cancer tissues and cancer xenografts with anti-101P3A11 mAb show strong extensive staining in carcinoma but significantly lower or undetectable levels in normal tissues. Detection of 101P3A11 in carcinoma and in metastatic disease demonstrates the usefulness of the mAb as a diagnostic and/or prognostic indicator. Anti-101P3A11 antibodies are therefore used in diagnostic applications such as immunohistochemistry of kidney biopsy specimens to detect cancer from suspect patients.
As determined by flow cytometry, anti-101P3A11 mAb specifically binds to carcinoma cells. Thus, anti-101P3A11 antibodies are used in diagnostic whole body imaging applications, such as radioimmunoscintigraphy and radioimmunotherapy, (see, e.g., Potamianos S., et. al. Anticancer Res 20(2A):925-948 (2000)) for the detection of localized and metastatic cancers that exhibit expression of 101P3A11. Shedding or release of an extracellular domain of 101P3A11 into the extracellular milieu, such as that seen for alkaline phosphodiesterase B10 (Meerson, N. R., Hepatology 27:563-568 (1998)), allows diagnostic detection of 101P3A11 by anti-101P3A11 antibodies in serum and/or urine samples from suspect patients.
Anti-101P3A11 antibodies that specifically bind 101P3A11 are used in therapeutic applications for the treatment of cancers that express 101P3A11. Anti-101P3A11 antibodies are used as an unconjugated modality and as conjugated form in which the antibodies are attached to one of various therapeutic or imaging modalities well known in the art, such as a prodrugs, enzymes or radioisotopes. In preclinical studies, unconjugated and conjugated anti-101P3A11 antibodies are tested for efficacy of tumor prevention and growth inhibition in the SCID mouse cancer xenograft models, e.g., kidney cancer models AGS-K3 and AGS-K6, (see, e.g., the Example entitled “101P3A11 Monoclonal Antibody-mediated Inhibition of Bladder, Kidney and Ovarian Tumors In vivo”). Conjugated and unconjugated anti-101P3A11 antibodies are used as a therapeutic modality in human clinical trials either alone or in combination with other treatments as described in following Examples.
Example 37
Human Clinical Trials for the Treatment and Diagnosis of Human Carcinomas Through Use of Human Anti-101P3A11 Antibodies In Vivo
Antibodies are used in accordance with the present invention which recognize an epitope on 101P3A11, and are used in the treatment of certain tumors such as those listed in Table I. Based upon a number of factors, including 101P3A11 expression levels, tumors such as those listed in Table I are presently preferred indications. In connection with each of these indications, three clinical approaches are successfully pursued.
I.) Adjunctive therapy: In adjunctive therapy, patients are treated with anti-101P3A11 antibodies in combination with a chemotherapeutic or antineoplastic agent and/or radiation therapy. Primary cancer targets, such as those listed in Table I, are treated under standard protocols by the addition anti-101P3A11 antibodies to standard first and second line therapy. Protocol designs address effectiveness as assessed by reduction in tumor mass as well as the ability to reduce usual doses of standard chemotherapy. These dosage reductions allow additional and/or prolonged therapy by reducing dose-related toxicity of the chemotherapeutic agent. Anti-101P3A11 antibodies are utilized in several adjunctive clinical trials in combination with the chemotherapeutic or antineoplastic agents adriamycin (advanced prostrate carcinoma), cisplatin (advanced head and neck and lung carcinomas), taxol (breast cancer), and doxorubicin (preclinical).
II.) Monotherapy: In connection with the use of the anti-101P3A11 antibodies in monotherapy of tumors, the antibodies are administered to patients without a chemotherapeutic or antineoplastic agent. In one embodiment, monotherapy is conducted clinically in end stage cancer patients with extensive metastatic disease. Patients show some disease stabilization. Trials demonstrate an effect in refractory patients with cancerous tumors.
III.) Imaging Agent: Through binding a radionuclide (e.g., iodine or yttrium (I131, Y90) to anti-101P3A11 antibodies, the radiolabeled antibodies are utilized as a diagnostic and/or imaging agent. In such a role, the labeled antibodies localize to both solid tumors, as well as, metastatic lesions of cells expressing 101P3A11. In connection with the use of the anti-101P3A11 antibodies as imaging agents, the antibodies are used as an adjunct to surgical treatment of solid tumors, as both a pre-surgical screen as well as a post-operative follow-up to determine what tumor remains and/or returns. In one embodiment, a (111In)-101P3A11 antibody is used as an imaging agent in a Phase I human clinical trial in patients having a carcinoma that expresses 101P3A11 (by analogy see, e.g., Divgi et al. J. Natl. Cancer Inst. 83:97-104 (1991)). Patients are followed with standard anterior and posterior gamma camera. The results indicate that primary lesions and metastatic lesions are identified
Dose and Route of Administration
As appreciated by those of ordinary skill in the art, dosing considerations can be determined through comparison with the analogous products that are in the clinic. Thus, anti-101P3A11 antibodies can be administered with doses in the range of 5 to 400 mg/m2, with the lower doses used, e.g., in connection with safety studies. The affinity of anti-101P3A11 antibodies relative to the affinity of a known antibody for its target is one parameter used by those of skill in the art for determining analogous dose regimens. Further, anti-101P3A11 antibodies that are fully human antibodies, as compared to the chimeric antibody, have slower clearance; accordingly, dosing in patients with such fully human anti-101P3A11 antibodies can be lower, perhaps in the range of 50 to 300 mg/m2, and still remain efficacious. Dosing in mg/m2, as opposed to the conventional measurement of dose in mg/kg, is a measurement based on surface area and is a convenient dosing measurement that is designed to include patients of all sizes from infants to adults.
Three distinct delivery approaches are useful for delivery of anti-101P3A11 antibodies. Conventional intravenous delivery is one standard delivery technique for many tumors. However, in connection with tumors in the peritoneal cavity, such as tumors of the ovaries, biliary duct, other ducts, and the like, intraperitoneal administration may prove favorable for obtaining high dose of antibody at the tumor and to also minimize antibody clearance. In a similar manner, certain solid tumors possess vasculature that is appropriate for regional perfusion. Regional perfusion allows for a high dose of antibody at the site of a tumor and minimizes short term clearance of the antibody.
Clinical Development Plan (CDP)
Overview: The CDP follows and develops treatments of anti-101P3A11 antibodies in connection with adjunctive therapy, monotherapy, and as an imaging agent. Trials initially demonstrate safety and thereafter confirm efficacy in repeat doses. Trails are open label comparing standard chemotherapy with standard therapy plus anti-101P3A11 antibodies. As will be appreciated, one criteria that can be utilized in connection with enrollment of patients is 101P3A11 expression levels in their tumors as determined by biopsy.
As with any protein or antibody infusion-based therapeutic, safety concerns are related primarily to (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 101P3A11. Standard tests and follow-up are utilized to monitor each of these safety concerns. Anti-101P3A11 antibodies are found to be safe upon human administration.
Example 38
Human Clinical Trial Adjunctive Therapy with Human Anti-101P3A11 Antibody and Chemotherapeutic Agent(s)
A phase I human clinical trial is initiated to assess the safety of six intravenous doses of a human anti-101P3A11 antibody in connection with the treatment of a solid tumor, e.g., a cancer of a tissue listed in Table I. In the study, the safety of single doses of anti-101P3A11 antibodies when utilized as an adjunctive therapy to an antineoplastic or chemotherapeutic agent, such as cisplatin, topotecan, doxorubicin, adriamycin, taxol, or the like, is assessed. The trial design includes delivery of six single doses of an anti-101P3A11 antibody with dosage of antibody escalating from approximately about 25 mg/m2 to about 275 mg/m2 over the course of the treatment in accordance with the following schedule:


















Day 0
Day 7
Day 14
Day 21
Day 28
Day 35






















mAb Dose
25
75
125
175
225
275



mg/m2
mg/m2
mg/m2
mg/m2
mg/m2
mg/m2


Chemotherapy
+
+
+
+
+
+


(standard dose)









Patients are closely followed for one-week following each administration of antibody and chemotherapy. In particular, patients are assessed for the safety concerns mentioned above: (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the human antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 101P3A11. Standard tests and follow-up are utilized to monitor each of these safety concerns. Patients are also assessed for clinical outcome, and particularly reduction in tumor mass as evidenced by MRI or other imaging.
The anti-101P3A11 antibodies are demonstrated to be safe and efficacious, Phase II trials confirm the efficacy and refine optimum dosing.
Example 39
Human Clinical Trial
Monotherapy with Human Anti-101P3A11 Antibody
Anti-101P3A11 antibodies are safe in connection with the above-discussed adjunctive trial, a Phase II human clinical trial confirms the efficacy and optimum dosing for monotherapy. Such trial is accomplished, and entails the same safety and outcome analyses, to the above-described adjunctive trial with the exception being that patients do not receive chemotherapy concurrently with the receipt of doses of anti-101P3A11 antibodies.
Example 40
Human Clinical Trial
Diagnostic Imaging with Anti-101P3A11 Antibody
Once again, as the adjunctive therapy discussed above is safe within the safety criteria discussed above, a human clinical trial is conducted concerning the use of anti-101P3A11 antibodies as a diagnostic imaging agent. The protocol is designed in a substantially similar manner to those described in the art, such as in Divgi et al. J. Natl. Cancer Inst. 83:97-104 (1991). The antibodies are found to be both safe and efficacious when used as a diagnostic modality.
Example 41
Identification of 101P3A11 Sequences Involved in Ligand Binding
As shown in FIG. 4, the transmembrane regions of 101P3A11 and mouse olfactory receptor S25 (ORS25) predicted using the TMHMM algorithm are highlighted in gray. The amino acids of ORS25 predicted by Floriano, et al. to be involved in binding of the ligand hexanol and/or involved in the formation of the ligand binding pocket are italicized and bolded in FIG. 4, and are listed below. (Floriano, W. B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716)
















Leu 131
Ala 230



Val 134
Ile 231



Val 135
Gly 234



Gly 138
Thr 284



Thr139
Phe 287



Ser 193
Gln 300



Ser 197,
Lys 302



Phe 225










Sequences of 101P3A11 involved in ligand binding are identified based on homology to mouse olfactory receptor S25. Shown is the amino acid alignment of 101P3A11 with mouse olfactory receptor S25 depicting the predicted transmembrane domains of each GPCR. The amino acids of S25 involved in the recognition and binding of its ligand hexanol or that lie in the proximity of the binding pocket (Floriano, W. B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716), are also shown. These amino acids lie close to or within the transmembrane domains of ORS25. Accordingly, the structurally homologous regions of 101P3A11 are involved in the binding of its cognate ligand. These regions encode the amino acids of the first extracellular loop and of the amino terminal end of transmembrane domain 3 (amino acids 82-112), the amino acids at the carboxyl terminal end of transmembrane domain 4 and into the second extracellular loop (amino acids 160-185), the amino acids at the end of the second extracellular loop and into transmembrane domain 5 (amino acids 186-212), and the amino acids at the carboxyl terminal end of transmembrane domain 6, the third extracellular loop, and the amino terminal end of transmembrane domain 7 (amino acids 250-280). Thus, ligands of 101P3A11 are identified that interact with at least 3 of the following regions of 101P3A11: amino acids 82-112, amino acids 160-185, amino acids 186-212, and, amino acids 250-280.
Example 42
Homology Comparison of 101P3A11 to Known Sequences
The 101P3A11 protein of FIG. 3 has 318 amino acids with calculated molecular weight of 35.2 kDa, and pI of 8.7. 101P3A11 is predicted to be a cell surface protein. Cellular localization was demonstrated by FACS analysis and immunofluorescence in cells engineered to express 101P3A11, as shown in Figure M17 (panel B). Immunofluorescence staining of permeabilized cells revealed that 101P3A11 becomes internalized and localizes then to the cytosol (Figure M17).
101P3A11 shows best homology to rat olfactory receptor RA1c (gi 3420759) sharing 59% identity and 76% homology with that protein. 101P3A11 also shows homology to human prostate specific GPCR (gi 13540539) and human olfactory receptor 51I12 (gi 14423836), sharing 59% identities/77% homology, and 53% identities/69% homology with each, respectively (FIGS. 23-25). More recent studies have identified a mouse homolog of 101P3A11, namely MOR 18-1, (gi 18479284, FIG. 65). MOR18-1 is a mouse olfactory receptor that shares 93% identity and 96% homology with the 101P3A11 protein.
In addition to 101P3A11 variant I used predominantly in the studies listed below, 101P3A11 has 2 additional variants. Variant 3 is a SNP of variant 1 and exhibits a mutation at position 104, with an exchange of isoleusine to methionine at that position. Variant 3 is expected to be localized to the cell surface, in a manner similar to variant 1, and exhibits the same motifs and transmembrane domains as variant 1 (table XXI). Variant 2 of 101P3A11 is 72 amino acids long, contains 2 transmembranes and localizes predominantly at the cell surface with some cytoplasmic localization.
Sequence and motif analysis indicate that 101P3A11 belongs to the family of olfactory receptors. Bioinformatic analysis revealed 101P3A11 to be a 7 transmembrane protein, with strong domain and structural homology to G-protein coupled receptors (GPCRs) (see Table XXI, TM Pred, Sosui, Pfam, Blocks, Print). Proteins that are members of the G-protein coupled receptor family exhibit an extracellular amino-terminus, three extracellular loops, three intracellular loops and an intracellular carboxyl terminus. G-protein coupled receptors are seven-transmembrane receptors that are stimulated by polypeptide hormones, neurotransmitters, chemokines and phospholipids (Civelli O et al, Trends Neurosci. 2001, 24:230; Vrecl M et al Mol Endocrinol. 1998, 12:1818). Ligand binding traditionally occurs between the first and second extracellular loops of the GPCR. Upon ligand binding GPCRs transduce signals across the cell surface membrane by associating with trimeric G proteins. Their signals are transmitted via trimeric guanine-nucleotide binding proteins (G proteins) to effector enzymes or ion channels (Simon et al., 1991, Science 252: 802). Signal transduction and biological output mediated by GPCR can be modulated through various mechanisms including peptide mimics, small molecule inhibitors and GPCR kinases or GRK (Pitcher J A et al, J Biol Chem. 1999, 3; 274:34531; Fawzi A B, et al. 2001, Mol. Pharmacol., 59:30).
Recently, GPCRs have also been shown to link to mitogenic signaling pathways of tyrosine kinases (Luttrell et al., 1999, Science 283: 655; Luttrell et al., 1999 Curr Opin Cell Biol 11: 177). GPCRs are regulated by phosphorylation mediated by GPCR kinases (GRKs), which themselves are indirectly activated by the GPCRs (Pitcher et al., 1998, Ann. Rev. Biochem. 67: 653). Olfactory GPCRs transmit their signals by activating the cAMP pathway via adenylate cyclase resulting in downstream signaling to protein kinase A, and by activating the phospholipase C pathway by generating inositol 1,4,5-trisphosphate (IP3) and diacyl-glycerol (DAG) (Breer, 1993, Ciba Found Symp 179: 97; Bruch, 1996, Comp Biochem Physiol B Biochem Mol Biol 113:451). IP3 results in an increase in intracellular calcium, while DAG activates protein kinase C.
Recent studies have associated GPCRs with cellular transformation. In particular, KSHV G protein-coupled receptor was found to transform NIH 3T3 cells in vitro and induces multifocal KS-like lesions in KSHV-GPCR-transgenic mice (Schwarz M, Murphy P M. J Immunol 2001, 167:505). KSHV-GPCR was capable of producing its effect on endothelial cells and fibroblasts by activating defined signaling pathways, including the AKT survival pathway (Montaner S et al, Cancer Res 2001, 61:2641). In addition, KSHV-GPCR induced the activation of mitogenic pathways such as AP-1 and NFkB, resulting in the expression of pro-inflammatory genes (Schwarz M, Murphy P M. J Immunol 2001, 167:505). Other GPCR associated with tumor formation include G2A, and the PAR-1, which has been found to induce transformation of NIH 3T3 cells (Whitehead I et al, Oncogene 2001, 20:1547).
This information indicates that 101P3A11 plays a role in the transformation of mammalian cells, induces mitogenic responses including activation of various signaling pathways, and regulate gene transcription by transmitting cell surface signals to the nucleus, see also, the Example entitled, “In vivo Assay for 101P3A11 Tumor Growth Promotion”.
Accordingly, when 101P3A11 functions as a regulator of cell transformation, tumor formation, or as a modulator of transcription involved in activating genes associated with inflammation, tumorigenesis or proliferation, 101P3A11 is used for therapeutic, diagnostic, prognostic and/or preventative purposes, in manners analogous to or that track other GPCRs as discussed herein and in the art.
Example 43
Identification and Confirmation of Potential Signal Transduction Pathways
Many mammalian proteins have been reported to interact with signaling molecules and to participate in regulating signaling pathways. (J Neurochem. 2001; 76:217-223). In particular, GPCRs have been reported to activate MAK cascades as well as G proteins, and been associated with the EGFR pathway in epithelial cells (Naor, Z., et al, Trends Endocrinol Metab. 2000, 11:91; Vacca F et al, Cancer Res. 2000, 60:5310; Della Rocca G. J., et al, J Biol Chem. 1999, 274:13978). Using immunoprecipitation and Western blotting techniques, proteins are identified that associate with 101P3A11 and mediate signaling events. Several pathways known to play a role in cancer biology can be regulated by 101P3A11, including phospholipid pathways such as PI3K, AKT, etc, adhesion and migration pathways, including FAK, Rho, Rac-1, etc, as well as mitogenic/survival cascades such as ERK, p38, etc (Cell Growth Differ. 2000, 11:279; J Biol Chem. 1999, 274:801; Oncogene. 2000, 19:3003; J. Cell Biol. 1997, 138:913).
Using Western blotting and other techniques, the ability of 101P3A11 to regulate these pathways is confirmed. Cells expressing or lacking 101P3A11 are either left untreated or stimulated with cytokines, androgen and anti-integrin antibodies. Cell lysates were analyzed using anti-phospho-specific antibodies (Cell Signaling, Santa Cruz Biotechnology) in order to detect phosphorylation and regulation of ERK, p38, AKT, PI3K, PLC and other signaling molecules. Using such techniques, we showed that 101P3A11 alters the tyrosine phosphorylation pattern of NIH 3T3 cells (FIG. 26) indicating that 101P3A11 is regulating protein kinases and phosphatases. In the experiment, data shown in FIG. 26, control 3T3-neo and 3T3-101P3A11 cells were either treated with 0.5 or 10% FBS and whole cell lysates were analyzed by anti-phosphotyrosine Western blotting. Expression of 101P3A11 resulted in reduced phosphorylation of several proteins in NIH-3T3 cells, while inducing the phosphorylation of proteins at 79-81 and 28-32 kDa.
Using anti-Phospho-ERK antibodies, we demonstrated that expression of 101P3A11 induced ERK phosphorylation in the prostate cancer cell line PC3 (FIG. 27A and FIG. 27B), and that ERK phosphorylation in 101P3A11 expressing cells was regulated by GPCR ligands. In this experiment, control PC3-neo cells and PC3-101P3A11 cells were left untreated (0.1% FBS) or were stimulated with 10% FBS, lipophosphatidic acid (LPA), gastrin releasing peptide (GRP), leukotriene (LKB4) or platelet activating factor (PAF). The cells were lysed and analyzed by Western blotting using anti-Phospho-ERK (FIG. 27A) or anti-ERK (FIG. 27B) mAb. The results showed that expression of 101P3A11 mediated significant ERK phosphorylation by FBS, LPA, GRP and PAF, while LKB4 resulted in a more modest level of ERK phosphorylation in PC3-101P3A11 cells. In contrast, none of the GPCR ligands induced significant ERK phosphorylation in PC3-Neo cells, demonstrating the specificity of GPCR ligands-mediated responses in 101P3A11 expressing cells. The ERK overlay demonstrated equal loading, supporting the specificity of this data. In order to delineate the signaling pathway by which 101P3A11 mediates ERK phosphorylation in cancer cells, it was confirmed which of the two pathway inhibitors: MEK inhibitor PD98059 or the p38 inhibitor SB203580 regulate 101P3A11 mediated ERK phosphorylation (FIG. 28). To obtain this data, PC3-neo and PC3-101P3A11 cells were treated with media alone or in the presence of PD98059, SB203580, or genistein were stimulated with FBS or GRP. Cells were lysed and analyzed by Western blotting using anti-Phospho-ERK or anti-ERK mAb. Treatment with 10% FBS or with GRP induced the phosphorylation of ERK in PC3-101P3A11 but not in control PC3-neo cells. 101P3A11-mediated ERK phosphorylation was inhibited by the MEK-1 inhibitor PD98059 but not the p38 inhibitor SB203580 or genistein. The ERK overlay demonstrated equal loading, supporting the specificity of the results. These results were confirmed by those obtained in two additional sets of experiments. The inhibition of 101P3A11-mediated ERK phosphorylation by PD98059 demonstrates that 101P3A11 activated the classical MEK-ERK cascade, a pathway associated with mitogenesis, proliferation and tumorigenesis.
Results in FIGS. 26-28 indicate that 101P3A11 regulates the activity of kinases, including ERK, and phosphatases. In order to confirm the association of 101P3A11 with phosphatase activity, the effect of the protein phosphatase inhibitor sodium orthovanadate on 101P3A11 mediated ERK phosphorylation was determined (FIG. 29). PC3-neo and PC3-101P3A11 cells were grown in media alone or in the presence of sodium orthovanadate (Na3VO4), and were stimulated with 0.1% or 10% FBS. Cells were lysed and analyzed by Western blotting using anti-Phospho-ERK or anti-ERK mAb. Treatment with Na3VO4 resulted in a 4.5-fold increase in ERK phosphorylation in PC3-101P3A11 cells, compared to a two-fold increase in PC3-neo cells. Results in FIG. 29 confirm the contribution of protein phosphatases to 101P3A11 mediated signaling.
Several GPCRs have been shown to transactivate receptor tyrosine kinases associated with the cell membrane, such as the EGF receptor (EGFR) (Pierce K. L., et al, J Biol Chem. 2001, 276:23155; Nath, D., et al, J Cell Sci. 2001, 114:1213). In order to determine whether 101P3A11 signaling results in the activation of EGFR, we compared the effect of the EGFR inhibitor, AG1517, on EGFR- and 101P3A11-mediated ERK phosphorylation (FIG. 30). In FIG. 30, PC3-neo and PC3-101P3A11 cells were grown in media alone (0.1% FBS) or in the presence of AG1517. The cells were stimulated with 0.1% or 10% FBS, GRP or EGF, lysed and analyzed by Western blotting using anti-Phospho-ERK or anti-ERK mAb. Treatment with 10% FBS, GRP and EGF induced ERK phosphorylation in PC3-101P3A11 cells. ERK phosphorylation by EGF was completely inhibited by AG1517. 101P3A11 mediated ERK phosphorylation in cells treated with 10% FBS was partially inhibited by AG1517. Data in FIG. 30 indicate that some cross talk occurred between 101P3A11 and EGFR signaling pathways.
In addition to activating the ERK cascade, 101P3A11 activated a parallel MAK pathway, namely p38. In FIG. 31A and FIG. 31B, PC3-neo and PC3-101P3A11 cells were grown in 1% or % FBS. Cells were lysed and analyzed by Western blotting using anti-Phospho-p38 (FIG. 31A) or anti-p38 (FIG. 31B) monoclonal antibody (mAb). Our results demonstrate that expression of 101P3A11 mediated p38 phosphorylation in cells treated with 10% FBS. Equal loading was demonstrated in the p38 overlay.
Results shown in FIGS. 26-30 and FIG. 31A-31B confirm that 101P3A11 activates several signaling pathways in cancer cells, including the ERK and p38 cascades. In addition to MAPK, 101P3A11 signaling was associated with protein phosphatase activity and EGFR transactivation. These signaling pathways have been associated with cell growth, survival and transcriptional activation, all of which play an important role in tumor initiation and progression. When 101P3A11 plays a role in the regulation of signaling pathways, whether individually or communally, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.
To confirm that 101P3A11 directly or indirectly activates known signal transduction pathways in cells, luciferase (luc) based transcriptional reporter assays are carried out in cells expressing individual genes. These transcriptional reporters contain consensus-binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways. The reporters and examples of these associated transcription factors, signal transduction pathways, and activation stimuli are listed below.
1. NFkB-luc, NFkB/Rel; Ik-kinase/SAPK; growth/apoptosis/stress
2. SRE-luc, SRF/TCF/ELK1; MAPK/SAPK; growth/differentiation
3. AP-1-luc, FOS/JUN; MAPK/SAPK/PKC; growth/apoptosis/stress
4. ARE-luc, androgen receptor; steroids/MAPK; growth/differentiation/apoptosis
5. p53-luc, p53; SAPK; growth/differentiation/apoptosis
6. CRE-luc, CREB/ATF2; PKA/p38; growth/apoptosis/stress
Gene-mediated effects can be assayed in cells showing mRNA expression. Luciferase reporter plasmids can be introduced by lipid-mediated transfection (TFX-50, Promega). Luciferase activity, an indicator of relative transcriptional activity, is measured by incubation of cell extracts with luciferin substrate and luminescence of the reaction is monitored in a luminometer.
Signaling pathways activated by 101P3A11 are mapped and used for the identification and validation of therapeutic targets. When 101P3A11 is involved in cell signaling, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.
Example 44
101P3A11 Functions as a GPCR
Sequence and homology analysis of 101P3A11 indicated that 101P3A11 is a member of the olfactory receptor family of GPCR. Olfactory receptors are known to regulate biological responses by activating adenylate cyclase. In order to confirm that 101P3A11 functions as a GPCR and mediates the activation of adenylate cyclase, cAMP accumulation in PC3 and PC3-101P3A11 cells were compared (FIG. 32). Control PC3 and PC3-101P3A11 cells were grown in a low concentration of fetal bovine serum (FBS) for 14 hrs in the presence or absence of pertussis toxin (PTX). The cells were stimulated with 0.1% or 10% FBS, washed in PBS and lysed using a lysis buffer provided by Amersham Pharmacia. Intracellular concentration of cAMP was measured using a commercially available enzyme immunoassay (EIA) according to the manufacturer's recommendations (Amersham Pharmacia). Each assay was performed in duplicate. Calculations of cAMP concentrations were based on OD450 of the standard curve. Expression of 101P3A11 induced a four-fold increase in cAMP accumulation in the absence of stimulation. Treatment with 10% FBS further enhanced cAMP accumulation in PC3-101P3A11 cells to nearly seven-fold over control PC3-neo cells. 101P3A11 mediated cAMP accumulation was inhibited by PTX. These results were confirmed by two separate sets of experiments. Results shown in FIG. 32 demonstrate that 101P3A11 functions as a GPCR in prostate cancer cells and exhibits classical GPCR characteristics, such as cAMP accumulation that is inhibited by PTX.
Since adenylate cyclase activity modulates intracellular levels of cAMP and induce downstream signaling events such as activation of protein kinase A, calcium and ERK MAPK signaling (Pierce K. L., et al, Oncogene. 2001, 20: 1532), we determined that PTX, an inhibitor of adenylate cyclase signaling, prevents 101P3A11-mediated ERK phosphorylation along with inhibiting cAMP accumulation (FIG. 33 and FIG. 34). PC3-neo and PC3-101P3A11 cells were grown overnight in 0.1% FBS in media alone or in the presence of pertussis toxin (PTX). Cells were stimulated with 0.1% or 10% FBS (FIG. 33) or 10% FBS, EGF or GRP (FIG. 34). Cells were lysed and analyzed by Western blotting using anti-Phospho-ERK mAb. Expression of 101P3A11 mediated ERK phosphorylation by 10% FBS in PC3 cells, which was inhibited by PTX (FIG. 33 and FIG. 34). In contrast, GRP and EGF-mediated ERK phosphorylation was relatively unaffected by PTX (FIG. 34), demonstrating the specificity of 101P3A11 mediated responses. These results were replicated in additional experiments. In addition to inhibiting ERK phosphorylation and 101P3A11-mediated signaling, PTX had a marked effect on the proliferation of PC3-101P3A11 but not control PC3-neo cells (Figure M6). Figure M6 shows that PTX inhibited the proliferation f 101P3A11 expressing cells in a dose dependent manner, and confirms that the GPCR function of 101P3A11 is important for tumor growth.
GPCR transmit their signal by activating trimeric G proteins. Once GPCRs are activated, the associated Ga subunit binds GTP, dissociates from the receptor and participates in downstream signaling events (Schild, D., and Restrepo, D. Physiol Rev. 1998, 78:429-66). In order to determine that inhibition of Ga subunits has an effect on 101P3A11 mediated cell growth, the effect of two Ga inhibitors on the proliferation of 3T3-101P3A11 cells was investigated. Control 3T3 and 3T3-101P3A11 cells were grown in the presence or absence of suramin or its derivative NF 449 (Sigma). Cells were analyzed for proliferation 72 hours later (FIG. 35). The experiment was performed in triplicate. The data showed that suramin and NF449 inhibited the proliferation of 3T3-101P3A11 cells by 60% and 80%, respectively. This response was 101P3A11 specific as suramin and NF449 had no effect on the proliferation of control 3T3 cells. Similarly, inhibition of G protein activation by suramin and NF449 in PC3 cells inhibits the proliferation of PC3-101P3A11 cells grown in 5% FBS (Figure M4). In parallel with the inhibitory effect of suramin and NF449 on PC3-101P3A11 proliferation, we demonstrate their inhibitory effect on 101P3A11-mediated signaling in prostate cancer cells (Figure M2). As shown in FIGS. 27 and 28, treatment with FBS induces ERK phosphorylation in 101P3A11-expressing cells. This ERK phosohorylation and activation was inhibited by suramin and NF449 in PC3-101P3A11 and 3T3-101P3A11 cells. ERK phosphorylation was inhibited in a dose dependent manner in PC3-101P3A11 cells treated with suramin. Thus, as 101P3A11 is involved in GPCR activity, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.
GPCRs can be activated by a variety of ligands, including hormones, neuropeptides, chemokines, odorants and phospholipids. In the case of olfactory receptors, individual olfactory receptors may recognize multiple odorants, and can are activated by a diverse array of molecules. These ligands and molecules recognized by a receptor (as described above) are small molecules as described herein.
In order to identify 101P3A11 (small molecule) ligand(s), the possibility that epithelial cells may be secreting 101P3A11 activators was investigated (FIG. 36A and FIG. 36B). Prostate cancer epithelial cells, (PC3, PC3-101P3A11, LAPC42hT), normal prostate cells (PrEC), fibroblasts (3T3, 3T3-101P3A11), and human kidney epithelial cells (293T) were grown in the presence or absence of FBS. Cell supernatants were collected and used to stimulate PC3 and PC3-101P3A11 cells. Cell lysates from resting and supernatant treated PC3 and PC3-101P3A11 cells were lysed and analyzed by Western blotting with anti-Phospho-ERK (FIG. 36A) and anti-ERK (FIG. 36B) mAb. As shown in FIG. 36A and FIG. 36B, supernatants form normal prostate cells, PrEC, and prostate cancer cells, PC3, PC3-101P3A11 and LAPC42hT, induced the phosphorylation of ERK in PC3-101P3A11 but not control PC3 cells. In contrast, no specific ERK phosphorylation was observed using supernatants from 3T3 or 293T cells. Our results show that prostate cells, grown in the absence of serum, produce one or more factors that contribute to the activation of 101P3A11 mediated signaling events. Thus, as 101P3A11 responds to stimuli and functions in signaling and GPCR activity, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.
Example 45
Inhibitors of 101P3A11 GPCR Function
As mentioned in the Example entitled “Homology Comparison of 101P3A11 to Known Sequences,” GPCRs are activated by ligand binding to the extracellular loops, resulting in the activation of trimeric G proteins and the initiation of several signaling cascades. Using this information, several therapeutic and small molecule strategies are utilized to inhibit GPCR activation or downstream signaling events.
One strategy inhibits receptor and ligand binding. Recent studies using several types of GPCRs, have demonstrated the effectiveness of this strategy (Fawzi A B, et al. 2001, Mol. Pharmacol., 59:30). Using a compound named SCH-202676, they inhibited agonist and antagonist binding to GPCRs by allosterically hindering ligand-GPCR interaction. Using this and even more specific allosteric (small molecule) inhibitors, signal transduction through 101P3A11 is inhibited, thereby providing therapeutic, prognostic, diagnostic and/or prophylactic benefit.
A second approach is to inhibit G alpha subunit activation. Activation of GPCRs results in the exchange of GTP for GDP on the G alpha subunit of the trimeric G protein. Inhibition of Gα activation prevents the activation of downstream signaling cascades and therefore biological effects of GPCR. One molecule used to inhibit GDP exchange on Gα subunits is Suranim (Freissmuth M et al, 1996, Mol. Pharmacol, 49:602). Since suranim functions as a universal Gα inhibitor, it prevents the activation of most Gα subunits. Using techniques described, for example and without limitation, in the present Examples entitled “In vivo Assay for 101P3A11 Tumor Growth Promotion;” “Identification and Confirmation of Potential Signal Transduction Pathways,” “101P3A11 Functions as a GPCR,” and “Regulation of Transcription”, small molecules are identified that selectively inhibit the Gα subunit that associates with 101P3A11, thereby providing therapeutic, prognostic, diagnostic and/or prophylactic benefit.
A third approach is to inhibit Gα subunit association with GPCR. In order for trimeric G proteins to be activated following GPCR/ligand interaction, it is necessary for them to associate with their corresponding GPCR. Mutational analysis has mapped the interaction of Gα to the first and third intracellular loops of GPCRs (Heller R at al. 1996, Biochem. Biophys. Res. Commun). Several studies have used synthetic (small molecule) peptides corresponding to the intracellular sequence of loops 1 and 3 as inhibitors (Mukherjee, S., et al. 1999, J. Biol. Chem.). Using such short peptides that serve as receptor mimics, they are used to compete for binding of Ga subunits to 101P3A11 and thereby provide therapeutic, prognostic, diagnostic and/or prophylactic benefit.
Thus, compounds and small molecules designed to inhibit 101P3A11 function and downstream signaling events are used for therapeutic diagnostic, prognostic and/or preventative purposes.
Example 46
Involvement in Tumor Progression
The 101P3A11 gene can contribute to the growth of cancer cells. The role of 101P3A11 in tumor growth is confirmed in a variety of primary and transfected cell lines including prostate, colon, bladder and kidney cell lines, as well as NIH 3T3 cells engineered to stably express 101P3A11. Parental cells lacking 101P3A11 and cells expressing 101P3A11 are evaluated for cell growth using a well-documented proliferation assay (Fraser S P, et al., Prostate 2000; 44:61, Johnson D E, Ochieng J, Evans S L. Anticancer Drugs. 1996, 7:288). Using such a technique, we demonstrated (see FIG. 37) that 101P3A11 imparts a growth advantage on NIH 3T3 cells. 3T3-neo and 3T3-101P3A11 cells were grown in 0.5% or 10% FBS and analyzed 48 hours later. The assay was performed in triplicate. Expression of 101P3A11 resulted in 6-fold increase in proliferation relative to control 3T3 cells grown in 0.5% FBS. In addition, 101P3A11 imparts a growth advantage to PC3 cells as shown in Figures M7 and M16. PC3 cells grown in 0.5% and 10% FBS were compared to PC3-101P3A11. Figure M7 shows that expression of 101P3A11 enhances the proliferation of PC3 cells under both conditions. The effect of 101P3A11 was also observed on cell cycle progression. Control and 101P3A11-expressing cells were grown in low serum overnight, and treated with 10% FBS for 48 and 72 hrs. Cells were analyzed for BrdU and propidium iodide incorporation by FACS analysis. Figure M16 shows that expression of 101P3A11 enhances cell cycle entry in both 3T3 and PC3 cells.
To confirm the role of 101P3A11 in the transformation process, its effect in colony forming assays was investigated. Parental NIH-3T3 cells lacking 101P3A11 were compared to NIH-3T3 cells expressing 101P3A11, using a soft agar assay under stringent and more permissive conditions (Song Z. et al. Cancer Res. 2000; 60:6730). The results are shown in FIG. 43, where 101P3A11 induces colony formation of over 100 fold increase relative to neo resistant controls. We previously showed that expression of 101P3A11 in NIH 3T3 cells induces the growth of these cells in soft agar (129-24usu1), indicating that 101P3A11 participates in the process of transformation.
To confirm the role of 101P3A11 in invasion and metastasis of cancer cells, a well-established assay is used. A non-limiting example is the use of an assay which provides a basement membrane or an analog thereof used to detect whether cells are invasive (e.g., a Transwell Insert System assay (Becton Dickinson) (Cancer Res. 1999; 59:6010)). Control cells, including prostate, colon, bladder and kidney cell lines lacking 101P3A11 are compared to cells expressing 101P3A11. Cells are loaded with the fluorescent dye, calcein, and plated in the top well of a support structure coated with a basement membrane analog (e.g. the Transwell insert) and used in the assay. Invasion is determined by fluorescence of cells in the lower chamber relative to the fluorescence of the entire cell population.
101P3A11 can also play a role in cell cycle and apoptosis. Parental cells and cells expressing 101P3A11 are compared for differences in cell cycle regulation using a well-established BrdU assay (Abdel-Malek Z A. J Cell Physiol. 1988, 136:247). In short, cells are grown under both optimal (full serum) and limiting (low serum) conditions are labeled with BrdU and stained with anti-BrdU Ab and propidium iodide. Cells are analyzed for entry into the G1, S, and G2M phases of the cell cycle. Alternatively, the effect of stress on apoptosis is evaluated in control parental cells and cells expressing 101P3A11, including normal and tumor prostate, colon and lung cells. Engineered and parental cells are treated with various chemotherapeutic agents, such as etoposide, flutamide, etc, and protein synthesis inhibitors, such as cycloheximide. Cells are stained with annexin V-FITC and cell death is measured by FACS analysis. The modulation of cell death by 101P3A11 can play a critical role in regulating tumor progression and tumor load.
When 101P3A11 plays a role in cell growth, transformation, invasion or apoptosis, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.
Example 47
Involvement in Angiogenesis
Angiogenesis or new capillary blood vessel formation is necessary for tumor growth (Hanahan, D.; Folkman, J.; Cell. 1996, 86:353; Folkman J. Endocrinology. 1998 139:441). Several assays have been developed to measure angiogenesis in vitro and in vivo, such as the tissue culture assays endothelial cell tube formation and endothelial cell proliferation. Using these assays as well as in vitro neo-vascularization, the role of 101P3A11 in angiogenesis, enhancement or inhibition, is confirmed.
For example, endothelial cells engineered to express 101P3A11 are evaluated using tube formation and proliferation assays. The effect of 101P3A11 is also confirmed in animal models in vivo. For example, cells either expressing or lacking 101P3A11 are implanted subcutaneously in immunocompromised mice. Endothelial cell migration and angiogenesis are evaluated 5-15 days later using immunohistochemistry techniques. 101P3A11 affects angiogenesis, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes
Example 48
Regulation of Transcription
The cell surface localization of 101P3A11 and its similarity to GPCRs indicate that 101P3A11 is effectively used as a modulator of the transcriptional regulation of eukaryotic genes. Regulation of gene expression is confirmed, e.g., by studying gene expression in cells expressing or lacking 101P3A11. For this purpose, two types of experiments are performed.
In the first set of experiments, RNA from parental and 101P3A11-expressing cells are extracted and hybridized to commercially available gene arrays (Clontech) (Smid-Koopman E et al. Br J Cancer. 2000. 83:246). Resting cells as well as cells treated with FBS or androgen are compared. Differentially expressed genes are identified in accordance with procedures known in the art. The differentially expressed genes are then mapped to biological pathways (Chen K et al. Thyroid. 2001. 11:41.).
In the second set of experiments, specific transcriptional pathway activation is evaluated using commercially available (Stratagene) luciferase reporter constructs including: NFkB-luc, SRE-luc, ELK1-luc, ARE-luc, p53-luc, and CRE-luc. These transcriptional reporters contain consensus binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways, and represent a good tool to ascertain pathway activation and screen for positive and negative modulators of pathway activation.
Thus, 101P3A11 plays a role in gene regulation, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.
Example 49
Involvement in Cell Adhesion
Cell adhesion plays a critical role in tissue colonization and metastasis. 101P3A11 can participate in cellular organization, and as a consequence cell adhesion and motility. To confirm that 101P3A11 regulates cell adhesion, control cells lacking 101P3A11 are compared to cells expressing 101P3A11, using techniques previously described (see, e.g., Haier et al, Br. J. Cancer. 1999, 80:1867; Lehr and Pienta, J. Natl. Cancer Inst. 1998, 90:118). Briefly, in one embodiment, cells labeled with a fluorescent indicator, such as calcein, are incubated on tissue culture wells coated with media alone or with matrix proteins. Adherent cells are detected by fluorimetric analysis and percent adhesion is calculated. In another embodiment, cells lacking or expressing 101P3A11 are analyzed for their ability to mediate cell-cell adhesion using similar experimental techniques as described above. Both of these experimental systems are used to identify proteins, antibodies and/or small molecules that modulate cell adhesion to extracellular matrix and cell-cell interaction. Cell adhesion plays a critical role in tumor growth, progression, and, colonization, and 101P3A11 is involved in these processes. Thus, it serves as a diagnostic, prognostic, preventative and/or therapeutic modality.
Example 50
Protein-Protein Association
Several GPCRs have been shown to interact with other proteins, thereby regulating signal transduction, gene transcription, transformation and cell adhesion (Sexton P M et al, Cell Signal. 2001, 13:73; Turner C E, J Cell Sci. 2000, 23:4139). Using immunoprecipitation techniques as well as two yeast hybrid systems, proteins are identified that associate with 101P3A11. Immunoprecipitates from cells expressing 101P3A11 and cells lacking 101P3A11 are compared for specific protein-protein associations.
Studies are performed to confirm the extent of association of 101P3A11 with effector molecules, such as receptors, adaptor proteins and paxillin, kinases, phsophates and Ga proteins. Studies comparing 101P3A11 positive and 101P3A11 negative cells as well as studies comparing unstimulated/resting cells and cells treated with epithelial cell activators, such as cytokines, growth factors, androgen and anti-integrin Ab reveal unique interactions.
In addition, protein-protein interactions are confirmed using two yeast hybrid methodology (Curr Opin Chem. Biol. 1999, 3:64). A vector carrying a library of proteins fused to the activation domain of a transcription factor is introduced into yeast expressing a 101P3A11-DNA-binding domain fusion protein and a reporter construct. Protein-protein interaction is detected by colorimetric reporter activity. Specific association with effector molecules and transcription factors directs one of skill to the mode of action of 101P3A11, and thus identifies therapeutic, prognostic, preventative and/or diagnostic targets for cancer. This and similar assays are also used to identify and screen for small molecules that interact with 101P3A11.
Thus it is found that 101P3A11 associates with proteins and small molecules. Accordingly, 101P3A11 and these proteins and small molecules are used for diagnostic, prognostic, preventative and/or therapeutic purposes.
Example 51
Biological Effect of Anti-101P3A11 Antibodies
The generation of anti-101P3A11 polyclonal Ab (pAb) using an amino-terminal peptide encoding amino acids 1-14 (MVDPNGNESSATYF; SEQ ID NO: 46) as antigen was reported in our Priority Application. The effect of this antibody on 101P3A11 mediated ERK phosphorylation (FIG. 38) and cAMP accumulation (FIG. 39) was determined. 293T cells were transfected with control or 101P3A11 cDNA. Cells were allowed to rest overnight, and treated with anti-101P3A11 or control Ab in the presence of 0.5% or 10% FBS. Cells were lysed and analyzed by Western blotting with anti-Phospho-ERK and anti-ERK mAb. FIG. 38 shows that expression of 101P3A11 induces ERK phosphorylation in cells treated with 0.5 or 10% FBS. Anti-101P3A11 pAb reduced the phosphorylation of ERK in 293T-101P3A11 cells treated with 0.5% FBS. The ERK overlay demonstrated equal loading, supporting the specificity of this data.
In order to confirm that anti-101P3A11 pAb has a detectable effect on cAMP accumulation, PC3 and PC3-101P3A11 cells were grown in 0.1% FBS and treated with anti-101P3A11 pAb. Cells were analyzed for cAMP content as described in FIG. 32. Expression of 101P3A11 induced a 5-fold increase in cAMP accumulation in PC3 cells, which was partially inhibited by PTX. Treatment of PC3-101P3A11 cells with anti-101P3A11 pAb resulted in a 4-fold increase in cAMP accumulation in PC3-101P3A11 but not control PC3 cells. Results shown in FIG. 38 and FIG. 39 indicate that anti-101P3A11 pAb produces a measurable biological effect in cells expressing 101P3A11. Accordingly, 101P3A11 is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.
Example 52
101P3A11 Promoters
A eukaryotic cells promoter is a short DNA sequence located in the 5′ region of a gene. It provides binding sites for RNA polymerase and associated transcriptional cofactors, which upon assembly promotes transcription of the gene. In humans, most genes are transcribed by RNA polymerase II. The promoter DNA sequence normally contains binding motifs for RNA polymerases and its associated cofactors and activators including a TATA-box, cap signal, CCAAT-box and the GC-box. A eukaryotic cell enhancer is DNA sequence where transcriptional factors and their associated coactivators or suppressors bind and interact with promoter-bound RNA polymerase to regulate the expression of the gene located next to the promoter. While a promoter(s) locates close to the transcription starting site(s) of a gene (usually 25-30 base pairs), enhancers can be found up to 50,000 base pairs in either direction to the transcription starting site(s) of the gene. There are many different gene regulatory proteins, namely transcription factors and their associated coactivators and cosuppressors that bind to specific enhancer sequences and regulate gene expression. These proteins, upon interaction with specific DNA regulatory sequences and with each other, allow each gene to be regulated up or down in different tissues and cell types. Chapter 9. “Control of gene expression” in Molecular Biology of the Cell. 3rd ed. Ed. by Alberts et al., (New York and London) Garland Publishing, 1994).
Tissue specific gene expression is associated with the presence of specific combinations of transcription factors and their associated coactivators and suppressors, the presence of specific binding sites present in the DNA regulatory region of the gene for these factors, and the activation or inactivation of signaling pathways that modulate their relative activity. For example, prostate specific expression of prostate specific antigen, (PSA, or human kallikrein 3), is dependent on the presence of androgen receptor binding elements in defined 5′ upstream enhancer and promoter sequences of the gene and intact androgen receptor signaling pathway (Pang S, et al., Cancer Res 1997 Feb. 1; 57(3):495-9). It is also dependent on the presence of other cis-acting DNA regulatory elements in the promoter region (Zhang J, et al., Nucleic Acids Res. 1997, Aug. 1; 25(15):3143-50.) and on the expression of other transcription factors, such as the prostate specific ets-like transcription factor (Oettgen P, et al., J Biol Chem. 2000, Jan. 14; 275(2): 1216-25).
With the accumulation of data and knowledge on human gene expression, promoters and enhancers are identified using different algorithms and computer programs (Chapter 8 “Gene Prediction” in Bioinformatics—Sequence and Genome Analysis, ed. by David W. Mount. Cold Spring Harbor Laboratory Press, 2001). Accordingly, we identified (Table LV) promoters in a 5.04 kB 5′ upstream genomic region of the 101P3A11 coding sequence using Neural Network Promoter Prediction computer program (Reese, M. G. and Eeckman, F. H. (1995) Novel Neural Network Algorithms for Improved Eukaryotic Promoter Site Recognition. Accepted talk for The Seventh International Genome Sequencing and Analysis Conference, Hyatt Regency, Hilton Head Island, S.C., Sep. 16-20, 1995), indicated by the underlined sequences in Table LIV. Using a program called SIGNAL SCAN (Prestridge D. S. (1991) SIGNAL SCAN: A computer program that scans DNA sequences for eukaryotic transcriptional elements. CABIOS 7, 203-206.), which searches a comprehensive database of regulatory element binding sites, we found numerous transcriptional binding sites for various known transcription factors in the 5.04 kB sequence 5′ to the 101P3A11 gene, suggesting the presence of specific enhancer regions that may mediate tissue specific 101P3A11 transcription. Such transcription factors include, but are not limited to, NFAT, NF-1, NF-E, CP2, AP1, AP-2, Spl, OCT-I, OCT-2, NFKB, CREB, CTF, TFIIA, TFIIB, TFIID, Pit-I, C/EBP, SRF, and various steroid receptors, such as glucocorticoid receptor (GR) and androgen receptors (AR) (Mitchell P J and Tijan R (1989) Science 245: 371). Comparison of the 5 kB upstream sequence of the 101P3A11 gene to the 5 kB upstream sequence of the PSA gene, 5 homologous regions were found that are important for prostate cell specific expression. Table LVI shows the alignment of the these sequences and also indicates predicted transcription factor binding sites common to both sequences identified using SIGNAL SCAN.
Experimentally, one defines the regions in the 5′ genomic upstream regions of the 101P3A11 gene using various methods well known in the art, such as deletion and mutation analysis of the putative regulatory regions fused to a transcriptional reporter gene such as luciferase or chloramphenicol acetyl-transferase. These transcriptional reporter vectors are then introduced into cell lines, tissues, or transgenic animals to analyze the tissue and cell type specificity of transcription and expression of the reporter gene. To identify transcription factors and proteins that interact with specific 101P3A11 transcriptional regulatory sequences, one employs one or more of various techniques known in the art such as DNAse footprinting, gel mobility shift assays, and DNA/protein affinity chromatography. Various techniques concerning use of promoters are set forth, e.g., U.S. Pat. No. 5,919,652 which concerns embodiments of nucleic acid compositions that comprise prostate specific antigen (PSA) promoter alone or in combination with a cytomegalovirus (CMV) promoter and related uses; and, U.S. Pat. No. 6,110,702 which concerns PSA positive regulatory sequence (PSAR) and related uses.
Once regulatory sequences are identified that mediate 101P3A11 tissue-specific expression, these sequences are employed in various gene therapeutic strategies for cancer, such as driving tissue-specific expression of a toxic gene or a cell suicide gene. Such cell suicide strategies are currently employed using the PSA-promoter enhancer using the thymidine kinase/ganciclovir system (Suzuki S, Tadakuma T, Asano T, Hayakawa M. Cancer Res. 2001 Feb. 15; 61(4):1276-90). Unlike PSA, which is an androgen regulated gene, 101P3A11 does not exhibit androgen regulated expression. Thus, identification and use of regulatory sequences of the 101P3A11 gene that mediate, e.g., prostate-specific, but androgen insensitive gene expression, is useful for the treatment of both early stage androgen sensitive and late stage androgen insensitive or hormone refractory prostate cancer.
Example 53
Generation of PHOR-1 Monoclonal Antibodies
The use of agents to identify the presence of PHOR-1 in biopsy specimens or to neutralize the effect of PHOR-1 has a beneficial effect in diagnosis, prognosis, prophylaxis and/or therapy. One particularly useful class of anti PHOR-1 agents is antibodies, in particular monoclonal antibodies (mAbs) to PHOR-1. Anti PHOR-1 Abs, such as mAbs, are generated that react with the epitopes of the PHOR-1 protein such that they either indicate it's presence, disrupt or modulate it's biological function (for example those that would disrupt the interaction with ligands or proteins that mediate or are involved in it's biological activity) or are able to carry a toxin to the cell which is expressing PHOR-1.
The term anti PHOR-1 antibody as used herein is to be understood to cover antibodies to any epitope of the PHOR-1 gene product. Diagnostic mAbs, e.g. those used for imaging or immunocytochemistry, comprise those that specifically bind epitopes of PHOR-1 protein and thus demonstrate its presence. Therapeutic mAbs include those that are useful for diagnosis but also comprise those that specifically bind epitopes of PHOR-1 exposed on the cell surface and thus are useful to modulate growth and survival of cells expressing PHOR-1 by disrupting the function of a cell expressing PHOR-1 and/or disrupting the interaction of cells expressing PHOR-1 and the ligand for PHOR-1.
Preferred antibodies which form one aspect of the invention include but are not limited to antibodies named X18(1)4, X18(1)10, X18(1)23, X18(4)7 or prefixed by the number X20 and X47 and derivatives thereof, the production of which is described herein. Hybridomas, respectively, that produce these antibodies were deposited with the ATCC on 14 May 2002.
Pathological conditions which are characterized by the presence of PHOR-1 expression include, but are not restricted to, neoplasms of tissues such as those listed in Table I. One aspect of the invention provides a method of detecting the presence of PHOR-1. A further aspect of the invention provides a method of treatment of conditions characterized by the presence of PHOR-1, comprising administering an effective amount of an anti PHOR-1 antibody. The administration of anti-PHOR-1 antibody is particularly advantageous in the treatment of conditions characterized by the presence of PHOR-1.
The antibodies against PHOR-1 for use according to the invention can be from any species, and can belong to any immunoglobulin class. Thus, for example, the anti PHOR-1 antibody for use according to the invention can be an immunoglobulin G, Immunoglobulin M or immunoglobulin A, Immunoglobulin E.
The anti PHOR-1 antibody can be from an animal, for example mammalian or avian origin, and can be for example of murine, rat or human origin. The antibody can be a whole immunoglobulin, or a fragment thereof, for example a fragment derived by proteolytic cleavage of a whole antibody, such as F(ab′)2, Fab′ or Fab fragments or fragments obtained by recombinant DNA techniques, for example Fv fragments.
Particularly useful antibodies for use according to the invention include humanized or fully human anti PHOR-1 antibodies and fragments thereof. These antibodies are produced by any suitable procedure including, but not restricted to, mammalian cell and bacterial cell fermentation systems.
The anti PHOR-1 mAbs are prepared by immunological techniques employing PHOR-1 antigens. Thus, for example, any suitable host can be injected (immunized) with a suitable reagent which makes PHOR-1 available as an immunogen. Immune cells from the host, for example splenocytes or lymphocytes, are recovered from the immunized host and immortalized, using for example the method of Kohler et al, Eur. J. Immunol. 6, 511 (1976), or their immunoglobulin genes can be isolated and transferred to an appropriate DNA vector for expression in an appropriate cell type. The resulting cells, generated by either technique, will be selected to obtain a single genetic line producing a single unique type of antibody more commonly known as a monoclonal antibody. Antibody fragments can be produced using techniques such as enzymatic digestion of whole antibodies e.g. with pepsin (Parham, J. Immunol. 131:2895 (1983)) or papain (Lamoyi and Nisonoff, J. Immunol. Meth. 56:235 (1983)), or by recombinant DNA techniques.
Suitable hosts for the production of Mab's to PHOR-1 include mice, rats, hamsters and rabbits. For example, mice are immunized with a number of different reagents which make PHOR-1 available as a source of antigenic material (immunogen). The route and timing if the immunizations will depend on the source and/or embodiment of the immunogen. Sources of immunogen for PHOR-1 include, but are not restricted to, peptide, protein, fusion protein, DNA, RNA, cells or cell membranes. These can be used separately as immunogens or in combination to produce a specific immune reaction to PHOR-1. The use and application of these various immunogens is described fully in the accompanying examples.
Example 54
Generation of Antibodies to PHOR1 Using Peptide Encoding the First 23 N′ Terminal Amino Acids of PHOR-1 as the Immunogen
In one embodiment eptides encoding the first 23 amino acids of PHOR-1 (MVDPNGNESSATYFILIGLPGLE) (SEQ ID: 47) were generated. These were, synthesized by SigmaGenosys using their custom peptide services. The peptide was synthesized with the addition of a Serine-Glycine-Serine-Glycine-Cysteine (SGSGC) C-terminal linker sequence and then coupled to KLH through the C-terminal cysteine residue. In this orientation the N-terminal PHOR-1 sequence remains free for antigenic recognition.
Balb/c mice were immunized intraperitoneally (i.p.) with 10 μg of peptide every 2 weeks over a 4 week period. The initial immunization was given i.p. in Complete Freunds Adjuvant (CFA) and the subsequent two immunizations were given i.p. in Incomplete Freunds Adjuvant (IFA).
To determine the specificity of the response following immunization, mice were bled 10 days after the final immunization. Reactivity was determined by Enzyme Linked Immunosorbent Assay (ELISA) using non-KLH conjugated (free) peptide as a target. All five mice had very high titers to the antigen.
Two mice with the highest titers were given a final boost of 10 μg peptide in PBS and sacrificed for fusion 3 days later. Spleen cells from the immunized mice were fused with mouse Sp2/0 myeloma cells using PEG 1500 according to standard protocols (Kohler et al, Eur. J. Immunol 6: 511 (1976)). Fused cells were plated in 10 96 well microtiter plates and hybridomas were selected using HAT media supplement. Supernatants from fusion wells were screened 10-17 days later by ELISA against PHOR-1 peptide. Twenty-one positive hybridomas were identified; these hybridomas are set forth in Table L










TABLE L







Clone number
O.D.









X20(5)1
0.157



X20(5)2
0.511



X20(5)3
0.310



X20(5)4
0.735



X20(5)5
0.160



X20(5)6
0.322



X20(5)7
0.179



X20(5)8
0.173



X20(5)9
0.170



X20(5)10
1.171



X20(5)11
0.172



X20(5)12
0.159



X20(5)13
0.244



X20(5)14
1.204



X20(5)15
0.245



X20(5)16
0.220



X20(5)17
0.225



X20(5)18
0.186



X20(5)19
0.176



X20(5)20
0.224



X20(5)21
0.502










Example 55
Generation mAbs to PHOR1 Using DNA Immunization
Therapeutic mAbs to PHOR-1 comprise those that react with PHOR-1 epitopes that disrupt or modulate the biological function of PHOR-1, for example those that disrupt its interaction with ligands or proteins that mediate or are involved in its biological activity. Structural modeling and experimental binding data of the murine olfactory receptor S25 indicates that amino acid residues at the junction of extracellular loop 1 and transmembrane domain 3, the region of extracellular loop 2 between transmembrane domains 4 and 5, and the region of extracellular loop 3 between transmembrane domains 6 and 7 are involved in the binding of the ligand hexanol (Floriano, W. B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716).
Thus, in one embodiment, a vector was constructed that encodes the amino acids of extracellular loop 2 (159-202) between transmembrane domains 4 and 5 of PHOR-1 fused at the C-terminus to the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions). This construct was used in a DNA based immunization strategy.
Five Balb/c mice were immunized intra-dermally (ID) at the base of their tail. Three immunizations were given to each mouse of 100 μg of DNA in PBS over a two week period. To increase the immune response, each mouse was given an i.p. boost of 2 μg of PHOR-1-Fc protein in tissue culture media 10 days after the final DNA immunization. Bleeds were collected 10 days after the final immunization and reactivity in the sera to the middle loop of PHOR-1 was tested by ELISA using PHOR-1-Fc fusion protein as a target (test 1). In parallel the sera were also tested on an unrelated human Fc fusion protein (test 2). Specific reactivity to the PHOR-1 portion of the fusion protein was indicated.
All mice were sacrificed and fusions and hybridoma selection was carried out as described in Example 54. Hybridoma supernatants were screened 10-17 days later by ELISA using PHOR1-Fc protein as target. PHOR-1-Fc positives were subsequently cross screened on irrelevant Fc proteins to identify PHOR specific clones. A total of 16 positives specific for PHOR1-Fc but not reactive to other Fc fusion proteins were identified, these hybridomas are set forth in Table LI.










TABLE LI







Clone number
O.D.



















X1(1)1
0.557



X1(1)2
0.511



X1(1)3
0.610



X1(1)4
0.735



X1(1)5
0.860



X1(1)6
0.322



X1(1)7
0.779



X1(1)8
0.473



X1(1)9
0.770



X1(1)10
0.541



X1(1)11
0.672



X1(1)12
1.209



X1(1)13
0.244



X1a(2)1
1.109



X1a(2)2
.654



X1a(2)3
0.220










Example 56
Generation of Monoclonal Antibodies Specific to Amino Acids 86-310 of PHOR-1
A fusion protein was constructed that encodes amino acids 86-310 of PHOR-1 fused at the amino terminus to glutathione-S-transferase (GST). This fusion protein, GST-PHOR-1, encompasses sequences that proceed transmembrane domain 3 through transmembrane domain 7 so that all of the extracellular loops of PHOR-1 are represented and the only extra-cellular domain that is not represented is the N′ terminal. The fusion protein was purified from induced bacteria using standard glutathione affinity chromatography and used to immunize five mice following the protocol of Example 54. The PHOR-1 specific titer of the sera was determined following the fourth immunization (bleed 2) using a fusion protein composed of amino acids 86-310 of PHOR-1 fused to maltose binding protein (PHOR 1-MBP), see Table LII below and FIG. 49. The sera from each mouse specifically recognized PHOR-1 protein in 293T cells transfected with an epitope tagged PHOR-1 cDNA as assessed by Western analysis (FIG. 48). When screened on 293T-PHOR1 cells compared to 293T-neo cells by FACS several of the sera were positive indicating generation of antibodies specific to cell associated PHOR1, see FIG. 50.








TABLE LII





Mouse
Titer, Bleed 2







1
1 × 10−6


2
1 × 10−6


3
2 × 10−6


4
1 × 10−6


5
5 × 10−5









Two mice with high titers were given a final boost of MBP-PHOR-1 fusion protein in PBS and sacrificed for fusion 3 days later. Fusion and hybridoma growth selection was carried out as in Example 54. Hybridomas were screened by ELISA against GST-PHOR1 and cross-screened against MBP-PHOR-1 to identify PHOR-1 sequence reactive clones. 48 hybridomas were identified that exhibited specific reactivity to MBP-PHOR-1. These hybridomas are set forth in Table LIII.









TABLE LIII





Number
Clone number
O.D.

















1
X18(1)1
0.425


2
X18(1)2
0.445


3
X18(1)3
0.573


4
X18(1)4
0.228


5
X18(1)5
0.218


6
X18(1)6
0.333


7
X18(1)7
1.459


8
X18(1)8
0.260


9
X18(1)9
0.253


10
X18(1)10
0.282


11
X18(1)11
0.362


12
X18(1)12
0.343


13
X18(1)13
0.261


14
X18(1)14
0.773


15
X18(1)15
0.631


16
X18(1)16
1.427


17
X18(1)17
0.372


18
X18(1)18
0.657


19
X18(1)19
0.677


20
X18(1)20
0.338


21
X18(1)21
0.398


22
X18(1)22
0.232


23
X18(1)23
0.560


24
X18(1)24
0.554


25
X18(1)25
0.442


26
X18(4)1
0.848


27
X18(4)2
0.420


28
X18(4)3
0.230


29
X18(4)4
0.333


30
X18(4)5
0.389


31
X18(4)6
0.264


32
X18(4)7
0.358


33
X18(4)8
0.669


34
X18(4)9
0.429


35
X18(4)10
0.253


36
X18(4)11
0.277


37
X18(4)12
0.536


38
X18(4)13
0.662


39
X18(4)14
0.344


40
X18(4)15
0.256


41
X18(4)16
0.212


42
X18(4)17
0.304


43
X18(4)18
0.531


44
X18(4)19
0.286


45
X18(4)20
0.472


46
X18(4)21
0.770


47
X18(4)22
0.877


48
X18(4)23
0.450









Four hybridomas reactive to MBP-PHOR-1 exhibited strong specific reactivity to PHOR-1 protein expressed in cells. This was demonstrated by Western analysis of 293T cells transfected with the epitope tagged PHOR-1 cDNA (FIG. 47). The positive clones are indicated in bold, namely 18(1)4; 18(1)10; 18(1)23; and, 18(4)7. Hybridomas expressing, respectively, 18(1)4; 18(1)10; 18(1)23; and, 18(4)7 were deposited with the ATCC on 14 May 2002.
Example 57
Activation of 101P3A11
It is possible to measure the constitutive and ligand-mediated activation of 101P3A11 using the cAMP accumulation assay mentioned in example 44 above or by measuring the binding of the GTP analog, namely [35S]GTPyS. [35S]GTPyS binding is generically applicable to all GPCRs; and occurs proximal to the membrane surface, where the GPCR is located. Preferably, a GPCR:Fusion-Protein is utilized for these assays. The assay utilizes the ability of G protein-coupled receptors to stimulate [35S] GTPyS binding to membranes expressing the relevant receptors. Therefore, the assay may be used to directly screen compounds and antibodies for their effect on the activation of 101P3A11.
A scintillation proximity assay can be utilized to monitor the binding of [35S] GTP7S to membranes expressing 101P3A11-Gs-Fusion Protein (expressed in 293 or 3T3 cells). In brief, membrane proteins are incubated with [35 S]GTPyS and GDP for 60 minutes. The assay plates are-counted in a scintillation counter.
Throughout this application, various website data content, publications, patent applications and patents are referenced. The disclosures of each of these references are hereby incorporated by reference herein in their entireties.
The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.







TABLE I





Tissues that Express 101P3A11 When Malignant

















Normal Tissues:



Prostate



Ovary (by RT-PCR only)



Malignant Tissues:



Rectum



Prostate



Colon



Kidney



Breast



Uterus



Cervix



Stomach



Metastases Pool

















TABLE II







Amino Acid Abbreviations











SINGLE LETTER
THREE LETTER
FULL NAME







F
Phe
phenylalanine



L
Leu
leucine



S
Ser
serine



Y
Tyr
tyrosine



C
Cys
cysteine



W
Trp
tryptophan



P
Pro
proline



H
His
histidine



Q
Gln
glutamine



R
Arg
arginine



I
Ile
isoleucine



M
Met
methionine



T
Thr
threonine



N
Asn
asparagine



K
Lys
lysine



V
Val
valine



A
Ala
alanine



D
Asp
aspartic acid



E
Glu
glutamic acid



G
Gly
glycine

















TABLE III







Amino Acid Substitution Matrix



























A
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y
.






























4
0
−2
−1
−2
0
−2
−1
−1
−1
−1
−2
−1
−1
−1
1
0
0
−3
−2
A



9
−3
−4
−2
−3
−3
−1
−3
−1
−1
−3
−3
−3
−3
−1
−1
−1
−2
−2
C




6
2
−3
−1
−1
−3
−1
−4
−3
1
−1
0
−2
0
−1
−3
−4
−3
D





5
−3
−2
0
−3
1
−3
−2
0
−1
2
0
0
−1
−2
−3
−2
E






6
−3
−1
0
−3
0
0
−3
−4
−3
−3
−2
−2
−1
1
3
F







6
−2
−4
−2
−4
−3
0
−2
−2
−2
0
−2
−3
−2
−3
G








8
−3
−1
−3
−2
1
−2
0
0
−1
−2
−3
−2
2
H









4
−3
2
1
−3
−3
−3
−3
−2
−1
3
−3
−1
I










5
−2
−1
0
−1
1
2
0
−1
−2
−3
−2
K











4
2
−3
−3
−2
−2
−2
−1
1
−2
−1
L












5
−2
−2
0
−1
−1
−1
1
−1
−1
M













6
−2
0
0
1
0
−3
−4
−2
N














7
−1
−2
−1
−1
−2
−4
−3
P















5
1
0
−1
−2
−2
−1
Q
















5
−1
−1
−3
−3
−2
R

















4
1
−2
−3
−2
S


















5
0
−2
−2
T



















4
−3
−1
V




















11
2
W





















7
Y





Adapted from the GCG Software 9.0 BLOSUM62 amino acid substitution matrix (block substitution matrix). The higher the value, the more likely a substitution is found in related, natural proteins.













TABLE IV





HLA Class I/II Motifs/Supermotifs







TABLE IV (A): HLA Class I Supermotifs/Motifs













POSITION
POSITION
POSITION




2 (Primary Anchor)
3 (Primary Anchor)
C Terminus (Primary Anchor)






SUPERMOTIFS






A1
TILVMS (SEQ ID NO: 48)

FWY


 



A2
LIVMATQ (SEQ ID NO: 49)

IVMATL (SEQ ID NO: 50)


 



A3
VSMATLI (SEQ ID NO: 51)

RK


 



A24
YFWIVLMT (SEQ ID NO: 52)

FIYWLM (SEQ ID NO: 53)


 



B7
P

VILFMWYA (SEQ ID NO: 54)


 



B27
RHK

FYLWMIVA (SEQ ID NO: 55)


 



B44
ED

FWYLIMVA (SEQ ID NO: 56)


 



B58
ATS

FWYLIVMA (SEQ ID NO: 57)


 



B62
QLIVMP (SEQ ID NO: 58)

FWYMIVLA (SEQ ID NO: 59)


 



MOTIFS






A1
TSM

Y


 



A1

DEAS
Y





(SEQ ID NO: 60)



 



A2.1
LMVQIAT (SEQ ID NO: 61)

VLIMAT (SEQ ID NO: 62)


 



A3
LMVISATFCGD

KYRHFA (SEQ ID NO: 64)




(SEQ ID NO: 63)




 



A11
VTMLISAGNCDF

KRYH (SEQ ID NO: 66)




(SEQ ID NO: 65)




 



A24
YFWM (SEQ ID NO: 67)

FLIW (SEQ ID NO: 68)


 



A*3101
MVTALIS (SEQ ID NO: 69)

RK


 



A*3301
MVALFIST (SEQ ID NO: 70)

RK


 



A*6801
AVTMSLI (SEQ ID NO: 71)

RK


 



B*0702
P

LMFWYAIV (SEQ ID NO: 72)


 



B*3501
P

LMFWYIVA (SEQ ID NO: 73)


 



B51
P

LIVFWYAM (SEQ ID NO: 74)


 



B*5301
P

IMFWYALV (SEQ ID NO: 75)


 



B*5401
P

ATIVLMFWY(SEQ ID NO: 76)










Bolded residues are preferred, italicized residues are less preferred: A peptide is considered


motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified


in the above table.


TABLE IV (B): HLA Class II Supermotif











1
6
9






W, F, Y, V, .I, L
A, V, I, L, P, C, S, T
A, V, I, L, C, S, T, M, Y










TABLE IV (C): HLA Class II Motifs



















MOTIFS

1° anchor 1
2
3
4
5
1° anchor 6
7
8
9






DR4
preferred
FMYLIVW
M
T

I
VSTCPALIM
MH

MH




deleterious
(SEQ ID NO: 77)


W

(SEQ ID NO: 78)
R

WDE


 



DR1
preferred
MFLIVWY


PAMQ

VMATSPLIC
M

AVM





(SEQ ID NO: 79)


(SEQ ID NO: 80)

(SEQ ID NO: 81)







deleterious

C
CH
FD
CWD

GDE
D



 



DR7
preferred
MFLIVWY
M
W
A

IVMSACTPL
M

IV





(SEQ ID NO: 79)












deleterious

C

G

(SEQ ID NO: 82)
GRD
N
G


 



DR3
MOTIFS
1° anchor 1
2
3
1° anchor 4
5
1° anchor 6






motif a

LIVMFY


D








preferred

(SEQ ID NO: 83)











motif b

LIVMFAY


DNQEST

KRH






preferred

(SEQ ID NO: 84)


(SEQ ID NO: 85)







 



DR

MFLIVWY




VMSTACPLI






Supermotif

(SEQ ID NO: 79)




(SEQ ID NO: 86)










Italicized residues indicate less preferred or “tolerated” residues


TABLE IV (D): HLA Class I Supermotifs











SUPER-
POSITION:




















MOTIFS

1
2
3
4
5
6
7
8
C-terminus






A1


1° Anchor






1° Anchor






TILVMS






FWY






(SEQ ID NO: 48)









 



A2


1° Anchor






1° Anchor






LIVMATQ






LIVMAT






(SEQ ID NO: 49)






(SEQ ID NO: 87)


 



A3
preferred

1° Anchor
YFW


YFW
YFW
P
1° Anchor






VSMATLI
(4/5)


(3/5)
(4/5)
(4/5)
RK




deleterious
DE (3/5); P (5/5)
(SEQ ID NO: 51)
DE (4/5)








 



A24


1° Anchor






1° Anchor






YFWIVLMT






FIYWLM






(SEQ ID NO: 52)






(SEQ ID NO: 88)


 



B7
preferred
FWY (5/5)
1° Anchor
FWY




FWY
1° Anchor





LIVM (3/5)
P
(4/5)




(3/5)
VILFMWYA





(SEQ ID NO: 89)







(SEQ ID NO: 54)




deleterious
DE (3/5); P(5/5); G(4/5);



DE
G
QN
DE






A(3/5); QN(3/5)



(3/5)
(4/5)
(4/5)
(4/5)



 



B27


1° Anchor






1° Anchor






RHK






FYLWMIVA













(SEQ ID NO: 55)


 



B44


1° Anchor






1° Anchor






ED






FWYLIMVA













(SEQ ID NO: 56)


 



B58


1° Anchor






1° Anchor






ATS






FWYLIVMA













(SEQ ID NO: 57)


 



B62


1° Anchor






1° Anchor






QLIVMP






FWYMIVLA






(SEQ ID NO: 58)






(SEQ ID NO: 59)










Italicized residues indicate less preferred or “tolerated” residues


TABLE IV (E): HLA Class I Motifs










POSITION:





























9













or





1
2
3
4
5
6
7
8
C-terminus
C-terminus





A1 9-mer
preferred
GFYW
1° Anchor
DEA
YFW

P
DEQN
YFW
1° Anchor





(SEQ ID
STM




(SEQ ID

Y





NO: 90)





NO: 91)






deleterious
DE

RHKLIVMP
A
G
A










(SEQ ID













NO: 132)









 


A1 9-mer
preferred
GRHK
ASTCLIVM
1° Anchor
GSTC

ASTC
LIVM
DE
1° Anchor





(SEQ ID
(SEQ ID
DEAS
(SEQ ID

(SEQ ID
(SEQ ID

Y





NO: 92)
NO: 93)

NO: 94)

NO: 95)
NO: 89)






deleterious
A
RHKDEPYFW
(SEQ ID
DE
PQN
RHK
PG
GP







(SEQ ID
NO: 60)












NO: 102)










 


A1
preferred
YFW
1° Anchor
DEAQN
A
YFWQN

PASTC
GDE
P
1° Anchor


10-mer


STM
(SEQ ID

(SEQ ID

(SEQ ID


Y






NO: 96)

NO: 97)

NO: 98)






deleterious
GP

RHKGLIVM
DE
RHK
QNA
RHKYFW
RHK
A







(SEQ ID



(SEQ ID









NO: 79)



NO: 100)





 


A1
preferred
YFW
STCLIVM
1° Anchor
A
YFW

PG
G
YFW
1° Anchor


10-mer


(SEQ ID
DEAS






Y





NO: 101)
(SEQ ID













NO: 60)










deleterious
RHK
RHKDEPY


P
G

PRHK
QN






FW





(SEQ ID







(SEQ ID





NO: 103)







NO: 102)










 


A2.1
preferred
YFW
1° Anchor
YFW
STC
YFW

A
P
1° Anchor



9-mer


LMIVQAT






VLIMAT




deleterious
DEP
(SEQ ID
DERKH


RKH
DERKH

(SEQ ID






NO: 104)
(SEQ ID



(SEQ ID

NO: 62)







NO: 105)



NO: 105)





 


A2.1
preferred
AYFW
1° Anchor
LVIM
G

G

FYWL

1° Anchor


10-mer

(SEQ ID
LMIVQAT
(SEQ




VIM

VLIMAT




NO: 114)
(SEQ ID NO: 104)
ID




(SEQ ID

(SEQ ID NO: 62)






NO: 91)




NO: 106)





deleterious
DEP

DE
RKHA
P

RKH
DERKH
RKH








(SEQ ID



(SEQ ID









NO: 107)



NO: 105)




 


A3
preferred
RHK
1° Anchor
YFW
PRHKYFW
A
YFW

P
1° Anchor






LMVISATFCGD

(SEQ ID




KYRHFA






(SEQ ID NO: 108)

NO: 109)




(SEQ ID













NO: 64)




deleterious
DEP

DE









 


A11
preferred
A
1° Anchor
YFW
YFW
A
YFW
YFW
P
1° Anchor






VTLMISAGNCDF






KRYH






(SEQ ID NO: 110)






(SEQ ID













NO: 66)




deleterious
DEP





A
G




 


A24
preferred
YFWRHK
1° Anchor

STC


YFW
YFW
1° Anchor



9-mer

(SEQ ID
YFWM






FLIW





NO: 111)
(SEQ ID NO: 67)






(SEQ ID













NO: 68)




deleterious
DEG

DE
G
QNP
DERHK
G
AQN











(SEQ ID













NO: 112)






 


A24 10-mer
preferred

1° Anchor

P
YFWP

P


1° Anchor





YFWM


(SEQ ID




FLIW





(SEQ ID NO: 67)


NO: 113)




(SEQ ID NO: 68)



deleterious


GDE
QN
RHK
DE
A
QN
DEA



 


A3101
preferred
RHK
1° Anchor
YFW
P

YFW
YFW
AP
1° Anchor






MVTALIS






RK




deleterious
DEP
(SEQ ID NO: 69)
DE

ADE
DE
DE
DE




 


A3301
preferred

1° Anchor
YFW



AYFW

1° Anchor






MVALFIST




(SEQ ID

RK






(SEQ ID NO: 70




NO: 114)






deleterious
GP

DE









 


A6801
preferred
YFWSTC
1° Anchor


YFWLIVM

YFW
P
1° Anchor





(SEQ ID NO: 115)
AVTMSLI


(SEQ ID



RK






(SEQ ID


NO: 116)










NO: 71)











deleterious
GP

DEG

RHK


A




 


B0702
preferred
RHKFWY
1° Anchor
RHK

RHK
RHK
RHK
PA
1° Anchor





(SEQ ID NO: 117)
P






LMFWYAIV













(SEQ ID NO: 72)




deleterious
DEQNP

DEP
DE
DE
GDE
QN
DE






(SEQ ID NO: 118)











 


B3501
preferred
FWYLIVM
1° Anchor
FWY



FWY

1° Anchor





(SEQ ID NO: 119)
P






LMFWYIVA













(SEQ ID NO: 73)




deleterious
AGP



G
G






 


B51
preferred
LIVMFWY
1° Anchor
FWY
STC
FWY

G
FWY
1° Anchor





(SEQ ID NO: 121)
P






LIVFWYAM (SEQ













ID NO: 74)




deleterious
AGPDERHKSTC



DE
G
DEQN
GDE






(SEQ ID NO: 122)





(SEQ ID













NO: 91)





 


B5301
preferred
LIVMFWY
1° Anchor
FWY
STC
FWY

LIVMFWY
FWY
1° Anchor





(SEQ ID NO: 121)
P




(SEQ ID

IMFWYALV











NO: 121)

(SEQ ID NO: 123




deleterious
AGPQN




G
RHKQN
DE






(SEQ ID NO: 124)





(SEQ ID













NO: 125)





 


B5401
preferred
FWY
1° Anchor
FWYLIVM

LIVM

ALIVM
FWYAP
1° Anchor






P
(SEQ ID



(SEQ ID
(SEQ ID
ATIVLMFWY







NO: 119)



NO: 126)
NO: 127)
(SEQ ID NO: 76




deleterious
GPQNDE

GDESTC

RHKDE
DE
QNDGE
DE






(SEQ ID NO: 128)

(SEQ ID

(SEQ ID

(SEQ ID









NO: 129)

NO: 130)

NO: 131)










Italicized residues indicate less preferred or “tolerated” residues. The information in this Table is specific for 9-mers unless otherwise specified.













TABLE V







101P3A11-V1-A1-9mers










Start
Subsequence
Score





211
GLDSLLISF
25.000
Portion of SEQ


30
LAFPLCSLY
5.000
ID NO: 28; each


2
MVDPNGNES
5.000
start position is


22
GLEEAQFWL
4.500
specified - the


213
DSLLISFSY
3.750
length of each


42
VLGNLTIIY
2.500
peptide is 9


246
HVCAVFIFY
2.500
amino acids, the


112
GMESTVLLA
2.250
end position for


58
LHEPMYIFL
2.250
each peptide is


7
GNESSATYF
2.250
the start position


260
LSMVHRFSK
1.500
plus eight


115
STVLLAMAF
1.250


191
ACDDIRVNV
1.000


159
MAPLPVFIK
1.000


75
LISTSSMPK
1.000


173
RSNILSHSY
0.750


79
SSMPKMLAI
0.750


71
GIDILISTS
0.500


135
HATVLTLPR
0.500


118
LLAMAFDRY
0.500


117
VLLAMAFDR
0.500


45
NLTIIYIVR
0.500


232
TREAQAKAF
0.450


181
YCLHQDVMK
0.400


138
VLTLPRVTK
0.400


184
HQDVMKLAC
0.375


139
LTLPRVTKI
0.250


6
NGNESSATY
0.250


53
RTEHSLHEP
0.225


257
FIGLSMVHR
0.200


57
SLHEPMYIF
0.200


243
CVSHVCAVF
0.200


146
KIGVAAVVR
0.200


126
YVAICHPLR
0.200


157
ALMAPLPVF
0.200


249
AVFIFYVPF
0.200


288
VLNPIVYGV
0.200


160
APLPVFIKQ
0.125


274
LPVILANIY
0.125


96
QFDACLLQI
0.125


12
ATYFILIGL
0.125


272
SPLPVILAN
0.125


284
LVPPVLNPI
0.100


158
LMAPLPVFI
0.100


129
ICHPLRHAT
0.100


9
ESSATYFIL
0.075


177
LSHSYCLHQ
0.075


91
NSTTIQFDA
0.075


217
ISFSYLLIL
0.075


56
HSLHEPMYI
0.075


219
FSYLLILKT
0.075


271
DSPLPVILA
0.075


10
SSATYFILI
0.075


78
TSSMPKMLA
0.075


69
LSGIDILIS
0.075


286
PPVLNPIVY
0.062


163
PVFIKQLPF
0.050


63
YIFLCMLSG
0.050


254
YVPFIGLSM
0.050


46
LTIIYIVRT
0.050


182
CLHQDVMKL
0.050


165
FIKQLPFCR
0.050


289
LNPIVYGVK
0.050


269
RRDSPLPVI
0.050


216
LISFSYLLI
0.050


234
EAQAKAFGT
0.050


127
VAICHPLRH
0.050


66
LCMLSGIDI
0.050


84
MLAIFWFNS
0.050


98
DACLLQIFA
0.050


55
EHSLHEPMY
0.050


277
ILANIYLLV
0.050


241
GTCVSHVCA
0.050


20
LPGLEEAQF
0.050


101
LLQIFAIHS
0.050


136
ATVLTLPRV
0.050


283
LLVPPVLNP
0.050


156
AALMAPLPV
0.050


251
FIFYVPFIG
0.050


261
SMVHRFSKR
0.050


99
ACLLQIFAI
0.050


11
SATYFILIG
0.050


198
NVVYGLIVI
0.050


34
LCSLYLIAV
0.050


68
MLSGIDILI
0.050


40
IAVLGNLTI
0.050


206
IISAIGLDS
0.050


204
IVIISAIGL
0.050


218
SFSYLLILK
0.050


189
KLACDDIRV
0.050


209
AIGLDSLLI
0.050


247
VCAVFIFYV
0.050


93
TTIQFDACL
0.050


23
LEEAQFWLA
0.045


298
TKEIRQRIL
0.045


35
CSLYLIAVL
0.030


76
ISTSSMPKM
0.030


114
ESTVLLAMA
0.030


244
VSHVCAVFI
0.030


92
STTIQFDAC
0.025










101P3A11-V2-A1-9mers










Start
Subsequence
Score





7
VLASGVTLR
0.100
Portion of SEQ ID


18
SSWPISICW
0.075
NO: 30; each start


22
ISICWFLLC
0.075
position is


23
SICWFLLCS
0.050
specified - the


28
LLCSTQLSM
0.050
length of each


8
LASGVTLRC
0.050
peptide is 9 amino


15
RCPSSWPIS
0.020
acids, the end


6
AVLASGVTL
0.020
position for each


3
YLIAVLASG
0.020
peptide is the start


11
GVTLRCPSS
0.020
position plus eight


1
SLYLIAVLA
0.020


16
CPSSWPISI
0.013


27
FLLCSTQLS
0.010


5
IAVLASGVT
0.010


4
LIAVLASGV
0.010


14
LRCPSSWPI
0.005


21
PISICWFLL
0.005


19
SWPISICWF
0.005


20
WPISICWFL
0.003


2
LYLIAVLAS
0.003


12
VTLRCPSSW
0.003


10
SGVTLRCPS
0.003


9
ASGVTLRCP
0.002


17
PSSWPISIC
0.002


24
ICWFLLCST
0.001


29
LCSTQLSME
0.001


25
CWFLLCSTQ
0.001


26
WFLLCSTQL
0.001


13
TLRCPSSWP
0.000










101P3A11-V3-A1-9mers










Start
Subsequence
Score





1
QFDACLLQM
0.125
Portion of SEQ ID


3
DACLLQMFA
0.050
NO: 32; each start


4
ACLLQMFAI
0.050
position is


6
LLQMFAIHS
0.050
specified - the


5
CLLQMFAIH
0.020
length of each


8
QMFAIHSLS
0.005
peptide is 9 amino


2
FDACLLQMF
0.005
acids, the end


9
MFAIHSLSG
0.003
position for each


7
LQMFAIHSL
0.002
peptide is the start





position plus eight
















TABLE VI







101P3A11-V1-A1-10mers










Start
Subsequence
Score





158
LMAPLPVFIK
5.000
Portion of SEQ ID


2
MVDPNGNESS
5.000
NO: 28; each start


79
SSMPKMLAIF
3.000
position is


192
CDDIRVNVVY
2.500
specified - the


41
AVLGNLTIIY
2.500
length of each


23
LEEAQFWLAF
2.250
peptide is 10


298
TKEIRQRILR
2.250
amino acids, the


53
RTEHSLHEPM
2.250
end position for


58
LHEPMYIFLC
2.250
each peptide is the


112
GMESTVLLAM
2.250
start position plus


288
VLNPIVYGVK
2.000
nine


217
ISFSYLLILK
1.500


259
GLSMVHRFSK
1.000


74
ILISTSSMPK
1.000


22
GLEEAQFWLA
0.900


114
ESTVLLAMAF
0.750


244
VSHVCAVFIF
0.750


285
VPPVLNPIVY
0.625


191
ACDDIRVNVV
0.500


117
VLLAMAFDRY
0.500


211
GLDSLLISFS
0.500


116
TVLLAMAFDR
0.500


71
GIDILISTSS
0.500


29
WLAFPLCSLY
0.500


30
LAFPLCSLYL
0.500


7
GNESSATYFI
0.450


137
TVLTLPRVTK
0.400


56
HSLHEPMYIF
0.300


139
LTLPRVTKIG
0.250


96
QFDACLLQIF
0.250


129
ICHPLRHATV
0.200


284
LVPPVLNPIV
0.200


242
TCVSHVCAVF
0.200


156
AALMAPLPVF
0.200


248
CAVFIFYVPF
0.200


19
GLPGLEEAQF
0.200


260
LSMVHRFSKR
0.150


210
IGLDSLLISF
0.125


162
LPVFIKQLPF
0.125


44
GNLTIIYIVR
0.125


77
STSSMPKMLA
0.125


245
SHVCAVFIFY
0.125


212
LDSLLISFSY
0.125


283
LLVPPVLNPI
0.100


257
FIGLSMVHRF
0.100


232
TREAQAKAFG
0.090


9
ESSATYFILI
0.075


10
SSATYFILIG
0.075


69
LSGIDILIST
0.075


271
DSPLPVILAN
0.075


78
TSSMPKMLAI
0.075


272
SPLPVILANI
0.050


216
LISFSYLLIL
0.050


273
PLPVILANIY
0.050


224
ILKTVLGLTR
0.050


126
YVAICHPLRH
0.050


106
AIHSLSGMES
0.050


199
VVYGLIVIIS
0.050


269
RRDSPLPVIL
0.050


94
TIQFDACLLQ
0.050


25
EAQFWLAFPL
0.050


92
STTIQFDACL
0.050


215
LLISFSYLLI
0.050


54
TEHSLHEPMY
0.050


42
VLGNLTIIYI
0.050


39
LIAVLGNLTI
0.050


205
VIISAIGLDS
0.050


159
MAPLPVFIKQ
0.050


68
MLSGIDILIS
0.050


36
SLYLIAVLGN
0.050


100
CLLQIFAIHS
0.050


57
SLHEPMYIFL
0.050


65
FLCMLSGIDI
0.050


203
LIVIISAIGL
0.050


276
VILANIYLLV
0.050


261
SMVHRFSKRR
0.050


208
SAIGLDSLLI
0.050


246
HVCAVFIFYV
0.050


176
ILSHSYCLHQ
0.050


290
NPIVYGVKTK
0.050


196
RVNVVYGLIV
0.050


11
SATYFILIGL
0.050


251
FIFYVPFIGL
0.050


98
DACLLQIFAI
0.050


222
LLILKTVLGL
0.050


181
YCLHQDVMKL
0.050


229
LGLTREAQAK
0.050


155
GAALMAPLPV
0.050


103
QIFAIHSLSG
0.050


209
AIGLDSLLIS
0.050


35
CSLYLIAVLG
0.030


110
LSGMESTVLL
0.030


83
KMLAIFWFNS
0.025


241
GTCVSHVCAV
0.025


172
CRSNILSHSY
0.025


270
RDSPLPVILA
0.025


6
NGNESSATYF
0.025


226
KTVLGLTREA
0.025


134
RHATVLTLPR
0.025


136
ATVLTLPRVT
0.025










101P3A11-V2-A1-10mers










Start
Subsequence
Score





19
SSWPISICWF
0.150
Portion of SEQ ID


7
AVLASGVTLR
0.100
NO: 30; each start


23
ISICWFLLCS
0.075
position is


28
FLLCSTQLSM
0.050
specified - the


2
SLYLIAVLAS
0.050
length of each


8
VLASGVTLRC
0.050
peptide is 10


16
RCPSSWPISI
0.050
amino acids, the


1
CSLYLIAVLA
0.030
end position for


6
IAVLASGVTL
0.020
each peptide is the


10
ASGVTLRCPS
0.015
start position plus


21
WPISICWFLL
0.013
nine


12
GVTLRCPSSW
0.010


24
SICWFLLCST
0.010


4
YLIAVLASGV
0.010


15
LRCPSSWPIS
0.010


5
LIAVLASGVT
0.010


18
PSSWPISICW
0.008


22
PISICWFLLC
0.005


11
SGVTLRCPSS
0.005


17
CPSSWPISIC
0.003


29
LLCSTQLSME
0.001


14
TLRCPSSWPI
0.001


25
ICWFLLCSTQ
0.001


9
LASGVTLRCP
0.001


3
LYLIAVLASG
0.001


27
WFLLCSTQLS
0.001


26
CWFLLCSTQL
0.001


20
SWPISICWFL
0.001


13
VTLRCPSSWP
0.000










101P3A11-V3-A1-10mers










Start
Subsequence
Score





2
QFDACLLQMF
0.250
Portion of SEQ ID


4
DACLLQMFAI
0.050
NO: 32; each start


6
CLLQMFAIHS
0.050
position is specified - 


9
QMFAIHSLSG
0.025
the length of each


5
ACLLQMFAIH
0.020
peptide is 10 amino


7
LLQMFAIHSL
0.010
acids, the end


1
IQFDACLLQM
0.007
position for each


3
FDACLLQMFA
0.003
peptide is the start


8
LQMFAIHSLS
0.002
postion plus nine


10
MFAIHSLSGM
0.001
















TABLE VII







101P3A11-V1-A2-9mers










Start
Subsequence
Score





214
SLLISFSYL
825.977
Portion of SEQ


288
VLNPIVYGV
271.948
ID NO: 28; each


189
KLACDDIRV
243.432
start position is


29
WLAFPLCSL
226.014
specified - the


247
VCAVFIFYV
215.192
length of each


22
GLEEAQFWL
178.815
peptide is 9


277
ILANIYLLV
177.358
amino acids, the


221
YLLILKTVL
149.071
end position for


215
LLISFSYLL
138.001
each peptide is


15
FILIGLPGL
114.985
the start position


158
LMAPLPVFI
70.450
plus eight


280
NIYLLVPPV
70.387


109
SLSGMESTV
69.552


83
KMLAIFWFN
54.625


182
CLHQDVMKL
49.134


26
AQFWLAFPL
46.480


223
LILKTVLGL
42.494


276
VILANIYLL
42.494


38
YLIAVLGNL
29.382


67
CMLSGIDIL
26.377


119
LAMAFDRYV
25.398


202
GLIVIISAI
23.995


307
RLFHVATHA
18.382


68
MLSGIDILI
17.736


86
AIFWFNSTT
14.407


50
YIVRTEHSL
13.512


175
NILSHSYCL
10.868


168
QLPFCRSNI
10.433


61
PMYIFLCML
9.493


102
LQIFAIHSL
8.469


255
VPFIGLSMV
6.568


121
MAFDRYVAI
5.605


84
MLAIFWFNS
4.747


199
VVYGLIVII
4.683


161
PLPVFIKQL
4.108


305
ILRLFHVAT
3.659


216
LISFSYLLI
3.658


156
AALMAPLPV
3.574


284
LVPPVLNPI
3.569


99
ACLLQIFAI
3.361


41
AVLGNLTII
3.185


204
IVIISAIGL
3.178


94
TIQFDACLL
2.937


32
FPLCSLYLI
2.666


136
ATVLTLPRV
2.222


12
ATYFILIGL
2.184


111
SGMESTVLL
2.115


139
LTLPRVTKI
2.096


254
YVPFIGLSM
2.000


304
RILRLFHVA
1.969


34
LCSLYLIAV
1.775


39
LIAVLGNLT
1.742


219
FSYLLILKT
1.647


44
GNLTIIYIV
1.584


120
AMAFDRYVA
1.471


43
LGNLTIIYI
1.465


209
AIGLDSLLI
1.435


201
YGLIVIISA
1.270


282
YLLVPPVLN
1.268


93
TTIQFDACL
1.127


8
NESSATYFI
1.116


242
TCVSHVCAV
1.044


198
NVVYGLIVI
0.861


217
ISFSYLLIL
0.827


191
ACDDIRVNV
0.745


105
FAIHSLSGM
0.730


244
VSHVCAVFI
0.637


79
SSMPKMLAI
0.580


117
VLLAMAFDR
0.544


112
GMESTVLLA
0.528


273
PLPVILANI
0.528


35
CSLYLIAVL
0.487


101
LLQIFAIHS
0.481


70
SGIDILIST
0.459


143
RVTKIGVAA
0.435


151
AVVRGAALM
0.435


66
LCMLSGIDI
0.428


251
FIFYVPFIG
0.415


46
LTIIYIVRT
0.405


63
YIFLCMLSG
0.401


113
MESTVLLAM
0.378


169
LPFCRSNIL
0.360


85
LAIFWFNST
0.334


227
TVLGLTREA
0.322


154
RGAALMAPL
0.321


197
VNVVYGLIV
0.316


285
VPPVLNPIV
0.316


128
AICHPLRHA
0.314


150
AAVVRGAAL
0.297


208
SAIGLDSLL
0.297


77
STSSMPKML
0.297


57
SLHEPMYIF
0.288


207
ISAIGLDSL
0.267


157
ALMAPLPVF
0.260


40
IAVLGNLTI
0.246


36
SLYLIAVLG
0.238


18
IGLPGLEEA
0.230


275
PVILANIYL
0.226


187
VKMLACDDI
0.220


100
CLLQIFAIH
0.215










101P3A11-V2-A2-9mers










Start
Subsequence
Score





20
WPISICWFL
26.460
Portion of SEQ


4
LIAVLASGV
16.258
ID NO: 30; each


1
SLYLIAVLA
15.898
start position is


28
LLCSTQLSM
8.446
specified - the


6
AVLASGVTL
6.916
length of each


24
ICWFLLCST
1.579
peptide is 9


27
FLLCSTQLS
1.268
amino acids, the


3
YLIAVLASG
0.788
end position for


21
PISICWFLL
0.637
each peptide is


26
WFLLCSTQL
0.252
the start position


8
LASGVTLRC
0.117
plus eight


22
ISICWFLLC
0.105


23
SICWFLLCS
0.090


16
CPSSWPISI
0.068


7
VLASGVTLR
0.058


14
LRCPSSWPI
0.018


5
IAVLASGVT
0.009


11
GVTLRCPSS
0.007


12
VTLRCPSSW
0.007


13
TLRCPSSWP
0.006


18
SSWPISICW
0.004


17
PSSWPISIC
0.001


10
SGVTLRCPS
0.000


29
LCSTQLSME
0.000


15
RCPSSWPIS
0.000


2
LYLIAVLAS
0.000


19
SWPISICWF
0.000


9
ASGVTLRCP
0.000


25
CWFLLCSTQ
0.000










101P3A11-V3-A2-9mers










Start
Subsequence
Score





7
LQMFAIHSL
31.334
Portion of SEQ


4
ACLLQMFAI
3.361
ID NO: 32; each


6
LLQMFAIHS
0.481
start position is


5
CLLQMFAIH
0.215
specified - the


8
QMFAIHSLS
0.199
length of each


3
DACLLQMFA
0.028
peptide is 9


1
QFDACLLQM
0.003
amino acids, the


2
FDACLLQMF
0.001
end position for


9
MFAIHSLSG
0.000
each peptide is





the start position





plus eight
















TABLE VIII







101P3A11-V1-A2-10mers










Start
Subsequence
Score





57
SLHEPMYIFL
722.583
Portion of SEQ


118
LLAMAFDRYV
494.237
ID NO: 28; each


214
SLLISFSYLL
300.355
start position is


42
VLGNLTIIYI
224.357
specified - the


157
ALMAPLPVFI
212.307
length of each


251
FIFYVPFIGL
94.987
peptide is 10


276
VILANIYLLV
90.231
amino acids, the


222
LLILKTVLGL
83.527
end position for


101
LLQIFAIHSL
83.527
each peptide is


140
TLPRVTKIGV
69.552
the start position


254
YVPFIGLSMV
64.388
plus nine


95
IQFDACLLQI
62.741


246
HVCAVFIFYV
57.690


63
YIFLCMLSGI
56.155


65
FLCMLSGIDI
47.991


249
AVFIFYVPFI
42.727


283
LLVPPVLNPI
40.792


138
VLTLPRVTKI
40.792


38
YLIAVLGNLT
34.279


238
KAFGTCVSHV
28.772


67
CMLSGIDILI
27.879


235
AQAKAFGTCV
26.797


215
LLISFSYLLI
26.604


83
KMLAIFWFNS
26.114


84
MLAIFWFNST
24.070


22
GLEEAQFWLA
18.576


45
NLTIIYIVRT
17.140


219
FSYLLILKTV
15.371


304
RILRLFHVAT
14.407


143
RVTKIGVAAV
13.997


167
KQLPFCRSNI
13.698


182
CLHQDVMKLA
11.426


120
AMAFDRYVAI
11.302


30
LAFPLCSLYL
10.264


109
SLSGMESTVL
8.759


168
QLPFCRSNIL
8.759


228
VLGLTREAQA
8.446


302
RQRILRLFHV
7.149


190
LACDDIRVNV
6.733


206
IISAIGLDSL
5.628


181
YCLHQDVMKL
5.459


86
AIFWFNSTTI
5.308


243
CVSHVCAVFI
5.021


203
LIVIISAIGL
4.993


230
GLTREAQAKA
4.968


292
IVYGVKTKEI
4.966


216
LISFSYLLIL
4.709


160
APLPVFIKQL
4.510


284
LVPPVLNPIV
4.242


280
NIYLLVPPVL
3.854


26
AQFWLAFPLC
3.541


33
PLCSLYLIAV
3.519


299
KEIRQRILRL
3.344


75
LISTSSMPKM
2.671


201
YGLIVIISAI
2.666


196
RVNVVYGLIV
2.495


39
LIAVLGNLTI
2.439


241
GTCVSHVCAV
2.222


223
LILKTVLGLT
1.927


121
MAFDRYVAIC
1.678


21
PGLEEAQFWL
1.485


8
NESSATYFIL
1.482


17
LIGLPGLEEA
1.309


274
LPVILANIYL
1.304


221
YLLILKTVLG
1.268


287
PVLNPIVYGV
1.139


111
SGMESTVLLA
1.132


92
STTIQFDACL
1.127


100
CLLQIFAIHS
1.048


279
ANIYLLVPPV
1.044


128
AICHPLRHAT
1.025


155
GAALMAPLPV
0.966


90
FNSTTIQFDA
0.865


198
NVVYGLIVII
0.861


233
REAQAKAFGT
0.840


129
ICHPLRHATV
0.772


43
LGNLTIIYIV
0.728


191
ACDDIRVNVV
0.702


11
SATYFILIGL
0.682


85
LAIFWFNSTT
0.669


188
MKLACDDIRV
0.608


282
YLLVPPVLNP
0.583


272
SPLPVILANI
0.580


36
SLYLIAVLGN
0.548


112
GMESTVLLAM
0.528


149
VAAVVRGAAL
0.504


163
PVFIKQLPFC
0.448


117
VLLAMAFDRY
0.436


151
AVVRGAALMA
0.435


66
LCMLSGIDIL
0.405


213
DSLLISFSYL
0.404


113
MESTVLLAMA
0.378


211
GLDSLLISFS
0.377


1
MMVDPNGNES
0.375


29
WLAFPLCSLY
0.343


32
FPLCSLYLIA
0.339


60
EPMYIFLCML
0.338


93
TTIQFDACLL
0.297


80
SMPKMLAIFW
0.296


307
RLFHVATHAS
0.276










101P3A11-V2-A2-10mers










Start
Subsequence
Score





4
YLIAVLASGV
319.939
Portion of SEQ


28
FLLCSTQLSM
84.555
ID NO: 30; each


8
VLASGVTLRC
8.446
start position is


21
WPISICWFLL
6.325
specified - the


14
TLRCPSSWPI
5.947
length of each


24
SICWFLLCST
2.357
peptide is 10


2
SLYLIAVLAS
0.548
amino acids, the


6
IAVLASGVTL
0.504
end position for


20
SWPISICWFL
0.122
each peptide is


1
CSLYLIAVLA
0.120
the start position


5
LIAVLASGVT
0.093
plus nine


16
RCPSSWPISI
0.068


29
LLCSTQLSME
0.058


19
SSWPISICWF
0.051


17
CPSSWPISIC
0.031


22
PISICWFLLC
0.029


7
AVLASGVTLR
0.011


26
CWFLLCSTQL
0.011


23
ISICWFLLCS
0.007


13
VTLRCPSSWP
0.007


12
GVTLRCPSSW
0.007


25
ICWFLLCSTQ
0.001


27
WFLLCSTQLS
0.001


11
SGVTLRCPSS
0.000


10
ASGVTLRCPS
0.000


9
LASGVTLRCP
0.000


3
LYLIAVLASG
0.000


15
LRCPSSWPIS
0.000


18
PSSWPISICW
0.000










101P3A11-V3-A2-10mers










Start
Subsequence
Score





7
LLQMFAIHSL
83.257
Portion of SEQ


1
IQFDACLLQM
29.877
ID NO: 32; each


6
CLLQMFAIHS
1.048
start position is


9
QMFAIHSLSG
0.199
specified - the


3
FDACLLQMFA
0.175
length of each


4
DACLLQMFAI
0.145
peptide is 10


8
LQMFAIHSLS
0.048
amino acids, the


10
MFAIHSLSGM
0.013
end position for


5
ACLLQMFAIH
0.001
each peptide is


2
QFDACLLQMF
0.000
the start position





plus nine
















TABLE IX







101P3A11-V1-A3-9mers










Start
Subsequence
Score





230
GLTREAQAK
60.000
Portion of SEQ


138
VLTLPRVTK
30.000
ID NO: 28; each


57
SLHEPMYIF
20.250
start position is


211
GLDSLLISF
18.000
specified - the


261
SMVHRFSKR
18.000
length of each


117
VLLAMAFDR
18.000
peptide is 9 amino


45
NLTIIYIVR
12.000
acids, the end


118
LLAMAFDRY
12.000
position for each


215
LLISFSYLL
8.100
peptide is the start


22
GLEEAQFWL
8.100
position plus eight


42
VLGNLTIIY
8.000


157
ALMAPLPVF
6.750


202
GLIVIISAI
6.075


288
VLNPIVYGV
4.050


75
LISTSSMPK
4.000


112
GMESTVLLA
3.600


246
HVCAVFIFY
3.600


182
CLHQDVMKL
3.600


249
AVFIFYVPF
3.000


80
SMPKMLAIF
3.000


68
MLSGIDILI
2.700


214
SLLISFSYL
2.700


159
MAPLPVFIK
2.700


307
RLFHVATHA
1.500


29
WLAFPLCSL
1.350


61
PMYIFLCML
1.350


100
CLLQIFAIH
1.350


67
CMLSGIDIL
1.350


83
KMLAIFWFM
1.215


146
KIGVAAVVR
1.200


165
FIKQLPFCR
1.200


189
KLACDDIRV
1.200


221
YLLILKTVL
0.900


158
LMAPLPVFI
0.900


199
VVYGLIVII
0.675


12
ATYFILIGL
0.675


38
YLIAVLGNL
0.608


120
AMAFDRYVA
0.600


257
FIGLSMVHR
0.600


277
ILANIYLLV
0.600


168
QLPFCRSNI
0.600


187
VMKLACDDI
0.600


262
MVHRFSKRR
0.600


223
LILKTVLGL
0.540


291
PIVYGVKTK
0.450


260
LSMVHRFSK
0.450


283
LLVPPVLNP
0.405


276
VILANIYLL
0.405


126
YVAICHPLR
0.400


84
MLAIFWFNS
0.360


115
STVLLAMAF
0.300


305
ILRLFHVAT
0.300


280
NIYLLVPPV
0.300


109
SLSGMESTV
0.300


181
YCLHQDVMK
0.300


243
CVSHVCAVF
0.300


30
LAFPLCSLY
0.300


26
AQFWLAFPL
0.270


198
NVVYGLIVI
0.270


175
NILSHSYCL
0.270


101
LLQIFAIHS
0.240


139
LTLPRVTKI
0.203


297
KTKEIRQRI
0.203


41
AVLGNLTII
0.203


284
LVPPVLNPI
0.203


176
ILSHSYCLH
0.200


163
PVFIKQLPF
0.200


204
IVIISAIGL
0.180


36
SLYLIAVLG
0.150


86
AIFWFNSTT
0.150


48
IIYIVRTEH
0.150


93
TTIQFDACL
0.135


273
PLPVILANI
0.135


217
ISFSYLLIL
0.135


161
PLPVFIKQL
0.135


15
FILIGLPGL
0.135


209
AIGLDSLLI
0.120


216
LISFSYLLI
0.120


299
KEIRQRILR
0.108


50
YIVRTEHSL
0.090


304
RILRLFHVA
0.090


19
GLPGLEEAQ
0.090


135
HATVLTLPR
0.080


224
ILKTVLGLT
0.068


218
SFSYLLILK
0.060


94
TIQFDACLL
0.060


274
LPVILANIY
0.060


254
YVPFIGLSM
0.060


152
VVRGAALMA
0.060


300
EIRQRILRL
0.054


10
SSATYFILI
0.054


251
FIFYVPFIG
0.045


282
YLLVPPVLN
0.045


238
KAFGTCVSH
0.045


32
FPLCSLYLI
0.041


99
ACLLQIFAI
0.041


102
LQIFAIHSL
0.041


213
DSLLISFSY
0.041


33
PLCSLYLIA
0.040


46
LTIIYIVRT
0.034










101P3A11-V2-A3-9mers










Start
Subsequence
Score





7
VLASGVTLR
12.000
Portion of SEQ


1
SLYLIAVLA
1.500
ID NO: 30; each


28
LLCSTQLSM
0.400
start position is


6
AVLASGVTL
0.090
specified - the


3
YLIAVLASG
0.068
length of each


27
FLLCSTQLS
0.060
peptide is 9 amino


20
WPISICWFL
0.041
acids, the end


23
SICWFLLCS
0.036
position for each


16
CPSSWPISI
0.036
peptide is the start


13
TLRCPSSWP
0.030
position plus eight


22
ISICWFLLC
0.027


18
SSWPISICW
0.022


4
LIAVLASGV
0.020


21
PISICWFLL
0.018


12
VTLRCPSSW
0.015


11
GVTLRCPSS
0.012


8
LASGVTLRC
0.009


24
ICWFLLCST
0.007


19
SWPISICWF
0.003


14
LRCPSSWPI
0.003


26
WFLLCSTQL
0.001


5
IAVLASGVT
0.000


15
RCPSSWPIS
0.000


2
LYLIAVLAS
0.000


29
LCSTQLSME
0.000


17
PSSWPISIC
0.000


25
CWFLLCSTQ
0.000


10
SGVTLRCPS
0.000


9
ASGVTLRCP
0.000










101P3A11-V3-A3-9mers










Start
Subsequence
Score





5
CLLQMFAIH
0.900
Portion of SEQ ID


8
QMFAIHSLS
0.300
NO: 32; each start


6
LLQMFAIHS
0.240
position is specified -


7
LQMFAIHSL
0.041
the length of each


4
ACLLQMFAI
0.041
peptide is 9 amino


2
FDACLLQMF
0.003
acids, the end


3
DACLLQMFA
0.001
position for each


1
QFDACLLQM
0.001
peptide is the start


9
MFAIHSLSG
0.000
position plus eight
















TABLE X







101P3A11-V1-A3-10mers










Start
Subsequence
Score





158
LMAPLPVFIK
405.000
Portion of SEQ


259
GLSMVHRFSK
180.000
ID NO: 28; each


74
ILISTSSMPK
60.000
start postion is


117
VLLAMAFDRY
18.000
specified - the


288
VLNPIVYGVK
13.500
length of each


19
GLPGLEEAQF
9.000
peptide is 10


261
SMVHRFSKRR
9.000
amino acids, the


214
SLLISFSYLL
8.100
end position for


22
GLEEAQFWLA
8.100
each peptide is


224
ILKTVLGLTR
8.000
the start position


222
LLILKTVLGL
5.400
plus nine


137
TVLTLPRVTK
4.500


187
VMKLACDDIR
4.000


29
WLAFPLCSLY
4.000


283
LLVPPVLNPI
3.038


249
AVFIFYVPFI
2.700


112
GMESTVLLAM
2.700


251
FIFYVPFIGL
2.700


67
CMLSGIDILI
2.700


116
TVLLAMAFDR
1.800


42
VLGNLTIIYI
1.800


57
SLHEPMYIFL
1.800


138
VLTLPRVTKI
1.800


41
AVLGNLTIIY
1.800


215
LLISFSYLLI
1.800


83
KMLAIFWFNS
1.620


217
ISFSYLLILK
1.500


65
FLCMLSGIDI
1.200


101
LLQIFAIHSL
0.900


157
ALMAPLPVFI
0.900


109
SLSGMESTVL
0.900


84
MLAIFWFNST
0.900


36
SLYLIAVLGN
0.600


305
ILRLFHVATH
0.600


168
QLPFCRSNIL
0.600


230
GLTREAQAKA
0.600


120
AMAFDRYVAI
0.600


257
FIGLSMVHRF
0.600


216
LISFSYLLIL
0.540


63
YIFLCMLSGI
0.450


280
NIYLLVPPVL
0.450


290
NPIVYGVKTK
0.450


45
NLTIIYIVRT
0.450


140
TLPRVTKIGV
0.400


273
PLPVILANIY
0.400


80
SMPKMLAIFW
0.400


100
CLLQIFAIHS
0.360


132
PLRHATVLTL
0.360


86
AIFWFNSTTI
0.300


246
HVCAVFIFYV
0.270


95
IQFDACLLQI
0.270


282
YLLVPPVLNP
0.270


199
VVYGLIVIIS
0.270


194
DIRVNVVYGL
0.243


292
IVYGVKTKEI
0.225


182
CLHQDVMKLA
0.225


228
VLGLTREAQA
0.200


307
RLFHVATHAS
0.200


203
LIVIISAIGL
0.180


68
MLSGIDILIS
0.180


277
ILANIYLLVP
0.180


33
PLCSLYLIAV
0.180


211
GLDSLLISFS
0.180


295
GVKTKEIRQR
0.180


38
YLIAVLGNLT
0.150


198
NVVYGLIVII
0.135


16
ILIGLPGLEE
0.135


202
GLIVIISAIG
0.135


238
KAFGTCVSHV
0.135


167
KQLPFCRSNI
0.121


196
RVNVVYGLIV
0.120


176
ILSHSYCLHQ
0.120


39
LIAVLGNLTI
0.120


44
GNLTIIYIVR
0.108


56
HSLHEPMYIF
0.101


92
STTIQFDACL
0.090


244
VSHVCAVFIF
0.090


121
MAFDRYVAIC
0.090


206
IISAIGLDSL
0.090


81
MPKMLAIFWF
0.090


276
VILANIYLLV
0.090


241
GTCVSHVCAV
0.090


30
LAFPLCSLYL
0.090


260
LSMVHRFSKR
0.090


248
CAVFIFYVPF
0.090


26
AQFWLAFPLC
0.090


285
VPPVLNPIVY
0.080


231
LTREAQAKAF
0.075


156
AALMAPLPVF
0.068


151
AVVRGAALMA
0.060


243
CVSHVCAVFI
0.060


162
LPVFIKQLPF
0.060


143
RVTKIGVAAV
0.060


1
MMVDPNGNES
0.060


118
LLAMAFDRYV
0.060


245
SHVCAVFIFY
0.054


181
YCLHQDVMKL
0.054


93
TTIQFDACLL
0.045


304
RILRLFHVAT
0.045


47
TIIYIVRTEH
0.045










101P3A11-V2-A3-10mers










Start
Subsequence
Score





14
TLRCPSSWPI
1.800
Portion of SEQ ID


7
AVLASGVTLR
1.800
NO: 30; each start


2
SLYLIAVLAS
1.200
position is specified -


28
FLLCSTQLSM
0.600
the length of each


8
VLASGVTLRC
0.600
peptide is 10 amino


4
YLIAVLASGV
0.300
acids, the end


19
SSWPISICWF
0.113
position for each


12
GVTLRCPSSW
0.060
peptide is the start


22
PISICWFLLC
0.036
position plus nine


16
RCPSSWPISI
0.036


29
LLCSTQLSME
0.030


21
WPISICWFLL
0.027


24
SICWFLLCST
0.015


6
IAVLASGVTL
0.009


17
CPSSWPISIC
0.005


26
CWFLLCSTQL
0.003


5
LIAVLASGVT
0.003


20
SWPISICWFL
0.003


23
ISICWFLLCS
0.003


13
VTLRCPSSWP
0.002


1
CSLYLIAVLA
0.002


25
ICWFLLCSTQ
0.001


18
PSSWPISICW
0.000


10
ASGVTLRCPS
0.000


3
LYLIAVLASG
0.000


27
WFLLCSTQLS
0.000


11
SGVTLRCPSS
0.000


15
LRCPSSWPIS
0.000


9
LASGVTLRCP
0.000










101P3A11-V3-A3-10mers










Start
Subsequence
Score





7
LLQMFAIHSL
0.900
Portion of SEQ


6
CLLQMFAIHS
0.360
ID NO: 32; each


9
QMFAIHSLSG
0.200
start position is


1
IQFDACLLQM
0.090
specified - the


5
ACLLQMFAIH
0.009
length of each


4
DACLLQMFAI
0.008
peptide is 10


2
QFDACLLQMF
0.003
amino acids, the


8
LQMFAIHSLS
0.003
end position for


3
FDACLLQMFA
0.000
each peptide is


10
MFAIHSLSGM
0.000
the start position





plus nine
















TABLE XI







101P3A11-V1-A3-9mers










Start
Subsequence
Score





230
GLTREAQAK
1.200
Portion of SEQ


75
LISTSSMPK
0.800
ID NO: 28; each


159
MAPLPVFIK
0.600
start position is


126
YVAICHPLR
0.400
specified - the


218
SFSYLLILK
0.400
length of each


138
VLTLPRVTK
0.400
peptide is 9


117
VLLAMAFDR
0.360
amino acids, the


181
YCLHQDVMK
0.300
end position for


146
KIGVAAVVR
0.240
each peptide is


165
FIKQLPFCR
0.240
the start position plus


262
MVHRFSKRR
0.200
eight


45
NLTIIYIVR
0.160


260
LSMVHRFSK
0.120


261
SMVHRFSKR
0.120


299
KEIRQRILR
0.108


135
HATVLTLPR
0.080


257
FIGLSMVHR
0.080


196
RVNVVYGLI
0.060


143
RVTKIGVAA
0.060


198
NVVYSLIVI
0.060


204
IVIISAIGL
0.060


289
LNPIVYSVK
0.040


254
YVPFISLSM
0.040


12
ATYFILIGL
0.040


199
VVYSLIVII
0.040


152
VVRGAALMA
0.040


249
AVFIFYVPF
0.040


246
HVCAVFIFY
0.040


22
GLEEAQFWL
0.036


26
AQFWLAFPL
0.036


302
RQRILRLFH
0.036


291
PIVYGVKTK
0.030


297
KTKEIRQRI
0.030


115
STVLLAMAF
0.030


151
AVVRGAALM
0.030


41
AVLGNLTII
0.030


241
GTCVSHVCA
0.030


112
GMESTVLLA
0.024


189
KLACDDIRV
0.024


211
GLDSLLISF
0.024


307
RLFHVATHA
0.024


243
CVSHVCAVF
0.020


51
IVRTEHSLH
0.020


284
LVPPVLNPI
0.020


202
GLIVIISAI
0.018


125
RYVAICHPL
0.018


304
RILRLFHVA
0.018


136
ATVLTLPRV
0.015


139
LTLPRVTKI
0.015


93
TTIQFDACL
0.015


276
VILANIYLL
0.012


223
LILKTVLGL
0.012


215
LLISFSYLL
0.012


175
NILSHSYCL
0.012


295
GVKTKEIRQ
0.012


238
KAFGTCVSH
0.012


231
LTREAQAKA
0.010


144
VTKIGVAAV
0.010


99
ACLLQIFAI
0.009


102
LQIFAIHSL
0.009


163
PVFIKQLPF
0.008


252
IFYVPFIGL
0.008


182
CLHQDVMKL
0.008


216
LISFSYLLI
0.008


42
VLGNLTIIY
0.008


288
VLNPIVYGV
0.008


66
LCMLSGIDI
0.008


225
LKTVLGLTR
0.008


68
MLSGIDILI
0.008


277
ILANIYLLV
0.008


209
AIGLDSLLI
0.008


120
AMAFDRYVA
0.008


280
NIYLLVPPV
0.008


57
SLHEPMYIF
0.008


48
IIYIVRTEH
0.008


157
ALMAPLPVF
0.008


188
MKLACDDIR
0.006


294
YGVKTKEIR
0.006


275
PVILANIYL
0.006


67
CMLSGIDIL
0.006


148
GVAAVVRGA
0.006


281
IYLLVPPVL
0.006


221
YLLILKTVL
0.006


15
FILIGLPGL
0.006


214
SLLISFSYL
0.006


100
CLLQIFAIH
0.006


127
VAICHPLRH
0.006


32
FPLCSLYLI
0.006


247
VCAVFIFYV
0.006


40
IAVLGNLTI
0.006


156
AALMAPLPV
0.006


50
YIVRTEHSL
0.006


38
YLIAVLGNL
0.006


77
STSSMPKML
0.005


226
KTVLGLTRE
0.005


80
SMPKMLAIF
0.004


29
WLAFPLCSL
0.004


109
SLSGMESTV
0.004


30
LAFPLCSLY
0.004


187
VMKLACDDI
0.004










101P3A11-V2-A11-9mers










Start
Subsequence
Score





7
VLASGVTLR
0.080
Portion of SEQ


6
AVLASGVTL
0.030
ID NO: 30; each


12
VTLRCPSSW
0.015
start position is


28
LLCSTQLSM
0.008
specified - the


1
SLYLIAVLA
0.008
length of each


11
GVTLRCPSS
0.006
peptide is 9


20
WPISICWFL
0.006
amino acids, the


16
CPSSWPISI
0.004
end position for


4
LIAVLASGV
0.004
each peptide is


26
WFLLCSTQL
0.003
the start position


21
PISICWFLL
0.001
plus eight


2
LYLIAVLAS
0.001


23
SICWFLLCS
0.001


18
SSWPISICW
0.001


27
FLLCSTQLS
0.001


15
RCPSSWPIS
0.001


3
YLIAVLASG
0.001


13
TLRCPSSWP
0.000


14
LRCPSSWPI
0.000


8
LASGVTLRC
0.000


24
ICWFLLCST
0.000


5
IAVLASGVT
0.000


29
LCSTQLSME
0.000


19
SWPISICWF
0.000


22
ISICWFLLC
0.000


25
CWFLLCSTQ
0.000


10
SGVTLRCPS
0.000


9
ASGVTLRCP
0.000


17
PSSWPISIC
0.000










101P3A11-V3-A11-9mers










Start
Subsequence
Score





7
LQMFAIHSL
0.012
Portion of SEQ


4
ACLLQMFAI
0.009
ID NO: 32, each


5
CLLQMFAIH
0.006
start position is


1
QFDACLLQM
0.004
specified - the


3
DACLLQMFA
0.001
length of each


8
QMFAIHSLS
0.001
peptide is 9


6
LLQMFAIHS
0.001
amino acids, the


9
MFAIHSLSG
0.000
end position for


2
FDACLLQMF
0.000
each peptide is





the start position





plus eight
















TABLE XII







101P3A11-V1-A11-10mers










Start
Subsequence
Score





259
GLSMVHRFSK
3.600
Portion of SEQ


137
TVLTLPRVTK
3.000
ID NO: 28, each


116
TVLLAMAFDR
1.800
start position is


158
LMAPLPVFIK
1.200
specified - the


74
ILISTSSMPK
1.200
length of each


288
VLNPIVYGVK
0.400
peptide is 10


180
SYCLHQDVMK
0.400
amino acids, the


125
RYVAICHPLR
0.360
end position for


164
VFIKQLPFCR
0.180
each peptide is


224
ILKTVLGLTR
0.160
the start position plus


290
NPIVYSVKTK
0.150
nine


295
GVKTKEIRQR
0.120


196
RVNVVYGLIV
0.120


217
ISFSYLLILK
0.080


187
VMKLACDDIR
0.080


293
VYGVKTKEIR
0.080


44
GNLTIIYIVR
0.072


246
HVCAVFIFYV
0.060


151
AVVRGAALMA
0.060


148
GVAAVVRGAA
0.060


143
RVTKIGVAAV
0.060


261
SMVHRFSKRR
0.060


41
AVLGNLTIIY
0.060


302
RQRILRLFHV
0.054


126
YVAICHPLRH
0.040


249
AVFIFYVPFI
0.040


229
LGLTREAQAK
0.030


241
GTCVSHVCAV
0.030


53
RTEHSLHEPM
0.030


198
NVVYGLIVII
0.030


167
KQLPFCRSNI
0.027


134
RHATVLTLPR
0.024


112
GMESIVLLAM
0.024


95
IQFDACLLQI
0.024


22
GLEEAQFWLA
0.024


77
STSSMPKMLA
0.020


254
YVPFIGLSMV
0.020


292
IVYGVKTKEI
0.020


284
LVPPVLNPIV
0.020


243
CVSHVCAVFI
0.020


251
FIFYVPFIGL
0.016


93
TTIQFDACLL
0.015


186
DVMKLACDDI
0.012


222
LLILKTVLGL
0.012


230
GLTREAQAKA
0.012


155
GAALMAPLPV
0.012


214
SLLISFSYLL
0.012


253
FYVPFIGLSM
0.012


238
KAFGTCVSHV
0.012


276
VILANIYLLV
0.012


215
LLISFSYLLI
0.012


19
GLPGLEEAQF
0.012


203
LIVIISAIGL
0.012


67
CMLSGIDILI
0.012


92
STTIQFDACL
0.010


144
VTKIGVAAVV
0.010


30
LAFPLCSLYL
0.008


80
SMPKMLAIFW
0.008


280
NIYLLVPPVL
0.008


63
YIFLCMLSGI
0.008


57
SLHEPMYIFL
0.008


119
LAMAFDRYVA
0.008


199
VVYGLIVIIS
0.008


216
LISFSYLLIL
0.008


42
VLGNLTIIYI
0.008


255
VPFIGLSMVH
0.008


157
ALMAPLPVFI
0.008


200
VYGLIVIISA
0.008


39
LIAVLGNLTI
0.008


140
TLPRVTKIGV
0.008


298
TKEIRQRILR
0.008


65
FLCMLSGIDI
0.008


86
AIFWFNSTTI
0.008


260
LSMVHRFSKR
0.008


256
PFIGLSMVHR
0.006


145
TKIGVAAVVR
0.006


50
YIVRTEHSLH
0.006


162
LPVFIKQLPF
0.006


47
TIIYIVRTEH
0.006


265
RFSKRRDSPL
0.006


81
MPKMLAIFWF
0.006


37
LYLIAVLGNL
0.006


220
SYLLILKTVL
0.006


275
PVILANIYLL
0.006


175
NILSHSYCLH
0.006


181
YCLHQDVMKL
0.006


283
LLVPPVLNPI
0.006


32
FPLCSLYLIA
0.006


287
PVLNPIVYGV
0.006


235
AQAKAFGTCV
0.006


274
LPVILANIYL
0.006


49
IYIVRTEHSL
0.006


117
VLLAMAFDRY
0.006


208
SAIGLDSLLI
0.006


83
KMLAIFWFNS
0.005


299
KEIRQRILRL
0.005


231
LTREAQAKAF
0.005


226
KTVLGLTREA
0.005


305
ILRLFHVATH
0.004


101
LLQIFAIHSL
0.004










101P3A11-V2-A11-10mers










Start
Subsequence
Score





7
AVLASGVTLR
0.600
Portion of SEQ


12
GVTLRCPSSW
0.060
ID NO: 30; each


16
RCPSSWPISI
0.012
start position is


28
FLLCSTQLSM
0.012
specified - the


21
WPISICWFLL
0.009
length of each


14
TLRCPSSWPI
0.008
peptide is 10


4
YLIAVLASGV
0.006
amino acids, the


6
IAVLASGVTL
0.003
end position for


2
SLYLIAVLAS
0.002
each peptide is


13
VTLRCPSSWP
0.002
the start


8
VLASGVTLRC
0.001
position plus


3
LYLIAVLASG
0.001
nine


26
CWFLLCSTQL
0.000


19
SSWPISICWF
0.000


25
ICWFLLCSTQ
0.000


5
LIAVLASGVT
0.000


24
SICWFLLCST
0.000


29
LLCSTQLSME
0.000


20
SWPISICWFL
0.000


1
CSLYLIAVLA
0.000


27
WFLLCSTQLS
0.000


17
CPSSWPISIC
0.000


22
PISICWFLLC
0.000


23
ISICWFLLCS
0.000


18
PSSWPISICW
0.000


11
SGVTLRCPSS
0.000


15
LRCPSSWPIS
0.000


10
ASGVTLRCPS
0.000


9
LASGVTLRCP
0.000










101P3A11-V3-A11-10mers










Start
Subsequence
Score





1
IQFDACLLQM
0.024
Portion of SEQ


7
LLQMFAIHSL
0.004
ID NO: 32; each


5
ACLLQMFAIH
0.003
start position is


2
QFDACLLQMF
0.002
specified - the


10
MFAIHSLSGM
0.002
length of each


4
DACLLQMFAI
0.002
peptide is 10


9
QMFAIHSLSG
0.002
amino acids, the


6
CLLQMFAIHS
0.001
end position for


8
LQMFAIHSLS
0.001
each peptide is


3
FDACLLQMFA
0.000
the start position





plus nine
















TABLE XIII







101P3A11-V1-A24-9mers










Start
Subsequence
Score





125
RYVAICHPL
840.000
Portion of


281
IYLLVPPVL
420.000
SEQ ID NO:


293
VYGVKTKEI
55.000
28; each start


31
AFPLCSLYL
30.000
position is


180
SYCLHQDVM
25.000
specified - the


252
IFYVPFIGL
24.000
length of each


89
WFNSTTIQF
15.000
peptide is 9


220
SYLLILKTV
10.500
amino acids,


154
RGAALMAPL
9.600
the end


62
MYIFLCMLS
9.000
position for


253
FYVPFIGLS
9.000
each peptide


38
YLIAVLGNL
8.400
is the start


250
VFIFYVPFI
7.500
position plus


64
IFLCMLSGI
7.500
eight


49
IYIVRTEHS
7.500


37
LYLIAVLGN
7.500


22
GLEEAQFWL
7.200


214
SLLISFSYL
7.200


111
SGMESTVLL
7.200


208
SAIGLDSLL
7.200


35
CSLYLIAVL
7.200


221
YLLILKTVL
7.200


200
VYGLIVIIS
7.000


150
AAVVRGAAL
6.000


67
CMLSGIDIL
6.000


131
HPLRHATVL
6.000


15
FILIGLPGL
6.000


175
NILSHSYCL
6.000


93
TTIQFDACL
6.000


215
LLISFSYLL
6.000


102
LQIFAIHSL
6.000


50
YIVRTEHSL
6.000


94
TIQFDACLL
6.000


276
VILANIYLL
6.000


204
IVIISAIGL
6.000


223
LILKTVLGL
6.000


12
ATYFILIGL
5.600


87
IFWFNSTTI
5.000


96
QFDACLLQI
5.000


169
LPFCRSNIL
4.800


26
AQFWLAFPL
4.800


182
CLHQDVMKL
4.400


196
RVNVVYGLI
4.200


297
KTKEIRQRI
4.032


9
ESSATYFIL
4.000


300
EIRQRILRL
4.000


266
FSKRRDSPL
4.000


29
WLAFPLCSL
4.000


110
LSGMESTVL
4.000


217
ISFSYLLIL
4.000


207
ISAIGLDSL
4.000


77
STSSMPKML
4.000


115
STVLLAMAF
3.600


284
LVPPVLNPI
3.024


7
GNESSATYF
3.000


157
ALMAPLPVF
3.000


258
IGLSMVHRF
3.000


80
SMPKMLAIF
3.000


243
CVSHVCAVF
2.800


57
SLHEPMYIF
2.400


211
GLDSLLISF
2.400


202
GLIVIISAI
2.100


249
AVFIFYVPF
2.000


20
LPGLEEAQF
2.000


139
LTLPRVTKI
1.980


79
SSMPKMLAI
1.800


41
AVLGNLTII
1.500


32
FPLCSLYLI
1.500


66
LCMLSGIDI
1.500


99
ACLLQIFAI
1.500


40
IAVLGNLTI
1.500


198
NVVYGLIVI
1.500


56
HSLHEPMYI
1.500


168
QLPFCRSNI
1.500


43
LGNLTIIYI
1.500


158
LMAPLPVFI
1.440


68
MLSGIDILI
1.400


60
EPMYIFLCM
1.260


10
SSATYFILI
1.200


121
MAFDRYVAI
1.200


199
VVYGLIVII
1.200


270
RDSPLPVIL
1.152


254
YVPFIGLSM
1.050


216
LISFSYLLI
1.000


244
VSHVCAVFI
1.000


187
VMKLACDDI
1.000


209
AIGLDSLLI
1.000


195
IRVNVVYGL
0.840


164
VFIKQLPFC
0.750


151
AVVRGAALM
0.750


73
DILISTSSM
0.750


105
FAIHSLSGM
0.750


58
LHEPMYIFL
0.720


13
TYFILIGLP
0.600


298
TKEIRQRIL
0.600


275
PVILANIYL
0.600


161
PLPVFIKQL
0.600


27
QFWLAFPLC
0.600


76
ISTSSMPKM
0.550


83
KMLAIFWFN
0.504










101P3A11-V2-A24-9mers










Start
Subsequence
Score





26
WFLLCSTQL
30.000
Portion of SEQ


20
WPISICWFL
8.400
ID NO: 30; each


2
LYLIAVLAS
7.500
start position is


6
AVLASGVTL
6.000
specified - the


19
SWPISICWF
3.000
length of each


16
CPSSWPISI
1.000
peptide is 9


28
LLCSTQLSM
0.500
amino acids, the


21
PISICWFLL
0.400
end position for


15
RCPSSWPIS
0.300
each peptide is


10
SGVTLRCPS
0.180
the start position


22
ISICWFLLC
0.180
plus eight


27
FLLCSTQLS
0.180


18
SSWPISICW
0.168


5
IAVLASGVT
0.150


12
VTLRCPSSW
0.150


8
LASGVTLRC
0.140


1
SLYLIAVLA
0.140


4
LIAVLASGV
0.120


14
LRCPSSWPI
0.120


24
ICWFLLCST
0.120


23
SICWFLLCS
0.100


11
GVTLRCPSS
0.100


3
YLIAVLASG
0.021


25
CWFLLCSTQ
0.012


9
ASGVTLRCP
0.010


29
LCSTQLSME
0.010


13
TLRCPSSWP
0.010


7
VLASGVTLR
0.010


17
PSSWPISIC
0.010










101P3A11-V3-A24-9mers










Start
Subsequence
Score





7
LQMFAIHSL
6.000
Portion of SEQ ID


1
QFDACLLQM
2.500
NO: 32; each start


4
ACLLQMFAI
1.500
position is


2
FDACLLQMF
0.288
specified - the


6
LLQMFAIHS
0.150
length of each


8
QMFAIHSLS
0.140
peptide is 9 amino


3
DACLLQMFA
0.120
acids, the end


9
MFAIHSLSG
0.050
position for each


5
CLLQMFAIH
0.018
peptide is the start





position plus eight
















TABLE XIV







101P3A11-V1-A24-10mers










Start
Subsequence
Score





37
LYLIAVLGNL
420.000
Portion of SEQ


220
SYLLILKTVL
360.000
ID NO: 28; each


49
IYIVRTEHSL
300.000
start position is


253
FYVPFISLSM
63.000
specified - the


265
RFSKRRDSPL
40.000
length of each


14
YFILIGLPGL
30.000
peptide is 10


96
QFDACLLQIF
14.400
amino acids, the


297
KTKEIRQRIL
9.600
end position for


31
AFPLCSLYLI
7.500
each peptide is


281
IYLLVPPVLN
7.500
the start position


168
QLPFCRSNIL
7.200
plus nine


213
DSLLISFSYL
7.200


160
APLPVFIKQL
7.200


25
EAQFWLAFPL
7.200


200
VYGLIVIISA
7.000


181
YCLHQDVMKL
6.600


274
LPVILANIYL
6.000


60
EPMYIFLCML
6.000


203
LIVIISAIGL
6.000


93
TTIQFDACLL
6.000


101
LLQIFAIHSL
6.000


28
FWLAFPLCSL
6.000


66
LCMLSGIDIL
6.000


214
SLLISFSYLL
6.000


174
SNILSHSYCL
6.000


222
LLILKTVLGL
6.000


194
DIRVNVVYGL
5.600


11
SATYFILIGL
5.600


280
NIYLLVPPVL
5.600


251
FIFYVPFIGL
4.800


34
LCSLYLIAVL
4.800


57
SLHEPMYIFL
4.800


30
LAFPLCSLYL
4.800


207
ISAIGLDSLL
4.800


210
IGLDSLLISF
4.320


242
TCVSHVCAVF
4.200


206
IISAIGLDSL
4.000


149
VAAVVRGAAL
4.000


109
SLSGMESTVL
4.000


216
LISFSYLLIL
4.000


92
STTIQFDACL
4.000


76
ISTSSMPKML
4.000


110
LSGMESTVLL
4.000


79
SSMPKMLAIF
3.600


6
NGNESSATYF
3.600


167
KQLPFCRSNI
3.600


283
LLVPPVLNPI
3.024


248
CAVFIFYVPF
3.000


162
LPVFIKQLPF
3.000


56
HSLHEPMYIF
3.000


19
GLPGLEEAQF
3.000


156
AALMAPLPVF
3.000


300
EIRQRILRLF
2.800


272
SPLPVILANI
2.520


104
IFAIHSLSGM
2.500


114
ESTVLLAMAF
2.400


231
LTREAQAKAF
2.400


67
CMLSGIDILI
2.100


201
YGLIVIISAI
2.100


257
FIGLSMVHRF
2.000


81
MPKMLAIFWF
2.000


88
FWFNSTTIQF
2.000


244
VSHVCAVFIF
2.000


198
NVVYGLIVII
1.800


53
RTEHSLHEPM
1.800


157
ALMAPLPVFI
1.800


197
VNVVYGLIVI
1.500


40
IAVLGNLTII
1.500


186
DVMKLACDDI
1.500


125
RYVAICHPLR
1.500


7
GNESSATYFI
1.500


215
LLISFSYLLI
1.500


208
SAIGLDSLLI
1.500


299
KEIRQRILRL
1.200


9
ESSATYFILI
1.200


95
IQFDACLLQI
1.200


138
VLTLPRVTKI
1.100


292
IVYGVKTKEI
1.100


112
GMESTVLLAM
1.050


65
FLCMLSGIDI
1.000


42
VLGNLTIIYI
1.000


98
DACLLQIFAI
1.000


249
AVFIFYVPFI
1.000


78
TSSMPKMLAI
1.000


243
CVSHVCAVFI
1.000


39
LIAVLGNLTI
1.000


86
AIFWFNSTTI
1.000


63
YIFLCMLSGI
1.000


120
AMAFDRYVAI
1.000


269
RRDSPLPVIL
0.960


150
AAVVRGAALM
0.750


62
MYIFLCMLSG
0.750


21
PGLEEAQFWL
0.720


239
AFGTCVSHVC
0.700


13
TYFILIGLPG
0.700


218
SFSYLLILKT
0.660


130
CHPLRHATVL
0.600


275
PVILANIYLL
0.600


124
DRYVAICHPL
0.560


75
LISTSSMPKM
0.550










101P3A11-V2-A24-10mers










Start
Subsequence
Score





20
SWPISICWFL
8.400
Portion of SEQ ID


21
WPISICWFLL
6.000
NO: 30; each start


6
IAVLASGVTL
6.000
position is specified -


26
CWFLLCSTQL
4.000
the length of each


16
RCPSSWPISI
3.000
peptide is 10 amino


19
SSWPISICWF
2.400
acids, the end


3
LYLIAVLASG
1.050
position for each


14
TLRCPSSWPI
1.000
peptide is the start


27
WFLLCSTQLS
0.900
position plus nine


28
FLLCSTQLSM
0.750


1
CSLYLIAVLA
0.210


4
YLIAVLASGV
0.180


23
ISICWFLLCS
0.150


11
SGVTLRCPSS
0.150


8
VLASGVTLRC
0.140


10
ASGVTLRCPS
0.120


24
SICWFLLCST
0.120


2
SLYLIAVLAS
0.100


17
CPSSWPISIC
0.100


12
GVTLRCPSSW
0.100


5
LIAVLASGVT
0.100


13
VTLRCPSSWP
0.015


7
AVLASGVTLR
0.015


18
PSSWPISICW
0.014


15
LRCPSSWPIS
0.012


25
ICWFLLCSTQ
0.012


22
PISICWFLLC
0.012


29
LLCSTQLSME
0.010


9
LASGVTLRCP
0.010










101P3A11-V3-A24-10mers










Start
Subsequence
Score





2
QFDACLLQMF
14.400
Portion of SEQ ID


7
LLQMFAIHSL
6.000
NO: 32; each


10
MFAIHSLSGM
2.500
start position is


4
DACLLQMFAI
1.000
specified - the


1
IQFDACLLQM
0.600
length of each


8
LQMFAIHSLS
0.210
peptide is 10


6
CLLQMFAIHS
0.150
amino acids, the


5
ACLLQMFAIH
0.018
end position for


3
FDACLLQMFA
0.012
each peptide is


9
QMFAIHSLSG
0.010
the start position





plus nine
















TABLE XV







101P3A11-V1-B7-9mers










Start
Subsequence
Score





169
LPFCRSNIL
80.000
Portion of SEQ


131
HPLRHATVL
80.000
ID NO: 28; each


60
EPMYIFLCM
60.000
start position is


141
LPRVTKISV
40.000
specified - the


300
EIRQRILRL
40.000
length of each


150
AAVVRGAAL
36.000
peptide is 9 amino


204
IVIISAIGL
20.000
acids, the end


151
AVVRSAALM
15.000
position for each


26
AQFWLAFPL
12.000
peptide is the start


208
SAISLDSLL
12.000
position plus eight


111
SGMESTVLL
12.000


12
ATYFILIGL
12.000


32
FPLCSLYLI
8.000


41
AVLGNLTII
6.000


29
WLAFPLCSL
6.000


254
YVPFIGLSM
5.000


152
VVRGAALMA
5.000


15
FILIGLPGL
4.000


50
YIVRTEHSL
4.000


102
LQIFAIHSL
4.000


276
VILANIYLL
4.000


110
LSGMESTVL
4.000


94
TIQFDACLL
4.000


93
TTIQFDACL
4.000


255
VPFIGLSMV
4.000


221
YLLILKTVL
4.000


77
STSSMPKML
4.000


35
CSLYLIAVL
4.000


182
CLHQDVMKL
4.000


215
LLISFSYLL
4.000


285
VPPVLNPIV
4.000


217
ISFSYLLIL
4.000


207
ISAIGLDSL
4.000


67
CMLSGIDIL
4.000


38
YLIAVLGNL
4.000


266
FSKRRDSPL
4.000


223
LILKTVLGL
4.000


175
NILSHSYCL
4.000


154
RGAALMAPL
4.000


214
SLLISFSYL
4.000


9
ESSATYFIL
4.000


105
FAIHSLSGM
3.000


275
PVILANIYL
2.000


4
DPNGNESSA
2.000


198
NVVYGLIVI
2.000


290
NPIVYGVKT
2.000


196
RVNVVYGLI
2.000


199
VVYGLIVII
2.000


284
LVPPVLNPI
2.000


156
AALMAPLPV
1.800


119
LAMAFDRYV
1.800


209
AIGLDSLLI
1.200


99
ACLLQIFAI
1.200


66
LCMLSGIDI
1.200


79
SSMPKMLAI
1.200


22
GLEEAQFWL
1.200


121
MAFDRYVAI
1.200


40
IAVLGNLTI
1.200


31
AFPLCSLYL
1.200


76
ISTSSMPKM
1.000


73
DILISTSSM
1.000


305
ILRLFHVAT
1.000


231
LTREAQAKA
1.000


252
IFYVPFISL
0.600


236
QAKAFGTCV
0.600


297
KTKEIRQRI
0.600


168
QLPFCRSNI
0.600


136
ATVLTLPRV
0.600


160
APLPVFIKQ
0.600


143
RVTKIGVAA
0.500


148
SVAAVVRGA
0.500


227
TVLGLTREA
0.500


137
TVLTLPRVT
0.500


51
IVRTEHSLH
0.500


149
VAAVVRGAA
0.450


128
AICHPLRHA
0.450


120
AMAFDRYVA
0.450


272
SPLPVILAN
0.400


216
LISFSYLLI
0.400


274
LPVILANIY
0.400


56
HSLHEPMYI
0.400


125
RYVAICHPL
0.400


195
IRVNVVYGL
0.400


270
RDSPLPVIL
0.400


43
LGNLTIIYI
0.400


158
LMAPLPVFI
0.400


81
MPKMLAIFW
0.400


187
VMKLACDDI
0.400


202
GLIVIISAI
0.400


281
IYLLVPPVL
0.400


161
PLPVFIKQL
0.400


68
MLSGIDILI
0.400


133
LRHATVLTL
0.400


139
LTLPRVTKI
0.400


61
PMYIFLCML
0.400


20
LPGLEEAQF
0.400


244
VSHVCAVFI
0.400


10
SSATYFILI
0.400


98
DACLLQIFA
0.300


235
AQAKAFGTC
0.300










101P3A11-V2-B7-9mers










Start
Subsequence
Score





20
WPISICWFL
80.000
Portion of SEQ


6
AVLASGVTL
60.000
ID NO: 30; each


16
CPSSWPISI
8.000
start position is


28
LLCSTQLSM
1.000
specified - the


21
PISICWFLL
0.400
length of each


26
WFLLCSTQL
0.400
peptide is 9 amino


8
LASGVTLRC
0.300
acids, the end


5
IAVLASGVT
0.300
position for each


4
LIAVLASGV
0.200
peptide is the start


13
TLRCPSSWP
0.150
position plus eight


22
ISICWFLLC
0.100


1
SLYLIAVLA
0.100


11
SVTLRCPSS
0.100


24
ICWFLLCST
0.100


14
LRCPSSWPI
0.040


9
ASGVTLRCP
0.030


10
SGVTLRCPS
0.030


27
FLLCSTQLS
0.020


18
SSWPISICW
0.020


12
VTLRCPSSW
0.020


23
SICWFLLCS
0.020


15
RCPSSWPIS
0.020


17
PSSWPISIC
0.015


7
VLASGVTLR
0.010


29
LCSTQLSME
0.010


3
YLIAVLASG
0.010


19
SWPISICWF
0.002


2
LYLIAVLAS
0.002


25
CWFLLCSTQ
0.001










101P3A11-V3-B7-9mers










Start
Subsequence
Score





7
LQMFAIHSL
12.000
Portion of SEQ


4
ACLLQMFAI
1.200
ID NO: 32; each


3
DACLLQMFA
0.300
start position is


1
QFDACLLQM
0.030
specified - the


8
QMFAIHSLS
0.020
length of each


6
LLQMFAIHS
0.020
peptide is 9 amino


5
CLLQMFAIH
0.010
acids, the end


2
FDACLLQMF
0.002
position for each


9
MFAIHSLSG
0.001
peptide is the start





position plus eight
















TABLE XVI







101P3A11-V1-B7-10mers










Start
Subsequence
Score





60
EPMYIFLCML
240.000
Portion of SEQ


160
APLPVFIKQL
240.000
ID NO: 28; each


274
LPVILANIYL
80.000
start position is


194
DIRVNVVYGL
40.000
specified - the


141
LPRVTKIGVA
20.000
length of each


149
VAAVVRGAAL
12.000
peptide is 10


30
LAFPLCSLYL
12.000
amino acids, the


11
SATYFILIGL
12.000
end position for


66
LCMLSGIDIL
12.000
each peptide is


25
EAQFWLAFPL
12.000
the start position


150
AAVVRGAALM
9.000
plus nine


272
SPLPVILANI
8.000


249
AVFIFYVPFI
6.000


251
FIFYVPFIGL
6.000


186
DVMKLACDDI
6.000


216
LISFSYLLIL
4.000


110
LSGMESTVLL
4.000


181
YCLHQDVMKL
4.000


93
TTIQFDACLL
4.000


297
KTKEIRQRIL
4.000


213
DSLLISFSYL
4.000


57
SLHEPMYIFL
4.000


168
QLPFCRSNIL
4.000


92
STTIQFDACL
4.000


206
IISAIGLDSL
4.000


203
LIVIISAIGL
4.000


222
LLILKTVLGL
4.000


280
NIYLLVPPVL
4.000


76
ISTSSMPKML
4.000


101
LLQIFAIHSL
4.000


132
PLRHATVLTL
4.000


174
SNILSHSYCL
4.000


214
SLLISFSYLL
4.000


207
ISAIGLDSLL
4.000


109
SLSGMESTVL
4.000


34
LCSLYLIAVL
4.000


157
ALMAPLPVFI
3.600


131
HPLRHATVLT
2.000


243
CVSHVCAVFI
2.000


32
FPLCSLYLIA
2.000


198
NVVYGLIVII
2.000


292
IVYGVKTKEI
2.000


4
DPNGNESSAT
2.000


275
PVILANIYLL
2.000


302
RQRILRLFHV
2.000


151
AVVRGAALMA
1.500


119
LAMAFDRYVA
1.350


120
AMAFDRYVAI
1.200


40
IAVLGNLTII
1.200


86
AIFWFNSTTI
1.200


98
DACLLQIFAI
1.200


208
SAIGLDSLLI
1.200


75
LISTSSMPKM
1.000


246
HVCAVFIFYV
1.000


284
LVPPVLNPIV
1.000


196
RVNVVYGLIV
1.000


143
RVTKIGVAAV
1.000


179
HSYCLHQDVM
1.000


254
YVPFIGLSMV
1.000


190
LACDDIRVNV
0.900


148
GVAAVVRGAA
0.750


135
HATVLTLPRV
0.600


28
FWLAFPLCSL
0.600


155
GAALMAPLPV
0.600


167
KQLPFCRSNI
0.600


235
AQAKAFGTCV
0.600


238
KAFGTCVSHV
0.600


268
KRRDSPLPVI
0.600


279
ANIYLLVPPV
0.600


152
VVRGAALMAP
0.500


51
IVRTEHSLHE
0.500


127
VAICHPLRHA
0.450


128
AICHPLRHAT
0.450


67
CMLSGIDILI
0.400


20
LPGLEEAQFW
0.400


124
DRYVAICHPL
0.400


299
KEIRQRILRL
0.400


81
MPKMLAIFWF
0.400


78
TSSMPKMLAI
0.400


138
VLTLPRVTKI
0.400


9
ESSATYFILI
0.400


265
RFSKRRDSPL
0.400


201
YGLIVIISAI
0.400


42
VLGNLTIIYI
0.400


37
LYLIAVLGNL
0.400


65
FLCMLSGIDI
0.400


283
LLVPPVLNPI
0.400


162
LPVFIKQLPF
0.400


215
LLISFSYLLI
0.400


130
CHPLRHATVL
0.400


285
VPPVLNPIVY
0.400


153
VRGAALMAPL
0.400


95
IQFDACLLQI
0.400


63
YIFLCMLSGI
0.400


14
YFILISLPSL
0.400


21
PGLEEAQFWL
0.400


220
SYLLILKTVL
0.400


49
IYIVRTEHSL
0.400


197
VNVVYGLIVI
0.400


39
LIAVLGNLTI
0.400










101P3A11-V2-B7-10mers










Start
Subsequence
Score





21
WPISICWFLL
80.000
Portion of SEQ


6
IAVLASGVTL
12.000
ID NO: 30; each


14
TLRCPSSWPI
4.000
start position is


17
CPSSWPISIC
3.000
specified - the


28
FLLCSTQLSM
1.000
length of each


16
RCPSSWPISI
0.400
peptide is 10


20
SWPISICWFL
0.400
amino acids, the


26
CWFLLCSTQL
0.400
end position for


4
YLIAVLASGV
0.200
each peptide is


7
AVLASGVTLR
0.150
the start position


8
VLASGVTLRC
0.100
plus nine


1
CSLYLIAVLA
0.100


5
LIAVLASGVT
0.100


24
SICWFLLCST
0.100


12
GVTLRCPSSW
0.100


10
ASGVTLRCPS
0.090


9
LASGVTLRCP
0.030


11
SGVTLRCPSS
0.020


19
SSWPISICWF
0.020


2
SLYLIAVLAS
0.020


23
ISICWFLLCS
0.020


13
VTLRCPSSWP
0.015


29
LLCSTQLSME
0.010


25
ICWFLLCSTQ
0.010


22
PISICWFLLC
0.010


18
PSSWPISICW
0.002


27
WFLLCSTQLS
0.002


15
LRCPSSWPIS
0.002


3
LYLIAVLASG
0.001










101P3A11-V3-B7-10mers










Start
Subsequence
Score





7
LLQMFAIHSL
4.000
Portion of SEQ ID


4
DACLLQMFAI
1.200
NO: 32; each start


1
IQFDACLLQM
1.000
position is


10
MFAIHSLSGM
0.100
specified - the


8
LQMFAIHSLS
0.060
length of each


5
ACLLQMFAIH
0.030
peptide is 10


6
CLLQMFAIHS
0.020
amino acids, the


3
FDACLLQMFA
0.010
end position for


9
QMFAIHSLSG
0.010
each peptide is the


2
QFDACLLQMF
0.001
start position plus





nine
















TABLE XVII







101P3A11-V1-B35-9mers










Start
Subsequence
Score





60
EPMYIFLCM
40.000
Portion of SEQ


274
LPVILANIY
40.000
ID NO: 28; each


20
LPGLEEAQF
30.000
start position is


81
MPKMLAIFW
30.000
specified - the


131
HPLRHATVL
20.000
length of each


169
LPFCRSNIL
20.000
peptide is 9


173
RSNILSHSY
20.000
amino acids, the


266
FSKRRDSPL
15.000
end position for


141
LPRVTKISV
12.000
each peptide is


213
DSLLISFSY
10.000
the start position


76
ISTSSMPKM
10.000
plus eight


32
FPLCSLYLI
8.000


110
LSGMESTVL
7.500


30
LAFPLCSLY
6.000


105
FAIHSLSGM
6.000


217
ISFSYLLIL
5.000


207
ISAIGLDSL
5.000


9
ESSATYFIL
5.000


35
CSLYLIAVL
5.000


297
KTKEIRQRI
4.800


285
VPPVLNPIV
4.000


255
VPFISLSMV
4.000


286
PPVLNPIVY
4.000


6
NGNESSATY
4.000


208
SAIGLDSLL
3.000


300
EIRQRILRL
3.000


150
AAVVRGAAL
3.000


56
HSLHEPMYI
3.000


121
MAFDRYVAI
2.400


254
YVPFIGLSM
2.000


4
DPNGNESSA
2.000


111
SGMESTVLL
2.000


290
NPIVYGVKT
2.000


272
SPLPVILAN
2.000


244
VSHVCAVFI
2.000


10
SSATYFILI
2.000


79
SSMPKMLAI
2.000


57
SLHEPMYIF
2.000


118
LLAMAFDRY
2.000


246
HVCAVFIFY
2.000


151
AVVRGAALM
2.000


73
DILISTSSM
2.000


42
VLGNLTIIY
2.000


154
RGAALMAPL
2.000


236
QAKAFGTCV
1.800


94
TIQFDACLL
1.500


182
CLHQDVMKL
1.500


40
IAVLGNLTI
1.200


187
VMKLACDDI
1.200


221
YLLILKTVL
1.000


215
LLISFSYLL
1.000


214
SLLISFSYL
1.000


115
STVLLAMAF
1.000


175
NILSHSYCL
1.000


67
CMLSGIDIL
1.000


38
YLIAVLSNL
1.000


93
TTIQFDACL
1.000


77
STSSMPKML
1.000


15
FILIGLPGL
1.000


26
AQFWLAFPL
1.000


243
CVSHVCAVF
1.000


276
VILANIYLL
1.000


204
IVIISAIGL
1.000


29
WLAFPLCSL
1.000


80
SMPKMLAIF
1.000


157
ALMAPLPVF
1.000


223
LILKTVLGL
1.000


249
AVFIFYVPF
1.000


102
LQIFAIHSL
1.000


258
IGLSMVHRF
1.000


179
HSYCLHQDV
1.000


12
ATYFILIGL
1.000


50
YIVRTEHSL
1.000


190
LACDDIRVN
0.900


196
RVNVVYGLI
0.800


69
LSGIDILIS
0.750


144
VTKIGVAAV
0.600


156
AALMAPLPV
0.600


189
KLACDDIRV
0.600


119
LAMAFDRYV
0.600


231
LIREAQAKA
0.600


209
AIGLDSLLI
0.600


22
GLEEAQFWL
0.600


271
DSPLPVILA
0.500


219
FSYLLILKT
0.500


78
TSSMPKMLA
0.500


114
ESTVLLAMA
0.500


108
HSLSGMEST
0.500


91
NSTTIQFDA
0.500


43
LGNLTIIYI
0.400


198
NVVYGLIVI
0.400


199
VVYGLIVII
0.400


216
LISFSYLLI
0.400


202
GLIVIISAI
0.400


284
LVPPVLNPI
0.400


158
LMAPLPVFI
0.400


68
MLSGIDILI
0.400


168
QLPFCRSNI
0.400


66
LCMLSGIDI
0.400


41
AVLGNLTII
0.400










101P3A11-V2-B35-9mers










Start
Subsequence
Score





20
WPISICWFL
20.000
Portion of SEQ


16
CPSSWPISI
8.000
ID NO: 30; each


18
SSWPISICW
2.500
start position is


28
LLCSTQLSM
2.000
specified - the


6
AVLASGVTL
1.000
length of each


12
VTLRCPSSW
0.500
peptide is 9


22
ISICWFLLC
0.500
amino acids, the


8
LASGVTLRC
0.300
end position for


5
IAVLASGVT
0.300
each peptide is


4
LIAVLASGV
0.200
the start position


15
RCPSSWPIS
0.200
plus eight


19
SWPISICWF
0.100


26
WFLLCSTQL
0.100


27
FLLCSTQLS
0.100


11
GVTLRCPSS
0.100


23
SICWFLLCS
0.100


10
SGVTLRCPS
0.100


21
PISICWFLL
0.100


1
SLYLIAVLA
0.100


24
ICWFLLCST
0.100


9
ASGVTLRCP
0.050


17
PSSWPISIC
0.050


14
LRCPSSWPI
0.040


13
TLRCPSSWP
0.030


29
LCSTQLSME
0.010


3
YLIAVLASG
0.010


7
VLASGVTLR
0.010


2
LYLIAVLAS
0.010


25
CWFLLCSTQ
0.001










101P3A11-V3-B35-9mers










Start
Subsequence
Score





7
LQMFAIHSL
1.000
Portion of SEQ ID


4
ACLLQMFAI
0.400
NO: 32; each start


3
DACLLQMFA
0.300
position is


8
QMFAIHSLS
0.100
specified - the


2
FDACLLQMF
0.100
length of each


6
LLQMFAIHS
0.100
peptide is 9 amino


1
QFDACLLQM
0.060
acids, the end


5
CLLQMFAIH
0.010
position for each


9
MFAIHSLSG
0.001
peptide is the start





position plus eight
















TABLE XVIII







101P3A11-V1-B35-10mers










Start
Subsequence
Score





81
MPKMLAIFWF
60.000
Portion of SEQ


285
VPPVLNPIVY
40.000
ID NO: 28; each


60
EPMYIFLCML
20.000
start position is


160
APLPVFIKQL
20.000
specified - the


162
LPVFIKQLPF
20.000
length of each


274
LPVILANIYL
20.000
peptide is 10


20
LPGLEEAQFW
15.000
amino acids, the


297
KTKEIRQRIL
12.000
end position for


179
HSYCLHQDVM
10.000
each peptide is


272
SPLPVILANI
8.000
the start position


141
LPRVTKIGVA
6.000
plus nine


150
AAVVRGAALM
6.000


231
LTREAQAKAF
6.000


110
LSGMESTVLL
5.000


114
ESTVLLAMAF
5.000


213
DSLLISFSYL
5.000


207
ISAIGLDSLL
5.000


76
ISTSSMPKML
5.000


79
SSMPKMLAIF
5.000


244
VSHVCAVFIF
5.000


56
HSLHEPMYIF
5.000


156
AALMAPLPVF
3.000


30
LAFPLCSLYL
3.000


4
DPNGNESSAT
3.000


300
EIRQRILRLF
3.000


149
VAAVVRSAAL
3.000


194
DIRVNVVYGL
3.000


248
CAVFIFYVPF
3.000


11
SATYFILIGL
3.000


25
EAQFWLAFPL
3.000


57
SLHEPMYIFL
2.000


169
LPFCRSNILS
2.000


210
IGLDSLLISF
2.000


6
NGNESSATYF
2.000


29
WLAFPLCSLY
2.000


75
LISTSSMPKM
2.000


131
HPLRHATVLT
2.000


41
AVLGNLTIIY
2.000


9
ESSATYFILI
2.000


32
FPLCSLYLIA
2.000


78
TSSMPKMLAI
2.000


117
VLLAMAFDRY
2.000


208
SAIGLDSLLI
1.800


109
SLSGMESTVL
1.500


181
YCLHQDVMKL
1.500


93
TTIQFDACLL
1.500


19
GLPGLEEAQF
1.500


190
LACDDIRVNV
1.200


98
DACLLQIFAI
1.200


302
RQRILRLFHV
1.200


40
IAVLGNLTII
1.200


238
KAFGTCVSHV
1.200


53
RTEHSLHEPM
1.200


92
STTIQFDACL
1.000


173
RSNILSHSYC
1.000


168
QLPFCRSNIL
1.000


216
LISFSYLLIL
1.000


174
SNILSHSYCL
1.000


66
LCMLSGIDIL
1.000


214
SLLISFSYLL
1.000


206
IISAIGLDSL
1.000


34
LCSLYLIAVL
1.000


242
TCVSHVCAVF
1.000


203
LIVIISAIGL
1.000


101
LLQIFAIHSL
1.000


222
LLILKTVLGL
1.000


280
NIYLLVPPVL
1.000


219
FSYLLILKTV
1.000


257
FIGLSMVHRF
1.000


251
FIFYVPFIGL
1.000


108
HSLSGMESTV
1.000


236
QAKAFGTCVS
0.900


95
IQFDACLLQI
0.800


167
KQLPFCRSNI
0.800


121
MAFDRYVAIC
0.600


144
VTKIGVAAVV
0.600


155
GAALMAPLPV
0.600


112
GMESTVLLAM
0.600


135
HATVLTLPRV
0.600


69
LSGIDILIST
0.500


271
DSPLPVILAN
0.500


80
SMPKMLAIFW
0.500


91
NSTTIQFDAC
0.500


268
KRRDSPLPVI
0.480


119
LAMAFDRYVA
0.450


201
YGLIVIISAI
0.400


198
NVVYGLIVII
0.400


243
CVSHVCAVFI
0.400


283
LLVPPVLNPI
0.400


67
CMLSGIDILI
0.400


120
AMAFDRYVAI
0.400


65
FLCMLSGIDI
0.400


42
VLGNLTIIYI
0.400


186
DVMKLACDDI
0.400


39
LIAVLGNLTI
0.400


157
ALMAPLPVFI
0.400


292
IVYGVKTKEI
0.400


143
RVTKIGVAAV
0.400


86
AIFWFNSTTI
0.400


196
RVNVVYGLIV
0.400










101P3A11-V2-B35-10mers










Start
Subsequence
Score





21
WPISICWFLL
20.000
Portion of SEQ


19
SSWPISICWF
5.000
ID NO: 30; each


6
IAVLASGVTL
3.000
start position is


28
FLLCSTQLSM
2.000
specified - the


17
CPSSWPISIC
2.000
length of each


14
TLRCPSSWPI
1.200
peptide is 10


16
RCPSSWPISI
0.800
amino acids, the


23
ISICWFLLCS
0.500
end position for


10
ASGVTLRCPS
0.500
each peptide is


12
GVTLRCPSSW
0.500
the start position


1
CSLYLIAVLA
0.500
plus nine


18
PSSWPISICW
0.250


4
YLIAVLASGV
0.200


26
CWFLLCSTQL
0.100


2
SLYLIAVLAS
0.100


8
VLASGVTLRC
0.100


24
SICWFLLCST
0.100


11
SGVTLRCPSS
0.100


20
SWPISICWFL
0.100


5
LIAVLASGVT
0.100


9
LASGVTLRCP
0.030


7
AVLASGVTLR
0.010


15
LRCPSSWPIS
0.010


27
WFLLCSTQLS
0.010


29
LLCSTQLSME
0.010


22
PISICWFLLC
0.010


25
ICWFLLCSTQ
0.010


13
VTLRCPSSWP
0.010


3
LYLIAVLASG
0.001










101P3A11-V3-B35-10mers










Start
Subsequence
Score





1
IQFDACLLQM
4.000
Portion of SEQ


4
DACLLQMFAI
1.200
ID NO: 32; each


7
LLQMFAIHSL
1.000
start position is


10
MFAIHSLSGM
0.200
specified - the


6
CLLQMFAIHS
0.100
length of each


8
LQMFAIHSLS
0.100
peptide is 10


2
QFDACLLQMF
0.030
amino acids, the


3
FDACLLQMFA
0.010
end position for


9
QMFAIHSLSG
0.010
each peptide is


5
ACLLQMFAIH
0.010
the start position





plus nine
















TABLE XIX





Motifs and Post-translational Modifications


of 101P3A11







N-glycosylation site


Number of matches: 3










1
 7-10
NESS
(SEQ ID NO: 133)


 


2
44-47
NLTI
(SEQ ID NO: 134)


 


3
90-93
NSTT
(SEQ ID NO: 135)







cAMP- and cGMP-dependent protein


kinase phosphorylation site











268-271
RRDS
(SEQ ID NO: 136)







Protein kinase C phosphorylation site










266-268
SKR







Casein kinase II phosphorylation site


Number of matches: 3










1
56-59
SLHE
(SEQ ID NO: 137)


 


2
69-72
SGID
(SEQ ID NO: 138)


 


3
110-113
SGME
(SEQ ID NO: 139)


 







N-myristoylation site


Number of matches: 4










1
 6-11
GNESSA
(SEQ ID NO: 140)


 


2
21-26
GLEEAQ
(SEQ ID NO: 141)


 


3
111-116
GMESTV
(SEQ ID NO: 142)


 


4
240-245
GTCVSH
(SEQ ID NO: 143)







G-protein coupled receptors family 1 signature











112-128
MESTVLLAMAFDRYVAI
(SEQ ID NO: 144)

















TABLE XX







Motifs











avrg. %




Name
identity
Description
Potential Function





zf-C2H2
34%
Zinc finger, C2H2 type
Nucleic acid-binding protein functions as





transcription factor, nuclear location probable


cytochrome b N
68%
Cytochrome b(N-
membrane bound oxidase, generate superoxide




terminal)/b6/petB


ig
19%
Immunoglobulin domain
domains are one hundred amino acids long and





include a conserved intradomain disulfide bond.


WD40
18%
WD domain, G-beta repeat
tandem repeats of about 40 residues, each





containing a Trp-Asp motif. Function in signal





transduction and protein interaction


PDZ
23%
PDZ domain
may function in targeting signaling molecules to





sub-membranous sites


LRR
28%
Leucine Rich Repeat
short sequence motifs involved in protein-protein





interactions


pkinase
23%
Protein kinase domain
conserved catalytic core common to both





serine/threonine and tyrosine protein kinases





containing an ATP binding site and a catalytic





site


PH
16%
PH domain
pleckstrin homology involved in intracellular





signaling or as constituents of the cytoskeleton


EGF
34%
EGF-like domain
30-40 amino-acid long found in the extracellular





domain of membrane-bound proteins or in





secreted proteins


rvt
49%
Reverse transcriptase (RNA-




dependent DNA polymerase)


ank
25%
Ank repeat
Cytoplasmic protein, associates integral





membrane proteins to the cytoskeleton


oxidored q1
32%
NADH-
membrane associated. Involved in proton




Ubiquinone/plastoquinone
translocation across the membrane




(complex I), various chains


efhand
24%
EF hand
calcium-binding domain, consists of a12 residue





loop flanked on both sides by a 12 residue alpha-





helical domain


rvp
79%
Retroviral aspartyl protease
Aspartyl or acid proteases, centered on a catalytic





aspartyl residue


Collagen
42%
Collagen triple helix repeat (20
extracellular structural proteins involved in




copies)
formation of connective tissue. The sequence





consists of the G-X-Y and the polypeptide chains





forms a triple helix.


fn3
20%
Fibronectin type III domain
Located in the extracellular ligand-binding region





of receptors and is about 200 amino acid residues





long with two pairs of cysteines involved in





disulfide bonds


7tm 1
19%
7 transmembrane receptor
seven hydrophobic transmembrane regions, with




(rhodopsin family)
the N-terminus located extracellularly while the





C-terminus is cytoplasmic. Signal through G





proteins
















TABLE XXI







Properties of 101P3A11










Bioinformatic Program
Outcome













Variants 1 and 3




ORF
ORF Finder
133-1086




(includes stop)


Protein Length
n/a
317 amino acids


Transmembrane region
TM Pred
7 TM at aa:




27-52, 63-88, 104-129, 146-165, 196-224,




239-262, 273-295



HMMTop
7 TM at aa:




27-50, 63-86, 99-121, 146-165, 201-224,




239-262, 275-294



Sosui
6 TM, at aa:




29-51, 63-85, 100-122, 203-225, 239-261,




273-295



TMHMM
7 TM, at aa:




29-51, 63-85, 100-122, 143-165, 202-224,




236-258, 273-295


Signal Peptide
Signal P
indicates no signal


pI
pI/MW tool
pI 8.7


Molecular weight
pI/MW tool
35.2 kDa


Localization
PSORT
Plasma membrane 64%



PSORT II
Plasma membrane 56.4%


Motifs
Pfam
7 transmembrane receptor (rhodopsin




family)



Prints
Rhodopsin-like GPCR superfamily



Blocks
Rhodopsin-like GPCR superfamily



Prosite
G-protein coupled receptors family 1


101P3A11 var.2


ORF
ORF finder
130-348 bp including stop


Protein length

72aa


Transmembrane region
TM Pred
2TM helices aa28-49, 55-72




N terminus extracellular



HMMTop
2TM helices




N terminus extracellular



Sosui
2TM helices aa28-50, 52-72



TMHMM
1 TM helix, aa27-49


Signal Peptide
Signal P
no


pI
pI/MW tool
pI 4.12


Molecular weight
pI/MW tool
7.95 kB


Localization
PSORT
82% extracellular, 16% peroxisome



PSORT II
39% cytoplasmic, 17% mitochondrial,




17% nuclear


Motifs
Pfam
no motifs found



Prints
no motifs found



Blocks
Zein seed storage protein
















TABLE XXII







101P3A11-V1-HLA-A1 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





246
H
V
C
A
V
F
I
F
Y
24
Portion of


30
L
A
F
P
L
C
S
L
Y
21
SEQ ID NO:


42
V
L
G
N
L
T
I
I
Y
21
28; each


286
P
P
V
L
N
P
I
V
Y
20
start position


112
G
M
E
S
T
V
L
L
A
19
is specified -


118
L
L
A
M
A
F
D
R
Y
19
the length of


173
R
S
N
I
L
S
H
S
Y
19
each peptide


193
D
D
I
R
V
N
V
V
Y
19
is 9 amino


213
D
S
L
L
I
S
F
S
Y
19
acids, the


58
L
H
E
P
M
Y
I
F
L
18
end position


23
L
E
E
A
Q
F
W
L
A
17
for each


10
S
S
A
T
Y
F
I
L
I
16
peptide is


53
R
T
E
H
S
L
H
E
P
16
the start


55
E
H
S
L
H
E
P
M
Y
16
position plus


79
S
S
M
P
K
M
L
A
I
16
8.


96
Q
F
D
A
C
L
L
Q
I
16


160
A
P
L
P
V
F
I
K
Q
16


184
H
Q
D
V
M
K
L
A
C
16


2
M
V
D
P
N
G
N
E
S
15


6
N
G
N
E
S
S
A
T
Y
15


211
G
L
D
S
L
L
I
S
F
15


274
L
P
V
I
L
A
N
I
Y
15


272
S
P
L
P
V
I
L
A
N
14


92
S
T
T
I
Q
F
D
A
C
13


122
A
F
D
R
Y
V
A
I
C
13


139
L
T
L
P
R
V
T
K
I
13


219
F
S
Y
L
L
I
L
K
T
13


283
L
L
V
P
P
V
L
N
P
13


191
A
C
D
D
I
R
V
N
V
12


192
C
D
D
I
R
V
N
V
V
12


232
T
R
E
A
Q
A
K
A
F
12


269
R
R
D
S
P
L
P
V
I
12


271
D
S
P
L
P
V
I
L
A
12


12
A
T
Y
F
I
L
I
G
L
11


22
G
L
E
E
A
Q
F
W
L
11


177
L
S
H
S
Y
C
L
H
Q
11


217
I
S
F
S
Y
L
L
I
L
11










101P3A11 v2 HLA A1-9-mers


















Pos
1
2
3
4
5
6
7
8
9
score
SEQ ID





22
I
S
I
C
W
F
L
L
C
15
Portion of SEQ ID


18
S
S
W
P
I
S
I
C
W
14
NO: 30; each start


8
L
A
S
G
V
T
L
R
C
9
position is


23
S
I
C
W
F
L
L
C
S
8
specified - the


2
L
Y
L
I
A
V
L
A
S
7
length of each


7
V
L
A
S
G
V
T
L
R
7
peptide is 9 amino


12
V
T
L
R
C
P
S
S
W
7
acids, the end


28
L
L
C
S
T
Q
L
S
M
7
position for each













peptide is the start













position plus 8.










101P3A11-V3-HLA A1 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score
SEQ ID





1
Q
F
D
A
C
L
L
Q
M
16
Portion of SEQ ID













NO: 32; each start













position is specified -













the length of each













peptide is 9 amino













acids, the end













position for each













peptide is the start













position plus 8.
















TABLE XXIII







101P3A11-V1- HLA-A0201 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score
SEQ ID





288
V
L
N
P
I
V
Y
G
V
30
Portion of SEQ ID NO:


15
F
I
L
I
G
L
P
G
L
29
28; each start position


29
W
L
A
F
P
L
C
S
L
28
is specified - the


38
Y
L
I
A
V
L
G
N
L
28
length of each


223
L
I
L
K
T
V
L
G
L
28
peptide is 9 amino


67
C
M
L
S
G
I
D
I
L
26
acids, the end position


109
S
L
S
G
M
E
S
T
V
26
for each peptide


182
C
L
H
Q
D
V
M
K
L
26
is the start position


202
G
L
I
V
I
I
S
A
I
26
plus 8.


215
L
L
I
S
F
S
Y
L
L
26



276
V
I
L
A
N
I
Y
L
L
26



158
L
M
A
P
L
P
V
F
I
25



221
Y
L
L
I
L
K
T
V
L
25



277
I
L
A
N
I
Y
L
L
V
25



280
N
I
Y
L
L
V
P
P
V
25



139
L
T
L
P
R
V
T
K
I
24



214
S
L
L
I
S
F
S
Y
L
24



50
Y
I
V
R
T
E
H
S
L
23



144
V
T
K
I
G
V
A
A
V
23



189
K
L
A
C
D
D
I
R
V
23



199
V
V
Y
G
L
I
V
I
I
23



22
G
L
E
E
A
Q
F
W
L
22



41
A
V
L
G
N
L
T
I
I
22



207
I
S
A
I
G
L
D
S
L
22



12
A
T
Y
F
I
L
I
G
L
21



61
P
M
Y
I
F
L
C
M
L
21



136
A
T
V
L
T
L
P
R
V
21



161
P
L
P
V
F
I
K
Q
L
21



175
N
I
L
S
H
S
Y
C
L
21



208
S
A
I
G
L
D
S
L
L
21



273
P
L
P
V
I
L
A
N
I
21



284
L
V
P
P
V
L
N
P
I
21



68
M
L
S
G
I
D
I
L
I
20



102
L
Q
I
F
A
I
H
S
L
20



283
L
L
V
P
P
V
L
N
P
20



300
E
I
R
Q
R
I
L
R
L
20



305
I
L
R
L
F
H
V
A
T
20



40
I
A
V
L
G
N
L
T
I
19



46
L
T
I
I
Y
I
V
R
T
19



93
T
T
I
Q
F
D
A
C
L
19



111
S
G
M
E
S
T
V
L
L
19



128
A
I
C
H
P
L
R
H
A
19



133
L
R
H
A
T
V
L
T
L
19



150
A
A
V
V
R
G
A
A
L
19



156
A
A
L
M
A
P
L
P
V
19



157
A
L
M
A
P
L
P
V
F
19



204
I
V
I
I
S
A
I
G
L
19



209
A
I
G
L
D
S
L
L
I
19



217
I
S
F
S
Y
L
L
I
L
19



220
S
Y
L
L
I
L
K
T
V
19



222
L
L
I
L
K
T
V
L
G
19



224
I
L
K
T
V
L
G
L
T
19



18
I
G
L
P
G
L
E
E
A
18



34
L
C
S
L
Y
L
I
A
V
18



35
C
S
L
Y
L
I
A
V
L
18



39
L
I
A
V
L
G
N
L
T
18



44
G
N
L
T
I
I
Y
I
V
18



86
A
I
F
W
F
N
S
T
T
18



119
L
A
M
A
F
D
R
Y
V
18



195
I
R
V
N
V
V
Y
G
L
18



211
G
L
D
S
L
L
I
S
F
18



216
L
I
S
F
S
Y
L
L
I
18



247
V
C
A
V
F
I
F
Y
V
18



255
V
P
F
I
G
L
S
M
V
18



16
I
L
I
G
L
P
G
L
E
17



64
I
F
L
C
M
L
S
G
I
17



73
D
I
L
I
S
T
S
S
M
17



94
T
I
Q
F
D
A
C
L
L
17



99
A
C
L
L
Q
I
F
A
I
17



112
G
M
E
S
T
V
L
L
A
17



121
M
A
F
D
R
Y
V
A
I
17



168
Q
L
P
F
C
R
S
N
I
17



198
N
V
V
Y
G
L
I
V
I
17



227
T
V
L
G
L
T
R
E
A
17



282
Y
L
L
V
P
P
V
L
N
17



32
F
P
L
C
S
L
Y
L
I
16



57
S
L
H
E
P
M
Y
I
F
16



71
G
I
D
I
L
I
S
T
S
16



79
S
S
M
P
K
M
L
A
I
16



80
S
M
P
K
M
L
A
I
F
16



105
F
A
I
H
S
L
S
G
M
16



120
A
M
A
F
D
R
Y
V
A
16



145
T
K
I
G
V
A
A
V
V
16



148
G
V
A
A
V
V
R
G
A
16



187
V
M
K
L
A
C
D
D
I
16



231
L
T
R
E
A
Q
A
K
A
16



239
A
F
G
T
C
V
S
H
V
16



250
V
F
I
F
Y
V
P
F
I
16



303
Q
R
I
L
R
L
F
H
V
16



304
R
I
L
R
L
F
H
V
A
16



19
G
L
P
G
L
E
E
A
Q
15



36
S
L
Y
L
I
A
V
L
G
15



43
L
G
N
L
T
I
I
Y
I
15



47
T
I
I
Y
I
V
R
T
E
15



70
S
G
I
D
I
L
I
S
T
15



77
S
T
S
S
M
P
K
M
L
15



132
P
L
R
H
A
T
V
L
T
15



138
V
L
T
L
P
R
V
T
K
15



154
R
G
A
A
L
M
A
P
L
15



191
A
C
D
D
I
R
V
N
V
15



192
C
D
D
I
R
V
N
V
V
15



205
V
I
I
S
A
I
G
L
D
15



242
T
C
V
S
H
V
C
A
V
15



252
I
F
Y
V
P
F
I
G
L
15



270
R
D
S
P
L
P
V
I
L
15



281
I
Y
L
L
V
P
P
V
L
15



307
R
L
F
H
V
A
T
H
A
15



17
L
I
G
L
P
G
L
E
E
14



26
A
Q
F
W
L
A
F
P
L
14



42
V
L
G
N
L
T
I
I
Y
14



63
Y
I
F
L
C
M
L
S
G
14



74
I
L
I
S
T
S
S
M
P
14



85
L
A
I
F
W
F
N
S
T
14



100
C
L
L
Q
I
F
A
I
H
14



118
L
L
A
M
A
F
D
R
Y
14



130
C
H
P
L
R
H
A
T
V
14



151
A
V
V
R
G
A
A
L
M
14



169
L
P
F
C
R
S
N
I
L
14



201
Y
G
L
I
V
I
I
S
A
14



219
F
S
Y
L
L
I
L
K
T
14



236
Q
A
K
A
F
G
T
C
V
14



269
R
R
D
S
P
L
P
V
I
14



297
K
T
K
E
I
R
Q
R
I
14










101P3A11-V2-HLA A0201 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score
SEQ ID





4
L
I
A
V
L
A
S
G
V
24
Portion of SEQ ID NO:


3
Y
L
I
A
V
L
A
S
G
22
30; each start position


6
A
V
L
A
S
G
V
T
L
22
is specified - the


1
S
L
Y
L
I
A
V
L
A
19
length of each peptide


7
V
L
A
S
G
V
T
L
R
19
is 9 amino acids,


28
L
L
C
S
T
Q
L
S
M
19
the end position


23
S
I
C
W
F
L
L
C
S
16
for each peptide is the


21
P
I
S
I
C
W
F
L
L
15
start position plus 8.


27
F
L
L
C
S
T
Q
L
S
15



24
I
C
W
F
L
L
C
S
T
13



14
L
R
C
P
S
S
W
P
I
12



20
W
P
I
S
I
C
W
F
L
12



26
W
F
L
L
C
S
T
Q
L
12



8
L
A
S
G
V
T
L
R
C
11



13
T
L
R
C
P
S
S
W
P
11










101P3A11-V3- HLA A0201 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score
SEQ ID





7
L
Q
M
F
A
I
H
S
L
19
Portion of SEQ ID NO:


5
C
L
L
Q
M
F
A
I
H
14
32; each start position


4
A
C
L
L
Q
M
F
A
I
13
is specified - the


6
L
L
Q
M
F
A
I
H
S
13
length of each peptide


1
Q
F
D
A
C
L
L
Q
M
9
is nine amino acids,


8
Q
M
F
A
I
H
S
L
S
9
the end position













for each peptide













is the start position













plus eight
















TABLE XXIV







101P3A11-V1 HLA-A0203 9-mers









No Results.



 







101P3A11-V2 HLA-A0203 9-mers









No Results.



 







101P3A11-V3 HLA-A0203 9-mers









No Results.

















TABLE XXV







101P3A11-V1- HLA-A3 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






138
V
L
T
L
P
R
V
T
K
30
Portion of SEQ ID


230
G
L
T
R
E
A
Q
A
K
27
NO: 28; each start


146
K
I
G
V
A
A
V
V
R
26
position is


151
A
V
V
R
G
A
A
L
M
24
specified - the


291
P
I
V
Y
G
V
K
T
K
24
length of each


36
S
L
Y
L
I
A
V
L
G
23
peptide is nine


157
A
L
M
A
P
L
P
V
F
23
amino acids,


48
I
I
Y
I
V
R
T
E
H
22
the end position


51
I
V
R
T
E
H
S
L
H
22
for each peptide


143
R
V
T
K
I
G
V
A
A
22
is the start


152
V
V
R
G
A
A
L
M
A
22
position plus eight


243
C
V
S
H
V
C
A
V
F
22



249
A
V
F
I
F
Y
V
P
F
22



117
V
L
L
A
M
A
F
D
R
21



193
D
D
I
R
V
N
V
V
Y
21



304
R
I
L
R
L
F
H
V
A
21



305
I
L
R
L
F
H
V
A
T
21



109
S
L
S
G
M
E
S
T
V
20



199
V
V
Y
G
L
I
V
I
I
20



292
I
V
Y
G
V
K
T
K
E
20



16
I
L
I
G
L
P
G
L
E
19



45
N
L
T
I
I
Y
I
V
R
19



74
I
L
I
S
T
S
S
M
P
19



75
L
I
S
T
S
S
M
P
K
19



100
C
L
L
Q
I
F
A
I
H
19



163
P
V
F
I
K
Q
L
P
F
19



204
I
V
I
I
S
A
I
G
L
19



222
L
L
I
L
K
T
V
L
G
19



246
H
V
C
A
V
F
I
F
Y
19



307
R
L
F
H
V
A
T
H
A
19



41
A
V
L
G
N
L
T
I
I
18



86
A
I
F
W
F
N
S
T
T
18



206
I
I
S
A
I
G
L
D
S
18



221
Y
L
L
I
L
K
T
V
L
18



254
Y
V
P
F
I
G
L
S
M
18



38
Y
L
I
A
V
L
G
N
L
17



42
V
L
G
N
L
T
I
I
Y
17



118
L
L
A
M
A
F
D
R
Y
17



132
P
L
R
H
A
T
V
L
T
17



137
T
V
L
T
L
P
R
V
T
17



181
Y
C
L
H
Q
D
V
M
K
17



202
G
L
I
V
I
I
S
A
I
17



214
S
L
L
I
S
F
S
Y
L
17



257
F
I
G
L
S
M
V
H
R
17



262
M
V
H
R
F
S
K
R
R
17



277
I
L
A
N
I
Y
L
L
V
17



282
Y
L
L
V
P
P
V
L
N
17



287
P
V
L
N
P
I
V
Y
G
17



289
L
N
P
I
V
Y
G
V
K
17



310
H
V
A
T
H
A
S
E
P
17



2
M
V
D
P
N
G
N
E
S
16



57
S
L
H
E
P
M
Y
I
F
16



71
G
I
D
I
L
I
S
T
S
16



73
D
I
L
I
S
T
S
S
M
16



116
T
V
L
L
A
M
A
F
D
16



126
Y
V
A
I
C
H
P
L
R
16



145
T
K
I
G
V
A
A
V
V
16



168
Q
L
P
F
C
R
S
N
I
16



176
I
L
S
H
S
Y
C
L
H
16



196
R
V
N
V
V
Y
G
L
I
16



198
N
V
V
Y
G
L
I
V
I
16



211
G
L
D
S
L
L
I
S
F
16



283
L
L
V
P
P
V
L
N
P
16



300
E
I
R
Q
R
I
L
R
L
16



302
R
Q
R
I
L
R
L
F
H
16



17
L
I
G
L
P
G
L
E
E
15



47
T
I
I
Y
I
V
R
T
E
15



103
Q
I
F
A
I
H
S
L
S
15



194
D
I
R
V
N
V
V
Y
G
15



209
A
I
G
L
D
S
L
L
I
15



224
I
L
K
T
V
L
G
L
T
15



238
K
A
F
G
T
C
V
S
H
15



6
N
G
N
E
S
S
A
T
Y
14



63
Y
I
F
L
C
M
L
S
G
14



101
L
L
Q
I
F
A
I
H
S
14



140
T
L
P
R
V
T
K
I
G
14



148
G
V
A
A
V
V
R
G
A
14



165
F
I
K
Q
L
P
F
C
R
14



189
K
L
A
C
D
D
I
R
V
14



225
L
K
T
V
L
G
L
T
R
14



227
T
V
L
G
L
T
R
E
A
14



256
P
F
I
G
L
S
M
V
H
14



275
P
V
I
L
A
N
I
Y
L
14



284
L
V
P
P
V
L
N
P
I
14



299
K
E
I
R
Q
R
I
L
R
14










101P3A11-V2-HLA A3 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






6
A
V
L
A
S
G
V
T
L
28
Portion of SEQ ID


1
S
L
Y
L
I
A
V
L
A
23
NO: 30; each start


3
Y
L
I
A
V
L
A
S
G
21
position is


7
V
L
A
S
G
V
T
L
R
18
specified - the


13
T
L
R
C
P
S
S
W
P
17
length of each


4
L
I
A
V
L
A
S
G
V
15
peptide is nine


11
G
V
T
L
R
C
P
S
S
15
amino acids,


28
L
L
C
S
T
Q
L
S
M
15
the end position













for each peptide













is the start













position plus eight










101P3A11-V3- HLA A3 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






5
C
L
L
Q
M
F
A
I
H
19
Portion of SEQ ID


6
L
L
Q
M
F
A
I
H
S
13
NO: 32; each start


1
Q
F
D
A
C
L
L
Q
M
10
position is













specified - the













length of each













peptide is nine













amino acids,













the end position













for each peptide













is the start













position plus eight
















TABLE XXVI







101P3A11-V1- HLA-A26 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






300
E
I
R
Q
R
I
L
R
L
30
Portion of SEQ ID


73
D
I
L
I
S
T
S
S
M
27
NO: 28; each start


249
A
V
F
I
F
Y
V
P
F
27
position is specified -


211
G
L
D
S
L
L
I
S
F
26
the length of each


15
F
I
L
I
G
L
P
G
L
24
peptide is nine amino


57
S
L
H
E
P
M
Y
I
F
24
acids, the end position


118
L
L
A
M
A
F
D
R
Y
24
for each peptide is the


223
L
I
L
K
T
V
L
G
L
24
start position plus


246
H
V
C
A
V
F
I
F
Y
24
eight


12
A
T
Y
F
I
L
I
G
L
23



38
Y
L
I
A
V
L
G
N
L
23



115
S
T
V
L
L
A
M
A
F
23



157
A
L
M
A
P
L
P
V
F
23



163
P
V
F
I
K
Q
L
P
F
23



182
C
L
H
Q
D
V
M
K
L
23



29
W
L
A
F
P
L
C
S
L
22



93
T
T
I
Q
F
D
A
C
L
22



161
P
L
P
V
F
I
K
Q
L
22



204
I
V
I
I
S
A
I
G
L
22



214
S
L
L
I
S
F
S
Y
L
22



276
V
I
L
A
N
I
Y
L
L
22



194
D
I
R
V
N
V
V
Y
G
21



243
C
V
S
H
V
C
A
V
F
21



77
S
T
S
S
M
P
K
M
L
20



254
Y
V
P
F
I
G
L
S
M
20



275
P
V
I
L
A
N
I
Y
L
20



24
E
E
A
Q
F
W
L
A
F
19



42
V
L
G
N
L
T
I
I
Y
19



50
Y
I
V
R
T
E
H
S
L
19



151
A
V
V
R
G
A
A
L
M
19



175
N
I
L
S
H
S
Y
C
L
19



193
D
D
I
R
V
N
V
V
Y
19



215
L
L
I
S
F
S
Y
L
L
19



252
I
F
Y
V
P
F
I
G
L
19



9
E
S
S
A
T
Y
F
I
L
18



22
G
L
E
E
A
Q
F
W
L
18



46
L
T
I
I
Y
I
V
R
T
18



55
E
H
S
L
H
E
P
M
Y
18



60
E
P
M
Y
I
F
L
C
M
18



89
W
F
N
S
T
T
I
Q
F
18



94
T
I
Q
F
D
A
C
L
L
18



186
D
V
M
K
L
A
C
D
D
18



199
V
V
Y
G
L
I
V
I
I
18



63
Y
I
F
L
C
M
L
S
G
17



71
G
I
D
I
L
I
S
T
S
17



80
S
M
P
K
M
L
A
I
F
17



97
F
D
A
C
L
L
Q
I
F
17



105
F
A
I
H
S
L
S
G
M
17



139
L
T
L
P
R
V
T
K
I
17



144
V
T
K
I
G
V
A
A
V
17



205
V
I
I
S
A
I
G
L
D
17



213
D
S
L
L
I
S
F
S
Y
17



221
Y
L
L
I
L
K
T
V
L
17



257
F
I
G
L
S
M
V
H
R
17



284
L
V
P
P
V
L
N
P
I
17



30
L
A
F
P
L
C
S
L
Y
16



41
A
V
L
G
N
L
T
I
I
16



47
T
I
I
Y
I
V
R
T
E
16



53
R
T
E
H
S
L
H
E
P
16



76
I
S
T
S
S
M
P
K
M
16



92
S
T
T
I
Q
F
D
A
C
16



136
A
T
V
L
T
L
P
R
V
16



148
G
V
A
A
V
V
R
G
A
16



202
G
L
I
V
I
I
S
A
I
16



258
I
G
L
S
M
V
H
R
F
16



280
N
I
Y
L
L
V
P
P
V
16



31
A
F
P
L
C
S
L
Y
L
15



102
L
Q
I
F
A
I
H
S
L
15



116
T
V
L
L
A
M
A
F
D
15



128
A
I
C
H
P
L
R
H
A
15



154
R
G
A
A
L
M
A
P
L
15



164
V
F
I
K
Q
L
P
F
C
15



216
L
I
S
F
S
Y
L
L
I
15



217
I
S
F
S
Y
L
L
I
L
15



226
K
T
V
L
G
L
T
R
E
15



273
P
L
P
V
I
L
A
N
I
15



283
L
L
V
P
P
V
L
N
P
15



287
P
V
L
N
P
I
V
Y
G
15



288
V
L
N
P
I
V
Y
G
V
15



297
K
T
K
E
I
R
Q
R
I
15



304
R
I
L
R
L
F
H
V
A
15



2
M
V
D
P
N
G
N
E
S
14



6
N
G
N
E
S
S
A
T
Y
14



33
P
L
C
S
L
Y
L
I
A
14



35
C
S
L
Y
L
I
A
V
L
14



58
L
H
E
P
M
Y
I
F
L
14



82
P
K
M
L
A
I
F
W
F
14



100
C
L
L
Q
I
F
A
I
H
14



196
R
V
N
V
V
Y
G
L
I
14



198
N
V
V
Y
G
L
I
V
I
14



207
I
S
A
I
G
L
D
S
L
14



208
S
A
I
G
L
D
S
L
L
14



227
T
V
L
G
L
T
R
E
A
14



231
L
T
R
E
A
Q
A
K
A
14



245
S
H
V
C
A
V
F
I
F
14



291
P
I
V
Y
G
V
K
T
K
14



301
I
R
Q
R
I
L
R
L
F
14










101P3A11-V2-HLA A26 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






6
A
V
L
A
S
G
V
T
L
20
Portion of SEQ ID


21
P
I
S
I
C
W
F
L
L
18
NO: 30; each start


28
L
L
C
S
T
Q
L
S
M
18
position is specified -


3
Y
L
I
A
V
L
A
S
G
16
the length of each


19
S
W
P
I
S
I
C
W
F
16
peptide is nine


26
W
F
L
L
C
S
T
Q
L
15
amino acids, the


4
L
I
A
V
L
A
S
G
V
14
end position for


7
V
L
A
S
G
V
T
L
R
14
each peptide is


23
S
I
C
W
F
L
L
C
S
14
the start position


11
G
V
T
L
R
C
P
S
S
12
plus eight


12
V
T
L
R
C
P
S
S
W
12



20
W
P
I
S
I
C
W
F
L
11



27
F
L
L
C
S
T
Q
L
S
10



1
S
L
Y
L
I
A
V
L
A
9



13
T
L
R
C
P
S
S
W
P
9










101P3A11-V3- HLA A26 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






1
Q
F
D
A
C
L
L
Q
M
20
Portion of SEQ ID


2
F
D
A
C
L
L
Q
M
F
18
NO: 32; each start


5
C
L
L
Q
M
F
A
I
H
14
position is specified -


7
L
Q
M
F
A
I
H
S
L
13
the length of each


6
L
L
Q
M
F
A
I
H
S
9
peptide is nine













amino acids, the













end position for













each peptide is













the start position













plus eight
















TABLE XXVII







101P3A11-V1- HLA-B0702 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






131
H
P
L
R
H
A
T
V
L
22
Portion of SEQ ID NO:


60
E
P
M
Y
I
F
L
C
M
21
28; each start position is


169
L
P
F
C
R
S
N
I
L
20
specified - the length of


290
N
P
I
V
Y
G
V
K
T
19
each peptide is nine amino


4
D
P
N
G
N
E
S
S
A
18
acids, the end position


20
L
P
G
L
E
E
A
Q
F
18
for each peptide is


141
L
P
R
V
T
K
I
G
V
18
the start position plus


285
V
P
P
V
L
N
P
I
V
17
eight


32
F
P
L
C
S
L
Y
L
I
16



255
V
P
F
I
G
L
S
M
V
16



270
R
D
S
P
L
P
V
I
L
16



150
A
A
V
V
R
G
A
A
L
15



154
R
G
A
A
L
M
A
P
L
15



157
A
L
M
A
P
L
P
V
F
15



252
I
F
Y
V
P
F
I
G
L
15



300
E
I
R
Q
R
I
L
R
L
15



9
E
S
S
A
T
Y
F
I
L
14



29
W
L
A
F
P
L
C
S
L
14



31
A
F
P
L
C
S
L
Y
L
14



111
S
G
M
E
S
T
V
L
L
14



133
L
R
H
A
T
V
L
T
L
14



160
A
P
L
P
V
F
I
K
Q
14



223
L
I
L
K
T
V
L
G
L
14



272
S
P
L
P
V
I
L
A
N
14



26
A
Q
F
W
L
A
F
P
L
13



110
L
S
G
M
E
S
T
V
L
13



125
R
Y
V
A
I
C
H
P
L
13



217
I
S
F
S
Y
L
L
I
L
13



269
R
R
D
S
P
L
P
V
I
13



281
I
Y
L
L
V
P
P
V
L
13



12
A
T
Y
F
I
L
I
G
L
12



35
C
S
L
Y
L
I
A
V
L
12



58
L
H
E
P
M
Y
I
F
L
12



77
S
T
S
S
M
P
K
M
L
12



143
R
V
T
K
I
G
V
A
A
12



152
V
V
R
G
A
A
L
M
A
12



191
A
C
D
D
I
R
V
N
V
12



195
I
R
V
N
V
V
Y
G
L
12



207
I
S
A
I
G
L
D
S
L
12



208
S
A
I
G
L
D
S
L
L
12



221
Y
L
L
I
L
K
T
V
L
12



268
K
R
R
D
S
P
L
P
V
12



305
I
L
R
L
F
H
V
A
T
12



15
F
I
L
I
G
L
P
G
L
11



24
E
E
A
Q
F
W
L
A
F
11



38
Y
L
I
A
V
L
G
N
L
11



41
A
V
L
G
N
L
T
I
I
11



78
T
S
S
M
P
K
M
L
A
11



79
S
S
M
P
K
M
L
A
I
11



81
M
P
K
M
L
A
I
F
W
11



93
T
T
I
Q
F
D
A
C
L
11



113
M
E
S
T
V
L
L
A
M
11



120
A
M
A
F
D
R
Y
V
A
11



128
A
I
C
H
P
L
R
H
A
11



132
P
L
R
H
A
T
V
L
T
11



156
A
A
L
M
A
P
L
P
V
11



158
L
M
A
P
L
P
V
F
I
11



182
C
L
H
Q
D
V
M
K
L
11



204
I
V
I
I
S
A
I
G
L
11



209
A
I
G
L
D
S
L
L
I
11



214
S
L
L
I
S
F
S
Y
L
11



249
A
V
F
I
F
Y
V
P
F
11



266
F
S
K
R
R
D
S
P
L
11



276
V
I
L
A
N
I
Y
L
L
11



286
P
P
V
L
N
P
I
V
Y
11



8
N
E
S
S
A
T
Y
F
I
10



22
G
L
E
E
A
Q
F
W
L
10



50
Y
I
V
R
T
E
H
S
L
10



61
P
M
Y
I
F
L
C
M
L
10



67
C
M
L
S
G
I
D
I
L
10



68
M
L
S
G
I
D
I
L
I
10



94
T
I
Q
F
D
A
C
L
L
10



96
Q
F
D
A
C
L
L
Q
I
10



102
L
Q
I
F
A
I
H
S
L
10



109
S
L
S
G
M
E
S
T
V
10



129
I
C
H
P
L
R
H
A
T
10



145
T
K
I
G
V
A
A
V
V
10



161
P
L
P
V
F
I
K
Q
L
10



162
L
P
V
F
I
K
Q
L
P
10



175
N
I
L
S
H
S
Y
C
L
10



199
V
V
Y
G
L
I
V
I
I
10



215
L
L
I
S
F
S
Y
L
L
10



216
L
I
S
F
S
Y
L
L
I
10



239
A
F
G
T
C
V
S
H
V
10



243
C
V
S
H
V
C
A
V
F
10



271
D
S
P
L
P
V
I
L
A
10



274
L
P
V
I
L
A
N
I
Y
10



275
P
V
I
L
A
N
I
Y
L
10



277
I
L
A
N
I
Y
L
L
V
10



298
T
K
E
I
R
Q
R
I
L
10










101P3A11-V2-HLA B0702 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






20
W
P
I
S
I
C
W
F
L
21
Portion of SEQ ID NO:


16
C
P
S
S
W
P
I
S
I
18
30; each start position is


6
A
V
L
A
S
G
V
T
L
16
specified - the length of


21
P
I
S
I
C
W
F
L
L
12
each peptide is nine amino


26
W
F
L
L
C
S
T
Q
L
11
acids, the end position













for each peptide is













the start position













plus eight










101P3A11-V3- HLA B0702 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






7
L
Q
M
F
A
I
H
S
L
11
Portion of SEQ ID NO:


1
Q
F
D
A
C
L
L
Q
M
10
32; each start position is


4
A
C
L
L
Q
M
F
A
I
9
specified - the length of


2
F
D
A
C
L
L
Q
M
F
7
each peptide is nine amino


3
D
A
C
L
L
Q
M
F
A
7
acids, the end position













for each peptide













is the start position













plus eight
















TABLE XXVIII







101P3A11-V1- HLA-B08 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






300
E
I
R
Q
R
I
L
R
L
31
Portion of SEQ ID NO:


266
F
S
K
R
R
D
S
P
L
29
28; each start position is


150
A
A
V
V
R
G
A
A
L
24
specified - the length of


169
L
P
F
C
R
S
N
I
L
24
each peptide is nine amino


295
G
V
K
T
K
E
I
R
Q
21
acids, the end position


121
M
A
F
D
R
Y
V
A
I
20
for each peptide is


293
V
Y
G
V
K
T
K
E
I
20
the start position


22
G
L
E
E
A
Q
F
W
L
19
plus eight


79
S
S
M
P
K
M
L
A
I
19



161
P
L
P
V
F
I
K
Q
L
19



187
V
M
K
L
A
C
D
D
I
18



214
S
L
L
I
S
F
S
Y
L
18



222
L
L
I
L
K
T
V
L
G
18



297
K
T
K
E
I
R
Q
R
I
18



298
T
K
E
I
R
Q
R
I
L
18



131
H
P
L
R
H
A
T
V
L
17



182
C
L
H
Q
D
V
M
K
L
17



224
I
L
K
T
V
L
G
L
T
17



29
W
L
A
F
P
L
C
S
L
16



38
Y
L
I
A
V
L
G
N
L
16



57
S
L
H
E
P
M
Y
I
F
16



81
M
P
K
M
L
A
I
F
W
16



163
P
V
F
I
K
Q
L
P
F
16



202
G
L
I
V
I
I
S
A
I
16



208
S
A
I
G
L
D
S
L
L
16



215
L
L
I
S
F
S
Y
L
L
16



221
Y
L
L
I
L
K
T
V
L
16



234
E
A
Q
A
K
A
F
G
T
16



276
V
I
L
A
N
I
Y
L
L
16



305
I
L
R
L
F
H
V
A
T
16



15
F
I
L
I
G
L
P
G
L
15



111
S
G
M
E
S
T
V
L
L
15



139
L
T
L
P
R
V
T
K
I
15



165
F
I
K
Q
L
P
F
C
R
15



223
L
I
L
K
T
V
L
G
L
15










101P3A11-V2-HLA B08 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






20
W
P
I
S
I
C
W
F
L
16
Portion of SEQ ID NO:


21
P
I
S
I
C
W
F
L
L
14
30; each start position


13
T
L
R
C
P
S
S
W
P
12
is specified - the length of


16
C
P
S
S
W
P
I
S
I
12
each peptide is nine amino


6
A
V
L
A
S
G
V
T
L
11
acids, the end position


26
W
F
L
L
C
S
T
Q
L
11
for each peptide is


1
S
L
Y
L
I
A
V
L
A
10
the start position


11
G
V
T
L
R
C
P
S
S
10
plus eight


19
S
W
P
I
S
I
C
W
F
9



7
V
L
A
S
G
V
T
L
R
8



27
F
L
L
C
S
T
Q
L
S
7










101P3A11-V3- HLA B08 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






7
L
Q
M
F
A
I
H
S
L
11
Portion of SEQ ID NO:


4
A
C
L
L
Q
M
F
A
I
8
32; each start position


2
F
D
A
C
L
L
Q
M
F
7
is specified - the length of


5
C
L
L
Q
M
F
A
I
H
6
each peptide is nine amino


6
L
L
Q
M
F
A
I
H
S
6
acids, the end position


3
D
A
C
L
L
Q
M
F
A
5
for each peptide is













the start position













plus eight
















TABLE XXIX







101P3A11-V1- HLA-B1510 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






58
L
H
E
P
M
Y
I
F
L
23
Portion of SEQ ID NO:


245
S
H
V
C
A
V
F
I
F
17
28; each start position is


270
R
D
S
P
L
P
V
I
L
16
specified - the length of


281
I
Y
L
L
V
P
P
V
L
16
each peptide is nine amino


263
V
H
R
F
S
K
R
R
D
15
acids, the end position


300
E
I
R
Q
R
I
L
R
L
15
for each peptide is


107
I
H
S
L
S
G
M
E
S
14
the start position plus


207
I
S
A
I
G
L
D
S
L
14
eight


221
Y
L
L
I
L
K
T
V
L
14



252
I
F
Y
V
P
F
I
G
L
14



298
T
K
E
I
R
Q
R
I
L
14



22
G
L
E
E
A
Q
F
W
L
13



35
C
S
L
Y
L
I
A
V
L
13



55
E
H
S
L
H
E
P
M
Y
13



111
S
G
M
E
S
T
V
L
L
13



195
I
R
V
N
V
V
Y
G
L
13



9
E
S
S
A
T
Y
F
I
L
12



15
F
I
L
I
G
L
P
G
L
12



29
W
L
A
F
P
L
C
S
L
12



67
C
M
L
S
G
I
D
I
L
12



77
S
T
S
S
M
P
K
M
L
12



93
T
T
I
Q
F
D
A
C
L
12



110
L
S
G
M
E
S
T
V
L
12



131
H
P
L
R
H
A
T
V
L
12



133
L
R
H
A
T
V
L
T
L
12



150
A
A
V
V
R
G
A
A
L
12



154
R
G
A
A
L
M
A
P
L
12



161
P
L
P
V
F
I
K
Q
L
12



182
C
L
H
Q
D
V
M
K
L
12



183
L
H
Q
D
V
M
K
L
A
12



204
I
V
I
I
S
A
I
G
L
12



217
I
S
F
S
Y
L
L
I
L
12



223
L
I
L
K
T
V
L
G
L
12



276
V
I
L
A
N
I
Y
L
L
12



38
Y
L
I
A
V
L
G
N
L
11



50
Y
I
V
R
T
E
H
S
L
11



94
T
I
Q
F
D
A
C
L
L
11



102
L
Q
I
F
A
I
H
S
L
11



130
C
H
P
L
R
H
A
T
V
11



134
R
H
A
T
V
L
T
L
P
11



178
S
H
S
Y
C
L
H
Q
D
11



208
S
A
I
G
L
D
S
L
L
11



258
I
G
L
S
M
V
H
R
F
11










101P3A11-V2-HLA B1510 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






6
A
V
L
A
S
G
V
T
L
13
Portion of SEQ ID NO:


21
P
I
S
I
C
W
F
L
L
11
30; each start position is


20
W
P
I
S
I
C
W
F
L
10
specified - the length of


26
W
F
L
L
C
S
T
Q
L
10
each peptide is nine amino


19
S
W
P
I
S
I
C
W
F
7
acids, the end position


28
L
L
C
S
T
Q
L
S
M
6
for each peptide is













the start position plus













eight










101P3A11-V3- HLA B1510 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






2
F
D
A
C
L
L
Q
M
F
7
32; each start position is


1
Q
F
D
A
C
L
L
Q
M
6
specified - the length of













each peptide is nine amino













acids, the end position













for each peptide is













the start position plus













eight
















TABLE XXX







101P3A11-V1- HLA-B2705 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






195
I
R
V
N
V
V
Y
G
L
25
Portion of SEQ ID NO:


269
R
R
D
S
P
L
P
V
I
24
28; each start position is


133
L
R
H
A
T
V
L
T
L
23
specified - the length of


301
I
R
Q
R
I
L
R
L
F
23
each peptide is nine amino


306
L
R
L
F
H
V
A
T
H
23
acids, the end position


232
T
R
E
A
Q
A
K
A
F
21
for each peptide is


35
C
S
L
Y
L
I
A
V
L
18
the start position plus


300
E
I
R
Q
R
I
L
R
L
18
eight


7
G
N
E
S
S
A
T
Y
F
17



67
C
M
L
S
G
I
D
I
L
17



163
P
V
F
I
K
Q
L
P
F
17



208
S
A
I
G
L
D
S
L
L
17



211
G
L
D
S
L
L
I
S
F
17



221
Y
L
L
I
L
K
T
V
L
17



238
K
A
F
G
T
C
V
S
H
17



270
R
D
S
P
L
P
V
I
L
17



281
I
Y
L
L
V
P
P
V
L
17



296
V
K
T
K
E
I
R
Q
R
17



12
A
T
Y
F
I
L
I
G
L
16



15
F
I
L
I
G
L
P
G
L
16



22
G
L
E
E
A
Q
F
W
L
16



26
A
Q
F
W
L
A
F
P
L
16



38
Y
L
I
A
V
L
G
N
L
16



93
T
T
I
Q
F
D
A
C
L
16



102
L
Q
I
F
A
I
H
S
L
16



125
R
Y
V
A
I
C
H
P
L
16



131
H
P
L
R
H
A
T
V
L
16



142
P
R
V
T
K
I
G
V
A
16



154
R
G
A
A
L
M
A
P
L
16



182
C
L
H
Q
D
V
M
K
L
16



202
G
L
I
V
I
I
S
A
I
16



204
I
V
I
I
S
A
I
G
L
16



217
I
S
F
S
Y
L
L
I
L
16



223
L
I
L
K
T
V
L
G
L
16



256
P
F
I
G
L
S
M
V
H
16



258
I
G
L
S
M
V
H
R
F
16



276
V
I
L
A
N
I
Y
L
L
16



48
I
I
Y
I
V
R
T
E
H
15



110
L
S
G
M
E
S
T
V
L
15



115
S
T
V
L
L
A
M
A
F
15



124
D
R
Y
V
A
I
C
H
P
15



146
K
I
G
V
A
A
V
V
R
15



157
A
L
M
A
P
L
P
V
F
15



169
L
P
F
C
R
S
N
I
L
15



173
R
S
N
I
L
S
H
S
Y
15



199
V
V
Y
G
L
I
V
I
I
15



207
I
S
A
I
G
L
D
S
L
15



230
G
L
T
R
E
A
Q
A
K
15



249
A
V
F
I
F
Y
V
P
F
15



252
I
F
Y
V
P
F
I
G
L
15



275
P
V
I
L
A
N
I
Y
L
15



291
P
I
V
Y
G
V
K
T
K
15



299
K
E
I
R
Q
R
I
L
R
15



20
L
P
G
L
E
E
A
Q
F
14



30
L
A
F
P
L
C
S
L
Y
14



31
A
F
P
L
C
S
L
Y
L
14



40
I
A
V
L
G
N
L
T
I
14



41
A
V
L
G
N
L
T
I
I
14



80
S
M
P
K
M
L
A
I
F
14



82
P
K
M
L
A
I
F
W
F
14



100
C
L
L
Q
I
F
A
I
H
14



138
V
L
T
L
P
R
V
T
K
14



139
L
T
L
P
R
V
T
K
I
14



151
A
V
V
R
G
A
A
L
M
14



161
P
L
P
V
F
I
K
Q
L
14



175
N
I
L
S
H
S
Y
C
L
14



181
Y
C
L
H
Q
D
V
M
K
14



193
D
D
I
R
V
N
V
V
Y
14



213
D
S
L
L
I
S
F
S
Y
14



214
S
L
L
I
S
F
S
Y
L
14



215
L
L
I
S
F
S
Y
L
L
14



261
S
M
V
H
R
F
S
K
R
14



264
H
R
F
S
K
R
R
D
S
14



268
K
R
R
D
S
P
L
P
V
14



294
Y
G
V
K
T
K
E
I
R
14



302
R
Q
R
I
L
R
L
F
H
14



303
Q
R
I
L
R
L
F
H
V
14



6
N
G
N
E
S
S
A
T
Y
13



24
E
E
A
Q
F
W
L
A
F
13



29
W
L
A
F
P
L
C
S
L
13



45
N
L
T
I
I
Y
I
V
R
13



52
V
R
T
E
H
S
L
H
E
13



57
S
L
H
E
P
M
Y
I
F
13



61
P
M
Y
I
F
L
C
M
L
13



73
D
I
L
I
S
T
S
S
M
13



75
L
I
S
T
S
S
M
P
K
13



76
I
S
T
S
S
M
P
K
M
13



99
A
C
L
L
Q
I
F
A
I
13



105
F
A
I
H
S
L
S
G
M
13



111
S
G
M
E
S
T
V
L
L
13



117
V
L
L
A
M
A
F
D
R
13



127
V
A
I
C
H
P
L
R
H
13



150
A
A
V
V
R
G
A
A
L
13



159
M
A
P
L
P
V
F
I
K
13



165
F
I
K
Q
L
P
F
C
R
13



171
F
C
R
S
N
I
L
S
H
13



172
C
R
S
N
I
L
S
H
S
13



188
M
K
L
A
C
D
D
I
R
13



218
S
F
S
Y
L
L
I
L
K
13



225
L
K
T
V
L
G
L
T
R
13



243
C
V
S
H
V
C
A
V
F
13



257
F
I
G
L
S
M
V
H
R
13



262
M
V
H
R
F
S
K
R
R
13



50
Y
I
V
R
T
E
H
S
L
12



58
L
H
E
P
M
Y
I
F
L
12



89
W
F
N
S
T
T
I
Q
F
12



97
F
D
A
C
L
L
Q
I
F
12



135
H
A
T
V
L
T
L
P
R
12



153
V
R
G
A
A
L
M
A
P
12



180
S
Y
C
L
H
Q
D
V
M
12



198
N
V
V
Y
G
L
I
V
I
12



245
S
H
V
C
A
V
F
I
F
12



266
F
S
K
R
R
D
S
P
L
12



274
L
P
V
I
L
A
N
I
Y
12



286
P
P
V
L
N
P
I
V
Y
12



289
L
N
P
I
V
Y
G
V
K
12



297
K
T
K
E
I
R
Q
R
I
12



298
T
K
E
I
R
Q
R
I
L
12










101P3A11-V2-HLA B2705 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






14
L
R
C
P
S
S
W
P
I
20
Portion of SEQ ID NO:


26
W
F
L
L
C
S
T
Q
L
17
30; each start position is


6
A
V
L
A
S
G
V
T
L
16
specified - the length of


7
V
L
A
S
G
V
T
L
R
15
each peptide is nine amino


19
S
W
P
I
S
I
C
W
F
14
acids, the end position


20
W
P
I
S
I
C
W
F
L
14
for each peptide is the


28
L
L
C
S
T
Q
L
S
M
12
start position plus


21
P
I
S
I
C
W
F
L
L
10
eight










101P3A11-V3- HLA B2705 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






7
L
Q
M
F
A
I
H
S
L
14
Portion of SEQ ID NO:


5
C
L
L
Q
M
F
A
I
H
13
32; each start position is


2
F
D
A
C
L
L
Q
M
F
12
specified - the length of


1
Q
F
D
A
C
L
L
Q
M
11
each peptide is nine amino


4
A
C
L
L
Q
M
F
A
I
10
acids, the end position













for each peptide is













the start position plus













eight
















TABLE XXXI







101P3A11-V1- HLA-B2709 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






195
I
R
V
N
V
V
Y
G
L
24
Portion of SEQ ID NO: 28;


269
R
R
D
S
P
L
P
V
I
24
each start position is


133
L
R
H
A
T
V
L
T
L
22
specified - the length of


268
K
R
R
D
S
P
L
P
V
21
each peptide is nine


301
I
R
Q
R
I
L
R
L
F
20
amino acids, the end


232
T
R
E
A
Q
A
K
A
F
19
position for each peptide


303
Q
R
I
L
R
L
F
H
V
19
is the start position plus


125
R
Y
V
A
I
C
H
P
L
16
eight


270
R
D
S
P
L
P
V
I
L
16



44
G
N
L
T
I
I
Y
I
V
15



217
I
S
F
S
Y
L
L
I
L
15



12
A
T
Y
F
I
L
I
G
L
14



26
A
Q
F
W
L
A
F
P
L
14



154
R
G
A
A
L
M
A
P
L
14



175
N
I
L
S
H
S
Y
C
L
14



223
L
I
L
K
T
V
L
G
L
14



258
I
G
L
S
M
V
H
R
F
14



281
I
Y
L
L
V
P
P
V
L
14



7
G
N
E
S
S
A
T
Y
F
13



15
F
I
L
I
G
L
P
G
L
13



22
G
L
E
E
A
Q
F
W
L
13



67
C
M
L
S
G
I
D
I
L
13



131
H
P
L
R
H
A
T
V
L
13



202
G
L
I
V
I
I
S
A
I
13



204
I
V
I
I
S
A
I
G
L
13



215
L
L
I
S
F
S
Y
L
L
13



252
I
F
Y
V
P
F
I
G
L
13



264
H
R
F
S
K
R
R
D
S
13



276
V
I
L
A
N
I
Y
L
L
13



306
L
R
L
F
H
V
A
T
H
13



31
A
F
P
L
C
S
L
Y
L
12



35
C
S
L
Y
L
I
A
V
L
12



38
Y
L
I
A
V
L
G
N
L
12



52
V
R
T
E
H
S
L
H
E
12



61
P
M
Y
I
F
L
C
M
L
12



76
I
S
T
S
S
M
P
K
M
12



94
T
I
Q
F
D
A
C
L
L
12



124
D
R
Y
V
A
I
C
H
P
12



136
A
T
V
L
T
L
P
R
V
12



139
L
T
L
P
R
V
T
K
I
12



150
A
A
V
V
R
G
A
A
L
12



156
A
A
L
M
A
P
L
P
V
12



169
L
P
F
C
R
S
N
I
L
12



182
C
L
H
Q
D
V
M
K
L
12



189
K
L
A
C
D
D
I
R
V
12



191
A
C
D
D
I
R
V
N
V
12



196
R
V
N
V
V
Y
G
L
I
12



211
G
L
D
S
L
L
I
S
F
12



214
S
L
L
I
S
F
S
Y
L
12



221
Y
L
L
I
L
K
T
V
L
12



249
A
V
F
I
F
Y
V
P
F
12



280
N
I
Y
L
L
V
P
P
V
12



288
V
L
N
P
I
V
Y
G
V
12



297
K
T
K
E
I
R
Q
R
I
12



300
E
I
R
Q
R
I
L
R
L
12



32
F
P
L
C
S
L
Y
L
I
11



40
I
A
V
L
G
N
L
T
I
11



41
A
V
L
G
N
L
T
I
I
11



50
Y
I
V
R
T
E
H
S
L
11



58
L
H
E
P
M
Y
I
F
L
11



64
I
F
L
C
M
L
S
G
I
11



77
S
T
S
S
M
P
K
M
L
11



93
T
T
I
Q
F
D
A
C
L
11



99
A
C
L
L
Q
I
F
A
I
11



102
L
Q
I
F
A
I
H
S
L
11



111
S
G
M
E
S
T
V
L
L
11



121
M
A
F
D
R
Y
V
A
I
11



142
P
R
V
T
K
I
G
V
A
11



151
A
V
V
R
G
A
A
L
M
11



161
P
L
P
V
F
I
K
Q
L
11



163
P
V
F
I
K
Q
L
P
F
11



172
C
R
S
N
I
L
S
H
S
11



199
V
V
Y
G
L
I
V
I
I
11



207
I
S
A
I
G
L
D
S
L
11



208
S
A
I
G
L
D
S
L
L
11



209
A
I
G
L
D
S
L
L
I
11



220
S
Y
L
L
I
L
K
T
V
11



242
T
C
V
S
H
V
C
A
V
11



250
V
F
I
F
Y
V
P
F
I
11



275
P
V
I
L
A
N
I
Y
L
11



277
I
L
A
N
I
Y
L
L
V
11










101P3A11-V2-HLA B2709 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






14
L
R
C
P
S
S
W
P
I
19
Portion of SEQ ID NO: 30;


6
A
V
L
A
S
G
V
T
L
14
each start position is


20
W
P
I
S
I
C
W
F
L
13
specified - the length of


26
W
F
L
L
C
S
T
Q
L
13
each peptide is nine


21
P
I
S
I
C
W
F
L
L
10
amino acids, the end


28
L
L
C
S
T
Q
L
S
M
10
position for each peptide


4
L
I
A
V
L
A
S
G
V
9
is the start position plus


16
C
P
S
S
W
P
I
S
I
9
eight










101P3A11-V3- HLA B2709 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score






4
A
C
L
L
Q
M
F
A
I
11
Portion of SEQ ID NO: 32;


1
Q
F
D
A
C
L
L
Q
M
10
each start position is


7
L
Q
M
F
A
I
H
S
L
10
specified - the length of


2
F
D
A
C
L
L
Q
M
F
8
each peptide is nine













amino acids, the end













position for each peptide













is the start position plus













eight
















TABLE XXXII







101P3A11-V1- HLA-B4402 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





24
E
E
A
Q
F
W
L
A
F
25
Portion of SEQ ID NO:


8
N
E
S
S
A
T
Y
F
I
21
28; each start position is


99
A
C
L
L
Q
I
F
A
I
18
specified - the length of


299
K
E
I
R
Q
R
I
L
R
18
each peptide is nine amino


102
L
Q
I
F
A
I
H
S
L
17
acids, the end position for


161
P
L
P
V
F
I
K
Q
L
17
each peptide is the start


202
G
L
I
V
I
I
S
A
I
17
position plus eight


300
E
I
R
Q
R
I
L
R
L
17


12
A
T
Y
F
I
L
I
G
L
16


26
A
Q
F
W
L
A
F
P
L
16


30
L
A
F
P
L
C
S
L
Y
16


31
A
F
P
L
C
S
L
Y
L
16


79
S
S
M
P
K
M
L
A
I
16


113
M
E
S
T
V
L
L
A
M
16


150
A
A
V
V
R
G
A
A
L
16


157
A
L
M
A
P
L
P
V
F
16


193
D
D
I
R
V
N
V
V
Y
16


208
S
A
I
G
L
D
S
L
L
16


249
A
V
F
I
F
Y
V
P
F
16


270
R
D
S
P
L
P
V
I
L
16


276
V
I
L
A
N
I
Y
L
L
16


35
C
S
L
Y
L
I
A
V
L
15


41
A
V
L
G
N
L
T
I
I
15


59
H
E
P
M
Y
I
F
L
C
15


77
S
T
S
S
M
P
K
M
L
15


82
P
K
M
L
A
I
F
W
F
15


111
S
G
M
E
S
T
V
L
L
15


115
S
T
V
L
L
A
M
A
F
15


121
M
A
F
D
R
Y
V
A
I
15


139
L
T
L
P
R
V
T
K
I
15


204
I
V
I
I
S
A
I
G
L
15


232
T
R
E
A
Q
A
K
A
F
15


275
P
V
I
L
A
N
I
Y
L
15


286
P
P
V
L
N
P
I
V
Y
15


301
I
R
Q
R
I
L
R
L
F
15


38
Y
L
I
A
V
L
G
N
L
14


55
E
H
S
L
H
E
P
M
Y
14


58
L
H
E
P
M
Y
I
F
L
14


67
C
M
L
S
G
I
D
I
L
14


131
H
P
L
R
H
A
T
V
L
14


169
L
P
F
C
R
S
N
I
L
14


209
A
I
G
L
D
S
L
L
I
14


215
L
L
I
S
F
S
Y
L
L
14


217
I
S
F
S
Y
L
L
I
L
14


281
I
Y
L
L
V
P
P
V
L
14


284
L
V
P
P
V
L
N
P
I
14


9
E
S
S
A
T
Y
F
I
L
13


10
S
S
A
T
Y
F
I
L
I
13


42
V
L
G
N
L
T
I
I
Y
13


43
L
G
N
L
T
I
I
Y
I
13


68
M
L
S
G
I
D
I
L
I
13


80
S
M
P
K
M
L
A
I
F
13


89
W
F
N
S
T
T
I
Q
F
13


93
T
T
I
Q
F
D
A
C
L
13


133
L
R
H
A
T
V
L
T
L
13


158
L
M
A
P
L
P
V
F
I
13


163
P
V
F
I
K
Q
L
P
F
13


199
V
V
Y
G
L
I
V
I
I
13


211
G
L
D
S
L
L
I
S
F
13


213
D
S
L
L
I
S
F
S
Y
13


214
S
L
L
I
S
F
S
Y
L
13


223
L
I
L
K
T
V
L
G
L
13


258
I
G
L
S
M
V
H
R
F
13


6
N
G
N
E
S
S
A
T
Y
12


15
F
I
L
I
G
L
P
G
L
12


20
L
P
G
L
E
E
A
Q
F
12


21
P
G
L
E
E
A
Q
F
W
12


23
L
E
E
A
Q
F
W
L
A
12


50
Y
I
V
R
T
E
H
S
L
12


81
M
P
K
M
L
A
I
F
W
12


94
T
I
Q
F
D
A
C
L
L
12


96
Q
F
D
A
C
L
L
Q
I
12


125
R
Y
V
A
I
C
H
P
L
12


175
N
I
L
S
H
S
Y
C
L
12


182
C
L
H
Q
D
V
M
K
L
12


195
I
R
V
N
V
V
Y
G
L
12


198
N
V
V
Y
G
L
I
V
I
12


221
Y
L
L
I
L
K
T
V
L
12


243
C
V
S
H
V
C
A
V
F
12


245
S
H
V
C
A
V
F
I
F
12


246
H
V
C
A
V
F
I
F
Y
12


250
V
F
I
F
Y
V
P
F
I
12


252
I
F
Y
V
P
F
I
G
L
12


266
F
S
K
R
R
D
S
P
L
12


274
L
P
V
I
L
A
N
I
Y
12


298
T
K
E
I
R
Q
R
I
L
12










101P3A11-V2-HLA B4402 - 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





6
A
V
L
A
S
G
V
T
L
16
Portion of SEQ ID NO: 30;


18
S
S
W
P
I
S
I
C
W
16
each start position is


19
S
W
P
I
S
I
C
W
F
15
specified - the length of each


20
W
P
I
S
I
C
W
F
L
14
peptide is nine amino acids,


12
V
T
L
R
C
P
S
S
W
13
the end position for each


26
W
F
L
L
C
S
T
Q
L
13
peptide is the start position


21
P
I
S
I
C
W
F
L
L
12
plus eight


14
L
R
C
P
S
S
W
P
I
11


16
C
P
S
S
W
P
I
S
I
11










101P3A11-V3- HLA B4402 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





4
A
C
L
L
Q
M
F
A
I
15
Portion of SEQ ID NO: 32;


7
L
Q
M
F
A
I
H
S
L
15
each start position is specified -


2
F
D
A
C
L
L
Q
M
F
11
the length of each peptide is













nine amino acids, the end













position for each peptide is the













start position plus eight
















TABLE XXXIII







101P3A11-V1- HLA-B5101 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





40
I
A
V
L
G
N
L
T
I
26
Portion of SEQ ID NO:


32
F
P
L
C
S
L
Y
L
I
25
28; each start position is


121
M
A
F
D
R
Y
V
A
I
24
specified - the length of


131
H
P
L
R
H
A
T
V
L
23
each peptide is nine amino


119
L
A
M
A
F
D
R
Y
V
22
acids, the end position for


141
L
P
R
V
T
K
I
G
V
22
each peptide is the start


156
A
A
L
M
A
P
L
P
V
22
position plus eight


43
L
G
N
L
T
I
I
Y
I
21


255
V
P
F
I
G
L
S
M
V
21


285
V
P
P
V
L
N
P
I
V
21


169
L
P
F
C
R
S
N
I
L
20


236
Q
A
K
A
F
G
T
C
V
20


139
L
T
L
P
R
V
T
K
I
19


160
A
P
L
P
V
F
I
K
Q
18


190
L
A
C
D
D
I
R
V
N
18


199
V
V
Y
G
L
I
V
I
I
18


278
L
A
N
I
Y
L
L
V
P
18


208
S
A
I
G
L
D
S
L
L
17


284
L
V
P
P
V
L
N
P
I
17


64
I
F
L
C
M
L
S
G
I
16


87
I
F
W
F
N
S
T
T
I
16


111
S
G
M
E
S
T
V
L
L
16


145
T
K
I
G
V
A
A
V
V
16


150
A
A
V
V
R
G
A
A
L
16


198
N
V
V
Y
G
L
I
V
I
16


272
S
P
L
P
V
I
L
A
N
16


281
I
Y
L
L
V
P
P
V
L
16


4
D
P
N
G
N
E
S
S
A
15


41
A
V
L
G
N
L
T
I
I
15


98
D
A
C
L
L
Q
I
F
A
15


133
L
R
H
A
T
V
L
T
L
15


223
L
I
L
K
T
V
L
G
L
15


280
N
I
Y
L
L
V
P
P
V
15


286
P
P
V
L
N
P
I
V
Y
15


290
N
P
I
V
Y
G
V
K
T
15


10
S
S
A
T
Y
F
I
L
I
14


66
L
C
M
L
S
G
I
D
I
14


85
L
A
I
F
W
F
N
S
T
14


127
V
A
I
C
H
P
L
R
H
14


158
L
M
A
P
L
P
V
F
I
14


159
M
A
P
L
P
V
F
I
K
14


192
C
D
D
I
R
V
N
V
V
14


201
Y
G
L
I
V
I
I
S
A
14


210
I
G
L
D
S
L
L
I
S
14


216
L
I
S
F
S
Y
L
L
I
14


220
S
Y
L
L
I
L
K
T
V
14


221
Y
L
L
I
L
K
T
V
L
14


238
K
A
F
G
T
C
V
S
H
14


248
C
A
V
F
I
F
Y
V
P
14


250
V
F
I
F
Y
V
P
F
I
14


252
I
F
Y
V
P
F
I
G
L
14


258
I
G
L
S
M
V
H
R
F
14


269
R
R
D
S
P
L
P
V
I
14


274
L
P
V
I
L
A
N
I
Y
14


30
L
A
F
P
L
C
S
L
Y
13


34
L
C
S
L
Y
L
I
A
V
13


56
H
S
L
H
E
P
M
Y
I
13


68
M
L
S
G
I
D
I
L
I
13


81
M
P
K
M
L
A
I
F
W
13


96
Q
F
D
A
C
L
L
Q
I
13


99
A
C
L
L
Q
I
F
A
I
13


105
F
A
I
H
S
L
S
G
M
13


147
I
G
V
A
A
V
V
R
G
13


149
V
A
A
V
V
R
G
A
A
13


154
R
G
A
A
L
M
A
P
L
13


234
E
A
Q
A
K
A
F
G
T
13


244
V
S
H
V
C
A
V
F
I
13


293
V
Y
G
V
K
T
K
E
I
13


297
K
T
K
E
I
R
Q
R
I
13


6
N
G
N
E
S
S
A
T
Y
12


11
S
A
T
Y
F
I
L
I
G
12


12
A
T
Y
F
I
L
I
G
L
12


20
L
P
G
L
E
E
A
Q
F
12


35
C
S
L
Y
L
I
A
V
L
12


38
Y
L
I
A
V
L
G
N
L
12


44
G
N
L
T
I
I
Y
I
V
12


60
E
P
M
Y
I
F
L
C
M
12


79
S
S
M
P
K
M
L
A
I
12


109
S
L
S
G
M
E
S
T
V
12


110
L
S
G
M
E
S
T
V
L
12


155
G
A
A
L
M
A
P
L
P
12


162
L
P
V
F
I
K
Q
L
P
12


179
H
S
Y
C
L
H
Q
D
V
12


195
I
R
V
N
V
V
Y
G
L
12


196
R
V
N
V
V
Y
G
L
I
12


217
I
S
F
S
Y
L
L
I
L
12


239
A
F
G
T
C
V
S
H
V
12


240
F
G
T
C
V
S
H
V
C
12


268
K
R
R
D
S
P
L
P
V
12


273
P
L
P
V
I
L
A
N
I
12


292
I
V
Y
G
V
K
T
K
E
12










101P3A11-V2-HLA B5101-9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





16
C
P
S
S
W
P
I
S
I
22
Portion of SEQ ID NO: 30;


8
L
A
S
G
V
T
L
R
C
17
each start position is


20
W
P
I
S
I
C
W
F
L
16
specified - the length of each


5
I
A
V
L
A
S
G
V
T
15
peptide is nine amino acids,


6
A
V
L
A
S
G
V
T
L
13
the end position for each


14
L
R
C
P
S
S
W
P
I
13
peptide is the start position


4
L
I
A
V
L
A
S
G
V
11
plus eight










101P3A11-V3- HLA B5101 9-mers


















Pos
1
2
3
4
5
6
7
8
9
score





3
D
A
C
L
L
Q
M
F
A
14
Portion of SEQ ID NO: 32;


4
A
C
L
L
Q
M
F
A
I
12
each start position is specified -


7
L
Q
M
F
A
I
H
S
L
9
the length of each peptide is













nine amino acids, the end













position for each peptide is the













start position plus eight
















TABLE XXXIV







101P3A11-V1- HLA-A1 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





192
C
D
D
I
R
V
N
V
V
Y
27
Portion of SEQ ID NO:


245
S
H
V
C
A
V
F
I
F
Y
24
28; each start position is


41
A
V
L
G
N
L
T
I
I
Y
21
specified - the length of


285
V
P
P
V
L
N
P
I
V
Y
21
each peptide is nine amino


117
V
L
L
A
M
A
F
D
R
Y
20
acids, the end position for


29
W
L
A
F
P
L
C
S
L
Y
18
each peptide is the start


298
T
K
E
I
R
Q
R
I
L
R
17
position plus nine


22
G
L
E
E
A
Q
F
W
L
A
16


23
L
E
E
A
Q
F
W
L
A
F
16


53
R
T
E
H
S
L
H
E
P
M
16


54
T
E
H
S
L
H
E
P
M
Y
16


58
L
H
E
P
M
Y
I
F
L
C
16


112
G
M
E
S
T
V
L
L
A
M
16


273
P
L
P
V
I
L
A
N
I
Y
16


2
M
V
D
P
N
G
N
E
S
S
15


5
P
N
G
N
E
S
S
A
T
Y
15


122
A
F
D
R
Y
V
A
I
C
H
15


172
C
R
S
N
I
L
S
H
S
Y
15


212
L
D
S
L
L
I
S
F
S
Y
15


9
E
S
S
A
T
Y
F
I
L
I
13


191
A
C
D
D
I
R
V
N
V
V
13










101P3A11-V2-- HLA A1 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





22
P
I
S
I
C
W
F
L
L
C
11
Portion of SEQ ID NO: 30;


2
S
L
Y
L
I
A
V
L
A
S
10
each start position is


19
S
S
W
P
I
S
I
C
W
F
10
specified - the length of each


23
I
S
I
C
W
F
L
L
C
S
10
peptide is ten amino acids,


8
V
L
A
S
G
V
T
L
R
C
8
the end position for each


18
P
S
S
W
P
I
S
I
C
W
8
peptide is the start position


28
F
L
L
C
S
T
Q
L
S
M
8
plus nine


13
V
T
L
R
C
P
S
S
W
P
7


1
C
S
L
Y
L
I
A
V
L
A
6


10
A
S
G
V
T
L
R
C
P
S
6










101P3A11-V3- HLA A1 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





2
Q
F
D
A
C
L
L
Q
M
F
11
Portion of SEQ ID NO: 32;


1
I
Q
F
D
A
C
L
L
Q
M
6
each start position is specified -


9
Q
M
F
A
I
H
S
L
S
G
6
the length of each peptide is ten


6
C
L
L
Q
M
F
A
I
H
S
5
amino acids, the end position














for each peptide is the start














position plus nine
















TABLE XXXV







101P3A11-V1- HLA-A0201 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





222
L
L
I
L
K
T
V
L
G
L
30
Portion of SEQ ID


101
L
L
Q
I
F
A
I
H
S
L
29
NO: 28; each start


283
L
L
V
P
P
V
L
N
P
I
27
position is specified -


206
I
I
S
A
I
G
L
D
S
L
26
the length of each


214
S
L
L
I
S
F
S
Y
L
L
25
peptide is ten amino


57
S
L
H
E
P
M
Y
I
F
L
24
acids, the end position


63
Y
I
F
L
C
M
L
S
G
I
24
for each peptide is the


109
S
L
S
G
M
E
S
T
V
L
24
start position plus nine


118
L
L
A
M
A
F
D
R
Y
V
24


132
P
L
R
H
A
T
V
L
T
L
24


138
V
L
T
L
P
R
V
T
K
I
24


216
L
I
S
F
S
Y
L
L
I
L
24


39
L
I
A
V
L
G
N
L
T
I
23


42
V
L
G
N
L
T
I
I
Y
I
23


157
A
L
M
A
P
L
P
V
F
I
23


194
D
I
R
V
N
V
V
Y
G
L
23


215
L
L
I
S
F
S
Y
L
L
I
23


33
P
L
C
S
L
Y
L
I
A
V
22


120
A
M
A
F
D
R
Y
V
A
I
22


238
K
A
F
G
T
C
V
S
H
V
22


276
V
I
L
A
N
I
Y
L
L
V
22


86
A
I
F
W
F
N
S
T
T
I
21


140
T
L
P
R
V
T
K
I
G
V
21


203
L
I
V
I
I
S
A
I
G
L
21


14
Y
F
I
L
I
G
L
P
G
L
20


17
L
I
G
L
P
G
L
E
E
A
20


30
L
A
F
P
L
C
S
L
Y
L
20


143
R
V
T
K
I
G
V
A
A
V
20


149
V
A
A
V
V
R
G
A
A
L
20


168
Q
L
P
F
C
R
S
N
I
L
20


181
Y
C
L
H
Q
D
V
M
K
L
20


223
L
I
L
K
T
V
L
G
L
T
20


241
G
T
C
V
S
H
V
C
A
V
20


249
A
V
F
I
F
Y
V
P
F
I
20


251
F
I
F
Y
V
P
F
I
G
L
20


272
S
P
L
P
V
I
L
A
N
I
20


280
N
I
Y
L
L
V
P
P
V
L
20


305
I
L
R
L
F
H
V
A
T
H
20


11
S
A
T
Y
F
I
L
I
G
L
19


16
I
L
I
G
L
P
G
L
E
E
19


28
F
W
L
A
F
P
L
C
S
L
19


36
S
L
Y
L
I
A
V
L
G
N
19


38
Y
L
I
A
V
L
G
N
L
T
19


45
N
L
T
I
I
Y
I
V
R
T
19


65
F
L
C
M
L
S
G
I
D
I
19


84
M
L
A
I
F
W
F
N
S
T
19


160
A
P
L
P
V
F
I
K
Q
L
19


190
L
A
C
D
D
I
R
V
N
V
19


208
S
A
I
G
L
D
S
L
L
I
19


254
Y
V
P
F
I
G
L
S
M
V
19


277
I
L
A
N
I
Y
L
L
V
P
19


282
Y
L
L
V
P
P
V
L
N
P
19


284
L
V
P
P
V
L
N
P
I
V
19


287
P
V
L
N
P
I
V
Y
G
V
19


34
L
C
S
L
Y
L
I
A
V
L
18


37
L
Y
L
I
A
V
L
G
N
L
18


40
I
A
V
L
G
N
L
T
I
I
18


43
L
G
N
L
T
I
I
Y
I
V
18


67
C
M
L
S
G
I
D
I
L
I
18


112
G
M
E
S
T
V
L
L
A
M
18


129
I
C
H
P
L
R
H
A
T
V
18


135
H
A
T
V
L
T
L
P
R
V
18


155
G
A
A
L
M
A
P
L
P
V
18


158
L
M
A
P
L
P
V
F
I
K
18


191
A
C
D
D
I
R
V
N
V
V
18


230
G
L
T
R
E
A
Q
A
K
A
18


246
H
V
C
A
V
F
I
F
Y
V
18


275
P
V
I
L
A
N
I
Y
L
L
18


279
A
N
I
Y
L
L
V
P
P
V
18


292
I
V
Y
G
V
K
T
K
E
I
18


299
K
E
I
R
Q
R
I
L
R
L
18


49
I
Y
I
V
R
T
E
H
S
L
17


66
L
C
M
L
S
G
I
D
I
L
17


68
M
L
S
G
I
D
I
L
I
S
17


75
L
I
S
T
S
S
M
P
K
M
17


92
S
T
T
I
Q
F
D
A
C
L
17


95
I
Q
F
D
A
C
L
L
Q
I
17


189
K
L
A
C
D
D
I
R
V
N
17


198
N
V
V
Y
G
L
I
V
I
I
17


201
Y
G
L
I
V
I
I
S
A
I
17


219
F
S
Y
L
L
I
L
K
T
V
17


228
V
L
G
L
T
R
E
A
Q
A
17


304
R
I
L
R
L
F
H
V
A
T
17


22
G
L
E
E
A
Q
F
W
L
A
16


93
T
T
I
Q
F
D
A
C
L
L
16


98
D
A
C
L
L
Q
I
F
A
I
16


128
A
I
C
H
P
L
R
H
A
T
16


144
V
T
K
I
G
V
A
A
V
V
16


196
R
V
N
V
V
Y
G
L
I
V
16


221
Y
L
L
I
L
K
T
V
L
G
16


297
K
T
K
E
I
R
Q
R
I
L
16


19
G
L
P
G
L
E
E
A
Q
F
15


31
A
F
P
L
C
S
L
Y
L
I
15


127
V
A
I
C
H
P
L
R
H
A
15


146
K
I
G
V
A
A
V
V
R
G
15


174
S
N
I
L
S
H
S
Y
C
L
15


202
G
L
I
V
I
I
S
A
I
G
15


209
A
I
G
L
D
S
L
L
I
S
15


211
G
L
D
S
L
L
I
S
F
S
15


268
K
R
R
D
S
P
L
P
V
I
15


46
L
T
I
I
Y
I
V
R
T
E
14


74
I
L
I
S
T
S
S
M
P
K
14


108
H
S
L
S
G
M
E
S
T
V
14


110
L
S
G
M
E
S
T
V
L
L
14


111
S
G
M
E
S
T
V
L
L
A
14


207
I
S
A
I
G
L
D
S
L
L
14


220
S
Y
L
L
I
L
K
T
V
L
14


224
I
L
K
T
V
L
G
L
T
R
14


235
A
Q
A
K
A
F
G
T
C
V
14


243
C
V
S
H
V
C
A
V
F
I
14


257
F
I
G
L
S
M
V
H
R
F
14


288
V
L
N
P
I
V
Y
G
V
K
14


302
R
Q
R
I
L
R
L
F
H
V
14










101P3A11-V2-- HLA-A0201 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





4
Y
L
I
A
V
L
A
S
G
V
25
Portion of SEQ ID NO: 30;


6
I
A
V
L
A
S
G
V
T
L
20
each start position is


24
S
I
C
W
F
L
L
C
S
T
20
specified - the length of each


28
F
L
L
C
S
T
Q
L
S
M
20
peptide is ten amino acids,


2
S
L
Y
L
I
A
V
L
A
S
19
the end position for each


14
T
L
R
C
P
S
S
W
P
I
18
peptide is the start position


5
L
I
A
V
L
A
S
G
V
T
16
plus nine


29
L
L
C
S
T
Q
L
S
M
E
16


8
V
L
A
S
G
V
T
L
R
C
14


3
L
Y
L
I
A
V
L
A
S
G
12


7
A
V
L
A
S
G
V
T
L
R
12


9
L
A
S
G
V
T
L
R
C
P
12


20
S
W
P
I
S
I
C
W
F
L
12


21
W
P
I
S
I
C
W
F
L
L
12










101P3A11-V3- HLA A0201 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





7
L
L
Q
M
F
A
I
H
S
L
29
Portion of SEQ ID NO: 32;














each start position is specified -














the length of each peptide is ten














amino acids, the end position














for each peptide is the start














position plus nine
















TABLE XXXVI







101P3A11-V1- HLA-A0203 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





142
P
R
V
T
K
I
G
V
A
A
19
Portion of SEQ ID


148
G
V
A
A
V
V
R
G
A
A
19
NO: 28; each start


113
M
E
S
T
V
L
L
A
M
A
18
position is specified -


228
V
L
G
L
T
R
E
A
Q
A
18
the length of each


230
G
L
T
R
E
A
Q
A
K
A
18
peptide is ten amino


143
R
V
T
K
I
G
V
A
A
V
17
acids, the end position


149
V
A
A
V
V
R
G
A
A
L
17
for each peptide is the


3
V
D
P
N
G
N
E
S
S
A
10
start position plus nine


17
L
I
G
L
P
G
L
E
E
A
10


22
G
L
E
E
A
Q
F
W
L
A
10


32
F
P
L
C
S
L
Y
L
I
A
10


77
S
T
S
S
M
P
K
M
L
A
10


90
F
N
S
T
T
I
Q
F
D
A
10


97
F
D
A
C
L
L
Q
I
F
A
10


111
S
G
M
E
S
T
V
L
L
A
10


119
L
A
M
A
F
D
R
Y
V
A
10


127
V
A
I
C
H
P
L
R
H
A
10


141
L
P
R
V
T
K
I
G
V
A
10


147
I
G
V
A
A
V
V
R
G
A
10


151
A
V
V
R
G
A
A
L
M
A
10


182
C
L
H
Q
D
V
M
K
L
A
10


200
V
Y
G
L
I
V
I
I
S
A
10


226
K
T
V
L
G
L
T
R
E
A
10


240
F
G
T
C
V
S
H
V
C
A
10


270
R
D
S
P
L
P
V
I
L
A
10


303
Q
R
I
L
R
L
F
H
V
A
10


306
L
R
L
F
H
V
A
T
H
A
10


4
D
P
N
G
N
E
S
S
A
T
9


18
I
G
L
P
G
L
E
E
A
Q
9


23
L
E
E
A
Q
F
W
L
A
F
9


33
P
L
C
S
L
Y
L
I
A
V
9


78
T
S
S
M
P
K
M
L
A
I
9


91
N
S
T
T
I
Q
F
D
A
C
9


98
D
A
C
L
L
Q
I
F
A
I
9


112
G
M
E
S
T
V
L
L
A
M
9


114
E
S
T
V
L
L
A
M
A
F
9


120
A
M
A
F
D
R
Y
V
A
I
9


128
A
I
C
H
P
L
R
H
A
T
9


152
V
V
R
G
A
A
L
M
A
P
9


183
L
H
Q
D
V
M
K
L
A
C
9


201
Y
G
L
I
V
I
I
S
A
I
9


227
T
V
L
G
L
T
R
E
A
Q
9


229
L
G
L
T
R
E
A
Q
A
K
9


231
L
T
R
E
A
Q
A
K
A
F
9


241
G
T
C
V
S
H
V
C
A
V
9


271
D
S
P
L
P
V
I
L
A
N
9


304
R
I
L
R
L
F
H
V
A
T
9


307
R
L
F
H
V
A
T
H
A
S
9










101P3A11-V2-- HLA A0203 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





1
C
S
L
Y
L
I
A
V
L
A
10
Portion of SEQ ID NO:


2
S
L
Y
L
I
A
V
L
A
S
9
30; each start position


3
L
Y
L
I
A
V
L
A
S
G
8
is specified - the














length of each peptide














is ten amino acids, the














end position for each














peptide is the start














position plus nine










101P3A11-V3- HLA A0203 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





3
F
D
A
C
L
L
Q
M
F
A
10
Portion of SEQ ID NO:


4
D
A
C
L
L
Q
M
F
A
I
9
32; each start position


5
A
C
L
L
Q
M
F
A
I
H
8
is specified - the














length of each peptide














is ten amino acids, the














end position for each














peptide is the start














position plus nine
















TABLE XXXVII







101P3A11-V1- HLA-A3 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





137
T
V
L
T
L
P
R
V
T
K
31
Portion of SEQ ID


288
V
L
N
P
I
V
Y
G
V
K
28
NO: 28; each start


224
I
L
K
T
V
L
G
L
T
R
27
position is specified -


305
I
L
R
L
F
H
V
A
T
H
27
the length of each


74
I
L
I
S
T
S
S
M
P
K
26
peptide is ten amino


16
I
L
I
G
L
P
G
L
E
E
23
acids, the end position


41
A
V
L
G
N
L
T
I
I
Y
23
for each peptide is the


151
A
V
V
R
G
A
A
L
M
A
23
start position plus nine


259
G
L
S
M
V
H
R
F
S
K
23


19
G
L
P
G
L
E
E
A
Q
F
22


304
R
I
L
R
L
F
H
V
A
T
22


277
I
L
A
N
I
Y
L
L
V
P
21


29
W
L
A
F
P
L
C
S
L
Y
20


116
T
V
L
L
A
M
A
F
D
R
20


117
V
L
L
A
M
A
F
D
R
Y
20


126
Y
V
A
I
C
H
P
L
R
H
20


132
P
L
R
H
A
T
V
L
T
L
20


145
T
K
I
G
V
A
A
V
V
R
20


157
A
L
M
A
P
L
P
V
F
I
20


196
R
V
N
V
V
Y
G
L
I
V
20


36
S
L
Y
L
I
A
V
L
G
N
19


273
P
L
P
V
I
L
A
N
I
Y
19


38
Y
L
I
A
V
L
G
N
L
T
18


50
Y
I
V
R
T
E
H
S
L
H
18


51
I
V
R
T
E
H
S
L
H
E
18


109
S
L
S
G
M
E
S
T
V
L
18


143
R
V
T
K
I
G
V
A
A
V
18


189
K
L
A
C
D
D
I
R
V
N
18


280
N
I
Y
L
L
V
P
P
V
L
18


292
I
V
Y
G
V
K
T
K
E
I
18


295
G
V
K
T
K
E
I
R
Q
R
18


47
T
I
I
Y
I
V
R
T
E
H
17


103
Q
I
F
A
I
H
S
L
S
G
17


152
V
V
R
G
A
A
L
M
A
P
17


180
S
Y
C
L
H
Q
D
V
M
K
17


204
I
V
I
I
S
A
I
G
L
D
17


205
V
I
I
S
A
I
G
L
D
S
17


221
Y
L
L
I
L
K
T
V
L
G
17


222
L
L
I
L
K
T
V
L
G
L
17


228
V
L
G
L
T
R
E
A
Q
A
17


243
C
V
S
H
V
C
A
V
F
I
17


290
N
P
I
V
Y
G
V
K
T
K
17


39
L
I
A
V
L
G
N
L
T
I
16


86
A
I
F
W
F
N
S
T
T
I
16


148
G
V
A
A
V
V
R
G
A
A
16


199
V
V
Y
G
L
I
V
I
I
S
16


202
G
L
I
V
I
I
S
A
I
G
16


215
L
L
I
S
F
S
Y
L
L
I
16


227
T
V
L
G
L
T
R
E
A
Q
16


229
L
G
L
T
R
E
A
Q
A
K
16


230
G
L
T
R
E
A
Q
A
K
A
16


2
M
V
D
P
N
G
N
E
S
S
15


45
N
L
T
I
I
Y
I
V
R
T
15


48
I
I
Y
I
V
R
T
E
H
S
15


68
M
L
S
G
I
D
I
L
I
S
15


73
D
I
L
I
S
T
S
S
M
P
15


100
C
L
L
Q
I
F
A
I
H
S
15


106
A
I
H
S
L
S
G
M
E
S
15


146
K
I
G
V
A
A
V
V
R
G
15


176
I
L
S
H
S
Y
C
L
H
Q
15


192
C
D
D
I
R
V
N
V
V
Y
15


209
A
I
G
L
D
S
L
L
I
S
15


276
V
I
L
A
N
I
Y
L
L
V
15


282
Y
L
L
V
P
P
V
L
N
P
15


300
E
I
R
Q
R
I
L
R
L
F
15


307
R
L
F
H
V
A
T
H
A
S
15










101P3A11-V2-- HLA A3 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





7
A
V
L
A
S
G
V
T
L
R
22
Portion of SEQ ID NO: 30;


4
Y
L
I
A
V
L
A
S
G
V
21
each start position is


2
S
L
Y
L
I
A
V
L
A
S
20
specified - the length of each


12
G
V
T
L
R
C
P
S
S
W
17
peptide is ten amino acids,


28
F
L
L
C
S
T
Q
L
S
M
17
the end position for each


5
L
I
A
V
L
A
S
G
V
T
14
peptide is the start position


6
I
A
V
L
A
S
G
V
T
L
14
plus nine


8
V
L
A
S
G
V
T
L
R
C
14


29
L
L
C
S
T
Q
L
S
M
E
14


14
T
L
R
C
P
S
S
W
P
I
13


22
P
I
S
I
C
W
F
L
L
C
12


24
S
I
C
W
F
L
L
C
S
T
11










101P3A11-V3- HLA A3 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





6
C
L
L
Q
M
F
A
I
H
S
15
Portion of SEQ ID NO: 32; each


5
A
C
L
L
Q
M
F
A
I
H
13
start position is specified - the


7
L
L
Q
M
F
A
I
H
S
L
12
length of each peptide is ten


1
I
Q
F
D
A
C
L
L
Q
M
9
amino acids, the end position


2
Q
F
D
A
C
L
L
Q
M
F
9
for each peptide is the start


9
Q
M
F
A
I
H
S
L
S
G
9
position plus nine
















TABLE XXXVIII







101P3A11-V1- HLA-A26 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





300
E
I
R
Q
R
I
L
R
L
F
31
Portion of SEQ ID


194
D
I
R
V
N
V
V
Y
G
L
29
NO: 28; each start


251
F
I
F
Y
V
P
F
I
G
L
25
position is specified -


257
F
I
G
L
S
M
V
H
R
F
25
the length of each


75
L
I
S
T
S
S
M
P
K
M
24
peptide is ten amino


275
P
V
I
L
A
N
I
Y
L
L
24
acids, the end position


19
G
L
P
G
L
E
E
A
Q
F
23
for each peptide is the


117
V
L
L
A
M
A
F
D
R
Y
23
start position plus nine


206
I
I
S
A
I
G
L
D
S
L
23


222
L
L
I
L
K
T
V
L
G
L
23


231
L
T
R
E
A
Q
A
K
A
F
23


14
Y
F
I
L
I
G
L
P
G
L
22


41
A
V
L
G
N
L
T
I
I
Y
22


57
S
L
H
E
P
M
Y
I
F
L
22


96
Q
F
D
A
C
L
L
Q
I
F
22


216
L
I
S
F
S
Y
L
L
I
L
22


93
T
T
I
Q
F
D
A
C
L
L
21


101
L
L
Q
I
F
A
I
H
S
L
21


104
I
F
A
I
H
S
L
S
G
M
21


297
K
T
K
E
I
R
Q
R
I
L
21


29
W
L
A
F
P
L
C
S
L
Y
20


132
P
L
R
H
A
T
V
L
T
L
20


60
E
P
M
Y
I
F
L
C
M
L
19


92
S
T
T
I
Q
F
D
A
C
L
19


203
L
I
V
I
I
S
A
I
G
L
19


213
D
S
L
L
I
S
F
S
Y
L
19


273
P
L
P
V
I
L
A
N
I
Y
19


280
N
I
Y
L
L
V
P
P
V
L
19


53
R
T
E
H
S
L
H
E
P
M
18


63
Y
I
F
L
C
M
L
S
G
I
18


73
D
I
L
I
S
T
S
S
M
P
18


109
S
L
S
G
M
E
S
T
V
L
18


114
E
S
T
V
L
L
A
M
A
F
18


152
V
V
R
G
A
A
L
M
A
P
18


79
S
S
M
P
K
M
L
A
I
F
17


143
R
V
T
K
I
G
V
A
A
V
17


163
P
V
F
I
K
Q
L
P
F
C
17


165
F
I
K
Q
L
P
F
C
R
S
17


168
Q
L
P
F
C
R
S
N
I
L
17


186
D
V
M
K
L
A
C
D
D
I
17


249
A
V
F
I
F
Y
V
P
F
I
17


254
Y
V
P
F
I
G
L
S
M
V
17


46
L
T
I
I
Y
I
V
R
T
E
16


146
K
I
G
V
A
A
V
V
R
G
16


199
V
V
Y
G
L
I
V
I
I
S
16


204
I
V
I
I
S
A
I
G
L
D
16


210
I
G
L
D
S
L
L
I
S
F
16


214
S
L
L
I
S
F
S
Y
L
L
16


256
P
F
I
G
L
S
M
V
H
R
16


265
R
F
S
K
R
R
D
S
P
L
16


295
G
V
K
T
K
E
I
R
Q
R
16


17
L
I
G
L
P
G
L
E
E
A
15


81
M
P
K
M
L
A
I
F
W
F
15


115
S
T
V
L
L
A
M
A
F
D
15


156
A
A
L
M
A
P
L
P
V
F
15


160
A
P
L
P
V
F
I
K
Q
L
15


175
N
I
L
S
H
S
Y
C
L
H
15


198
N
V
V
Y
G
L
I
V
I
I
15


211
G
L
D
S
L
L
I
S
F
S
15


215
L
L
I
S
F
S
Y
L
L
I
15


223
L
I
L
K
T
V
L
G
L
T
15


241
G
T
C
V
S
H
V
C
A
V
15


248
C
A
V
F
I
F
Y
V
P
F
15


287
P
V
L
N
P
I
V
Y
G
V
15


299
K
E
I
R
Q
R
I
L
R
L
15










101P3A11-V2-- HLA A26 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





28
F
L
L
C
S
T
Q
L
S
M
17
Portion of SEQ ID NO: 30;


19
S
S
W
P
I
S
I
C
W
F
16
each start position is


24
S
I
C
W
F
L
L
C
S
T
15
specified - the length of each


29
L
L
C
S
T
Q
L
S
M
E
15
peptide is ten amino acids,


7
A
V
L
A
S
G
V
T
L
R
14
the end position for each


22
P
I
S
I
C
W
F
L
L
C
14
peptide is the start position


2
S
L
Y
L
I
A
V
L
A
S
13
plus nine


4
Y
L
I
A
V
L
A
S
G
V
12


12
G
V
T
L
R
C
P
S
S
W
12


5
L
I
A
V
L
A
S
G
V
T
11


8
V
L
A
S
G
V
T
L
R
C
11


13
V
T
L
R
C
P
S
S
W
P
11


21
W
P
I
S
I
C
W
F
L
L
11


26
C
W
F
L
L
C
S
T
Q
L
11


6
I
A
V
L
A
S
G
V
T
L
9


20
S
W
P
I
S
I
C
W
F
L
9


14
T
L
R
C
P
S
S
W
P
I
8










101P3A11-V3- HLA A26 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





2
Q
F
D
A
C
L
L
Q
M
F
23
Portion of SEQ ID NO: 32;


7
L
L
Q
M
F
A
I
H
S
L
21
each start position is specified -


10
M
F
A
I
H
S
L
S
G
M
21
the length of each peptide is ten


1
I
Q
F
D
A
C
L
L
Q
M
16
amino acids, the end position


4
D
A
C
L
L
Q
M
F
A
I
11
for each peptide is the start














position plus nine
















TABLE XXXIX







101P3A11-V1- HLA-B0702 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





160
A
P
L
P
V
F
I
K
Q
L
23
Portion of SEQ ID


60
E
P
M
Y
I
F
L
C
M
L
22
NO: 28; each start


274
L
P
V
I
L
A
N
I
Y
L
20
position is specified -


4
D
P
N
G
N
E
S
S
A
T
19
the length of each


131
H
P
L
R
H
A
T
V
L
T
19
peptide is ten amino


141
L
P
R
V
T
K
I
G
V
A
19
acids, the end


162
L
P
V
F
I
K
Q
L
P
F
19
position for each


32
F
P
L
C
S
L
Y
L
I
A
18
peptide is the start


272
S
P
L
P
V
I
L
A
N
I
18
position plus nine


81
M
P
K
M
L
A
I
F
W
F
16


109
S
L
S
G
M
E
S
T
V
L
16


132
P
L
R
H
A
T
V
L
T
L
15


265
R
F
S
K
R
R
D
S
P
L
15


34
L
C
S
L
Y
L
I
A
V
L
14


110
L
S
G
M
E
S
T
V
L
L
14


153
V
R
G
A
A
L
M
A
P
L
14


206
I
I
S
A
I
G
L
D
S
L
14


216
L
I
S
F
S
Y
L
L
I
L
14


269
R
R
D
S
P
L
P
V
I
L
14


30
L
A
F
P
L
C
S
L
Y
L
13


149
V
A
A
V
V
R
G
A
A
L
13


157
A
L
M
A
P
L
P
V
F
I
13


194
D
I
R
V
N
V
V
Y
G
L
13


222
L
L
I
L
K
T
V
L
G
L
13


299
K
E
I
R
Q
R
I
L
R
L
13


8
N
E
S
S
A
T
Y
F
I
L
12


20
L
P
G
L
E
E
A
Q
F
W
12


25
E
A
Q
F
W
L
A
F
P
L
12


120
A
M
A
F
D
R
Y
V
A
I
12


130
C
H
P
L
R
H
A
T
V
L
12


207
I
S
A
I
G
L
D
S
L
L
12


220
S
Y
L
L
I
L
K
T
V
L
12


280
N
I
Y
L
L
V
P
P
V
L
12


286
P
P
V
L
N
P
I
V
Y
G
12


9
E
S
S
A
T
Y
F
I
L
I
11


14
Y
F
I
L
I
G
L
P
G
L
11


28
F
W
L
A
F
P
L
C
S
L
11


49
I
Y
I
V
R
T
E
H
S
L
11


57
S
L
H
E
P
M
Y
I
F
L
11


66
L
C
M
L
S
G
I
D
I
L
11


76
I
S
T
S
S
M
P
K
M
L
11


78
T
S
S
M
P
K
M
L
A
I
11


92
S
T
T
I
Q
F
D
A
C
L
11


124
D
R
Y
V
A
I
C
H
P
L
11


143
R
V
T
K
I
G
V
A
A
V
11


181
Y
C
L
H
Q
D
V
M
K
L
11


191
A
C
D
D
I
R
V
N
V
V
11


213
D
S
L
L
I
S
F
S
Y
L
11


235
A
Q
A
K
A
F
G
T
C
V
11


243
C
V
S
H
V
C
A
V
F
I
11


249
A
V
F
I
F
Y
V
P
F
I
11


251
F
I
F
Y
V
P
F
I
G
L
11


255
V
P
F
I
G
L
S
M
V
H
11


267
S
K
R
R
D
S
P
L
P
V
11


268
K
R
R
D
S
P
L
P
V
I
11


270
R
D
S
P
L
P
V
I
L
A
11


279
A
N
I
Y
L
L
V
P
P
V
11


285
V
P
P
V
L
N
P
I
V
Y
11


290
N
P
I
V
Y
G
V
K
T
K
11


297
K
T
K
E
I
R
Q
R
I
L
11










101P3A11-V2-- HLA B0702 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





21
W
P
I
S
I
C
W
F
L
L
20
Portion of SEQ ID NO: 30;


6
I
A
V
L
A
S
G
V
T
L
13
each start position is


17
C
P
S
S
W
P
I
S
I
C
12
specified - the length of each


20
S
W
P
I
S
I
C
W
F
L
11
peptide is ten amino acids,


26
C
W
F
L
L
C
S
T
Q
L
11
the end position for each


14
T
L
R
C
P
S
S
W
P
I
9
peptide is the start position














plus nine










101P3A11-V3- HLA B0702 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score





7
L
L
Q
M
F
A
I
H
S
L
10
Portion of SEQ ID NO: 32;


1
I
Q
F
D
A
C
L
L
Q
M
9
each start position is specified -


2
Q
F
D
A
C
L
L
Q
M
F
8
the length of each peptide is ten


3
F
D
A
C
L
L
Q
M
F
A
8
amino acids, the end position


4
D
A
C
L
L
Q
M
F
A
I
7
for each peptide is the start


10
M
F
A
I
H
S
L
S
G
M
7
position plus nine


5
A
C
L
L
Q
M
F
A
I
H
4
















TABLE XL







101P3A11 V1-HLA B08 10-mers









No Results.



 







101P3A11 V2-HLA B08 10-mers









No Results.



 







101P3A11 V3-HLA B08 10-mers









No Results.

















TABLE XLI 







101P3A11 v1-HLA B1510 10-mers









No results.



 







101P3A11 v2-HLA B1510 10-mers









No results.



 







101P3A11 v3 HLA B1510 10-mers









No results.

















TABLE XLII







101P3A11 v1-HLA B2705 10-mers









No results.



 







101P3A11 v2-HLA B2705 10-mers









No results.



 







101P3A11 v3 HLA B2705 10-mers









No results.

















TABLE XLIII







101P3A11 v1-HLA B2709 10-mers









No results.



 







101P3A11 v2-HLA B2709 10-mers









No results.



 







101P3A11 v3 HLA B2709 10-mers









No results.

















TABLE XLIV







101P3A11-V1- HLA-B4402 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score






299
K
E
I
R
Q
R
I
L
R
L
29
Portion of SEQ ID NO:


23
L
E
E
A
Q
F
W
L
A
F
23
28; each start position


160
A
P
L
P
V
F
I
K
Q
L
23
is specified - the length


8
N
E
S
S
A
T
Y
F
I
L
22
of each peptide is ten


54
T
E
H
S
L
H
E
P
M
Y
20
amino acids, the end


275
P
V
I
L
A
N
I
Y
L
L
18
position for each


41
A
V
L
G
N
L
T
I
I
Y
17
peptide is the start


30
L
A
F
P
L
C
S
L
Y
L
16
position plus nine


34
L
C
S
L
Y
L
I
A
V
L
16



79
S
S
M
P
K
M
L
A
I
F
16



88
F
W
F
N
S
T
T
I
Q
F
16



156
A
A
L
M
A
P
L
P
V
F
16



222
L
L
I
L
K
T
V
L
G
L
16



14
Y
F
I
L
I
G
L
P
G
L
15



31
A
F
P
L
C
S
L
Y
L
I
15



66
L
C
M
L
S
G
I
D
I
L
15



93
T
T
I
Q
F
D
A
C
L
L
15



114
E
S
T
V
L
L
A
M
A
F
15



174
S
N
I
L
S
H
S
Y
C
L
15



208
S
A
I
G
L
D
S
L
L
I
15



231
L
T
R
E
A
Q
A
K
A
F
15



300
E
I
R
Q
R
I
L
R
L
F
15



9
E
S
S
A
T
Y
F
I
L
I
14



49
I
Y
I
V
R
T
E
H
S
L
14



60
E
P
M
Y
I
F
L
C
M
L
14



80
S
M
P
K
M
L
A
I
F
W
14



86
A
I
F
W
F
N
S
T
T
I
14



95
I
Q
F
D
A
C
L
L
Q
I
14



98
D
A
C
L
L
Q
I
F
A
I
14



101
L
L
Q
I
F
A
I
H
S
L
14



109
S
L
S
G
M
E
S
T
V
L
14



120
A
M
A
F
D
R
Y
V
A
I
14



130
C
H
P
L
R
H
A
T
V
L
14



157
A
L
M
A
P
L
P
V
F
I
14



167
K
Q
L
P
F
C
R
S
N
I
14



201
Y
G
L
I
V
I
I
S
A
I
14



210
I
G
L
D
S
L
L
I
S
F
14



220
S
Y
L
L
I
L
K
T
V
L
14



249
A
V
F
I
F
Y
V
P
F
I
14



251
F
I
F
Y
V
P
F
I
G
L
14



272
S
P
L
P
V
I
L
A
N
I
14



280
N
I
Y
L
L
V
P
P
V
L
14



285
V
P
P
V
L
N
P
I
V
Y
14










101P3A11-V2-- HLA B4402 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score






19
S
S
W
P
I
S
I
C
W
F
17
Portion of SEQ ID NO: 30;


21
W
P
I
S
I
C
W
F
L
L
14
each start position is specified -


26
C
W
F
L
L
C
S
T
Q
L
14
the length of each peptide is


6
I
A
V
L
A
S
G
V
T
L
13
ten amino acids, the end


12
G
V
T
L
R
C
P
S
S
W
12
position for each peptide is


18
P
S
S
W
P
I
S
I
C
W
12
the start position plus nine


20
S
W
P
I
S
I
C
W
F
L
12



16
R
C
P
S
S
W
P
I
S
I
11



14
T
L
R
C
P
S
S
W
P
I
8










101P3A11-V3- HLA B4402 10-mers



















Pos
1
2
3
4
5
6
7
8
9
0
score






7
L
L
Q
M
F
A
I
H
S
L
14
Portion of SEQ ID NO: 32;


2
Q
F
D
A
C
L
L
Q
M
F
12
each start position is specified -


4
D
A
C
L
L
Q
M
F
A
I
11
the length of each peptide is ten


1
I
Q
F
D
A
C
L
L
Q
M
6
amino acids, the end position


5
A
C
L
L
Q
M
F
A
I
H
6
for each peptide is the start














position plus nine
















TABLE XLV







101P3A11 v1-HLA B5101 10-mers









No Results



 







101P3A11 v2-HLA B5101 10-mers









No Results



 







101P3A11 v3 HLA B5101 10-mers









No results.

















TABLE XLVI







101P3A11-V1- DRB-0101 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






201
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
L
36
Portion of SEQ ID


69
L
S
G
I
D
I
L
I
S
T
S
S
M
P
K
34
NO: 28; each start


63
Y
I
F
L
C
M
L
S
G
I
D
I
L
I
S
33
position is specified -


104
I
F
A
I
H
S
L
S
G
M
E
S
T
V
L
32
the length of each


46
L
T
I
I
Y
I
V
R
T
E
H
S
L
H
E
31
peptide is 15 amino


194
D
I
R
V
N
V
V
Y
G
L
I
V
I
I
S
31
acids, the end


278
L
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
31
position for each


98
D
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
30
peptide is the start


107
I
H
S
L
S
G
M
E
S
T
V
L
L
A
M
30
position plus


241
G
T
C
V
S
H
V
C
A
V
F
I
F
Y
V
30
fourteen


11
S
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
29



290
N
P
I
V
Y
G
V
K
T
K
E
I
R
Q
R
29



12
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
A
28



251
F
I
F
Y
V
P
F
I
G
L
S
M
V
H
R
27



141
L
P
R
V
T
K
I
G
V
A
A
V
V
R
G
26



184
H
Q
D
V
M
K
L
A
C
D
D
I
R
V
N
26



218
S
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
26



17
L
I
G
L
P
G
L
E
E
A
Q
F
W
L
A
25



25
E
A
Q
F
W
L
A
F
P
L
C
S
L
Y
L
25



37
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
I
25



71
G
I
D
I
L
I
S
T
S
S
M
P
K
M
L
25



112
G
M
E
S
T
V
L
L
A
M
A
F
D
R
Y
25



149
V
A
A
V
V
R
G
A
A
L
M
A
P
L
P
25



163
P
V
F
I
K
Q
L
P
F
C
R
S
N
I
L
25



198
N
V
V
Y
G
L
I
V
I
I
S
A
I
G
L
25



212
L
D
S
L
L
I
S
F
S
Y
L
L
I
L
K
25



219
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
R
25



14
Y
F
I
L
I
G
L
P
G
L
E
E
A
Q
F
24



31
A
F
P
L
C
S
L
Y
L
I
A
V
L
G
N
24



40
I
A
V
L
G
N
L
T
I
I
Y
I
V
R
T
24



78
T
S
S
M
P
K
M
L
A
I
F
W
F
N
S
24



86
A
I
F
W
F
N
S
T
T
I
Q
F
D
A
C
24



138
V
L
T
L
P
R
V
T
K
I
G
V
A
A
V
24



152
V
V
R
G
A
A
L
M
A
P
L
P
V
F
I
24



162
L
P
V
F
I
K
Q
L
P
F
C
R
S
N
I
24



197
V
N
V
V
Y
G
L
I
V
I
I
S
A
I
G
24



203
L
I
V
I
I
S
A
I
G
L
D
S
L
L
I
24



209
A
I
G
L
D
S
L
L
I
S
F
S
Y
L
L
24



249
A
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
24



252
I
F
Y
V
P
F
I
G
L
S
M
V
H
R
F
24



84
M
L
A
I
F
W
F
N
S
T
T
I
Q
F
D
23



102
L
Q
I
F
A
I
H
S
L
S
G
M
E
S
T
23



166
I
K
Q
L
P
F
C
R
S
N
I
L
S
H
S
23



204
I
V
I
I
S
A
I
G
L
D
S
L
L
I
S
23



222
L
L
I
L
K
T
V
L
G
L
T
R
E
A
Q
23



279
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
V
23



28
F
W
L
A
F
P
L
C
S
L
Y
L
I
A
V
22



36
S
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
22



62
M
Y
I
F
L
C
M
L
S
G
I
D
I
L
I
22



66
L
C
M
L
S
G
I
D
I
L
I
S
T
S
S
22



81
M
P
K
M
L
A
I
F
W
F
N
S
T
T
I
22



146
K
I
G
V
A
A
V
V
R
G
A
A
L
M
A
22



147
I
G
V
A
A
V
V
R
G
A
A
L
M
A
P
22



155
G
A
A
L
M
A
P
L
P
V
F
I
K
Q
L
22



206
I
I
S
A
I
G
L
D
S
L
L
I
S
F
S
22



244
V
S
H
V
C
A
V
F
I
F
Y
V
P
F
I
22



271
D
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
22



275
P
V
I
L
A
N
I
Y
L
L
V
P
P
V
L
22



282
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
V
22



35
C
S
L
Y
L
I
A
V
L
G
N
L
T
I
I
21



70
S
G
I
D
I
L
I
S
T
S
S
M
P
K
M
21



153
V
R
G
A
A
L
M
A
P
L
P
V
F
I
K
21



300
E
I
R
Q
R
I
L
R
L
F
H
V
A
T
H
21



101
L
L
Q
I
F
A
I
H
S
L
S
G
M
E
S
20



136
A
T
V
L
T
L
P
R
V
T
K
I
G
V
A
20



142
P
R
V
T
K
I
G
V
A
A
V
V
R
G
A
20



192
C
D
D
I
R
V
N
V
V
Y
G
L
I
V
I
20



200
V
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
20



263
V
H
R
F
S
K
R
R
D
S
P
L
P
V
I
20



272
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
P
20



29
W
L
A
F
P
L
C
S
L
Y
L
I
A
V
L
19



59
H
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
19



60
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
I
19



61
P
M
Y
I
F
L
C
M
L
S
G
I
D
I
L
19



99
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
M
19



216
L
I
S
F
S
Y
L
L
I
L
K
T
V
L
G
19



220
S
Y
L
L
I
L
K
T
V
L
G
L
T
R
E
19



229
L
G
L
T
R
E
A
Q
A
K
A
F
G
T
C
19



233
R
E
A
Q
A
K
A
F
G
T
C
V
S
H
V
19



247
V
C
A
V
F
I
F
Y
V
P
F
I
G
L
S
19



298
T
K
E
I
R
Q
R
I
L
R
L
F
H
V
A
19



4
D
P
N
G
N
E
S
S
A
T
Y
F
I
L
I
18



15
P
I
L
I
G
L
P
G
L
E
E
A
Q
P
W
18



26
A
Q
F
W
L
A
F
P
L
C
S
L
Y
L
I
18



43
L
G
N
L
T
I
I
Y
I
V
R
T
E
H
S
18



47
T
I
I
Y
I
V
R
T
E
H
S
L
H
E
P
18



79
S
S
M
P
K
M
L
A
I
F
W
F
N
S
T
18



85
L
A
I
F
W
F
N
S
T
T
I
Q
F
D
A
18



90
F
N
S
T
T
I
Q
F
D
A
C
L
L
Q
I
18



94
T
I
Q
F
D
A
C
L
L
Q
I
F
A
I
H
18



116
T
V
L
L
A
M
A
F
D
R
Y
V
A
I
C
18



120
A
M
A
F
D
R
Y
V
A
I
C
H
P
L
R
18



128
A
I
C
H
P
L
R
H
A
T
V
L
T
L
P
18



130
C
H
P
L
R
H
A
T
V
L
T
L
P
R
V
18



148
G
V
A
A
V
V
R
G
A
A
L
M
A
P
L
18



150
A
A
V
V
R
G
A
A
L
M
A
P
L
P
V
18



217
I
S
F
S
Y
L
L
I
L
K
T
V
L
G
L
18



228
V
L
G
L
T
R
E
A
Q
A
K
A
F
G
T
18



250
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
H
18



254
Y
V
P
F
I
G
L
S
M
V
H
R
F
S
K
18



285
V
P
P
V
L
N
P
I
V
Y
G
V
K
T
K
18



287
P
V
L
N
P
I
V
Y
G
V
K
T
K
E
I
18



304
R
I
L
R
L
F
H
V
A
T
H
A
S
E
P
18



13
T
Y
F
I
L
I
G
L
P
G
L
E
E
A
Q
17



23
L
E
E
A
Q
F
W
L
A
F
P
L
C
S
L
17



34
L
C
S
L
Y
L
I
A
V
L
G
N
L
T
I
17



73
D
I
L
I
S
T
S
S
M
P
K
M
L
A
I
17



96
Q
F
D
A
C
L
L
Q
I
F
A
I
H
S
L
17



114
E
S
T
V
L
L
A
M
A
F
D
R
Y
V
A
17



118
L
L
A
M
A
F
D
R
Y
V
A
I
C
H
P
17



123
F
D
R
Y
V
A
I
C
H
P
L
R
H
A
T
17



124
D
R
Y
V
A
I
C
H
P
L
R
H
A
T
V
17



133
L
R
H
A
T
V
L
T
L
P
R
V
T
K
I
17



140
T
L
P
R
V
T
K
I
G
V
A
A
V
V
R
17



180
S
Y
C
L
H
Q
D
V
M
K
L
A
C
D
D
17



196
R
V
N
V
V
Y
G
L
I
V
I
I
S
A
I
17



199
V
V
Y
G
L
I
V
I
I
S
A
I
G
L
D
17



207
I
S
A
I
G
L
D
S
L
L
I
S
F
S
Y
17



214
S
L
L
I
S
F
S
Y
L
L
I
L
K
T
V
17



224
I
L
K
T
V
L
G
L
T
R
E
A
Q
A
K
17



226
K
T
V
L
G
L
T
R
E
A
Q
A
K
A
F
17



248
C
A
V
F
I
F
Y
V
P
F
I
G
L
S
M
17



255
V
P
F
I
G
L
S
M
V
H
R
F
S
K
R
17



273
P
L
P
V
I
L
A
N
I
Y
L
L
V
P
P
17



281
I
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
17










101P3A11-V2-DRB 0101 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






29
S
I
C
W
F
L
L
C
S
T
Q
L
S
M
E
34
Portion of SEQ ID NO: 30;


7
S
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
32
each start position is


2
A
F
P
L
C
S
L
Y
L
I
A
V
L
A
S
24
specified - the length of each


4
P
L
C
S
L
Y
L
I
A
V
L
A
S
G
V
24
peptide is 15 amino acids,


17
G
V
T
L
R
C
P
S
S
W
P
I
S
I
C
24
the end position for each


5
L
C
S
L
Y
L
I
A
V
L
A
S
G
V
T
23
peptide is the start position


8
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
C
22
plus fourteen


23
P
S
S
W
P
I
S
I
C
W
F
L
L
C
S
21



9
Y
L
I
A
V
L
A
S
G
V
T
L
R
C
P
18



14
L
A
S
G
V
T
L
R
C
P
S
S
W
P
I
17



15
A
S
G
V
T
L
R
C
P
S
S
W
P
I
S
16










101P3A11-V3- DRB 0101 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






15
M
F
A
I
H
S
L
S
G
M
E
S
T
V
L
32
Portion of SEQ ID NO: 32;


9
D
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
30
each start position is


13
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
T
23
specified - the length of each


12
L
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
20
peptide is 15 amino acids, the


1
F
N
S
T
T
I
Q
F
D
A
C
L
L
Q
M
18
end position for each peptide


5
T
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
18
is the start position plus


7
Q
F
D
A
C
L
L
Q
M
F
A
I
H
S
L
17
fourteen


10
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
M
17



2
N
S
T
T
I
Q
F
D
A
C
L
L
Q
M
F
16



6
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
S
16
















TABLE XLVII







101P3A11-V1- DRB-0301 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






17
L
I
G
L
P
G
L
E
E
A
Q
F
W
L
A
26
Portion of SEQ ID



















NO: 28; each start



















position is specified -



















the length of each



















peptide is 15 amino



















acids, the end



















position for each



















peptide is the start



















position plus



















fourteen


207
I
S
A
I
G
L
D
S
L
L
I
S
F
S
Y
23



92
S
T
T
I
Q
F
D
A
C
L
L
Q
I
F
A
22



118
L
L
A
M
A
F
D
R
Y
V
A
I
C
H
P
22



39
L
I
A
V
L
G
N
L
T
I
I
Y
I
V
R
21



180
S
Y
C
L
H
Q
D
V
M
K
L
A
C
D
D
21



212
L
D
S
L
L
I
S
F
S
Y
L
L
I
L
K
21



220
S
Y
L
L
I
L
K
T
V
L
G
L
T
R
E
21



273
P
L
P
V
I
L
A
N
I
Y
L
L
V
P
P
21



27
Q
F
W
L
A
F
P
L
C
S
L
Y
L
I
A
20



115
S
T
V
L
L
A
M
A
F
D
R
Y
V
A
I
20



130
C
H
P
L
R
H
A
T
V
L
T
L
P
R
V
20



135
H
A
T
V
L
T
L
P
R
V
T
K
I
G
V
20



187
V
M
K
L
A
C
D
D
I
R
V
N
V
V
Y
20



201
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
L
20



271
D
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
20



298
T
K
E
I
R
Q
R
I
L
R
L
F
H
V
A
20



12
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
A
19



55
E
H
S
L
H
E
P
M
Y
I
F
L
C
M
L
19



107
I
H
S
L
S
G
M
E
S
T
V
L
L
A
M
19



166
I
K
Q
L
P
F
C
R
S
N
I
L
S
H
S
19



192
C
D
D
I
R
V
N
V
V
Y
G
L
I
V
I
19



204
I
V
I
I
S
A
I
G
L
D
S
L
L
I
S
19



214
S
L
L
I
S
F
S
Y
L
L
I
L
K
T
V
19



225
L
K
T
V
L
G
L
T
R
E
A
Q
A
K
A
19



228
V
L
G
L
T
R
E
A
Q
A
K
A
F
G
T
19



249
A
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
19



255
V
P
F
I
G
L
S
M
V
H
R
F
S
K
R
19



278
L
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
19



37
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
I
18



94
T
I
Q
F
D
A
C
L
L
Q
I
F
A
I
H
18



99
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
M
18



126
Y
V
A
I
C
H
P
L
R
H
A
T
V
L
T
18



159
M
A
P
L
P
V
F
I
K
Q
L
P
F
C
R
18



188
M
K
L
A
C
D
D
I
R
V
N
V
V
Y
G
18



218
S
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
18



226
K
T
V
L
G
L
T
R
E
A
Q
A
K
A
F
18



282
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
V
18



289
L
N
P
I
V
Y
G
V
K
T
K
E
I
R
Q
18



19
G
L
P
G
L
E
E
A
Q
F
W
L
A
F
P
17



45
N
L
T
I
I
Y
I
V
R
T
E
H
S
L
H
17



146
K
I
G
V
A
A
V
V
R
G
A
A
L
M
A
17



160
A
P
L
P
V
F
I
K
Q
L
P
F
C
R
S
17



257
F
I
G
L
S
M
V
H
R
F
S
K
R
R
D
17



260
L
S
M
V
H
R
F
S
K
R
R
D
S
P
L
17



138
V
L
T
L
P
R
V
T
K
I
G
V
A
A
V
16



263
V
H
R
F
S
K
R
R
D
S
P
L
P
V
I
16



295
G
V
K
T
K
E
I
R
Q
R
I
L
R
L
F
16



47
T
I
I
Y
I
V
R
T
E
H
S
L
H
E
P
15



52
V
R
T
E
H
S
L
H
E
P
M
Y
I
F
L
15



173
R
S
N
I
L
S
H
S
Y
C
L
H
Q
D
V
15



190
L
A
C
D
D
I
R
V
N
V
V
Y
G
L
I
15



213
D
S
L
L
I
S
F
S
Y
L
L
I
L
K
T
15



219
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
R
15



272
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
P
15



280
N
I
Y
L
L
V
P
P
V
L
N
P
I
V
Y
15



13
T
Y
F
I
L
I
G
L
P
G
L
E
E
A
Q
14



36
S
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
14



65
F
L
C
M
L
S
G
I
D
I
L
I
S
T
S
14



141
L
P
R
V
T
K
I
G
V
A
A
V
V
R
G
14



274
L
P
V
I
L
A
N
I
Y
L
L
V
P
P
V
14



302
R
Q
R
I
L
R
L
F
H
V
A
T
H
A
S
14



14
Y
F
I
L
I
G
L
P
G
L
E
E
A
Q
F
13



48
I
I
Y
I
V
R
T
E
H
S
L
H
E
P
M
13



72
I
D
I
L
I
S
T
S
S
M
P
K
M
L
A
13



81
M
P
K
M
L
A
I
F
W
F
N
S
T
T
I
13



110
L
S
G
M
E
S
T
V
L
L
A
M
A
F
D
13



114
E
S
T
V
L
L
A
M
A
F
D
R
Y
V
A
13



136
A
T
V
L
T
L
P
R
V
T
K
I
G
V
A
13



196
R
V
N
V
V
Y
G
L
I
V
I
I
S
A
I
13



203
L
I
V
I
I
S
A
I
G
L
D
S
L
L
I
13



221
Y
L
L
I
L
K
T
V
L
G
L
T
R
E
A
13



222
L
L
I
L
K
T
V
L
G
L
T
R
E
A
Q
13



265
R
F
S
K
R
R
D
S
P
L
P
V
I
L
A
13



281
I
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
13



303
Q
R
I
L
R
L
F
H
V
A
T
H
A
S
E
13



15
F
I
L
I
G
L
P
G
L
E
E
A
Q
F
W
12



20
L
P
G
L
E
E
A
Q
F
W
L
A
F
P
L
12



31
A
F
P
L
C
S
L
Y
L
I
A
V
L
G
N
12



34
L
C
S
L
Y
L
I
A
V
L
G
N
L
T
I
12



43
L
G
N
L
T
I
I
Y
I
V
R
T
E
H
S
12



49
I
Y
I
V
R
T
E
H
S
L
H
E
P
M
Y
12



59
H
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
12



63
Y
I
F
L
C
M
L
S
G
I
D
I
L
I
S
12



71
G
I
D
I
L
I
S
T
S
S
M
P
K
M
L
12



73
D
I
L
I
S
T
S
S
M
P
K
M
L
A
I
12



98
D
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
12



104
I
F
A
I
H
S
L
S
G
M
E
S
T
V
L
12



108
H
S
L
S
G
M
E
S
T
V
L
L
A
M
A
12



149
V
A
A
V
V
R
G
A
A
L
M
A
P
L
P
12



150
A
A
V
V
R
G
A
A
L
M
A
P
L
P
V
12



154
R
G
A
A
L
M
A
P
L
P
V
F
I
K
Q
12



155
G
A
A
L
M
A
P
L
P
V
F
I
K
Q
L
12



156
A
A
L
M
A
P
L
P
V
F
I
K
Q
L
P
12



163
P
V
F
I
K
Q
L
P
F
C
R
S
N
I
L
12



185
Q
D
V
M
K
L
A
C
D
D
I
R
V
N
V
12



200
V
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
12



202
G
L
I
V
I
I
S
A
I
G
L
D
S
L
L
12



209
A
I
G
L
D
S
L
L
I
S
F
S
Y
L
L
12



211
G
L
D
S
L
L
I
S
F
S
Y
L
L
I
L
12



285
V
P
P
V
L
N
P
I
V
Y
G
V
K
T
K
12



293
V
Y
G
V
K
T
K
E
I
R
Q
R
I
L
R
12










101P3A11-V2-DRB 0301 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






10
L
I
A
V
L
A
S
G
V
T
L
R
C
P
S
14
Portion of SEQ ID NO: 30;


5
L
C
S
L
Y
L
I
A
V
L
A
S
G
V
T
13
each start position is


2
A
F
P
L
C
S
L
Y
L
I
A
V
L
A
S
12
specified - the length of each


7
S
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
12
peptide is 15 amino acids,


9
Y
L
I
A
V
L
A
S
G
V
T
L
R
C
P
12
the end position for each


11
I
A
V
L
A
S
G
V
T
L
R
C
P
S
S
12
peptide is the start position


15
A
S
G
V
T
L
R
C
P
S
S
W
P
I
S
12
plus fourteen


17
G
V
T
L
R
C
P
S
S
W
P
I
S
I
C
12



25
S
W
P
I
S
I
C
W
F
L
L
C
S
T
Q
12



3
F
P
L
C
S
L
Y
L
I
A
V
L
A
S
G
11



24
S
S
W
P
I
S
I
C
W
F
L
L
C
S
T
11



27
P
I
S
I
C
W
F
L
L
C
S
T
Q
L
S
11



8
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
C
10



22
C
P
S
S
W
P
I
S
I
C
W
F
L
L
C
10



29
S
I
C
W
F
L
L
C
S
T
Q
L
S
M
E
9



23
P
S
S
W
P
I
S
I
C
W
F
L
L
C
S
8



13
V
L
A
S
G
V
T
L
R
C
P
S
S
W
P
7










101P3A11-V3- DRB 0301 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






3
S
T
T
I
Q
F
D
A
C
L
L
Q
M
F
A
22
Portion of SEQ ID NO: 32;


10
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
M
19
each start position is


5
T
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
18
specified - the length of each


9
D
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
12
peptide is 15 amino acids,


15
M
F
A
I
H
S
L
S
G
M
E
S
T
V
L
12
the end position for each


12
L
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
11
peptide is the start position


1
F
N
S
T
T
I
Q
F
D
A
C
L
L
Q
M
10
plus fourteen


2
N
S
T
T
I
Q
F
D
A
C
L
L
Q
M
F
10
















TABLE XLVIII







101P3A11-V1- DR1-0410 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






37
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
I
26
Portion of SEQ ID


46
L
T
I
I
Y
I
V
R
T
E
H
S
L
H
E
26
NO: 28; each start


69
L
S
G
I
D
I
L
I
S
T
S
S
M
P
K
26
position is specified -


84
M
L
A
I
F
W
F
N
S
T
T
I
Q
F
D
26
the length of each


135
H
A
T
V
L
T
L
P
R
V
T
K
I
G
V
26
peptide is 15 amino


146
K
I
G
V
A
A
V
V
R
G
A
A
L
M
A
26
acids, the end


225
L
K
T
V
L
G
L
T
R
E
A
Q
A
K
A
26
position for each


228
V
L
G
L
T
R
E
A
Q
A
K
A
F
G
T
26
peptide is the start


257
F
I
G
L
S
M
V
H
R
F
S
K
R
R
D
26
position plus


282
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
V
26
fourteen


290
N
P
I
V
Y
G
V
K
T
K
E
I
R
Q
R
26



302
R
Q
R
I
L
R
L
F
H
V
A
T
H
A
S
26



12
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
A
22



25
E
A
Q
F
W
L
A
F
P
L
C
S
L
Y
L
22



26
A
Q
F
W
L
A
F
P
L
C
S
L
Y
L
I
22



35
C
S
L
Y
L
I
A
V
L
G
N
L
T
I
I
22



85
L
A
I
F
W
F
N
S
T
T
I
Q
F
D
A
22



123
F
D
R
Y
V
A
I
C
H
P
L
R
H
A
T
22



198
N
V
V
Y
G
L
I
V
I
I
S
A
I
G
L
22



216
L
I
S
F
S
Y
L
L
I
L
K
T
V
L
G
22



218
S
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
22



251
F
I
F
Y
V
P
F
I
G
L
S
M
V
H
R
22



279
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
V
22



20
L
P
G
L
E
E
A
Q
F
W
L
A
F
P
L
20



31
A
F
P
L
C
S
L
Y
L
I
A
V
L
G
N
20



34
L
C
S
L
Y
L
I
A
V
L
G
N
L
T
I
20



36
S
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
20



40
I
A
V
L
G
N
L
T
I
I
Y
I
V
R
T
20



43
L
G
N
L
T
I
I
Y
I
V
R
T
E
H
S
20



45
N
L
T
I
I
Y
I
V
R
T
E
H
S
L
H
20



49
I
Y
I
V
R
T
E
H
S
L
H
E
P
M
Y
20



59
H
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
20



63
Y
I
F
L
C
M
L
S
G
I
D
I
L
I
S
20



66
L
C
M
L
S
G
I
D
I
L
I
S
T
S
S
20



72
I
D
I
L
I
S
T
S
S
M
P
K
M
L
A
20



81
M
P
K
M
L
A
I
F
W
F
N
S
T
T
I
20



82
P
K
M
L
A
I
F
W
F
N
S
T
T
I
Q
20



92
S
T
T
I
Q
F
D
A
C
L
L
Q
I
F
A
20



98
D
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
20



99
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
M
20



101
L
L
Q
I
F
A
I
H
S
L
S
G
M
E
S
20



104
I
F
A
I
H
S
L
S
G
M
E
S
T
V
L
20



107
I
H
S
L
S
G
M
E
S
T
V
L
L
A
M
20



116
T
V
L
L
A
M
A
F
D
R
Y
V
A
I
C
20



118
L
L
A
M
A
F
D
R
Y
V
A
I
C
H
P
20



126
Y
V
A
I
C
H
P
L
R
H
A
T
V
L
T
20



130
C
H
P
L
R
H
A
T
V
L
T
L
P
R
V
20



138
V
L
T
L
P
R
V
T
K
I
G
V
A
A
V
20



141
L
P
R
V
T
K
I
G
V
A
A
V
V
R
G
20



156
A
A
L
M
A
P
L
P
V
F
I
K
Q
L
P
20



163
P
V
F
I
K
Q
L
P
F
C
R
S
N
I
L
20



166
I
K
Q
L
P
F
C
R
S
N
I
L
S
H
S
20



180
S
Y
C
L
H
Q
D
V
M
K
L
A
C
D
D
20



184
H
Q
D
V
M
K
L
A
C
D
D
I
R
V
N
20



187
V
M
K
L
A
C
D
D
I
R
V
N
V
V
Y
20



194
D
I
R
V
N
V
V
Y
G
L
I
V
I
I
S
20



197
V
N
V
V
Y
G
L
I
V
I
I
S
A
I
G
20



200
V
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
20



201
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
L
20



203
L
I
V
I
I
S
A
I
G
L
D
S
L
L
I
20



204
I
V
I
I
S
A
I
G
L
D
S
L
L
I
S
20



207
I
S
A
I
G
L
D
S
L
L
I
S
F
S
Y
20



209
A
I
G
L
D
S
L
L
I
S
F
S
Y
L
L
20



212
L
D
S
L
L
I
S
F
S
Y
L
L
I
L
K
20



213
D
S
L
L
I
S
F
S
Y
L
L
I
L
K
T
20



219
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
R
20



241
G
T
C
V
S
H
V
C
A
V
F
I
F
Y
V
20



244
V
S
H
V
C
A
V
F
I
F
Y
V
P
F
I
20



247
V
C
A
V
F
I
F
Y
V
P
F
I
G
L
S
20



249
A
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
20



252
I
F
Y
V
P
F
I
G
L
S
M
V
H
R
F
20



273
P
L
P
V
I
L
A
N
I
Y
L
L
V
P
P
20



278
L
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
20



286
P
P
V
L
N
P
I
V
Y
G
V
K
T
K
E
20



19
G
L
P
G
L
E
E
A
Q
F
W
L
A
F
P
18



28
F
W
L
A
F
P
L
C
S
L
Y
L
I
A
V
18



70
S
G
I
D
I
L
I
S
T
S
S
M
P
K
M
18



95
I
Q
F
D
A
C
L
L
Q
I
F
A
I
H
S
18



100
C
L
L
Q
I
F
A
I
H
S
L
S
G
M
E
18



108
H
S
L
S
G
M
E
S
T
V
L
L
A
M
A
18



117
V
L
L
A
M
A
F
D
R
Y
V
A
I
C
H
18



127
V
A
I
C
H
P
L
R
H
A
T
V
L
T
L
18



165
F
I
K
Q
L
P
F
C
R
S
N
I
L
S
H
18



177
L
S
H
S
Y
C
L
H
Q
D
V
M
K
L
A
18



188
M
K
L
A
C
D
D
I
R
V
N
V
V
Y
G
18



206
I
I
S
A
I
G
L
D
S
L
L
I
S
F
S
18



234
E
A
Q
A
K
A
F
G
T
C
V
S
H
V
C
18



238
K
A
F
G
T
C
V
S
H
V
C
A
V
F
I
18



272
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
P
18



294
Y
G
V
K
T
K
E
I
R
Q
R
I
L
R
L
18



295
G
V
K
T
K
E
I
R
Q
R
I
L
R
L
F
18



11
S
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
16



29
W
L
A
F
P
L
C
S
L
Y
L
I
A
V
L
16



60
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
I
16



62
M
Y
I
F
L
C
M
L
S
G
I
D
I
L
I
16



86
A
I
F
W
F
N
S
T
T
I
Q
F
D
A
C
16



102
L
Q
I
F
A
I
H
S
L
S
G
M
E
S
T
16



178
S
H
S
Y
C
L
H
Q
D
V
M
K
L
A
C
16



237
A
K
A
F
G
T
C
V
S
H
V
C
A
V
F
16



250
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
H
16



254
Y
V
P
F
I
G
L
S
M
V
H
R
F
S
K
16



14
Y
F
I
L
I
G
L
P
G
L
E
E
A
Q
F
14



15
F
I
L
I
G
L
P
G
L
E
E
A
Q
F
W
14



17
L
I
G
L
P
G
L
E
E
A
Q
F
W
L
A
14



39
L
I
A
V
L
G
N
L
T
I
I
Y
I
V
R
14



48
I
I
Y
I
V
R
T
E
H
S
L
H
E
P
M
14



55
E
H
S
L
H
E
P
M
Y
I
F
L
C
M
L
14



61
P
M
Y
I
F
L
C
M
L
S
G
I
D
I
L
14



65
F
L
C
M
L
S
G
I
D
I
L
I
S
T
S
14



71
G
I
D
I
L
I
S
T
S
S
M
P
K
M
L
14



73
D
I
L
I
S
T
S
S
M
P
K
M
L
A
I
14



110
L
S
G
M
E
S
T
V
L
L
A
M
A
F
D
14



114
E
S
T
V
L
L
A
M
A
F
D
R
Y
V
A
14



136
A
T
V
L
T
L
P
R
V
T
K
I
G
V
A
14



144
V
T
K
I
G
V
A
A
V
V
R
G
A
A
L
14



149
V
A
A
V
V
R
G
A
A
L
M
A
P
L
P
14



150
A
A
V
V
R
G
A
A
L
M
A
P
L
P
V
14



155
G
A
A
L
M
A
P
L
P
V
F
I
K
Q
L
14



159
M
A
P
L
P
V
F
I
K
Q
L
P
F
C
R
14



174
S
N
I
L
S
H
S
Y
C
L
H
Q
D
V
M
14



185
Q
D
V
M
K
L
A
C
D
D
I
R
V
N
V
14



192
C
D
D
I
R
V
N
V
V
Y
G
L
I
V
I
14



196
R
V
N
V
V
Y
G
L
I
V
I
I
S
A
I
14



214
S
L
L
I
S
F
S
Y
L
L
I
L
K
T
V
14



221
Y
L
L
I
L
K
T
V
L
G
L
T
R
E
A
14



222
L
L
I
L
K
T
V
L
G
L
T
R
E
A
Q
14



226
K
T
V
L
G
L
T
R
E
A
Q
A
K
A
F
14



260
L
S
M
V
H
R
F
S
K
R
R
D
S
P
L
14



271
D
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
14



274
L
P
V
I
L
A
N
I
Y
L
L
V
P
P
V
14



275
P
V
I
L
A
N
I
Y
L
L
V
P
P
V
L
14



281
I
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
14



285
V
P
P
V
L
N
P
I
V
Y
G
V
K
T
K
14



303
Q
R
I
L
R
L
F
H
V
A
T
H
A
S
E
14



2
M
V
D
P
N
G
N
E
S
S
A
T
Y
F
I
12



3
V
D
P
N
G
N
E
S
S
A
T
Y
F
I
L
12



5
P
N
G
N
E
S
S
A
T
Y
F
I
L
I
G
12



6
N
G
N
E
S
S
A
T
Y
F
I
L
I
G
L
12



9
E
S
S
A
T
Y
F
I
L
I
G
L
P
G
L
12



51
I
V
R
T
E
H
S
L
H
E
P
M
Y
I
F
12



58
L
H
E
P
M
Y
I
F
L
C
M
L
S
G
I
12



67
C
M
L
S
G
I
D
I
L
I
S
T
S
S
M
12



68
M
L
S
G
I
D
I
L
I
S
T
S
S
M
P
12



80
S
M
P
K
M
L
A
I
F
W
F
N
S
T
T
12



83
K
M
L
A
I
F
W
F
N
S
T
T
I
Q
F
12



88
F
W
F
N
S
T
T
I
Q
F
D
A
C
L
L
12



91
N
S
T
T
I
Q
F
D
A
C
L
L
Q
I
F
12



93
T
T
I
Q
F
D
A
C
L
L
Q
I
F
A
I
12



96
Q
F
D
A
C
L
L
Q
I
F
A
I
H
S
L
12



111
S
G
M
E
S
T
V
L
L
A
M
A
F
D
R
12



122
A
F
D
R
Y
V
A
I
C
H
P
L
R
H
A
12



129
I
C
H
P
L
R
H
A
T
V
L
T
L
P
R
12



132
P
L
R
H
A
T
V
L
T
L
P
R
V
T
K
12



133
L
R
H
A
T
V
L
T
L
P
R
V
T
K
I
12



145
T
K
I
G
V
A
A
V
V
R
G
A
A
L
M
12



147
I
G
V
A
A
V
V
R
G
A
A
L
M
A
P
12



151
A
V
V
R
G
A
A
L
M
A
P
L
P
V
F
12



158
L
M
A
P
L
P
V
F
I
K
Q
L
P
F
C
12



160
A
P
L
P
V
F
I
K
Q
L
P
F
C
R
S
12



170
P
F
C
R
S
N
I
L
S
H
S
Y
C
L
H
12



171
F
C
R
S
N
I
L
S
H
S
Y
C
L
H
Q
12



172
C
R
S
N
I
L
S
H
S
Y
C
L
H
Q
D
12



176
I
L
S
H
S
Y
C
L
H
Q
D
V
M
K
L
12



189
K
L
A
C
D
D
I
R
V
N
V
V
Y
G
L
12



193
D
D
I
R
V
N
V
V
Y
G
L
I
V
I
I
12



199
V
V
Y
G
L
I
V
I
I
S
A
I
G
L
D
12



210
I
G
L
D
S
L
L
I
S
F
S
Y
L
L
I
12



211
G
L
D
S
L
L
I
S
F
S
Y
L
L
I
L
12



217
I
S
F
S
Y
L
L
I
L
K
T
V
L
G
L
12



224
I
L
K
T
V
L
G
L
T
R
E
A
Q
A
K
12



231
L
T
R
E
A
Q
A
K
A
F
G
T
C
V
S
12



233
R
E
A
Q
A
K
A
F
G
T
C
V
S
H
V
12



256
P
F
I
G
L
S
M
V
H
R
F
S
K
R
R
12



261
S
M
V
H
R
F
S
K
R
R
D
S
P
L
P
12



265
R
F
S
K
R
R
D
S
P
L
P
V
I
L
A
12



268
K
R
R
D
S
P
L
P
V
I
L
A
N
I
Y
12



270
R
D
S
P
L
P
V
I
L
A
N
I
Y
L
L
12



277
I
L
A
N
I
Y
L
L
V
P
P
V
L
N
P
12



287
P
V
L
N
P
I
V
Y
G
V
K
T
K
E
I
12



299
K
E
I
R
Q
R
I
L
R
L
F
H
V
A
T
12



300
E
I
R
Q
R
I
L
R
L
F
H
V
A
T
H
12










101P3A11-V2-DRB 0401 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






29
S
I
C
W
F
L
L
C
S
T
Q
L
S
M
E
28
Portion of SEQ ID NO: 30;


8
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
C
26
each start position is


2
A
F
P
L
C
S
L
Y
L
I
A
V
L
A
S
20
specified - the length of each


5
L
C
S
L
Y
L
I
A
V
L
A
S
G
V
T
20
peptide is 15 amino acids,


7
S
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
20
the end position for each


17
G
V
T
L
R
C
P
S
S
W
P
I
S
I
C
20
peptide is the start position


27
P
I
S
I
C
W
F
L
L
C
S
T
Q
L
S
20
plus fourteen


6
C
S
L
Y
L
I
A
V
L
A
S
G
V
T
L
16



23
P
S
S
W
P
I
S
I
C
W
F
L
L
C
S
16



11
I
A
V
L
A
S
G
V
T
L
R
C
P
S
S
14










101P3A11-V3- DRB 0401 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score






3
S
T
T
I
Q
F
D
A
C
L
L
Q
M
F
A
20
Portion of SEQ ID NO: 32;


10
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
M
20
each start position is specified -


12
L
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
20
the length of each peptide is


15
M
F
A
I
H
S
L
S
G
M
E
S
T
V
L
20
15 amino acids, the end


6
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
S
18
position for each peptide is


11
C
L
L
Q
M
F
A
I
H
S
L
S
G
M
E
18
the start position plus


13
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
T
16
fourteen


9
D
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
14



2
N
S
T
T
I
Q
F
D
A
C
L
L
Q
M
F
12



4
T
T
I
Q
F
D
A
C
L
L
Q
M
F
A
I
12



7
Q
F
D
A
C
L
L
Q
M
F
A
I
H
S
L
12



5
T
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
10
















TABLE XLIX







101P3A11-V1- DRB1-1101 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score
SEQ ID





146
K
I
G
V
A
A
V
V
R
G
A
A
L
M
A
28
Portion of SEQ


123
F
D
R
Y
V
A
I
C
H
P
L
R
H
A
T
25
ID NO: 28; each


218
S
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
25
start position is


198
N
V
V
Y
G
L
I
V
I
I
S
A
I
G
L
24
specified - the


11
S
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
23
length of each


256
P
F
I
G
L
S
M
V
H
R
F
S
K
R
R
23
peptide is 15


45
N
L
T
I
I
Y
I
V
R
T
E
H
S
L
H
22
amino acids, the


60
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
I
22
end position for


159
M
A
P
L
P
V
F
I
K
Q
L
P
F
C
R
22
each peptide is


238
K
A
F
G
T
C
V
S
H
V
C
A
V
F
I
22
the start position


75
L
I
S
T
S
S
M
P
K
M
L
A
I
F
W
21
plus fourteen


135
H
A
T
V
L
T
L
P
R
V
T
K
I
G
V
20



138
V
L
T
L
P
R
V
T
K
I
G
V
A
A
V
20



163
P
V
F
I
K
Q
L
P
F
C
R
S
N
I
L
20



200
V
Y
G
L
I
V
I
I
S
A
I
G
L
D
S
20



225
L
K
T
V
L
G
L
T
R
E
A
Q
A
K
A
20



257
F
I
G
L
S
M
V
H
R
F
S
K
R
R
D
20



291
P
I
V
Y
G
V
K
T
K
E
I
R
Q
R
I
20



302
R
Q
R
I
L
R
L
F
H
V
A
T
H
A
S
20



66
L
C
M
L
S
G
I
D
I
L
I
S
T
S
S
19



101
L
L
Q
I
F
A
I
H
S
L
S
G
M
E
S
19



197
V
N
V
V
Y
G
L
I
V
I
I
S
A
I
G
19



219
F
S
Y
L
L
I
L
K
T
V
L
G
L
T
R
19



248
C
A
V
F
I
F
Y
V
P
F
I
G
L
S
M
19



275
P
V
I
L
A
N
I
Y
L
L
V
P
P
V
L
19



46
L
T
I
I
Y
I
V
R
T
E
H
S
L
H
E
18



69
L
S
G
I
D
I
L
I
S
T
S
S
M
P
K
18



81
M
P
K
M
L
A
I
F
W
F
N
S
T
T
I
18



98
D
A
C
L
L
Q
I
F
A
I
H
S
L
S
G
18



104
I
F
A
I
H
S
L
S
G
M
E
S
T
V
L
18



209
A
I
G
L
D
S
L
L
I
S
F
S
Y
L
L
18



250
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
H
18



62
M
Y
I
F
L
C
M
L
S
G
I
D
I
L
I
17



216
L
I
S
F
S
Y
L
L
I
L
K
T
V
L
G
17



260
L
S
M
V
H
R
F
S
K
R
R
D
S
P
L
17



279
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
V
17



289
L
N
P
I
V
Y
G
V
K
T
K
E
I
R
Q
17



12
A
T
Y
F
I
L
I
G
L
P
G
L
E
E
A
16



25
E
A
Q
F
W
L
A
F
P
L
C
S
L
Y
L
16



43
L
G
N
L
T
I
I
Y
I
V
R
T
E
H
S
16



254
Y
V
P
F
I
G
L
S
M
V
H
R
F
S
K
16



48
I
I
Y
I
V
R
T
E
H
S
L
H
E
P
M
15



100
C
L
L
Q
I
F
A
I
H
S
L
S
G
M
E
15



117
V
L
L
A
M
A
F
D
R
Y
V
A
I
C
H
15



144
V
T
K
I
G
V
A
A
V
V
R
G
A
A
L
15



180
S
Y
C
L
H
Q
D
V
M
K
L
A
C
D
D
15



228
V
L
G
L
T
R
E
A
Q
A
K
A
F
G
T
15



261
S
M
V
H
R
F
S
K
R
R
D
S
P
L
P
15



262
M
V
H
R
F
S
K
R
R
D
S
P
L
P
V
15



278
L
A
N
I
Y
L
L
V
P
P
V
L
N
P
I
15



286
P
P
V
L
N
P
I
V
Y
G
V
K
T
K
E
15



115
S
T
V
L
L
A
M
A
F
D
R
Y
V
A
I
14



126
Y
V
A
I
C
H
P
L
R
H
A
T
V
L
T
14



127
V
A
I
C
H
P
L
R
H
A
T
V
L
T
L
14



141
L
P
R
V
T
K
I
G
V
A
A
V
V
R
G
14



171
F
C
R
S
N
I
L
S
H
S
Y
C
L
H
Q
14



181
Y
C
L
H
Q
D
V
M
K
L
A
C
D
D
I
14



194
D
I
R
V
N
V
V
Y
G
L
I
V
I
I
S
14



230
G
L
T
R
E
A
Q
A
K
A
F
G
T
C
V
14



271
D
S
P
L
P
V
I
L
A
N
I
Y
L
L
V
14



299
K
E
I
R
Q
R
I
L
R
L
F
H
V
A
T
14



10
S
S
A
T
Y
F
I
L
I
G
L
P
G
L
E
13



20
L
P
G
L
E
E
A
Q
F
W
L
A
F
P
L
13



33
P
L
C
S
L
Y
L
I
A
V
L
G
N
L
T
13



36
S
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
13



37
L
Y
L
I
A
V
L
G
N
L
T
I
I
Y
I
13



59
H
E
P
M
Y
I
F
L
C
M
L
S
G
I
D
13



107
I
H
S
L
S
G
M
E
S
T
V
L
L
A
M
13



152
V
V
R
G
A
A
L
M
A
P
L
P
V
F
I
13



156
A
A
L
M
A
P
L
P
V
F
I
K
Q
L
P
13



207
I
S
A
I
G
L
D
S
L
L
I
S
F
S
Y
13



237
A
K
A
F
G
T
C
V
S
H
V
C
A
V
F
13



249
A
V
F
I
F
Y
V
P
F
I
G
L
S
M
V
13



268
K
R
R
D
S
P
L
P
V
I
L
A
N
I
Y
13



280
N
I
Y
L
L
V
P
P
V
L
N
P
I
V
Y
13



282
Y
L
L
V
P
P
V
L
N
P
I
V
Y
G
V
13










101P3A11-V2-DRB 1101 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score
SEQ ID





5
L
C
S
L
Y
L
I
A
V
L
A
S
G
V
T
18
Portion of SEQ ID NO: 30;


6
C
S
L
Y
L
I
A
V
L
A
S
G
V
T
L
18
each start position is


29
S
I
C
W
F
L
L
C
S
T
Q
L
S
M
E
17
specified - the length of each


13
V
L
A
S
G
V
T
L
R
C
P
S
S
W
P
15
peptide is 15 amino acids,


8
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
C
14
the end position for each


4
P
L
C
S
L
Y
L
I
A
V
L
A
S
G
V
13
peptide is the start position


12
A
V
L
A
S
G
V
T
L
R
C
P
S
S
W
13
plus fourteen


2
A
F
P
L
C
S
L
Y
L
I
A
V
L
A
S
12



7
S
L
Y
L
I
A
V
L
A
S
G
V
T
L
R
12



14
L
A
S
G
V
T
L
R
C
P
S
S
W
P
I
12



11
I
A
V
L
A
S
G
V
T
L
R
C
P
S
S
10



23
P
S
S
W
P
I
S
I
C
W
F
L
L
C
S
10



15
A
S
G
V
T
L
R
C
P
S
S
W
P
I
S
8










101P3A11-V3- DRB 1101 15-mers
























Pos
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
score
SEQ ID





12
L
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
19
Portion of SEQ ID NO: 32;


9
D
A
C
L
L
Q
M
F
A
I
H
S
L
S
G
18
each start position is


15
M
F
A
I
H
S
L
S
G
M
E
S
T
V
L
18
specified - the length of each


11
C
L
L
Q
M
F
A
I
H
S
L
S
G
M
E
15
peptide is 15 amino acids,


6
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
S
12
the end position for each


5
T
I
Q
F
D
A
C
L
L
Q
M
F
A
I
H
10
peptide is the start position


13
L
Q
M
F
A
I
H
S
L
S
G
M
E
S
T
10
plus fourteen
















TABLE LIV





Nucleotide sequence in the 5′ region close to 101P3A11 gene


(SEQ ID NO: 1).
















1
TGCGCTCCAC CAAGCCTGGC TAACTTTTGC ATTTTTAATA GAGGCAGGGT TTCACCATGT


 


61
TGGCCTGGCT GGTCTCGAAC CCCTGACCTT GCGATCTGCC CACCTCGGCC TCCCAAAGTG


 


121
CTGGGATTAC AGGCGTGAGC CACTGTACCT GGCGGGGCTT ATTGTTTTTT AAAAAGATTT


 


181
CCAAAACCTT GCCCTGGCAA TTCTGATTTT CTGGGCCTGG AGCAGGACCT GGAGGGATGG


 


241
TGTTGTCAAT TACTTTAGAT GTTTCTATCA GGAAAGTTTG AGAAATGGTA TTCAGGCCTA


 


301
AACACAAACC TCTCTTGAAA TCTCATCCCA GACTGAGCCC CTGCTCCCTA TCTTAAATTA


 


361
GATTATAGTA GGTCTTAAAG TCAGCTGTAG ACTGAGCCTC TAAATCTGAA CCAAGACCAA


 


421
CCCTAACCCC AGGATACATC AGAAGAGCTG GTCAATGTGG ACCATTCTGA GCAATCCTGC


 


481
AAGTCTACTC TGATGGGAAA AGGCTAAGAG CAGTGCCCTG GGCAGCAACA TCAGCTCTGA


 


541
AGATGCAGGA CTGTGTTACA TGTTTTATGA GTGGGTCTTC ACACACTGAG ATTCATGGGA


 


601
CAGTAATAGA ATCTGCTTGT GCAGCACTGG GGCCTTGGAG GGTCAGGGTA AGGCTCAAGA


 


661
TGTCCAGGAA GTTGTATATA AGGAGAATCA GAGCAGAGAG AGACTAGGGT TCAGAATTAC


 


721
CAGGATGACT TAGTCCTGTT TGTTACTGTC ACCACTCCAA TGCCTTTTCC TCATTAGTCC


 


781
TTTCTCTCCT CTGAGCCACA ACTAAATGAT GTTTCTACTT TTCCCTTTCT ACTTTCCTAG


 


841
ACCCTGGATT TTGTATGCAG AAGCCCCAGC TCTTGGTCCC TATCATAGCC ACTTCAAATG


 


901
GAAATCTGGT CCACGCAGCA TACTTCCTTT TGGTGGGTAT CCCTGGCCTG GGGCCTACCA


 


961
TACACTTTTG GCTGGCTTTC CCACTGTGTT TTATGTATGC CTTGGCCACC CTGGGTAACC


 


1021
TGACCATTGT CCTCATCATT CGTGTGGAGA GGCGACTGCA TGAGCCCATG TACCTCTTCC


 


1081
TGGCCATGCT TTCCACTATT GACCTAGTCC TCTCCTCTAT CACCATGCCC AAGATGGCCA


 


1141
GTCTTTTCCT GATGGGCATC CAGGAGATCG AGTTCAACAT TTGCCTGGCC CAGATGTTCC


 


1201
TTATCCATGC TCTGTCAGCC GTGGAGTCAG CTGTCCTGCT GGCCATGGCT TTTGACCGCT


 


1261
TTGTGGCCAT TTGCCACCCA TTGCGCCATG CTTCTGTGCT GACAGGGTGT ACTGTGGCCA


 


1321
AGATTGGACT ATCTGCCCTG ACCAGGGGGT TTGTATTCTT CTTCCCACTG CCCTTCATCC


 


1381
TCAAGTGGTT GTCCTACTGC CAAACACATA CTGTCACACA CTCCTTCTGT CTGCACCAAG


 


1441
ATATTATGAA GCTGTCCTGT ACTGACACCA GGGTCAATGT GGTTTATGGA CTCTTCATCA


 


1501
TCCTCTCAGT CATGGGTGTG GACTCTCTCT TCATTGGCTT CTCATATATC CTCATCCTGT


 


1561
GGGCTGTTTT GGAGCTGTCC TCTCGGAGGG CAGCACTCAA GGCTTTCAAC ACCTGCATCT


 


1621
CCCACCTCTG TGCTGTTCTG GTCTTCTATG TACCCCTCAT TGGGCTCTCG GTGGTGCATA


 


1681
GGCTGGGTGG TCCCACCTCC CTCCTCCATG TGGTTATGGC TAATACCTAC TTGCTGCTAC


 


1741
CACCTGTAGT CAACCCCCTT GTCTATGGAG CCAAGACCAA AGAGATCTGT TCAAGGGTCC


 


1801
TCTGTATGTT CTCACAAGGT GGCAAGTGAG ACACCTTAGT GTCTCGCTTC TACTACTACT


 


1861
ACAGAAGATG GGAATATTAG GATCCTATTG AATGCCTTGG TGATTAAAGT ATCAAACCTA


 


1921
TTGTGCTGTC TTCTTCCAGC AATTTAAGTA GATCATGTAT TCTGTCTCCA GGAATGTGTC


 


1981
AGTACTGAAC TTATGACCCT GTCTGGACAT CCTGGAGAAT GACTGCACTA GTCCCTCTGC


 


2041
TATGGTGGTC TTGCCTTCTC CTTCTCTCTC AGCTAGAAAA TACATCTAGT TTTGACATGG


 


2101
GGAGGCTGTA AAGATCACAC CTCATGGTTC ATTCCAGTTT TGAAGTATGA TTTTAATGTT


 


2161
CTTGCCCCCA TGTGCCCATG TTGGTGAATT TGCATGGACT ATAAACGTTA TTGCAAATAC


 


2221
CCTAAAGTGG TTACCCAGCC ATAATCAGGG GTTAATGAAG GTATTTGGGG AATAGTAACT


 


2281
GGAGAGACAG CAACAAGACA AGAGGCAGCT CACATGCAAT GTTGAAGTTT CTGTATGCAA


 


2341
GAGGGTGTGT TGGCAGATTT GTGAAATCTG CCCATTTGCA TCTGTATGGC TCTATATGAC


 


2401
TATTTGTCCA TAAGGGTGCC ATGTATTCTG GTTGTGGGTG TGAATGTGTG GGTGTGTTTA


 


2461
TGTGGACACT TGCTTTTCAG TGTGCGTATA TGTGAGAGAG AGGGTGCACA CATGGAATAC


 


2521
GTACTGGTTG TGTCCTGGTG AGTGTGGTAG CTATGTCCTG GCACATGTAT GTTTCATGAG


 


2581
ACGTGTCTCT GATTGCGCAT TTGTATTTCT GTGGTATCTG TTAGTTGGTA TATGATATGT


 


2641
GTCTACGTGA GAATGCTGGT GTCTGTATCT GCATGGTGGG CAGTACCTTT ATGTGTATCT


 


2701
GGTAAGAATG CTGCCTCTAC CTTTTCTTCC TATTTGTACT ATGTGAATGT GGTGCATGAA


 


2761
TGTGTGGAAT GTGTGGAATG TGTAGTATTG GGATGCCTGT ATCTTTCAGC GTGTTTGGGT


 


2821
GTATGTCCAC TGTGCATAAT ATTTGAGATG TAAAACCATT TTGTGCGGTA TATGTGTTAT


 


2881
TAGTTGTAAG TCGGTGAAAT GTACATCTGA ATTCTGTGTG CATATTGTTG GTACTGATGC


 


2941
TATTTTCGTG CATATGTCTA GTGTATATGT TTTAAGGCAA ACTTTCTTTG TGTGTTGGGT


 


3001
GTGTATGTGA CACGAATGGG GACAGCATCT GTATTTCTGA GCATGGATTG ATGTGTGGTG


 


3061
TCTGTATGTA TCTTGGAATG GAGGAGGGAG ATTGAAGAAG TCTGGCTGTG AGCAGCAGAA


 


3121
ATAATTTCCA AAGTTGAGTG ACATGACTCT AAGATGCCCA GTTTCTCGGC CTGGGGTCAG


 


3181
CCTGGGTGAT AGCTCAGTCT GTCAGAATGA AAGGAAACAC GGTGCTTCCT TGCTCCACCT


 


3241
TTTCACAGGC CAGACCACAC CTTCTTCATC CTGAACACAA GGATTTCAAG GGCTTTTGTT


 


3301
ACCTCTTCCT ACGTTTCCTG CCTCTGCTAT CCGAGGCACT GGCCTCCCTA AACCCTGCCC


 


3361
TCCTGCCTCA ATAGCAAGTC ATGGTATCCT CACCTCTCCC TTCCCTTTTT GGCTTATCTG


 


3421
CCAAACATGT ATAAAAGTCC TTGGTTCCCC ATCTCTACTA AAAATACAAC AATTAGCCGG


 


3481
GTGTGATGGC GCGTGCCTGT AGTCCCAGCT AGTTGGGAGG CTGAGGCAGG AGAAACGCTT


 


3541
GAGCCCGCAA GGTGGAGGTT GCAGTGAGCC GAGATCATGC CACTGCACTC CAGCCTGGTG


 


3601
ACAGAGCAAG ACTCTGTGTC AAAAAAAAAA AAAAAAAAAA AGCCTTGGTT GTAGGGAGTT


 


3661
TCTCCTAATC CCTCTGGGAA AGCAAGGGTG GAGGGGAAGC CAGTCAATCT CCCTTCTGTT


 


3721
GCCGCATGGA AACTCCCTTA AGGCAGGAAG CTGAAAAAAC TGTAGCATTC ACCTCATTAT


 


3781
TCACCTTGTC TCATGTCTCA CTGTCCTTCC ACATGTCTCA TTGTTACTCC ATATTGGATG


 


3841
GAAGTAGAAG TCCCTTTGGT ATTTTTTAAA GTCTTTGCCA TGTCTAAGTT AATGAGGTTA


 


3901
ATGGAGGCAG CAGAGATGGC TCCAGGGTTC TGATAGCAAG TGTCAGGCTG CGTGCTCTGT


 


3961
AGGCACCAGA AACTGTTGTC ACCAGTAATT TTGATGTGGT CTGAGTTAGA ATGGTCTGAT


 


4021
TTGCCATGAT CTATTTAACA TAGCTTGATT TAGCGTGTCC TGTGTTCTGA ATTTAAAACT


 


4081
CACAGTTGTG AAACTGATCA GTAAAAAATA AGGGGAGACC AACTAAAAAC CATGTTGTTC


 


4141
TATTTATAGA TGTAGTTTTT ACTTATTTCA AAATACGAGG TATTTAGTTT TACATTCAAA


 


4201
TTGTTCTCTA ACTCTCTAAA ATGTTCTCTG ACTATTTTTG CCCTTAAGGG AGAAACCAGA


 


4261
TGTCATTGGT CTTACGTGGC TGGTGTTGGG GGTGGGGAGG GTTAAAGAAA CCACGTTCTC


 


4321
TGTCCTCAGC CAGAAGTTCA GTAATCCAAG GCCAGAGAGT GGACGGCAGA GGCACTGTCC


 


4381
CTGGGGACCT TGGTTATAAG TTATCCAGAC ACAGGGACCA GAGCCTGGGA GACAAAAAAA


 


4441
GATGTAGCCC TAGGGCTTTG GGAAAAGGAG GATGGACCCA GTGAATTCCA CGCTTAGCAA


 


4501
GGACCTAAAC AGTGTCCCCC AAATGAGAGA AGGGAGGACA GAAAGAACAC TTCAGGATGG


 


4561
AAATGGGCTG ACACTTAACC GTGGAGTGTC TCTGCAAACT TCCTTTGCCA TTCTCCTGTT


 


4621
TGAGTTTGAT AAACCTGAGA AGAGACTTGG ATAAAGACCG TCACGAAGAC TACACTAATG


 


4681
AGTTTCTTCT AGCTTTTTTC TACTCACTTT CCCTATCTAT CCTTCACATT GGGAGTTGGC


 


4741
ATGAGGATCC CAGCAGCCCA TCAGGGGAGG ACTCTAGAGA TCCCTTTCCC CATTGCCTCT


 


4801
CCTCCCCATA CCCCCAGGCA TATCCTCCCA GGGCACGGAA GCTGAGAAGC AGTCCAGAAC


 


4861
CACAGTGGGC TAGTGAGGGG TACCTGCTGA TGTACCCTTT GGACAGCATT CTGCCCCACC


 


4921
CTGCAGGAAG AAGCAGAAGG AGGGAGAGGG TGAGGCAGAG AATAAATAAC CCTGACCAGG


 


4981
GAGGTCCAAG GGAGTAGGCG GAGAcagaga ggctgtattt cagtgcagcc tgccagacct





Note:


The three high score predictions of promoters were bold and underlined.


The lower case sequence indicates the beginning part of the transcript of 101P3A11 gene.













TABLE LV







Promoters and their positions predicted by


Neural Network Promoter Prediction


computer program.














SEQ ID



Start
End
Score
NO:
Promoter Sequence














25
75
0.91
2
TTTTGCATTTTTAATAGAGGCAGGGT






TTCACCATGTTGGCCTGGCTGGTC


 


665
715
0.95
3
CAGGAAGTTGTATATAAGGAGAATC






AGAGCAGAGAGAGACTAGGGTTCAG


 


2477
2527
0.91
4
TCAGTGTGCGTATATGTGAGAGAGA






GGGTGCACACATGGAATACGTACTG


 


3139
3189
0.82
5
TGACATGACTCTAAGATGCCCAGTT






TCTCGGCCTGGGGTCAGCCTGGGTG


 


3420
3470
0.96
6
GCCAAACATGTATAAAAGTCCTTGG






TTCCCCATCTCTACTAAAAATACAA


 


4092
4142
0.99
7
AACTGATCAGTAAAAAATAAGGGGA






GACCAACTAAAAACCATGTTGTTCT


 


4953
5003
0.97
8
AGGCAGAGAATAAATAACCCTGACC






AGGGAGGTCCAAGGGAGTAGGCGGA
















TABLE LVI





Alignment of five homologous 5′ upstream genomic regulatory regions of


the human 101P3A11 and PSA genes.















Query: 5′ upstream regulatory region of the PSA gene)


Subject: Putative 5′ upstream regulatory region of the 101P3A11 gene


SEQ ID NO: 10).


Nucleic acid sequences predicted to be binding sites for the indicated


transcription factors are bolded, underlined, or italicized.


 























TABLE LVII








>101P3A11 v.1 aa 1-318: for 9-mers, 10-mers,



15-mers







(SEQ ID NO: 19)









MMVDPNGNES SATYFILIGL PGLEEAQFWL AFPLCSLYLI



AVLGNLTIIY IVRTEHSLHE PMYIFLCMLS GIDILISTSS



MPKMLAIFWF NSTTIQFDAC LLQIFAIHSL SGMESTVLLA



MAFDRYVAIC HPLRHATVLT LPRVTKIGVA AVVRGAALMA



PLPVFIKQLP FCRSNILSHS YCLHQDVMKL ACDDIRVNVV



YGLIVIISAI GLDSLLISFS YLLILKTVLG LTREAQAKAF



GTCVSHVCAV FIFYVPFIGL SMVHRFSKRR DSPLPVILAN



IYLLVPPVLN PIVYGVKTKE IRQRILRLFH VATHASEP


 



>101P3A11 v.2



9-mers, aa 36-72







(SEQ ID NO: 20)









SLYLIAVLASGVTLRCPSSWPISICWFLLCSTQLSME


 



10-mers, aa 35-72







(SEQ ID NO: 21)









CSLYLIAVLASGVTLRCPSSWPISICWFLLCSTQLSME


 



15-mers, aa 30-72







(SEQ ID NO: 22)









LAFPLCSLYLIAVLASGVTLRCPSSWPISICWFLLCSTQLSME


 



>101P3A11 v.3



9-mers: aa 96-112







(SEQ ID NO: 23)









QFDACLLQMFAIHSLSG


 



10-mers: aa 95-113







(SEQ ID NO: 24)









IQFDACLLQMFAIHSLSGM


 



15-mers, aa 90-118







(SEQ ID NO: 25)









FNSTTIQFDACLLQMFAIHSLSGMESTVL

## Claims

1. A method to identify a peptide that elicits an immune response to a protein comprising the amino acid sequence of SEQ ID NO: 28, which method comprises:
(a) identifying an HLA supertype for which binding of epitopes of said peptide is desired;
(b) selecting from the peptides listed for SEQ ID No: 28 in one of Tables V-XVIII and XXII-XLIX any peptides that comprise epitopes that bind alleles of said identified supertype;
(c) experimentally assessing the ability of said peptides to bind to at least one allele of said HLA supertype; and
(d) identifying a peptide that binds with an IC50 equal to, or less than, 500 nanomolar to said HLA supertype allele.

2. The method of claim 1, wherein peptides are selected that bind with an IC50 equal to, or less than, 500 nanomolar to three alleles of said HLA supertype.